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Integrated sensor-augmented pump therapy systems [the
MiniMed® Paradigm™ Veo system and the Vibe™ and G4®
PLATINUM CGM (continuous glucose monitoring) system]
for managing blood glucose levels in type 1 diabetes:
a systematic review and economic evaluation
Rob Riemsma,1* Isaac Corro Ramos,2 Richard Birnie,1
Nasuh Büyükkaramikli,2 Nigel Armstrong,1 Steve Ryder,1
Steven Duffy,1 Gill Worthy,1 Maiwenn Al,2 Johan Severens2
and Jos Kleijnen1,3
1Kleijnen Systematic Reviews Ltd, York, UK
2Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam,
the Netherlands
3School for Public Health and Primary Care, Maastricht University, Maastricht, the Netherlands
*Corresponding author rob@systematicreviews.com
Background: In recent years, meters for continuous monitoring of interstitial fluid glucose have been
introduced to help people with type 1 diabetes mellitus (T1DM) to achieve better control of their disease.
Objective: The objective of this project was to summarise the evidence on the clinical effectiveness and
cost-effectiveness of the MiniMed® Paradigm™ Veo system (Medtronic Inc., Northridge, CA, USA) and the
Vibe™ (Animas® Corporation, West Chester, PA, USA) and G4® PLATINUM CGM (continuous glucose
monitoring) system (Dexcom Inc., San Diego, CA, USA) in comparison with multiple daily insulin injections
(MDIs) or continuous subcutaneous insulin infusion (CSII), both with either self-monitoring of blood
glucose (SMBG) or CGM, for the management of T1DM in adults and children.
Data sources: A systematic review was conducted in accordance with the principles of the Centre for
Reviews and Dissemination guidance and the National Institute for Health and Care Excellence Diagnostic
Assessment Programme manual. We searched 14 databases, three trial registries and two conference
proceedings from study inception up to September 2014. In addition, reference lists of relevant systematic
reviews were checked. In the absence of randomised controlled trials directly comparing Veo or an
integrated CSII+CGM system, such as Vibe, with comparator interventions, indirect treatment comparisons
were performed if possible.
Methods: A commercially available cost-effectiveness model, the IMS Centre for Outcomes Research and
Effectiveness diabetes model version 8.5 (IMS Health, Danbury, CT, USA), was used for this assessment.
This model is an internet-based, interactive simulation model that predicts the long-term health outcomes
and costs associated with the management of T1DM and type 2 diabetes. The model consists of
15 submodels designed to simulate diabetes-related complications, non-specific mortality and costs over
time. As the model simulates individual patients over time, it updates risk factors and complications to
account for disease progression.
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Results: Fifty-four publications resulting from 19 studies were included in the review. Overall, the evidence
suggests that the Veo system reduces hypoglycaemic events more than other treatments, without any
differences in other outcomes, including glycated haemoglobin (HbA1c) levels. We also found significant
results in favour of the integrated CSII+CGM system over MDIs with SMBG with regard to HbA1c levels
and quality of life. However, the evidence base was poor. The quality of the included studies was generally
low, often with only one study comparing treatments in a specific population at a specific follow-up time.
In particular, there was only one study comparing Veo with an integrated CSII+CGM system and only one
study comparing Veo with a CSII+ SMBG system in a mixed population. Cost-effectiveness analyses
indicated that MDI+ SMBG is the option most likely to be cost-effective, given the current threshold of
£30,000 per quality-adjusted life-year gained, whereas integrated CSII+CGM systems and Veo are
dominated and extendedly dominated, respectively, by stand-alone, non-integrated CSII with CGM.
Scenario analyses did not alter these conclusions. No cost-effectiveness modelling was conducted for
children or pregnant women.
Conclusions: The Veo system does appear to be better than the other systems considered at reducing
hypoglycaemic events. However, in adults, it is unlikely to be cost-effective. Integrated systems are also
generally unlikely to be cost-effective given that stand-alone systems are cheaper and, possibly, no less
effective. However, evidence in this regard is generally lacking, in particular for children. Future trials
in specific child, adolescent and adult populations should include longer term follow-up and ratings
on the European Quality of Life-5 Dimensions scale at various time points with a view to informing
improved cost-effectiveness modelling.
Study registration: PROSPERO Registration Number CRD42014013764.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Cost-effectiveness analysis An economic analysis that converts effects into health benefits and describes
the costs for additional health gains.
Decision modelling A mathematical construct that allows the comparison of the relationship between
costs and outcomes for alternative health-care interventions.
Diabetic ketoacidosis Occurs when the body is unable to use blood glucose because of inadequate
insulin. Instead, fat is broken down as an alternative source of fuel; this process leads to the build-up of
by-products called ketones.
False negative Incorrect negative test result (e.g. the number of diseased persons with a negative
test result).
False positive Incorrect positive test result (e.g. the number of non-diseased persons with a positive
test result).
Glycated haemoglobin test The glycated haemoglobin test measures diabetes management over
2–3 months.
Hyperglycaemic and hypoglycaemic area under the curve The area under the curve is the product of
the magnitude and duration of the sensor-measured glucose level above or below a specified cut-off level.
Higher values for this calculation indicate more numerous, severe or protracted glycaemic events.
Hypocalcaemia Low blood calcium level.
Hypomagnesaemia Low levels of magnesium in the blood.
Impaired awareness of hypoglycaemia When people with diabetes, usually type 1 diabetes,
are frequently unable to notice when they have low blood sugar.
Incremental cost-effectiveness ratio The difference in the mean costs of two interventions in the
population of interest divided by the difference in the mean outcomes in the population of interest.
Index test The test whose performance is being evaluated.
Integrated CSII+ CGM An integrated continuous glucose monitoring and insulin pump system intended
to aid the effective management of diabetes, without a low glucose suspend function.
Ketonaemia The presence of an abnormally high concentration of ketone bodies in the blood.
Ketonuria The presence of abnormally high amounts of ketones and ketone bodies (by-products of the
breakdown of cells) in the urine. Ketonuria is a sign seen in badly controlled diabetes.
Low glucose suspend function Stops insulin delivery for 2 hours if there is no response to a low
glucose warning.
Markov model An analytical method particularly suited to modelling repeated events or the progression
of a chronic disease over time.
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Meta-analysis Statistical techniques used to combine the results of two or more studies and obtain a
combined estimate of effect.
Meta-regression Statistical technique used to explore the relationship between study characteristics and
study results.
MiniMed® Paradigm™ Veo System (Medtronic Inc., Northridge, CA, USA) An integrated continuous
glucose monitoring and insulin pump system intended to aid the effective management of diabetes, with
added insulin suspend function intended to prevent hypoglycaemia, including nocturnal hypoglycaemia.
Opportunity costs The costs of forgone outcomes that could have been achieved through
alternative investments.
Polycythaemia An abnormally increased concentration of haemoglobin in the blood, as a result of either
a reduction in plasma volume or an increase in red blood cell numbers.
Publication bias Bias arising from the preferential publication of studies with statistically
significant results.
Quality-adjusted life-year A measure of health gain, used in economic evaluations, in which survival
duration is weighted or adjusted by a patient’s quality of life during the survival period.
Quality of life An individual’s emotional, social and physical well-being, and their ability to perform the
ordinary tasks of living.
Receiver operating characteristic curve A graph which illustrates the trade-offs between sensitivity and
specificity which result from varying the diagnostic threshold.
Reference standard The best currently available diagnostic test, against which the index test
is compared.
Retinopathy Diabetic retinopathy is a common complication of diabetes. It occurs when high blood sugar
levels damage the cells at the back of the eye (known as the retina). If it is not treated, it can
cause blindness.
Sensitivity Proportion of people with the target disorder who have a positive test result.
Specificity Proportion of people without the target disorder who have a negative test result.
True negative Correct negative test result (i.e. the number of non-diseased persons with a negative
test result).
True positive Correct positive test result (i.e. the number of diseased persons with a positive test result).
Type 1 diabetes mellitus A condition in which the body does not produce insulin.
Vibe™ (Animas® Corporation, West Chester, PA, USA) and Dexcom G4® PLATINUM (Dexcom Inc.,
San Diego, CA, USA) system An integrated continuous glucose monitoring and insulin pump system
intended to aid the effective management of diabetes, without a low glucose suspend function.
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List of abbreviations
AUC area under the curve
BG blood glucose
BMI body mass index
CEAC cost-effectiveness acceptability
curve
CGM continuous glucose monitoring
CHF congestive heart failure
CI confidence interval
CSII continuous subcutaneous insulin
infusion
CSII+CGM non-integrated, stand-alone
continuous subcutaneous insulin
infusion and continuous glucose
monitoring
CSII+ SMBG continuous subcutaneous insulin
infusion with self-monitoring of
blood glucose by capillary blood
testing
CVD cardiovascular disease
DCCT Diabetes Control and Complications
Trial
DKA diabetic ketoacidosis
EQ-5D European Quality of Life-5
Dimensions
HbA1c glycated haemoglobin
HCHS Hospital and Community Health
Services
HFS Hypoglycaemia Fear Survey
HRQoL health-related quality of life
HTA Health Technology Assessment
ICER incremental cost-effectiveness ratio
IMS CDM IMS Centre for Outcomes Research
and Effectiveness diabetes model
(IMS Health, Danbury, CT, USA)
LGS low glucose suspend
MD mean difference
MDI multiple daily insulin injection
MDI+CGM multiple daily insulin injections with
continuous monitoring of blood
glucose
MDI+ SMBG multiple daily insulin injections with
self-monitoring of blood glucose by
capillary blood testing
MI myocardial infarction
NICE National Institute for Health and
Care Excellence
PSA probabilistic sensitivity analysis
PSSRU Personal Social Services Research
Unit
PVD peripheral vascular disease
QALY quality-adjusted life-year
RCT randomised controlled trial
RR relative risk
SAP sensor-augmented insulin pump
SAPT sensor-augmented pump therapy
SBP systolic blood pressure
SD standard deviation
SMBG self-monitoring of blood glucose
T1DM type 1 diabetes mellitus
T2DM type 2 diabetes mellitus
WMD weighted mean difference
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Plain English summary
People who have type 1 diabetes need treatment with insulin every day. They usually inject themselvesmultiple times each day using a needle and syringe. Some people use a device called an insulin pump
which can give them a continuous dose of insulin through a needle in the skin. Getting the dose of
insulin treatment right is essential in order to avoid people having too much sugar (hyperglycaemia) or
too little sugar (hypoglycaemia) in their blood. In this project, we studied the clinical effectiveness and
cost-effectiveness of two insulin delivery systems for the management of type 1 diabetes in adults
and children.
The MiniMed® Paradigm™ Veo system (Medtronic Inc., Northridge, CA, USA) is an insulin pump with an
in-built glucose monitor and an insulin suspend function that stops (suspends) insulin entering the pump
for up to 2 hours. The Vibe™ (Animas® Corporation, West Chester, PA, USA) and G4® PLATINUM CGM
(continuous glucose monitoring) (Dexcom Inc., San Diego, CA, USA) system is similar to the MiniMed Veo
system, but without the suspend function.
These two insulin delivery systems were compared in patients who inject themselves with insulin multiple
times per day and in patients who use insulin pumps, along with either a separate continuous glucose
monitor or with self-monitoring of blood glucose (SMBG) by finger prick tests.
We found that the MiniMed Paradigm Veo system reduces hypoglycaemic events in comparison with other
treatments, without any differences in other health outcomes; however, the evidence we looked at was
limited. We also found that self-injection of insulin multiple times a day along with SMBG by finger prick
tests was the combination most likely to be cost-effective.
In summary, our review shows that the Veo system reduces hypoglycaemic events in comparison with
other treatments, without any differences in other outcomes. However, the evidence base was poor.
Cost-effectiveness analyses indicated that multiple daily insulin injections along with SMBG is the option
most likely to be cost-effective, whereas integrated pump+CGM systems and the Veo system are
more expensive and less clinically effective than the use of pumps along with separate CGM. No
cost-effectiveness modelling was possible for children or pregnant women because of a lack of data.
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Scientific summary
Background
Diabetes affects an estimated 3.75 million people in the UK. Approximately 250,000 of these 3.75 million
people have type 1 diabetes mellitus (T1DM).
This assessment will focus on the use of integrated sensor-augmented pump therapy systems for people
with T1DM.
The characteristic feature of diabetes is high blood glucose (BG) levels, also known as hyperglycaemia.
T1DM is caused by the destruction of the pancreatic beta cells that produce insulin, and the mainstay
of treatment is injection of insulin, which is necessary to sustain life. Intensive insulin treatment, aimed
at tightly controlling BG levels, reduces the risk of the long-term complications of diabetes, such as
retinopathy and renal disease. Intensive insulin treatment is a package of care consisting of either multiple
daily insulin injections (MDIs) or continuous subcutaneous insulin infusion (CSII) with an insulin pump,
frequent testing of BG, self-adjustment of insulin dosages in response to BG levels and lifestyle
interventions, such as a restricted diet and undertaking required levels of physical activity.
In recent years, meters for the continuous monitoring of interstitial fluid glucose have been introduced to help
people with T1DM to achieve better control of their disease. Increasingly sophisticated integrated methods of
glucose monitoring and insulin delivery are designed to provide a closer approximation to the body’s natural
system and achieve acceptable glycaemic control while minimising the risk of hypoglycaemic episodes.
Current continuous glucose monitoring (CGM) systems rely on the user taking action, and this may not occur,
particularly at night. Hypoglycaemia that occurs at night is known as nocturnal hypoglycaemia. Alarms may
wake people up, but those with nocturnal hypoglycaemic events often sleep through them and recurrent
hypoglycaemic events can lead to hypoglycaemia unawareness.
A recent development in CGM/pump technology, available in the UK since 2009, is the MiniMed®
Paradigm™ Veo system (Medtronic Inc., Northridge, CA, USA), wherein the CGM device can stop (suspend)
the insulin infusion from the pump for up to 2 hours. After that, insulin infusion is restored at a basal rate.
The population considered for the current assessment comprised adults and children with T1DM.
The interventions assessed (integrated CGM and insulin pump systems with or without a suspend function)
aim to provide better monitoring and dose adjustment and hence achieve acceptable glycaemic control
while minimising hypoglycaemic episodes.
Objective
The overall objective of this project was to summarise the evidence on the clinical effectiveness and
cost-effectiveness of the MiniMed Paradigm Veo system and the Vibe™ (Animas® Corporation,
West Chester, PA, USA) and G4® PLATINUM CGM system (Dexcom Inc., San Diego, CA, USA) for the
management of T1DM in adults and children.
To address this objective, we assessed the clinical effectiveness and cost-effectiveness of integrated insulin
pump systems compared with:
l CSII with self-monitoring of blood glucose (SMBG) by capillary blood testing (CSII+ SMBG)
l MDIs with SMBG by capillary blood testing (MDI+ SMBG)
l non-integrated, stand-alone CSII and CGM (CSII+CGM)
l MDIs with CGM (MDI+CGM).
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Methods
Assessment of clinical effectiveness
The study populations eligible for inclusion were adults, including pregnant women, and children with
T1DM, and the relevant setting was self-use supervised by primary or secondary care. The interventions are
described above (see Background) and the main outcomes were glycated haemoglobin (HbA1c) levels,
the frequency of hyperglycaemic events and the frequency of hypoglycaemic events.
We searched 14 databases, three trial registries and two conference proceedings from inception up to
September 2014. Data relating to study details, participants, intervention and comparator tests, and
outcome measures were extracted, using a piloted, standard data extraction form. The assessment of the
methodological quality of each included study was based on the Cochrane Collaboration quality
assessment checklist.
In the absence of randomised controlled trials directly comparing the MiniMed Paradigm Veo System or an
integrated CSII+CGM system, such as the Vibe and G4 PLATINUM CGM system, with comparator
interventions, indirect treatment comparisons were performed, if possible. Where meta-analysis was
considered unsuitable for some or all of the data identified, we employed a narrative synthesis.
Assessment of cost-effectiveness
The IMS Centre for Outcomes Research and Effectiveness diabetes model (IMS CDM) version 8.5
(IMS Health, Danbury, CT, USA) was used for this assessment. This is an internet-based, interactive
simulation model that predicts the long-term health outcomes and costs associated with the management
of T1DM and type 2 diabetes mellitus. The model consists of 15 submodels designed to simulate
diabetes-related complications, non-specific mortality and costs over time. As the model simulates
individual patients over time, it updates risk factors and complications to account for disease progression.
Given the degree of validation of the model, and in order to be in line with the updated T1DM National
Institute for Health and Care Excellence (NICE) guideline NG17 [National Institute for Health and Care
Excellence. Type 1 Diabetes in Adults: Diagnosis and Management. NICE Guideline (NG17). London: NICE;
2015. URL: www.nice.org.uk/guidance/indevelopment/gid-cgwaver122/documents (accessed 15 January
2015)] it was considered important not to use an alternative model or develop a de novo cost-effectiveness
model for this evaluation. When possible, we estimated input parameters based on the studies identified in
the systematic review. This was done to properly reflect our base-case population (i.e. those with T1DM
eligible for an insulin pump). We used the results of indirect comparisons of change in HbA1c levels and the
rate ratios of severe hypoglycaemic events to model the treatment effects.
As the IMS CDM is not suitable for modelling long-term outcomes for children and pregnant women
(because the background risk adjustment/risk factor progression equations are all based on adults), we had
to limit the population for assessment to adults only.
The impact of the uncertainty about a number of input parameters and model assumptions on the model
outcomes was explored through probabilistic sensitivity analyses and scenario analyses.
Results
Fifty-four publications resulting from 19 studies were included in the review. Two studies compared the
MiniMed Paradigm Veo system with an integrated CSII+CGM system or with CSII+ SMBG, respectively.
Seven other studies compared an integrated CSII+CGM system with CSII+ SMBG (three studies) or with
MDI+ SMBG (four studies). The remaining studies compared CSII+ SMBG with MDI+ SMBG (10 studies).
None of the studies included a treatment arm with CSII+CGM or MDI+CGM as comparators. Although
several studies included the integrated CSII+CGM system as a treatment arm, it is important to note that
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none of these studies looked at the Vibe and G4 PLATINUM CGM system; in the included studies, the
integrated CSII+CGM system was always a MiniMed Paradigm pump with an integrated CGM system.
Twelve studies reported data for adults, five studies reported data for children and five studies reported
data for mixed populations (adults and children). Two of these studies reported data for all three groups.
One study included pregnant women.
Most studies (11 out of 19) were rated as having a high risk of bias, four studies were rated with an
unclear risk of bias and another four studies were rated as having a low risk of bias.
Twelve studies were included in the analyses for adults. The main conclusion from these trials is that the
MiniMed Paradigm Veo system reduces hypoglycaemic events in adults more than the integrated
CSII+CGM system does, without any differences in other outcomes, including changes in HbA1c levels.
Nocturnal hypoglycaemic events occurred 31.8% less frequently in the MiniMed Veo group than in the
integrated CSII+CGM group {1.5 events per patient per week [standard deviation (SD) 1.0 event per
patient per week] vs. 2.2 events per patient per week (SD 1.3 events per patient per week); p< 0.001}.
Similarly, the MiniMed Veo group had significantly lower rates of combined daytime and night-time events
than the integrated CSII+CGM group [3.3 events per patient per week (SD 2.0 events per patient per
week) vs. 4.7 events per patient per week (SD 2.7 events per patient per week); p< 0.001]. Indirect
evidence suggests that that there are no significant differences between the MiniMed Paradigm Veo
system, CSII+ SMBG and MDI+ SMBG with regard to change in HbA1c levels at 3-month follow-up.
However, if all studies are combined (i.e. combining different follow-up times and including mixed
populations), the MiniMed Paradigm Veo system is significantly better than MDI+ SMBG, with regard to
HbA1c levels [weighted mean difference (WMD) –0.66%; 95% confidence interval (CI) –1.05% to –0.27%].
For the integrated CSII+CGM system versus other treatments, head-to-head results showed significant
effects, with regard to HbA1c levels, in favour of the integrated CSII+CGM system compared with
MDI+ SMBG (WMD –1.1%; 95% CI –1.46% to –0.74%), but not if compared with CSII+ SMBG
(WMD –0.05%; 95% CI –0.31% to 0.21%); and significant results, with regard to quality of life, in favour
of the integrated CSII+CGM system compared with MDI+ SMBG (WMD 8.60; 95% CI 6.28 to 10.92) or
with CSII+ SMBG (WMD 5.90; 95% CI 2.22 to 9.58) were also found.
When comparing CSII versus MDI, only one of six trials showed a significant difference between CSII+ SMBG
and MDI+ SMBG in terms of a change in HbA1c levels: after 16 weeks of the trial, mean HbA1c levels were
0.84% lower (mean= –0.84%, 95% CI –1.31% to –0.36%) lower in the CSII+ SMBG group than in the
MDI+ SMBG group. No differences in the number of severe hypoglycaemic events were found in any trial.
Six studies were included in the analyses for children. None of the studies directly compared the MiniMed
Paradigm Veo system with the integrated CSII+CGM system. An indirect comparison was possible using
data obtained from 6-month follow-up from two of these studies, but only for HbA1c levels, which showed
no significant difference between groups.
One study compared the MiniMed Paradigm Veo system with CSII+ SMBG. The only significant difference
between treatment groups was the rate of moderate and severe hypoglycaemic events, which favoured
the MiniMed Paradigm Veo system.
One study compared the integrated CSII+CGM system with CSII+ SMBG. This trial found no significant
difference in HbA1c levels between groups [mean difference (MD) after 6 months of 0.4894% (standard
error 0.2899%); p= 0.10]. One study compared the integrated CSII+CGM system with MDI+ SMBG.
This trial showed a significant difference in HbA1c levels in favour of the integrated CSII+CGM system
(MD after 12 months –0.5%; 95% CI –0.8% to –0.2%), but no significant difference in the number
of children achieving HbA1c levels of ≤ 7% (10 out of 78 vs. 4 out of 78; p= 0.15). Hyperglycaemia
(as determined by BG levels of > 250mg/dl) was significantly less common in the integrated CSII+CGM
DOI: 10.3310/hta20170 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 17
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Riemsma et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxix
group than in the MDI+ SMBG group [area under the curve (AUC) 9.2 (SD 8.08) vs. 17.64 (SD 14.62);
p< 0.001], but there was no significant difference in the occurrence of hypoglycaemia (as determined by
BG levels of < 70mg/dl) in these groups [AUC 0.23 (SD 0.41) vs. 0.25 (SD 0.41); p= 0.79]. There were no
significant differences between groups for other outcomes.
For pregnant women, we found only one trial comparing CSII+ SMBG with MDI+ SMBG, which is not
relevant to the decision problem.
The comparator MDI+CGM was not included in the cost-effectiveness analyses, since no evidence was
found. In the absence of data comparing the clinical effectiveness of integrated CSII+CGM systems with
stand-alone CSII+CGM systems, we assumed, in our cost-effectiveness analyses, that both technologies
would be equally effective. The immediate consequence of this assumption is that stand-alone CSII+CGM
systems always dominate the integrated CSII+CGM systems since stand-alone systems are cheaper,
according to our estimated cost, but equally effective.
Overall, the cost-effectiveness results suggest that technologies which use SMBG (either with CSII or MDIs)
are more likely to be cost-effective than the technologies which use CGM, since the higher quality of life
and/or life expectancy provided by the latter do not compensate for the difference in costs. The MiniMed
Paradigm Veo is extendedly dominated by stand-alone CSII+CGM. This means that CSII+CGM is more
effective than MiniMed Paradigm Veo, but also better value, that is that the increase in cost compared with
the next most effective choice, which is CSII+ SMBG, is less for CSII+CGM than for the MiniMed Paradigm
Veo system. We estimated that the incremental cost-effectiveness ratio (ICER) of stand-alone CSII+CGM
compared with the next most effective choice, CSII+ SMBG, is £660,376 and the ICER of CSII+ SMBG
compared with the least effective choice, MDI+ SMBG, is £52,381. Thus, assuming a common threshold of
£30,000 per quality-adjusted life-year (QALY) gained, MDI+ SMBG, while being the least clinically effective
option, would be considered the optimal choice; when uncertainty is taken into account, at that threshold,
MDI+ SMBG would have a 98% probability of being the optimal choice.
The finding that CSII+CGM is more effective than the MiniMed Paradigm Veo system might appear to
contradict the clinical effectiveness conclusions, but this is explained by the fact that effectiveness is
affected by both the difference in hypoglycaemic event rate and HbA1c levels. Although the evidence
shows that MiniMed Paradigm Veo is probably better in terms of reducing the hypoglycaemic event rate,
it does show a small, albeit not statistically significant, disadvantage in terms of HbA1c levels. Even this
small difference seems to be sufficient, as a result of the consequences of hyperglycaemia, to outweigh
the difference in hypoglycaemia, which is relatively rare and generally has less severe consequences.
However, all of these results should be interpreted with caution as some studies on which effect estimates
were based included all T1DM patients, whereas others included patients who had been on a pump for at
least 6 months already and others included patients without experience of using a pump but with poor
glycaemic control at baseline.
These results remained largely unchanged in scenario analyses, used to assess the potential impact of
various input parameters on the model outcomes. Even when a large array of scenarios is considered,
MDI+ SMBG would be considered the optimal choice in all instances, assuming a threshold of £30,000
per QALY gained.
Conclusions
Overall, the evidence seems to suggest that the MiniMed Paradigm Veo system reduces hypoglycaemic
events more than other treatments, without any differences in other outcomes, including changes in
HbA1c levels. In addition, we found significant results in favour of the integrated CSII+CGM system over
MDI+ SMBG with regard to HbA1c levels and quality of life. However, the evidence base was poor.
The quality of the included studies was generally low, often with only one study comparing treatments in a
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxx
specific population at a specific follow-up time. In particular, the evidence for the two interventions of
interest was limited, with only one study comparing the MiniMed Paradigm Veo system with an integrated
CSII+CGM system and only one study comparing the MiniMed Paradigm Veo system with CSII+ SMBG in
a mixed population.
Cost-effectiveness analyses indicated that MDI+ SMBG is the option most likely to be cost-effective, given
the current threshold of £30,000 per QALY gained, whereas integrated CSII+CGM systems and MiniMed
Paradigm Veo are dominated and extendedly dominated, respectively, by stand-alone CSII+CGM.
Scenario analyses, used to assess the potential impact of changing various input parameters, did not alter
these conclusions. No cost-effectiveness modelling was conducted for children or pregnant women.
Suggested research priorities
In adults, a trial comparing the MiniMed Paradigm Veo system with CSII+ SMBG is warranted. Similarly,
a trial comparing the Vibe and G4 PLATINUM CGM system, or any integrated CSII+CGM system,
with CSII+ SMBG is warranted. In children, a trial comparing the MiniMed Paradigm Veo system with
the Vibe and G4 PLATINUM CGM system, or any integrated CSII+CGM system, is warranted, as is a trial
comparing an integrated CSII+CGM system with CSII+ SMBG. For pregnant women, trials comparing
the MiniMed Paradigm Veo system and the Vibe and G4 PLATINUM CGM system, or any integrated
CSII+CGM system, with other interventions are warranted.
Future trials should include longer-term follow-ups and ratings on the European Quality of Life-5
Dimensions scale at various time points with a view to informing improved cost-effectiveness modelling.
Study registration
This study is registered as PROSPERO CRD42014013764.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background and definition of the
decision problem(s)
Population
Diabetes affects an estimated 3.75 million people in the UK;1,2 approximately 250,000 of these affected
people have type 1 diabetes mellitus (T1DM).3
Type 1 diabetes arises when the body does not produce insulin and is most commonly first diagnosed in the
teenage years. T1DM accounts for around 5–15% of all diabetes cases. Type 2 diabetes mellitus (T2DM),
which arises when the body develops a resistance to insulin, usually affects people over the age of 40 years.
However, T2DM is becoming increasingly more prevalent in younger people, and may be more common in
people of South Asian, African Caribbean or Middle Eastern descent. People who are overweight, have
inactive lifestyles or a family history of diabetes are at greater risk of developing diabetes.2,4,5
The characteristic feature of diabetes is high blood glucose (BG) levels, also known as hyperglycaemia;
low BG levels is called hypoglycaemia. Optimal BG levels for most people are 4–7mmol/l before meals,
6–10mmol/l at bedtime and 5–15mmol/l before exercise.6
Type 1 diabetes is caused by the destruction of the pancreatic beta cells which produce insulin, and the
mainstay of treatment are insulin injections, which are necessary to sustain life. The Diabetes Control and
Complications Trial (DCCT)7 and other studies8 have shown that intensive insulin treatment, aimed at
tightly controlling BG, reduces the risk of the long-term complications of diabetes, such as retinopathy and
renal disease. Diabetes is one of the most common causes of blindness and end-stage renal failure.9–11
Intensive insulin treatment is a package of care consisting of either multiple daily insulin injections
(MDIs) or continuous subcutaneous insulin infusion (CSII) with an insulin pump, frequent testing of BG,
self-adjustment of insulin dosages in response to BG levels, as well as lifestyle interventions such as a
restricted diet and undertaking required levels of physical activity.
However, insulin injections cannot provide the sort of fine tuning that can be achieved by a healthy
pancreas controlled by the body’s normal feedback mechanisms, and many people with T1DM do not
succeed in achieving good control of their diabetes. This is particularly true in children. The best measure
of BG control is glycated haemoglobin (HbA1c). An audit of diabetic control in Scottish children showed
that only about 10% achieved the National Institute for Health and Care Excellence (NICE) target of a
HbA1c level of ≤ 7.5%.12 In England and Wales, approximately 17% of children and young people with
diabetes achieved this NICE target.13 In 2008, NICE recommended CSII (‘insulin pump’) therapy as a
treatment option for adults and children, aged ≥ 12 years, with T1DM.14 NICE concluded that CSII therapy
had a valuable effect on BG control by reducing HbA1c levels and also reducing associated complications.
The provision of an insulin pump alone is not enough; for a pump to be used effectively, it should be
accompanied by intensive management. Hyperglycaemia can be controlled by increasing the amount of
insulin injected. However, this can lower BG too far. Low BG is called hypoglycaemia, and this is often the
limiting factor in attempts to control hyperglycaemia. NICE was also persuaded that CSII therapy could
reduce the rate of hypoglycaemic episodes, and it heard from patient experts that when hypoglycaemia
occurs in people using CSII therapy, it does so gradually and there is sufficient time for the pump user to
take remedial action.14
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The symptoms of hypoglycaemia range from feelings of hunger, faintness, sweating, anxiety and
sleepiness at the mild end of the spectrum, to confusion, difficulty in speaking and disturbances of
behaviour; and at the severe end of the spectrum, loss of consciousness, convulsions and, rarely, death can
occur. Hypoglycaemia is assumed to be the main cause of the ‘found dead in bed’ cases,15 which,
fortunately, are rare.
Hypoglycaemic events can be very frightening, especially in children and for their parents, and fear of
hypoglycaemia is very common, not just among those with diabetes but also among relatives and friends.
There is particular anxiety among parents of young children, some of whom may allow BG levels to run
high in order to avoid hypoglycaemia (‘hypo avoidance behaviour’).16
Parents of young children express considerable anxiety, and may feel a need to get up during the night to
check BG levels in their children. BG control may be easier if children are on an insulin pump, but even
then parents are likely to set alarms to get up during the night to check that their child is not experiencing
hypoglycaemia. Many severe hypoglycaemic events in children occur at night.
As soon as people with diabetes recognise the symptoms, they can consume fast-acting carbohydrates in
the form of a sugar-containing food, or just sugar itself, and thereby raise BG levels again. However, there
is a particular problem, known as hypoglycaemia unawareness, whereby some people do not develop
any warning symptoms. Being unaware of impending hypoglycaemia, such people may not consume
sugar-rich foods or sugar in time to prevent a serious hypoglycaemic event. Hypoglycaemia unawareness
usually occurs after frequent hypoglycaemic events, and a vicious circle can develop where frequent
hypoglycaemic events cause hypoglycaemia unawareness, which leads to more, and more severe,
hypoglycaemia, associated with the failure of the body to release the counter-regulatory hormones, such
as adrenaline, that cause warning symptoms.
Until recently, self-monitoring of blood glucose (SMBG) meant pricking a part of the body, such as the
fingertip, with a needle to make it bleed (sometimes up to 15 times a day), putting a drop of blood on a
test strip and measuring BG levels with the aid of a meter. Depending on the result, the patient could then
adjust their insulin dose or diet in order to try and keep BG levels within the optimum range.
In recent years, meters for continuous monitoring of interstitial fluid glucose have been introduced to help
people with T1DM to achieve better control of their disease. Increasingly sophisticated integrated methods of
glucose monitoring and insulin delivery are designed to provide a closer approximation to the body’s natural
system and achieve acceptable glycaemic control, while minimising the risk of hypoglycaemic episodes.
Interventions designed to help people with T1DM to achieve better control include structured education
(the dose adjustment for normal eating course17 or similar courses) and CSII with an insulin pump.
The aim of CSII is to provide a flexible method for administering insulin, which tries to mimic the body’s
natural pattern of a small amount of insulin being present all the time (basal infusion) and peaks of insulin
release after meals (boluses), aided by SMBG by capillary blood testing.
However, there are limits to what can be done with capillary blood testing (and it is painful – even more so
than insulin injections). In recent years, devices which continually measure BG (strictly speaking, they actually
measure the level of glucose in the subcutaneous tissue) have been introduced. These use a cannula inserted
under the skin, which is connected to a glucose meter. The first of these continuous glucose monitoring
(CGM) systems merely recorded BG levels for later downloading. However, there are now CGM devices that
display interstitial glucose levels – so-called ‘real-time CGM’ – so that users can see their most recent glucose
level (CGM is not actually continuous, as the name suggests, but measures glucose levels every 5–10minutes).
The psychosocial impact of CGM is mixed however, with both positive results with regard to the greater
control over diabetes, but also negative impacts resulting from intrusive false alarms and the additional burden
and visibility of the disease.18,19 In addition, CGM does not make capillary blood testing redundant; a
minimum of two tests per day is still required to calibrate CGM devices.
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The next step in the development of CGM systems was to have integrated alarm facilities, whereby the
CGM meter could alert the user to BG levels that are too high or too low. In theory, the user can then
adjust insulin dosage, by, for example, reducing the insulin infusion rate if BG levels are too low or
showing a decreasing trend. These integrated systems are called ‘sensor-augmented pump therapy’ (SAPT).
Current CGM systems rely on the user taking action, and this may not occur, particularly at night.
Hypoglycaemic events at night are known as nocturnal hypoglycaemia. Alarms may wake people up,
but those having nocturnal hypoglycaemic events often sleep through these alarms and recurrent
hypoglycaemic events can lead to hypoglycaemia unawareness.
CGM may initially raise anxiety, because it provides much more data on BG levels, and this can lead to
more anxiety among patients and parents. False alarms are a particular problem, leading to distrust of the
device and a lack of willingness to take appropriate action.
A recent development in CGM/pump technology, which has been available in the UK since 2009, is the
Medtronic Veo suspend combination (Medtronic Inc., Northridge, CA, USA); this CGM device can stop
(suspend) the insulin infusion from the pump for up to 2 hours. After that, insulin infusion is restored at a
basal rate. In practice, few suspensions are for as long as 2 hours because, in most cases, the pump user
takes corrective action.20 A small study (31 patients used this device for 3 weeks), performed in UK centres,
reported that 66% of suspend durations were for ≤ 10minutes, that most long episodes of suspension
occurred at night and that there was a reduction in nocturnal hypoglycaemia.
After insulin infusion stops, it takes 30 minutes for BG levels to increase,21 so hypoglycaemic events may be
shortened or made less severe, rather than always avoided.
Suspension can be controlled manually by the user, in response to an alarm or after checking real-time
results, or automatically by the device. Patients can over-ride the pump and cancel suspension, using food
to increase BG levels instead. One problem reported is that sleeping position may cause inaccurately low
readings because of tissue compression.22
This assessment will focus on the use of integrated SAPT systems in T1DM.14
The populations for the current assessment were adults and children with T1DM. The interventions
assessed (integrated CGM and insulin pump systems with or without a suspend function) aim to provide
better monitoring and dose adjustment and hence achieve acceptable glycaemic control while minimising
hypoglycaemic episodes.
Description of the technologies under assessment
The MiniMed® Paradigm™ Veo system (Medtronic Inc., Northridge, CA, USA) and the Vibe™ (Animas®
Corporation, West Chester, PA, USA) and G4® PLATINUM CGM system (Dexcom Inc., San Diego, CA, USA)
are integrated CGM and insulin pump systems intended to aid the effective management of diabetes. The
MiniMed Paradigm Veo System has an added insulin suspend function intended to prevent hypoglycaemia,
including nocturnal hypoglycaemia.
The MiniMed Paradigm Veo system
The MiniMed Paradigm Veo system has three components:
1. a small glucose sensor, placed under the skin, which measures glucose levels every 5 minutes, 24 hours
per day (this sensor must be replaced every 6 days)
2. the MiniLink™ transmitter (Medtronic Inc., Northridge, CA, USA), which sends the information to the
Paradigm Veo insulin pump
3. the Paradigm Veo insulin pump.
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The system is complete and stand alone and not directly interchangeable with other manufacturers’ pumps
or sensors. Many insulin formulations can be used in the insulin pump. In this report, we will focus on only
fast-acting insulin formulations, because this type of formulation in the preferred clinical option for use
with insulin pumps in the UK.23
Continuous glucose monitors measure the level of tissue glucose electronically on a continuous basis (every
few minutes). They use a subcutaneous, disposable glucose sensor placed just under the skin to measure
interstitial glucose levels. The glucose sensor of the Veo system is replaced every 6 days. The sensor is
connected to a non-implanted transmitter (MiniLink) which communicates glucose levels wirelessly to the
Paradigm Veo pump. The pump displays BG levels with nearly continuous updates, as well as monitoring
rising and falling trends. The pump can prompt a person with diabetes, or a carer, to take action to
maintain glucose levels. The insulin pump delivers continuous subcutaneous insulin according to a
pre-programmed pattern, which can be adapted by the user or a carer in response to real-time glucose trends.
The MiniMed Paradigm Veo system appears to be unique in that it will actively suspend insulin delivery if it
predicts a hypoglycaemic episode. This ‘low glucose suspend’ (LGS) function stops insulin delivery for
2 hours if there is no response to a low glucose warning.
Users of this system must perform regular (a minimum of two per day) capillary BG tests (such as a finger
prick tests), as CGM measures interstitial fluid glucose levels, not capillary BG levels. Further finger prick
tests are required to confirm a CGM value before making any adjustments to diabetes therapy.
The pump can be worn on a belt or in a pouch underneath clothes. Insulin is delivered through a small
tube (or ‘infusion set’) placed under the skin. The transmitter is directly connected to the glucose sensor,
which is inserted through the skin, usually in the stomach area. The manufacturer’s information for use
document states that the infusion set should be replaced every 3 days.
The Vibe and G4 PLATINUM CGM system
The Vibe and G4 PLATINUM CGM system is a CGM-enabled insulin pump, integrated with the G4
PLATINUM sensor. It is similar to the MiniMed Paradigm Veo system in that the glucose sensor is placed
under the skin and measures interstitial glucose levels rather than capillary BG levels. Confirmatory capillary
BG tests are also required to confirm the value displayed by the continuous glucose monitor before
making any adjustments to diabetes therapy. The sensor is approved for up to 7 days of wear.
The insulin pump in the Vibe and G4 PLATINUM CGM system also delivers insulin continuously from a
refillable storage reservoir by means of a subcutaneously placed cannula and the pump can be
programmed to deliver insulin at a basal rate throughout the day, with the option of triggering higher
infusion rates at mealtimes, either as a bolus dose or over time. The pump can be programmed to deliver
insulin at different basal rates at different times of the day and night.
The system produces glucose level readings in real time, alerts users of high or low readings, and glucose
trend information. It does not have an automated LGS function.
Comparators
The scope, as defined by NICE, specifies the following comparator technologies:
l CSII with SMBG by capillary blood testing (CSII+ SMBG)
l MDIs with SMBG by capillary blood testing (MDI+ SMBG)
l non-integrated, stand-alone CSII and CGM (CSII+CGM)
l MDIs with CGM (MDI+CGM).
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Non-integrated, stand-alone CSII and CGM require the simultaneous use, by patients, of both a
continuous glucose monitor and a pump to deliver the insulin. The two interventions (Veo and Vibe) also
both use a continuous glucose monitor and an insulin pump. However, for the non-integrated, stand-alone
CSII and CGM, the two devices are supplied separately and for the Veo and Vibe interventions, these
devices are supplied as a ‘system’, hence the term ‘integrated’. Although they may or may not differ in
terms of monitoring and insulin delivery, this review will seek to find any differences with regard to their
effectiveness and cost-effectiveness (see Chapter 2).
Within groups of comparator studies, there may be differences between studies (e.g. populations,
interventions and outcomes). The possibility of pooling results from different trials will depend on the
extent of these differences. In addition, the comparability of populations in studies evaluating insulin
pumps and MDIs is a potential problem. Based on 2008 guidance,14 NICE recommends CSII as a potential
treatment for children ≥ 12 years and adults, who have disabling hypoglycaemia (including anxiety about
hypoglycaemia) when trying to attain HbA1c < 7.5%, or HbA1c is constantly > 8.5%, while undergoing
multiple daily injection therapy (MDIT). Furthermore, CSII is recommended for children < 12 years when
MDIT would not be practical.14
In other words, insulin pumps are recommended for people with T1DM for whom MDIs are not suitable.
Therefore, it might be problematic to find studies comparing insulin pumps (especially modern pumps such
as the integrated systems) with MDIs in comparable populations.
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Chapter 2 Objective
The overall objective of this project was to summarise the evidence on the clinical effectiveness andcost-effectiveness of the MiniMed Paradigm Veo system and the Vibe and G4 PLATINUM CGM system
for the management of T1DM in adults and children.
The following research questions have been defined to address the review objective:
l What is the clinical effectiveness of integrated insulin pump systems compared with:
¢ CSII+ SMBG
¢ MDI+ SMBG
¢ CSII+CGM
¢ MDI+CGM.
l What is the cost-effectiveness of integrated insulin pump systems compared with:
¢ CSII+ SMBG
¢ MDI+ SMBG
¢ CSII+CGM
¢ MDI+CGM.
There are two interventions and four comparators. In this report, we will use the following descriptors for
these interventions and comparators:
l MiniMed Veo system An integrated CGM and insulin pump system with LGS function.
l Integrated CSII+ CGM Integrated CGM and insulin pump systems without LGS function (such as the
Vibe and G4 PLATINUM CGM system). Although the only integrated system available in the UK is
the Vibe and G4 PLATINUM CGM system, all integrated systems without a LGS function will be
included in this category. This also includes integrated Medtronic systems (such as the Paradigm
Revel™ and Paradigm REAL-Time systems).
l CSII+ CGM An insulin pump with stand-alone continuous glucose monitor.
l CSII+ SMBG An insulin pump with SMBG.
l MDI+ CGM MDIs with a continuous glucose monitor.
l MDI+ SMBG MDIs with SMBG.
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Chapter 3 Assessment of clinical effectiveness
Systematic review methods for the assessment of
clinical effectiveness
A systematic review was conducted to summarise the evidence on the clinical effectiveness of the MiniMed
Paradigm Veo system and the Vibe and G4 PLATINUM CGM system for the management of T1DM in
adults and children. Systematic review methods followed the principles outlined in the Centre for Reviews
and Dissemination guidance for undertaking reviews in health care,24 and the NICE Diagnostic Assessment
Programme manual.25
Inclusion and exclusion criteria
Participants
The study populations eligible for inclusion were adults, including pregnant women, and children
with T1DM.
Setting
The relevant setting was self-use supervised by primary or secondary care.
Interventions
The main intervention technology for this appraisal was the MiniMed Paradigm Veo with CGM system
and suspend function. In addition, we included fully integrated insulin pump systems as an alternative
technology, including the only existing fully integrated system currently available in the UK: the Vibe and
G4 PLATINUM CGM system.
Comparators
The scope, as defined by NICE, specified the following comparator technologies:
l capillary blood testing with CSII
l capillary blood testing with MDIs
l CGM with CSII (non-integrated)
l CGM with MDIs.
Studies comparing CSII with MDIs often use different types of monitoring (SMBG or CGM). Unless results
were reported separately for the different types of monitoring, such studies were excluded from our
review, because they do not allow a comparison of a relevant intervention with the comparators. The same
applies to studies comparing CGM with SMBG, without specifying the way in which insulin was delivered
(CSII or MDIs).
Outcomes
The main outcomes were:
l HbA1c levels (i.e. change from baseline and the number of participants achieving a specified level
of control)
l the frequency of hyperglycaemic events and the number of hyperglycaemic episodes, stratified by
severity into ‘mild’ or ‘severe’ if data were available.
l the frequency of (nocturnal) hypoglycaemic events and the number of hypoglycaemic episodes,
stratified by severity into ‘mild’ or ‘severe’ if data were available.
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Possible secondary outcomes were:
l mean BG levels, including fasting glucose levels
l postprandial glucose levels
l the amount of insulin being administered
l episodes of diabetic ketoacidosis and the number of ketone tests
l health-related quality of life (HRQoL)
l long-term complications of diabetes and treatment, including retinopathy, neuropathy, cognitive
impairment and end-stage renal disease
l morbidity and mortality
l adverse events from testing, false results, treatment and sequelae
l the acceptability of the testing method and the method of insulin administration
l anxiety about experiencing hypoglycaemia
l costs, including the costs related to the support received from health professionals.
In pregnant women, additional T1DM-related clinical outcomes included:
l premature birth
l macrosomia (excessive birth weight)
l respiratory distress syndrome in newborns.
Study design
Studies with the following types of study design were eligible for inclusion:
l randomised controlled trials (RCTs) or, if no RCTs were available for comparisons of interventions and
comparators, controlled clinical trials
l observational studies for additional information with regard to interventions, if no RCTs were found.
Studies of < 6 weeks’ duration and cross-over studies were excluded.
Subgroup analyses
If the evidence and the structure of the cost-effectiveness model were to permit, the following subgroups
would be explored:
l pregnant women, and women planning pregnancy (but not including those with gestational diabetes)
l people who need to self monitor their BG level > 10 times a day
l people with T1DM who are having difficulty managing their condition; such difficulties include:
¢ not being able to maintain the recommended HbA1c level of 8.5% (69.4mmol/mol) or less
¢ experiencing nocturnal hypoglycaemia
¢ an impaired awareness of hypoglycaemia
¢ experiencing severe hypoglycaemia, defined as having low BG levels that require assistance from
another person to treat.
Search strategy
Systematic literature searches were conducted to identify studies of SAPT for T1DM (specifically the
MiniMed Paradigm Veo system and the Vibe and G4 Platinum system), as well as RCTs and economic
evaluations of insulin pump/infusion therapy and MDIs for T1DM. Search strategies were developed using
the recommendations of the Centre for Reviews and Dissemination guidance for undertaking reviews in
health care,24 and the Cochrane Handbook.26 The search strategies used relevant search terms, comprising a
combination of indexed keywords (e.g. from medical subject headings and the EMBASE thesaurus EMTREE)
and free-text terms appearing in the titles and/or abstracts of database records. Search terms were identified
through discussion among the review team, by scanning background literature and ‘key articles’ already
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known to the review team, and by browsing database thesauri. The search strategies were structured using
search terms for ‘type 1 diabetes’ in combination with search terms for ‘sensor-augmented pump therapy’.
Two further search term facets were included to capture ‘insulin infusion’ and ‘multiple daily injections’.
In addition, the search strategy for clinical effectiveness studies included a sensitive methodological search
filter designed to identify RCTs. The EMBASE search strategy was translated so that it could be run
effectively in each of the databases searched. No date or language limits were applied. The main EMBASE
search strategies were independently peer reviewed by a second information specialist using the Canadian
Agency for Drugs and Technologies in Health peer review checklist.27
Details of the full search strategies are presented in Appendix 1.
The following databases and resources were searched for relevant RCTs, systematic reviews and health
technology assessments:
l MEDLINE (via OvidSP): 1946–2014/Aug week 4
l MEDLINE In-Process Citations and Daily Update (via OvidSP): up to 4 September 2014
l PubMed (National Library of Medicine): up to 5 September 2014
l EMBASE (via OvidSP): 1974–2014/week 34
l Cochrane Database of Systematic Reviews (Wiley Online Library): issue 9/September 2014
l Cochrane Central Register of Controlled Trials (Wiley Online Library): issue 8/August 2014
l Database of Abstracts of Reviews of Effects (Wiley Online Library): issue 3/July 2014
l Health Technology Assessment (HTA) Database (Wiley Online Library): issue 3/July 2014
l Science Citation Index (Web of Science): 1988–29 August 2014
l Latin American and Caribbean Health Sciences Literature (http://lilacs.bvsalud.org/en/):
1982–5 September 2014
l National Institute for Health Research HTA Programme (www.hta.ac.uk/): up to 5 September 2014
l PROSPERO (www.crd.york.ac.uk/prospero/): up to 5 September 2014
l US Food and Drug Administration (www.fda.gov): up to 5 September 2014
l Medicines and Healthcare products Regulatory Agency (www.mhra.gov.uk/): up to 5 September 2014
Completed and ongoing trials were identified by searches of the following trials registries:
l US National Institutes of Health ClinicalTrials.gov (www.clinicaltrials.gov/): up to 2 September 2014
l Current Controlled Trials (www.controlled-trials.com/): up to 5 September 2014
l World Health Organization International Clinical Trials Registry Platform (www.who.int/ictrp/en/):
up to 5 September 2014
Conference proceedings were also searched from the organisations: Diabetes UK, the European
Association for the Study of Diabetes and the American Diabetes Association (see Appendix 1).
The bibliographies of identified research and review articles were checked for relevant studies. As a
number of databases were searched, there was some degree of duplication. In order to manage this issue,
the titles and abstracts of bibliographic records were downloaded and imported into EndNote X7
(Thomson Reuters, CA, USA) reference management software and duplicate records removed. Rigorous
records were maintained as part of the searching process. Individual records within the Endnote reference
libraries were tagged with searching information, such as searcher, date searched, database host, database
searched, search strategy name and iteration, theme and search question. This enabled the information
specialist to track the origin of each individual database record and its progress through the screening and
review process.
DOI: 10.3310/hta20170 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 17
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Riemsma et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
11
Inclusion screening and data extraction
Two reviewers independently screened the titles and abstracts of all reports identified by searches and any
discrepancies were discussed and resolved by consensus. Full-text copies of all studies deemed potentially
relevant, after discussion, were obtained and the same two reviewers independently assessed these for
inclusion; any disagreements were resolved by consensus. Details of the studies excluded at the full-paper
screening stage are presented in Appendix 2.
Data relating to study details, participants, intervention and comparator tests, and outcome measures were
extracted by one reviewer, using a piloted, standard data extraction form. A second reviewer checked
data extraction and any disagreements were resolved by consensus.
Quality assessment
The methodological quality of included studies was assessed using standard tools.24 The assessment of
the methodological quality of each included study was based on the Cochrane Collaboration quality
assessment checklist,26 as detailed in Table 1.
Each study was awarded a ‘yes’, ‘no’ or ‘unclear/unknown’ rating for each individual item in the checklist.
Any additional clarifications or comments were also recorded.
Quality assessment was carried out independently by two reviewers. Any disagreements were resolved by
consensus. The results of the quality assessment were used for descriptive purposes to provide an
evaluation of the overall quality of the included studies and to provide a transparent method of
recommendation for the design of any future studies. Based on the findings of the quality assessment,
recommendations were made for the conduct of future studies.
TABLE 1 The assessment of risk of bias in included RCTs
Domain Item Description
Sequence generation Was the allocation sequence
adequately generated?
The method used to generate the allocation
sequence should be described in sufficient
detail to allow an assessment of whether or
not it should produce comparable groups
Allocation concealment Was allocation adequately
concealed?
The method used to conceal the allocation
sequence should be described in sufficient
detail to determine whether or not
intervention allocations could have been
foreseen in advance of, or during, enrolment
Blinding of participants, personnel
and outcome assessors
Assessments will be made for each
main outcome (or class of outcomes)
Was knowledge of the allocated
intervention adequately prevented
during the study?
All measures used, if any, to blind study
participants and personnel from knowledge
of which intervention a participant received,
should be described. Any information
relating to whether or not the intended
blinding was effective should also be
reported
Incomplete outcome data
Assessments will be made for each
main outcome (or class of outcomes)
Were incomplete outcome data
adequately addressed?
The completeness of outcome data for each
main outcome should be described, including
attrition and exclusions from the analysis.
The authors should report any attrition and
exclusions, the numbers in each intervention
group (compared with total randomised
participants), reasons for attrition/exclusions
and any re-inclusions in analyses
Other sources of bias Was the study apparently free of
other problems that could put it
at a high risk of bias?
Overall, the study should be free from any
important concerns about bias (i.e. bias from
other sources not previously addressed by
the other items)
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Methods of analysis/synthesis
If meta-analysis was considered unsuitable for some or all of the data identified (e.g. because of the
heterogeneity and/or small numbers of studies), we employed a narrative synthesis. Typically, this involves
the use of text and tables to summarise data. These allow the reader to consider any outcomes in the light
of differences in study designs and potential sources of bias for each of the studies being reviewed. Studies
were organised according to which therapies were being compared.
The methods used to synthesise the data were dependent on the types of outcome data included, and the
clinical effectiveness and statistical similarity of the studies. Possible methods of data synthesis include the
types of analysis discussed in the following sections.
Dichotomous outcomes
Dichotomous data were analysed by calculating the relative risk (RR) for each trial using the fixed-effect method
or the DerSimonian and Laird28 random-effects method and the corresponding 95% confidence intervals (CIs).
Continuous outcomes
Continuous data were analysed by calculating the weighted mean difference (WMD) between groups and
the corresponding 95% CI. If the standard deviations (SDs) and means were not determinable, they were
estimated from the data provided or using a representative value from other studies.
Systematic differences between studies (heterogeneity) were likely; therefore, the random-effects model was
used for the calculation of RRs or WMDs if heterogeneity was moderate or high (I2> 50%). Heterogeneity was
initially assessed by measuring the degree of inconsistency in the studies’ results (I2). The I2 value describes the
percentage of total variation across studies that was due to heterogeneity rather than chance. The value of I2 can
lie between 0% and 100%. Low, moderate and high I2 values correspond to 25%, 50% and 75%, respectively.
If significant heterogeneity was identified, we planned to formally investigate this using metaregression.
In particular, a model was planned to explore the possible modifying effects of the following pre-specified
factors: methodological quality of the primary studies, underlying illness and different age groups. The
coefficient describing the predictive value of each factor and the overall effect on the main outcome would
be modelled, using a fixed-effects model. However, because of the limited number of studies for each
comparison, this was not possible.
A funnel plot (plot of the logarithm value of the RR for efficacy against the precision of the logarithm value
of the RR) would have been used to estimate potential asymmetry, and this would have been indicative of
small study effects. HbA1c levels were chosen as an outcome since these are likely to be reported by the
majority of included studies. In addition, the Egger regression asymmetry test29 would have been used
to facilitate the prediction of potential publication biases. This test detects funnel plot asymmetry by
determining whether or not the intercept deviates significantly from zero in a regression of the
standardised effect estimates against their precision. However, because of the limited number of studies
for each comparison, this was not possible.
Network meta-analysis methods
In the absence of RCTs directly comparing the MiniMed Veo system or an integrated CSII+CGM system
(such as the Animas Vibe pump with Dexcom’s G4 continuous glucose monitor) with the comparators
(i.e. CSII+CGM, CSII+ SMBG, MDI+CGM or MDI+ SMBG), indirect treatment comparisons were
performed, if possible. As only limited networks could be formed, a mixed-treatment comparison was
not possible. However, if possible, indirect comparisons were made. Although ‘head-to-head’ comparisons
are preferred to indirect methods in health technology assessments, indirect methods are generally
considered acceptable; for all methods, consideration of basic assumptions of homogeneity, similarity and
consistency, as reported by Song et al.,30 should be applied. For this assessment, where ‘head-to-head’
trials (i.e. ‘A’ vs. ‘B’) of the MiniMed Paradigm Veo with CGM System versus the comparators (CSII+CGM,
CSII+ SMBG, MDI+CGM or MDI+ SMBG) were missing, the effect sizes (RR or mean difference) for
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‘A’ versus ‘B’ were estimated using ‘indirect’ methods; for example, effect sizes for ‘A’ versus ‘B’ were
estimated from ‘A’ versus ‘C’ and ‘B’ versus ‘C’, where ‘C’ was a common control group [e.g. CSII+CGM
(i.e. CSII with a stand-alone CGM system)]. All indirect comparisons were consistent with International
Society for Pharmacoeconomics and Outcomes Research taskforce recommendations for the conduct of
direct and indirect meta-analysis and used the method described by Bucher et al.31 A practical issue for
indirect comparisons concerns the limitations in the availability of the same outcomes in the studies of
interventions that are candidates for an indirect comparison. Only studies that provide the same outcome
measures at the same follow-up time can be compared with each other, which may limit the availability of
suitable trial networks. Depending on the data available, separate network analyses were performed for
each of the subgroups specified in the protocol. Indirect meta-analyses were performed using Microsoft
Excel® 2007 (Microsoft Corporation, Redmond, WA, USA), according to the method developed by Bucher
et al.31 Effect sizes with 95% CIs were calculated using results from the direct head-to-head meta-analyses.
Direct head-to-head meta-analyses were performed using fixed-effect models in Stata™ for Windows,
version 13 (StataCorp LP, College Station, TX, USA), unless significant heterogeneity was present, in which
case we used random-effects models.
Results of the assessment of clinical effectiveness
Results of literature searches
The literature searches of bibliographic databases identified 9870 references. After initial screening of titles
and abstracts, 555 were considered potentially relevant and were ordered for full-paper screening. Of the
total of 555 publications considered potentially relevant, 29 could not be obtained within the time scale of
this assessment. Most of these 29 unobtainable studies were published before 2000 or were conference
abstracts; only four were possibly relevant trials published after 2000, but, based on their abstracts, it was
unclear whether or not they fulfilled the inclusion criteria. Figure 1 shows the flow of studies through the
Titles and abtracts 
identified from bibliographic 
databases and screened for 
potential relevance
(n = 9870)
Total potentially relevant
publications obtained
as full text
(n = 555)
Total number of studies
included in the review
(n = 54 publications)
(n = 19 trials)
Ongoing studies
(n = 19 publications)
(n = 18 trials)
Could not be obtained
(n = 29)
Excluded at full-paper
screening
(n = 453)
• Population, n = 8
• Intervention, n = 86
• Outcome, n = 109
• Study design, n = 206
• Systematic review, n = 36
• Background, n = 3
• Duplicate, n = 5
Excluded at title and 
abstract screening
(n = 9315)
FIGURE 1 Flow of studies through the review process.
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review process and Appendix 2 provides details, with reasons for exclusions, of all the publications
excluded at the full-paper screening stage.
Based on the searches and inclusion screening described above, 54 publications resulting from 19 studies
were included in the review. In addition, 19 publications of 18 ongoing studies were found (see
Ongoing studies).
One study32 compared the MiniMed Veo system (with suspend function) with an integrated CSII+CGM
system (MiniMed Veo with suspend function turned off) and another33 compared it with CSII+ SMBG.
Seven other studies compared an integrated CSII+CGM system with CSII+ SMBG (three studies)34–36
or with MDI+ SMBG (four studies).37–40 The remaining 10 studies41–50 compared CSII+ SMBG with
MDI+ SMBG. None of the studies included a treatment arm with CSII+CGM or MDI+CGM as a
comparator (Table 2). Although several studies included an integrated CSII+CGM system as a treatment
arm, it is important to note that none of these studies looked at the Vibe and G4 PLATINUM CGM system;
in the included studies, the integrated CSII+CGM system was always a MiniMed Paradigm pump with an
integrated CGM system.
Out of the 19 studies, eight were performed in North America32,34,38–40,46,48,49 and eight in Europe.36,37,41–45,50
The remaining three studies were performed in Australia (two studies33,35) and Israel (one study47). Three
out of the eight European studies included patients from the UK.37,41,45
TABLE 2 Included studies and comparisons
Study Veo
Integrated
CSII+CGM CSII+CGM CSII+ SMBG MDI+CGM MDI+ SMBG
Bergenstal et al., 2013
(ASPIRE in-home)32
✓ ✓
Ly et al., 201333 ✓ ✓
Hirsch et al., 200834 ✓ ✓
O’Connell et al., 200935 ✓ ✓
Raccah et al., 2009 (RealTrend)36 ✓ ✓
Hermanides et al., 2011
(Eurythmics)37
✓ ✓
Lee et al., 200738 ✓ ✓
Peyrot and Rubin, 200939 ✓ ✓
Bergenstal et al., 2010 (STAR-3)40 ✓ ✓
Bolli et al., 200941 ✓ ✓
DeVries et al., 200242 ✓ ✓
aNosadini et al., 198843 ✓ ✓
Brinchmann-Hansen et al., 1985
(OSLO)44
✓ ✓
Thomas et al., 200745 ✓ ✓
Tsui et al., 200146 ✓ ✓
Weintrob et al., 200347 ✓ ✓
Thrailkill et al., 201148 ✓ ✓
Doyle et al., 200449 ✓ ✓
Nosari et al., 199350 ✓ ✓
a The study by Nosadini et al. (1988)43 was a three-arm study that compared two different versions of CSII+ SMBG
with MDI+ SMBG.
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Twelve studies reported data for adults, five studies reported data for children and five studies reported
data for mixed populations (adults and children). Two of these studies reported data for all three groups.
One study included pregnant women (Table 3).
Table 4 shows the inclusion criteria, regarding the HbA1c levels and hypoglycaemic events, used in the
included studies. Further details of the characteristics of study participants and the interventions,
comparators and results are reported in the data extraction tables presented in Appendix 3. It is clear from
Table 3 that most studies included patients who had never used a pump before. However, both of the
studies looking at the MiniMed Veo system (ASPIRE in-home32 and Ly et al.33) included patients who had at
least 6 months’ experience of using an insulin pump. In addition, baseline HbA1c levels differ considerably
among studies. DeVries et al.42 included patients with poor control at baseline who were pump-naive.
TABLE 3 Characteristics of included studies
Study
Population
(age range,
years) n
Mean baseline
age, years (SD)
Mean baseline
HbA1c levels,
% (SD)
Previous
pump use,
months
Follow-up,
months
Bergenstal et al., 2013
(ASPIRE in-home)32
A (16–70) 247 43 (13) 7.2 (0.7) > 6 3
Ly et al., 201333 M (4–50) 95 19 (12) 7.5 (0.8) > 6 6
Hirsch et al., 200834 M (12–72) 146 33 (16) 8.4 (0.7) > 6 6
A (18–72) 8.3 (0.6) > 6 6
C (12–17) 8.7 (0.9) > 6 6
O’Connell et al., 200935 M (13–40) 62 23 (8.4) 7.4 (0.7) > 3 3
Raccah et al., 2009
(RealTrend)36
M (2–65) 132 28 (16) 9.2 (1) NR 6
Hermanides et al., 2011
(Eurythmics)37
A (18–65) 83 38 (11) 8.6 (0.9) Naive 6
Lee et al., 200738 A (NR) 16 NR 9 (0.9) Naive 3.5
Peyrot and Rubin,
200939
A (NR) 29 47 (13) 8.6 (1) NR 3.7
Bergenstal et al., 2010
(STAR-3)40
M (7–70) 495 32 (17) 8.3 (0.5) Naive 12
A (19–70) 41 (12) Naive 12
C (7–18) 12 (3) Naive 12
Bolli et al., 200941 A (18–70) 58 40 (11) 7.7 (0.7) Naive 6
DeVries et al., 200242 A (18–70) 79 37 (10) 9.4 (1.4) Naive 3.7
Nosadini et al., 198843 A (NR) 96 34 (6) NR NR 12
Brinchmann-Hansen
et al., 1985 (OSLO)44
A (18–45) 45 26 (21) 8.5 (NR) NR 3, 6, 12
and 24
Thomas et al., 200745 A (NR) 21 43 (10) 8.5 (1.5) NR 4 and 6
Tsui et al., 200146 A (18–60) 27 36 (11) 8 (0.6) Naive 9
Weintrob et al., 200347 C (8–14) 23 12 (1.5) 8 (1) NR 3.5
Thrailkill et al., 201148 C (8–18) 24 12 (3) 11.5 (2.4) Naive 6 and 12
Doyle et al., 200449 C (8–21) 32 13 (3) 8.1 (1.2) Naive 3.7
Nosari et al., 199350 P (NR) 32 26 (2.4) NR Naive 9
A, adults; C, children; M, mixed; NR, not reported; P, pregnant women.
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The two studies looking at the MiniMed Veo system included patients with relatively good glycaemic control
at baseline; however, that might have been because those patients had been using an insulin pump for at
least 6 months. Other studies, such as Bolli et al.,41 included patients with relatively good glycaemic control at
baseline without any previous pump experience. Therefore, there is considerable heterogeneity among the
study populations.
Most studies were rated as having a high risk of bias (11 out of 19), four studies were rated as having an
unclear risk of bias and another four studies were rated as having a low risk of bias (see Appendix 2). The
most problematic factor with regard to the risk-of-bias assessment was the lack of blinding (of participants,
physicians and outcome assessors) in the included studies. For participants and physicians, it is almost
TABLE 4 Inclusion and exclusion criteria used in included studies for HbA1c levels and hypoglycaemic events
Study
Inclusion criteria
for HbA1c levels (%) Inclusion/exclusion criteria with regard to hypoglycaemia
Bergenstal et al., 2013
(ASPIRE in-home)32
5.8–10 Included if experienced two or more nocturnal hypoglycaemic events
during the run in phase. Excluded if experienced more than one
episode of severe hypoglycaemia in the previous 6 months
Ly et al., 201333 ≤ 8.5 Included those with an impaired awareness of hypoglycaemia
(HUS≥ 4). Mean HUS 6.2 (SD 1.5)
Hirsch et al., 200834 ≥ 7.5 There were no exclusions for hypoglycaemia unawareness
O’Connell et al., 200935 ≤ 8.5 Excluded those with any co-existent illness that otherwise predisposes
to hypoglycaemia (e.g. adrenal insufficiency) or a history of severe
hypoglycaemia while using insulin pump therapy
Raccah et al., 2009
(RealTrend)36
> 8 NR
Hermanides et al., 2011
(Eurythmics)37
≥ 8.2 NR
Lee et al., 200738 ≥ 7.5 NR
Peyrot and Rubin,
200939
NR NR
Bergenstal et al., 2010
(STAR-3)40
7.4–9.5 Excluded those with hypoglycaemia unawareness (two or more severe
hypoglycaemic episodes without warning of low BG levels within the
previous year)
Bolli et al., 200941 6.5–9 Excluded those who had more than two severe hypoglycaemic events
in the previous 6 months
DeVries et al., 200242 ≥ 8.5 NR
Nosadini et al., 198843 NR NR
Brinchmann-Hansen
et al., 1985 (OSLO)44
NR NR
Thomas et al., 200745 NR Included those with long-standing T1DM complicated by at least one
episode of severe hypoglycaemia within the preceding 6 months
Tsui et al., 200146 NR Excluded those who had a history of more than two severe
hypoglycaemic episodes in the last year
Weintrob et al., 200347 NR NR
Thrailkill et al., 201148 NR NR
Doyle et al., 200449 6.5–11 NR
Nosari et al., 199350 NR NR
HUS, hypoglycaemia unawareness score; NR, not reported.
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impossible to perform a trial with true blinding with these types of interventions. Nevertheless, the fact
that participants and physicians were not blinded may bias the results, and the outcome assessment for
HbA1c measurement could be performed blinded. Selective outcome reporting was assessed as having a
high risk of bias in only three trials. Incomplete data reporting was assessed as having a high risk of bias in
12 trials; this was rated as unclear in four trials. Overall, there was a high risk of bias in the included trials.
In the following chapters, we will discuss the results of the included studies by population (i.e. adults,
children and pregnant women) and by follow-up time (i.e. 3 months, 6 months and 9 months or more).
Effectiveness of interventions in adults
We found 12 studies that reported data for adults.32,34,37–46 As can be seen in Table 5, the age ranges
differed considerably; therefore, we asked a panel of four expert committee members whether or not they
thought that the results of these studies could be pooled. Three clinical experts agreed that the studies
were similar enough to be pooled, as far as the differences in age ranges were concerned, and the fourth
clinical expert did not respond.
TABLE 5 Included studies for adults
Study ID Veo
Integrated
CSII+CGM
CSII+
SMBG
MDI+
SMBG
Mean baseline
age, years (SD);
age range, years
Mean
baseline
HbA1c, %
(SD)
Previous
pump
use,
months
Follow-up,
months
Bergenstal
et al., 201332
✓ ✓ 43 (13); 16–70 7.2 (0.7) > 6 3
Hirsch et al.,
200834
✓ ✓ 33 (16); 18–72 8.3 (0.6) > 6 6
Hermanides
et al., 201137
✓ ✓ 38 (11); 18–65 8.6 (0.9) Naive 6
Lee et al.,
200738
✓ ✓ NR 9 (0.9) Naive 3.5
Peyrot and
Rubin, 200939
✓ ✓ 47 (13); NR 8.6 (1) NR 3.7
Bergenstal
et al., 201040
✓ ✓ 41 (12); 19–70 8.3 (0.5) Naive 12
Bolli et al.,
200941
✓ ✓ 40 (11); 18–70 7.7 (0.7) Naive 6
DeVries et al.,
200242
✓ ✓ 37 (10); 18–70 9.4 (1.4) Naive 3.7
aNosadini
et al., 198843
✓ ✓ 34 (6); NR NR NR 12
Brinchmann-
Hansen et al.,
198544
✓ ✓ 26 (21); 18–45 8.5 (NR) NR 3, 6, 12, 24
Thomas et al.,
200745
✓ ✓ 43 (10); NR 8.5 (1.5) NR 4, 6
Tsui et al.,
200146
✓ ✓ 36 (11); 18–60 8 (0.6) Naive 9
NR, not reported.
a The study by Nosadini et al. (1988)43 was a three-arm study that compared two different versions of CSII+ SMBG
with MDI+ SMBG.
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Veo versus integrated CSII+ CGM
One study compared the MiniMed Veo with an integrated CSII+CGM system at 3-month follow-up in
adults (ASPIRE in-home).32 The results of this study, for the head-to-head comparison of the MiniMed Veo
system with an integrated CSII+CGM system, are reported in Table 6.
No results were found for the MiniMed Veo system versus any other treatment at follow-up of 6 months
or more.
Nocturnal hypoglycaemic events occurred 31.8% less frequently in the MiniMed Veo group than in the
integrated CSII+CGM group [1.5 (SD 1.0) vs. 2.2 (SD 1.3) events per patient per week, p< 0.001].
Similarly, the MiniMed Veo group had significantly lower weekly rates of combined daytime and night-time
events than the integrated CSII+CGM group (p< 0.001).
The mean area under the curve (AUC) for nocturnal hypoglycaemic events was 37.5% lower in the
MiniMed Veo group than in the integrated CSII+CGM group [980mg/dl (SD 1200mg/dl) or 54.4 mmol/l
(SD 66.6mmol/l) × minutes vs. 1568mg/dl (SD 1995mg/dl) or 87.0 mmol/l (SD 110.7mmol/l) × minutes;
p< 0.001]. The mean AUC for daytime and night-time hypoglycaemic events was also significantly lower
in the threshold suspend group.
The other outcomes showed no significant differences between groups.
TABLE 6 Results for the MiniMed Veo vs. an integrated CSII+CGM system at 3-month follow-up in adults
Outcome
MiniMed Veo system (n= 121) Integrated CSII+CGM (n= 126)
Difference at
follow-upBaseline Follow-up Baseline Follow-up
Mean change in HbA1c
levels, % (SD)
7.26 (0.71) 7.24 (0.67) 7.21 (0.77) 7.14 (0.77) 0.05 (95% CI
–0.05 to 0.15)
Nocturnal hypoglycaemic
events per patient
per week
(glucose< 3.6mmol/l) (SD)
1.5 (1.0) 2.2 (1.3) NR; p< 0.001
Day and night
hypoglycaemic events
per patient per week
(glucose< 3.6 mmol/l) (SD)
3.3 (2.0) 4.7 (2.7) NR; p< 0.001
Nocturnal hypoglycaemic
AUCa (SD)
980 (1200) 1568 (1995) NR; p< 0.001
Day and night
hypoglycaemic AUCa (SD)
798 (965) 1164 (1590) NR; p< 0.001
Meter BG (previous
2 weeks, mg/dl) (SD)
151.4 (24.3) 167.5 (24.7) 151.8 (23.6) 163.9 (32.1) NS
Insulin use (U per patient
per day) (SD)
47.8 (19.40) 46.5 (21.66) NS
DKA 0 0 No difference
EQ-5D NR NR NR NR No difference
Device-related serious AEs 0 0 No difference
AE, death 0 0 No difference
AE, adverse event; AUC, area under the curve; DKA, diabetic ketoacidosis; EQ-5D, European Quality of Life-5 Dimensions
scale; NR, not reported; NS, not significant; U, units.
a The AUC is the product of the magnitude and duration of the sensor measured glucose level above or below a specified
cut-off level. Higher values for this calculation indicate more numerous, severe or protracted glycaemic events.
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Veo versus integrated CSII + CGM, CSII+ SMBG and MDI + SMBG
For two outcomes [change in HbA1c levels and diabetic ketoacidosis (DKA)], results of the MiniMed Veo
system versus other treatments were available for 3-month follow-up in adults from more than one
study,38,39 which could be combined in indirect comparisons. These two outcomes are reported below.
Change in glycated haemoglobin levels at 3-month follow-up
We found four studies32,38,39,42 comparing change in HbA1c levels at 3-month follow-up in adults, allowing a
comparison of the MiniMed Veo system with an integrated CSII+CGM, CSII+ SMBG and MDI+ SMBG.
Figure 2 shows the network linking these interventions and Table 7 shows the results.
The results of these indirect comparisons show that there are no significant differences between the
MiniMed Veo system and any other intervention in change in HbA1c levels at 3-month follow-up. Similarly,
there are no significant differences between the integrated CSII+CGM system and any other intervention
in change in HbA1c levels at 3-month follow-up. The only significant difference found in this analysis was
the difference between CSII+ SMBG versus MDI+ SMBG; in this regard, the results favour CSII+ SMBG.
Diabetic ketoacidosis at 3-month follow-up
The same four studies32,38,39,42 provided data for DKA at 3-month follow-up in adults, allowing a
comparison of the MiniMed Veo system with an integrated CSII+CGM system, CSII+ SMBG and
MDI+ SMBG. However, the study that compared the MiniMed Veo system with the integrated CSII+CGM
system (ASPIRE in-home)32 could not be included in the analysis as no events were reported in either arm.
The results of the indirect comparisons for DKA are shown in Table 8.
CSII + CGM MDI + CGM
Veo
Integrated
CSII + CGM
CSII + SMBG MDI + SMBG
ASPIRE
in-home32
Peyrot 200939
Lee 200738
DeVries 200242
FIGURE 2 Network of studies comparing change in HbA1c levels and DKA at 3-month follow-up in adults. Note:
green boxes represent the interventions; lines represent comparisons between interventions at 3-month follow-up;
and transparent boxes represent studies in adults.
TABLE 7 Results of the indirect comparisons with regard to change in HbA1c at 3-month follow-up
Intervention
Integrated CSII+CGM, WMD
(95% CI)
CSII+ SMBG, WMD
(95% CI)
MDI+ SMBG, WMD
(95% CI)
Veo 0.04 (–0.07 to 0.15) 0.41 (–0.31 to 1.13) –0.43 (–0.95 to 0.10)
Integrated CSII+CGM 0.37 (–0.34 to 1.08) –0.47 (–0.98 to 0.04)
CSII+ SMBG –0.84 (–1.33 to –0.35)
WMD values of < 0 indicate that the results favour the intervention listed in column 1. Differences are significant if the CIs
do not include 0 (indicated in bold).
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The results of these indirect comparisons show that there are no significant differences with between the
integrated CSII+CGM system and any other intervention with regard to DKA at 3-month follow-up.
The comparison between CSII+ SMBG and MDI+ SMBG also showed no significant difference.
Integrated CSII + CGM versus CSII+ SMBG
One study34 compared the integrated CSII+CGM system (Paradigm 722 System, Medtronic) with
CSII+ SMBG (Paradigm 715 Insulin Pump, Medtronic) at 6-month follow-up in adults.
At 6-month follow-up, results for the head-to-head comparison of the integrated CSII+CGM system
versus CSII+ SMBG were available for one outcome: change in HbA1c levels. Other outcomes were not
reported separately for adults. The results for change in HbA1c levels are reported in Table 9.
The results for the head-to-head comparison of the integrated CSII+CGM system versus CSII+ SMBG at
6-month follow-up in adults showed no significant difference in HbA1c levels between groups.
Integrated CSII + CGM versus MDI+ SMBG
Four studies37–40 compared the integrated CSII+CGM system (MiniMed Paradigm REAL-Time 722 System)
with MDI+ SMBG in adults. Two of these38,39 had results at 3 months, one37 at 6 months and one40 at
12-month follow-up.
At 3-month follow-up, results for the head-to-head comparison of the integrated CSII+CGM system
versus MDI+ SMBG were available for the following outcomes: change in HbA1c levels, hypoglycaemic
events, DKA and adverse events. These results are reported in Table 10.
At 6-month follow-up, results for the head-to-head comparison of the integrated CSII+CGM system
versus MDI+ SMBG were available for change in HbA1c levels, proportion achieving HbA1c levels of ≤ 7%,
hypoglycaemic events, hyperglycaemic events, insulin use and quality of life. These results are also reported
in Table 10, together with the results at 12-month follow-up for change in HbA1c levels, proportion
achieving HbA1c levels of ≤ 7%, proportion with severe hypoglycaemia, rate of severe hypoglycaemic
events, hypoglycaemic AUC, hyperglycaemic AUC, DKA and quality of life.
TABLE 8 Results of the indirect comparisons with regard to DKA at 3-month follow-up
Intervention
Integrated CSII+CGM, RR
(95% CI)
CSII+ SMBG, RR
(95% CI)
MDI+ SMBG, RR
(95% CI)
Veo No events No events No events
Integrated CSII+CGM 0.26 (0.01 to 8.53) 0.32 (0.04 to 2.86)
CSII+ SMBG 1.25 (0.08 to 19.22)
RR values of < 1 indicate that the results favour the interventions listed in column 1. Differences are significant if the CIs do
not include 1.
TABLE 9 Results for the head-to-head comparison of integrated CSII+CGM vs. CSII+ SMBG at 6-month follow-up
in adults
Outcome
Integrated CSII+CGM (n= 49) CSII+ SMBG (n= 49)
Difference at
follow-upBaseline (%) Follow-up (%) Baseline (%) Follow-up (%)
Change in HbA1c
levels (SD)
8.37 (0.6) 7.68 (0.84) 8.30 (0.54) 7.66 (0.67) –0.0364 (SE 0.1412);
p= 0.80
SE, standard error.
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TABLE 10 Results for the comparison of the integrated CSII+CGM system vs. MDI+ SMBG at 3-, 6- and 12-month
follow-up in adults
Outcome/study
Integrated CSII+CGM MDI+ SMBG
Difference at
follow-upBaseline Follow-up Baseline Follow-up
Three-month follow-up
Change in HbA1c levels, % (SD)
Peyrot and Rubin, 200939 (n= 27) 8.87 (0.89),
n= 14
7.16 (0.75) 8.32 (1.05),
n= 13
7.30 (0.92) –0.69; p= 0.071
Lee et al., 200738 (n= 16) 9.45 (0.55),
n= 8
7.40 (0.66) 8.58 (1.30),
n= 8
7.50 (1.01) –0.97; p= 0.02
Hypoglycaemic events (number of patients with events/total number of patients)
Peyrot and Rubin, 200939 (n= 27) NA 0/14 NA 3/13 NS
Lee et al., 200738 (n= 16) NA 0/8 NA 1/8 NS
DKA (number of patients with DKA/total number of patients)
Peyrot and Rubin, 200939 (n= 27) NA 0/14 NA 1/13 NS
Lee et al., 200738 (n= 16) NA 0/8 NA 1/8 NS
Serious AEs (number of patients with a serious AE/total number of patients)
Lee et al., 200738 NA 0/8 NA 1/8 NS
Six-month follow-up (Eurythmics37) n = 41 n = 36
Change in HbA1c levels, % (SD) 8.46 (0.95) 7.23 (0.65) 8.59 (0.82) 8.46 (1.04) –1.1, 95% CI
–1.47 to –0.73
Proportion achieving HbA1c levels of
≤ 7% (number of patients with HbA1c
≤ 7%/total number of patients)
NA 14/41 NA 0/36 p< 0.001
Hypoglycaemic events, mean number of
events (glucose levels of < 4.0 mmol/l)
per day (SD)
NA 0.7 (0.7) NA 0.6 (0.7) 0.1, 95% CI
–0.2 to 0.5
Hyperglycaemic events, mean number of
events (glucose levels of > 11.1 mmol/l)
per day (SD)
NA 2.1 (0.8) NA 2.2 (0.7) –0.2, 95% CI
–0.5 to 0.2
Insulin use, total daily dose (SD) in units NA 46.7 (16.5) NA 57.8 (18.1) –11.0, 95% CI
–16.1 to –5.9;
p< 0.001
QoL: SF-36 Health Survey measuring
general health, mean score (SD)
55.5 (20.3) 67.7 (21.6) 59.8 (22.3) 63.1 (19.1) 7.9, 95% CI
0.5 to 15.3;
p= 0.04
Twelve-month follow-up (STAR-340) n = 169 n = 167
Change in HbA1c levels, % (SD) 8.3 (0.5) 7.3 (NR) 8.3 (0.5) 7.9 (NR) –0.6, 95% CI
–0.8 to –0.4;
p< 0.001
Proportion achieving HbA1c levels of
≤ 7% (number of patients with HbA1c
≤ 7%/total number of patients)
NA 57/166 NA 19/163 p< 0.001
Severe hypoglycaemia (patients with
hypoglycaemic events/total patients)
NA 17/169 NA 13/167 NS
Severe hypoglycaemic event rate
(per 100 person-years; HbA1c
levels< 50mg/dl)
NA 15.31/169 NA 17.62/167 p= 0.66
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At 3-month follow-up, results were available from two small RCTs, with 2739 and 1638 adult respondents,
respectively. With regard to change in HbA1c levels, the results from these RCTs favoured the integrated
CSII+CGM system over MDI+ SMBG, but this was not significant in one of the trials.39 There were more
hypoglycaemic events, DKA and serious adverse events in the MDI+ SMBG groups at 3-month follow-up. None
of these results was significant; however, the study sizes were small and the number of events was limited.
At 6-month follow-up, results were available from one small RCT with 77 adult respondents.37 This trial
showed a significant difference in HbA1c change scores favouring the integrated CSII+CGM system, with a
significantly higher number of patients achieving HbA1c levels of ≤ 7%. Insulin use was significantly lower
and quality of life was significantly higher in the integrated CSII+CGM group than in the MDI+ SMBG
group. The number of hypoglycaemic and hyperglycaemic events showed no differences between groups.
At 12-month follow-up, results were available from one RCT with 336 adult participants.40 This trial also
showed a significant difference in HbA1c change scores in favour of the integrated CSII+CGM system and
a significantly higher number of patients achieving HbA1c levels of ≤ 7%. Hyperglycaemic AUC was
significantly lower in the integrated CSII+CGM group, but hypoglycaemic AUC showed no significant
difference. The results suggest that there were no significant differences between groups with regard to
severe hypoglycaemia, nor was there any difference in the number of patients with DKA. Quality of life
was more significantly improved in the integrated CSII+CGM group than in the MDI+ SMBG group.
The Hypoglycaemia Fear Survey (HFS) showed that there were significantly more reductions in fear in the
integrated CSII+CGM group than in the MDI+ SMBG group, for both worries and avoidant behaviour
related to hypoglycaemia.
TABLE 10 Results for the comparison of the integrated CSII+CGM system vs. MDI+ SMBG at 3-, 6- and 12-month
follow-up in adults (continued )
Outcome/study
Integrated CSII+CGM MDI+ SMBG
Difference at
follow-upBaseline Follow-up Baseline Follow-up
Hypoglycaemic AUC (threshold of
< 70mg/dl)
NA 0.25 (0.44) NA 0.29 (0.55) p= 0.63
Hyperglycaemic AUC (> 250mg/dl) NA 3.74 (5.01) NA 7.38 (8.62) p< 0.001
Patients with DKA NA 2/169 NA 0/167 NS
QoL NA NA NA NA NA
SF-36 General Health NA Change:
+2.7 (8.07)
NA Change:
–0.3 (7.13)
3 (SD 7.75),
95% CI 1.36
to 4.64
HFS NA Change:
–9 (16.04)
NA Change:
–2.4 (15.88)
–6.5 (SD 16.0),
95% CI –9.76
to –3.27)
AE, adverse event; HFS, Hypoglycaemia Fear Survey; NA, not applicable; NR, not reported; NS, not significant;
QoL, quality of life; SF-36, Short Form questionnaire-36 items.
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Integrated CSII + CGM versus CSII+ SMBG and MDI + SMBG
Results at 3-month follow-up
Proportion of patients with severe hypoglycaemia The results of these indirect comparisons (Figure 3
and references 38, 39 and 42 therein) suggest that there are no significant differences between the
integrated CSII+CGM system and any other intervention with regard to the ‘proportion of patients with
severe hypoglycaemia’ at 3-month follow-up. The comparison between CSII+ SMBG and MDI+ SMBG also
showed no significant difference. These findings are summarised in Table 11.
Results at 6-month follow-up
Change in glycated haemoglobin levels The results of these indirect comparisons (Figure 4 and
references 34, 37 and 41 therein) suggest that there are no significant differences between the integrated
CSII+CGM system and CSII+ SMBG with regard to change in HbA1c levels at 6-month follow-up.
The comparison between CSII+ SMBG and MDI+ SMBG also showed no significant difference. The
comparison between the integrated CSII+CGM system and MDI+ SMBG did show a significant
difference, favouring the integrated CSII+CGM system. These findings are summarised in Table 12.
CSII + CGM MDI + CGM
Veo
Integrated
CSII + CGM
CSII + SMBG MDI + SMBG
Peyrot 200939
Lee 200738
DeVries 200242
FIGURE 3 Network of studies comparing ‘severe hypoglycaemia’ at 3-month follow-up in adults.
TABLE 11 Results of the indirect comparisons with regard to the proportion of patients with severe hypoglycaemia
at 3-month follow-up in adults
Intervention CSII+ SMBG, RR (95% CI) MDI+ SMBG, RR (95% CI)
Integrated CSII+CGM 0.33 (0.03 to 3.87) 0.19 (0.02 to 1.51)
CSII+ SMBG 0.63 (0.17 to 2.31)
RR values of < 1 indicate that the results favour the intervention listed in column 1. Differences are significant if the CIs do
not include 1 (these are in bold).
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Proportion of patients achieving glycated haemoglobin levels < 7% Results of these indirect
comparisons (Figure 5 and references 34 and 37 therein) suggest that there are no significant differences
between the integrated CSII+CGM system and CSII+ SMBG with regard to ‘HbA1c levels < 7%’ at 6-month
follow-up. However, the comparison between the integrated CSII+CGM system and MDI+ SMBG did show a
significant difference in favour of the integrated CSII+CGM system. Similarly, the comparison between
CSII+ SMBG and MDI+ SMBG showed a significant difference in favour of CSII+ SMBG. These findings are
summarised in Table 13.
CSII + CGM MDI + CGM
Veo
Integrated
CSII + CGM
CSII + SMBG MDI + SMBG
Eurythmics37
Hirsch 200834
FIGURE 5 Network of studies comparing ‘HbA1c levels < 7%’ at 6-month follow-up in adults.
TABLE 12 Results of the indirect comparisons with regard to change in HbA1c levels at 6-month follow-up in adults
Intervention CSII+ SMBG, WMD (95% CI) MDI+ SMBG, WMD (95% CI)
Integrated CSII+CGM –0.05 (–0.31 to 0.21) –1.10 (–1.46 to –0.74)
CSII+ SMBG –0.10 (–0.52 to 0.32)
WMD values of < 0 indicate that the results favour intervention listed in column 1. Differences are significant if the CIs do
not include 0 (these are in bold).
CSII + CGM MDI + CGM
Veo
Eurythmics37
Bolli 200941
Hirsch 200834
Integrated
CSII + CGM
CSII + SMBG MDI + SMBG
FIGURE 4 Network of studies comparing change in HbA1c levels at 6-month follow-up in adults.
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Quality of life Different tools were used to measure HRQoL (Figure 6). Only those studies using the same
questionnaire could be combined in the analysis. Two studies reported results at 6-month follow-up
for the Diabetic Treatment Satisfaction Questionnaire (Eurythmics37 and Bolli et al.41) using a scale from
0 to 36, with higher scores indicating more satisfaction with treatment. These findings are summarised in
Table 14. Two studies reported results for the HFS (Eurythmics37 and Thomas et al.45); however, these could
not be analysed together as one reported only the worry subscale of the HFS, whereas the other reported
the total score.
The results of these indirect comparisons show that the integrated CSII+CGM system significantly
improved the quality-of-life scores at 6-month follow-up when compared with CSII+ SMBG or with
MDI+ SMBG. There was no significant difference between CSII+ SMBG and MDI+ SMBG.
CSII + CGM MDI + CGM
Veo
Eurythmics:37
SF-36, DTSQ,
HFS
Bolli 2009:41
DTSQ;
Thomas 2007:45
DQOL, HFS
Integrated
CSII + CGM
MDI + SMBGCSII + SMBG
FIGURE 6 Network of studies comparing ‘quality of life’ at 6-month follow-up in adults. DQOL, Diabetes Quality of
Life questionnaire; DTSQ, Diabetic Treatment Satisfaction Questionnaire; SF-36, Short Form questionnaire-36 items.
TABLE 14 Results of the indirect comparisons with regard to quality of life (DTSQ) at 6-month follow-up in adults
Intervention CSII+ SMBG, WMD (95% CI) MDI+ SMBG, WMD (95% CI)
Integrated CSII+CGM 5.90 (2.22 to 9.58) 8.60 (6.28 to 10.92)
CSII+ SMBG 2.70 (–0.16 to 5.56)
DTSQ, Diabetic Treatment Satisfaction Questionnaire.
WMD values of > 0 indicate that the results favour the intervention listed in column 1. Differences are significant if the CIs
do not include 0 (these are in bold).
TABLE 13 Results of the indirect comparisons with regard to HbA1c levels of < 7% at 6-month follow-up in adults
Intervention CSII+ SMBG, RR (95% CI) MDI+ SMBG, RR (95% CI)
Integrated CSII+CGM 1.45 (0.74 to 2.84) 25.55 (1.58 to 413.59)
CSII+ SMBG 17.56 (1.002 to 307.87)
RR values of > 1 indicate that the results favour the intervention listed in column 1. Differences are significant if the CIs do
not include 1 (these are in bold).
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Effectiveness of interventions in children
We found five studies34,40,47–49 that reported data for children. In addition, there was one study (Ly et al.33)
that included a mixed population of patients between 4 and 50 years old. Approximately 70% of patients
were children (< 18 years).
We asked our panel of four expert committee members whether or not they thought that the results
of these studies could be pooled, especially whether or not the study by Ly et al.33 (age range of 4 to
50 years, with 70% of participants < 18 years) could be included as if it was a study in children. One
clinical expert agreed that the six studies were similar enough, as far as the differences in age ranges were
concerned, to be pooled. A second clinical expert agreed that five of the studies were similar enough, as
far as the differences in age ranges were concerned, to be pooled, but given that approximately one-third
of participants were aged 18–50, it would be difficult to include the Ly et al.33 study in the analysis of the
interventions in children (if the adult group had been a younger cohort, e.g. 18–25 years, this expert’s
conclusion may have been different). The third clinical expert also thought the Ly et al.33 study could not
reasonably be included in analyses for either group (children or adults); this third expert also thought
that teenage children behave in a different way from pre-teen children and that, therefore, the 8- to
14-year-old cohort may be significantly different and should perhaps have been excluded from analyses.
The fourth clinical expert did not respond.
However, the study by Ly et al.33 was the only study looking at the MiniMed Veo system in children;
therefore, we will present the results from analyses that included this study as if it was a study in children.
In addition, the study by Weintrob et al.,47 with children aged 8 to 14 years old, is the only study with
results at 6-month follow-up linking MDI+ SMBG to the MiniMed Veo system and the integrated
CSII+CGM system; therefore, we included this study in the analyses as well. The results of these analyses
should be interpreted with great caution because of the differences in age ranges among the included
studies, as shown in Table 15.
TABLE 15 Included studies for children
Study Veo
Integrated
CSII+CGM
CSII+
SMBG
MDI+
SMBG
Mean baseline
age, years (SD);
age range, years
Mean
baseline
HbA1c,
% (SD)
Previous
pump use,
months
Follow-up,
months
Ly et al.,
201333
✓ ✓ 19 (12); 4–50 7.5 (0.8) > 6 6
Hirsch et al.,
200834
✓ ✓ 33 (16); 12–17 8.7 (0.9) > 6 6
Bergenstal
et al., 201040
✓ ✓ 12 (3); 7–18 8.3 (0.5) Naive 12
Weintrob
et al., 200347
✓ ✓ 12 (1.5); 8–14 8 (1) NR 3.5
Thrailkill et al.,
201148
✓ ✓ 12 (3); 8–18 11.5 (2.4) Naive 6, 12
Doyle et al.,
200449
✓ ✓ 13 (3); 8–21 8.1 (1.2) Naive 3.7
NR, not reported.
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Veo versus CSII+ SMBG
One study33 compared the MiniMed Veo system with CSII+ SMBG at 6-month follow-up in a mixed
population of patients between 4 and 50 years old. Results were not reported separately for adults and
children. However, approximately 70% of patients were children (< 18 years). As explained above, we
have included this study as a study of children. The results of this study are summarised in Table 16.
No results were found for the MiniMed Veo system versus any other treatment after 3 months, 9 months
or longer follow-up.
As shown in Table 16, the only significant difference between treatment groups was the rate of moderate
and severe hypoglycaemic events, which favoured the MiniMed Veo system. All other outcomes showed
no significant differences between groups.
TABLE 16 Results for the MiniMed Veo system vs. CSII+ SMBG at 6-month follow-up in a mixed population
(mainly children)
Outcome
MiniMed Veo system (n= 46) CSII+ SMBG (n= 49)
Difference at follow-upBaseline Follow-up Baseline Follow-up
Change in
HbA1c levels,
% (95% CI)
7.6 (7.4 to 7.9) 7.5 (7.3 to 7.7) 7.4 (7.2 to 7.6) 7.4 (7.2 to 7.7) 0.07 (–0.2 to 0.3); p= 0.55
Number of
people with
hypoglycaemic
events
0/41 6/45 NS
Hypoglycaemic
incidence ratea
9.5 (95% CI
5.2 to 17.4)
34.2 (95% CI
22.0 to 53.3)
IRR 3.6 (95% CI 1.7 to 7.5);
p< 0.001
HUSb 5.9 (95% CI
5.5 to 6.4)
4.7 (95% CI
4.0 to 5.1)
6.4 (95% CI
5.9 to 6.8)
5.1 (95% CI
4.5 to 5.6)
–0.2 (95% CI –0.9 to 0.5);
p= 0.58
HUS, Hypoglycaemia Unawareness Score (Clarke questionnaire), higher is worse; IRR, incidence rate ratio;
NS, not significant.
a The number of hypoglycaemic events per 100 patient-months.
b The higher the HUS, the higher the level of hypoglycaemia unawareness.
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Veo versus integrated CSII+ CGM and CSII + SMBG
Results at 6-month follow-up: change in glycated haemoglobin levels
The results of the indirect comparison, shown in Figure 7 and Table 17, demonstrate that there were no
significant differences between any of the interventions with regard to changes in HbA1c levels at 6-month
follow-up in children.
Integrated CSII + CGM versus CSII+ SMBG
One study compared the integrated CSII+CGM system with CSII+ SMBG at 6-month follow-up in children.34
At 6-month follow-up, results for the head-to-head comparison of the integrated CSII+CGM system with
CSII+ SMBG were available for one outcome: change in HbA1c levels. Other outcomes were not reported
separately for children. The results for change in HbA1c levels are reported in Table 18.
The results from the head-to-head comparison of the integrated CSII+CGM system with CSII+ SMBG at
6-month follow-up in children showed no significant difference in HbA1c levels between groups.
TABLE 17 Results of the indirect comparison of changes in HbA1c levels at 6-month follow-up
Intervention Integrated CSII+CGM, WMD (95% CI) CSII+ SMBG, WMD (95% CI)
Veo 0.38 (–0.16 to 0.92) –0.04 (–0.26 to 0.18)
Integrated CSII+CGM –0.42 (–0.92 to 0.08)
WMD values of < 0 indicate that the results favour the interventions listed in column 1. Differences are significant if the CIs
do not include 0.
CSII + CGM MDI + CGM
MDI + SMBG
Hirsch 200834
Ly 201333
Veo
Integrated
CSII + CGM
CSII + SMBG
FIGURE 7 Network of studies comparing change in HbA1c levels at 6-month follow-up in children.
TABLE 18 Results for the integrated CSII+CGM system vs. CSII+ SMBG at 6-month follow-up in children
Outcome
Integrated CSII+CGM
(n= 17) CSII+ SMBG (n= 23)
Difference at
follow-upBaseline Follow-up Baseline Follow-up
Change in HbA1c levels, % (SD) 8.82 (1.05) 8.02 (1.11) 8.59 (0.80) 8.21 (0.97) 0.4894 (SE 0.2899);
p= 0.10
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Integrated CSII + CGM versus MDI + SMBG
One study compared the integrated CSII+CGM system with MDI+ SMBG at 12-month follow-up in
159 children.40
At 12-month follow-up, results from the head-to-head comparison of the integrated CSII+CGM system
with MDI+ SMBG were available for change in HbA1c levels, proportion achieving HbA1c levels of≤ 7%,
proportion with severe hypoglycaemia, rate of severe hypoglycaemic events, hypoglycaemic AUC,
hyperglycaemic AUC, DKA and quality of life. These results are reported in Table 19.
The trial showed a significant difference in HbA1c change scores in favour of the integrated CSII+CGM
system, but no significant difference in the number of children achieving HbA1c levels of ≤ 7%.40 The
hyperglycaemic AUC was significantly lower in the integrated CSII+CGM group, but the hypoglycaemic
AUC showed no significant difference. The results for severe hypoglycaemia showed no differences
between groups; furthermore, there were no differences in the number of patients with DKA.
Quality-of-life scores showed no significant differences between groups. The HFD showed that fear
(as indicated by both worry and avoidance behaviour) was significantly reduced in both groups, but there
was no difference between groups at 12-month follow-up.
TABLE 19 Results for the integrated CSII+CGM system vs. MDI+ SMBG at 12-month follow-up in children
Outcome
Integrated CSII+CGM (n= 78) MDI+ SMBG (n= 81)
Difference at
follow-upBaseline Follow-up Baseline Follow-up
Change in HbA1c levels, % (SD) 8.3 (0.6) 7.9 (NR) 8.3 (0.5) 8.5 (NR) –0.5 (95% CI –0.8
to –0.2); p< 0.001
Proportion achieving HbA1c
levels of ≤ 7% (patients with
HbA1c level ≤ 7%/total
number of patients)
10/78 4/78 p= 0.15
Number of people with
severe hypoglycaemic events
(patients with severe
hypoglycaemic events/total
number of patients)
4/78 4/81 NS
Severe hypoglycaemic event
rate (per 100 person-years;
HbA1c levels of < 50mg/dl)
8.98/78 4.95/81 p= 0.35
Hypoglycaemic (< 70mg/dl)
AUC (SD)
0.23 (0.41) 0.25 (0.41) p= 0.79
Hyperglycaemic (>250mg/dl)
AUC (SD)
9.2 (8.08) 17.64 (14.62) p< 0.001
Patients with DKA 1/78 1/81 NS
QoL
PedsQLa – psychosocial,
mean score (SD)
78.38 (14.59) Change: 3.39 78.76 (10.27) Change: 3.64 NS
PedsQLa – physical, mean
score (SD)
86.99 (12.93) Change: 2.53 88.37 (11.16) Change: 1.41 NS
HFSb – worry, mean score
(SD)
28.88 (9.74) Change: –3.62 26.97 (8.06) Change: –2.43 NS
HFSb – avoidance, mean
score (SD)
30.60 (5.43) Change: –4.01 29.70 (6.04) Change: –2.25 NS
NR, not reported; NS, not significant; PedsQL, paediatric quality of life measurement tool; QoL, quality of life.
a The higher the PedsQL score, the higher the quality of life.
b The higher the HF score, the higher the quality of life.
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Effectiveness of interventions in pregnant women
We found one RCT50 that reported data for pregnant women (Table 20). The study included 32
pregnancies in 31 different women. The number of pregnancies was the unit of analysis. The study
compared CSII+ SMBG with MDI+ SMBG; as these are not the relevant interventions described by NICE,
the results will not be further discussed in this chapter. Full results are reported in Appendix 3.
Several non-RCTs (controlled clinical trials and observational studies) were identified; however, none of
these looked at the MiniMed Veo system or an integrated CSII+CGM system. One ongoing study was
identified; this is reported below (see Ongoing studies).
Additional analyses for the economic model
So far, we have adhered to the usual methods of meta-analyses, in accordance with which studies are
combined in one analysis only if they compare similar interventions in similar populations at similar
follow-up times, using similar outcomes.
We checked with clinical experts/committee members with regard to whether or not they agreed with
these intended analyses and there was general agreement on the following points:
l Age Studies in children and adults should be analysed separately and studies in mixed age groups
(adults and children), if data are not reported separately by age group, should not be included in
analyses for children or adults.
l Follow-up Studies with results at 3-, 6- or 9-month follow-up should be analysed separately. Results
from studies reporting outcomes at 2- to 4-month follow-ups can be pooled with results from studies
reporting at 3-month follow-up; results from studies reporting at ≥ 9-month follow-up can be pooled
in a ≥ 9-month follow-up group.
In cases in which the clinical experts disagreed with our suggested analyses, the clinical experts were
always more cautious. For instance, it was suggested that Ly et al.33 should not be treated as a study in
children because one-third of participants were aged 18–50 years; therefore, it would be difficult to
include this study with the analysis of children. If the adult age group in this study had been a younger
cohort (e.g. 18–25 years) it may have been different. Similarly, teenage children were considered to
behave in a different way from pre-teen children; therefore, the study by Weintrob et al.47 (in which
participants were aged 8 to 14 years) may be significantly different from the other studies in children
(of up to 18 years) and perhaps should be excluded.
However, because of the lack of data, we have included the studies by Ly et al.33 and Weintrob et al.47 in
the analyses for children. As a consequence, the results of these analyses are less reliable as a result of
clinical heterogeneity between studies.
TABLE 20 Included studies for pregnant women
Study Veo
Integrated
CSII+CGM
CSII+
SMBG
MDI+
SMBG
Mean baseline
age, years
(SD years);
age range
Mean
baseline
HbA1c
Previous
pump
use
Follow-up,
months
Nosari et al.,
199350
✓ ✓ 26 (2.4); NR NR Naive 9
NR, not reported.
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Despite trying to include as many studies as possible in the analyses for adults, we still have missing results
for key comparisons for the economic model. Most importantly, results for comparisons of the MiniMed
Veo system and the integrated CSII+CGM system with the comparators CSII+CGM, CSII+ SMBG,
MDI+CGM and MDI+ SMBG are missing for the outcomes change in HbA1c levels and severe
hypoglycaemic event rates. As can be seen in Table 2, none of the included studies looked at CSII+CGM
and MDI+CGM. Therefore, a comparison between these comparators cannot be made. However, it is
possible to calculate results for these outcomes (change in HbA1c and severe hypoglycaemic event rates) by
comparing the MiniMed Veo system and the integrated CSII+CGM system with CSII+ SMBG and with
MDI+ SMBG in a series of indirect comparisons, if we accept the following assumptions:
l All studies can be pooled, irrespective of length of follow-up (3, 6 or ≥ 9 months).
l Studies in mixed populations (including those of children and adults that do not report separate results by
age group) can be pooled in one analysis. This means that we will include O’Connell et al. (30 adults and
32 children),35 RealTrend (81 adults and 51 children)36 and Hirsch et al. (98 adults and 40 children),34 in
the analyses for adults. Ly et al.33 (30 adults and 65 children) will still be excluded from these analyses.
l For event rates, we assumed that if numbers of events were reported, the rate could be derived by
assuming that all patients had been observed for the follow-up duration of the trial.
It should be taken into account that the following analyses, including any subsequent analyses, such as the
economic model, are based on these assumptions and that the clinical experts advised against using these
wide inclusion criteria for pooling studies in one analysis. The results of these analyses are therefore likely
to be considerably less reliable because of higher levels of clinical heterogeneity between studies included
in these analyses for adults.
Change in glycated haemoglobin levels
The results of the indirect comparison, as shown in Figure 8 and Table 21, demonstrate that there were no
significant differences with regard to the change in HbA1c levels in adults (including mixed populations)
between the MiniMed Veo system and the integrated CSII+CGM system. Similarly, there were no
CSII + CGM MDI + CGM
Veo
Integrated
CSII + CGM
ASPIRE
in-home32
STAR-340
CSII + SMBG MDI + SMBG
DeVries 200242
Bolli 200941
Thomas 200745
Tsui 200146
OSLO44
Nosadini 198843
O’Connell 200935
Peyrot 200939
Lee 200738
Hirsch 200834
RealTrend36
Eurythmics37
FIGURE 8 Network of studies32,34–46 comparing change in HbA1c levels at all follow-up times in adults and mixed
populations. Green boxes represent the interventions; lines represent comparisons between interventions at
different follow-up times (blue line, 3 months; green line, 6 months; black line,≥ 9 months); and transparent boxes
represent studies (blue, mixed population; black, adult population).
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significant differences with regard to the change in HbA1c levels in adults (including mixed populations)
between the MiniMed Veo system and the integrated CSII+CGM system on the one hand and
CSII+ SMBG on the other. There was a significant difference in the change in HbA1c levels in adults
(including mixed populations) between the MiniMed Veo system and the integrated CSII+CGM system if
both systems are compared with MDI+ SMBG, favouring the MiniMed Veo system and the integrated
CSII+CGM system over MDI+ SMBG.
Overall, integrated systems (the MiniMed Veo system and the integrated CSII+CGM system) are superior to
SMBG (with CSII or MDIs) in terms of HbA1c levels. However, as reported above, the reliability of the results of
these analyses is reduced because of a relatively high level of heterogeneity between the studies included in
the analyses. This is particularly true for the comparison between the MiniMed Veo system and CSII+ SMBG,
which is based not only on an indirect comparison (using data from the ASPIRE in-home trial,32 O’Connell
et al.,35 Hirsch et al.34 and RealTrend36), but also on data from 3-month follow-up (ASPIRE in-home32 and
O’Connell et al.35) combined with data from 6-month follow-up (Hirsch et al.34 and RealTrend36), and on data
from adults (ASPIRE in-home32 and Hirsch et al.34) and mixed populations (O’Connell et al.35 and RealTrend36).
Severe hypoglycaemic event rate
The results of the indirect comparison, as shown in Figure 9 and Table 22, show that there were no
significant differences in the severe hypoglycaemic event rate in adults (including mixed populations)
between the MiniMed Veo system and any of the other treatments. Similarly, there were no significant
differences in the change in severe hypoglycaemic event rate between the integrated CSII+CGM system
and MDI+ SMBG. There was a significant difference in the severe hypoglycaemic event rate between the
integrated CSII+CGM system and CSII+ SMBG, in favour of CSII+ SMBG. However, as reported above,
the reliability of the results of these analyses is reduced because of a relatively high level of heterogeneity
between the studies included in the analyses. With regard to the significant difference in particular, it is
important to point out that this result relies upon the data from three trials with different follow-up times
(3 months for O’Connell et al.35 and 6 months for Hirsch et al.34 and RealTrend36), and that data from all
three trials are from mixed populations, including adults and children.
Overall, the main conclusion regarding the evidence for hypoglycaemic event rate, and change in HbA1c
levels, in adults is that the evidence is limited and when all available evidence is combined, the results
become highly unreliable.
TABLE 21 Results of the indirect comparison with regard to change in HbA1c levels at all follow-up times in adults
and mixed populations
Intervention
Integrated CSII+CGM,
WMD (95% CI)
CSII+ SMBG,
WMD (95% CI)
MDI+ SMBG,
WMD (95% CI)
Veo 0.04 (–0.07 to 0.15) –0.07 (–0.31 to 0.17) –0.66 (–1.05 to –0.27)
Integrated CSII+CGM –0.11 (–0.32 to 0.10) –0.70 (–1.05 to –0.30)a
CSII+ SMBG –0.46 (–1.18 to 0.27)b
WMD values of < 0 indicate that the results favour the interventions listed in column 1. Statistically significant differences
are those where the 95% CIs do not include 0 (shown in bold).
a This result was from a random-effects analysis as I2 was 62.5%.
b This result was from a random-effects analysis as I2 was 80.2%.
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FIGURE 9 Network of studies32,34–46 comparing severe hypoglycaemic event rate at all follow-up times in adults and
mixed populations. Green boxes represent the interventions; lines represent comparisons between interventions at
different follow-up times (blue line, 3 months; green line, 6 months; black line,≥ 9 months); transparent boxes
represent studies (blue, mixed population; black, adult population; green, adults and all hypoglycaemic events).
TABLE 22 Results of the indirect comparison for severe hypoglycaemic event rate at all follow-up times in adults
and mixed populations
Intervention
Integrated CSII+CGM,
rate ratio (95% CI)
CSII+ SMBG,
rate ratio (95% CI)
MDI+ SMBG,
rate ratio (95% CI)
Veo 0.12 (0.01 to 2.14) 0.39 (0.02 to 8.40) 0.10 (0.01 to 1.93)
Integrated CSII+CGM 3.23 (1.10 to 9.49) 0.86 (0.51 to 1.46)
CSII+ SMBG 0.67 (0.38 to 1.20)
Rate ratio values of < 1 indicate that the results favour the intervention listed in column 1. Statistically significant differences
are those where the 95% CIs do not include 1 (shown in bold).
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Ongoing studies
We found 18 ongoing studies51–68 – 17 RCTs51–55,57–68 and one observational study56 looking at the use of a
threshold suspend feature at home with a sensor-augmented insulin pump (SAP) (MiniMed 530G). Most
ongoing studies are in children (12 out of 18 studies51,53,54,56,60–62,64–68), five are in a general population
(adults or adults and children)52,55,57,59,63 and one study is in pregnant women.58 Seven studies include the
MiniMed Veo system51,52,54–56,59,64 and four studies include the integrated CSII+CGM system.55,63,64,66 Details
of ongoing studies are reported in Table 23.
TABLE 23 Ongoing studies
Study ID Year Intervention RCT Comment Age
Lawson et al.51 2014 Veo vs.
CSII+ SMBG
Yes Complex design. Trial uses the Veo
system. Patients are randomised to
simultaneous initiation of pump
and CGM vs. initiation of pump
with CGM started 6 months later.
Outcomes were measured after
6 and 12 months. Group B is
pump+ SMBG for 6 months then
pump+CGM for the next
6 months
5–18 years
Troub et al.52 2013 Veo vs.
CSII+CGM
Yes General
Blair et al.53 2010 CSII+ SMBG vs.
MDI+ SMBG
Yes CSII compared with MDI regimens
in children and young people at
diagnosis of T1DM; protocol only
Children
Assistance Publique – Hôpitaux
de Paris NCT0094922154
2012 Veo vs.
CSII+ SMBG
Yes Device: Medtronic’s Paradigm
754 Veo monitor with MiniLink
REAL-Time transmitter (Conformité
Européenne). 3 months and
9months of SMBG vs. 12months
of using the Veo system
2–18 years
Steno Diabetes Centre
NCT0145470055
2012 Veo vs. integrated
CSII+CGM vs.
MDI+ SMBG
Yes CSII plus CGM (Medtronic’s
MiniMed Paradigm REAL-Time
system or Veo) vs. MDIs
General
Medtronic Diabetes
NCT0212079456
2014 Veo Obs Use of threshold suspend feature at
home with a SAP [MiniMed 530G
(Medtronic)] in children with T1DM
over 1 year
2–15 years
Vastra Gotaland Region
NCT0209205157
2014 MDI+CGM vs.
MDI+ SMBG
Yes CGM vs. SMBG in individuals with
T1DM treated with MDIs
General
University of British Columbia
NCT0206402358
2014 CSII+ SMBG vs.
MDI+ SMBG
Yes Comparison of CSII with MDIs for
the treatment of pregestational
diabetes during pregnancy (T1DM
and T2DM)
Pregnant
Sheffield Teaching Hospitals
NHSFT (REPOSE Trial)
NCT01616784EUCTR2010-
023198–21-GB59
2013 Veo vs.
CSII+ SMBG vs.
MDI+ SMBG
Yes CSII (insulin pump) plus DAFNE
versus MDI [insulin detemir
(Levemir®, Novo Nordisk) and
quick-acting insulin] plus DAFNE
> 18 years
Seattle Children’s Hospital
NCT0087529060
2011 CSII+CGM vs.
CSII+ SMBG
Yes CSII alone vs. CSII+ RTSA in infants
with T1DM
0–3 years
Nemours Children’s Clinic
NCT0035789061
2012 CSII+ SMBG vs.
MDI+ SMBG
Yes MDI vs. CSII in adolescents with
newly diagnosed T1DM
12–17 years
continued
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Summary of results
In this summary of results, we will describe the results by population (adults, children and pregnant
women) and by comparison. First, we will describe comparisons between the MiniMed Veo system and
other treatments, then comparisons between the integrated CSII+CGM system and other treatments,
and, finally, we will describe the main remaining comparisons.
Nineteen trials were included:32–50 12 reported data for adults,32,34,37–46 six reported data for children33,34,40,47–49
and one trial reported data for pregnant women.57 Four trials were in mixed populations (adults and
children);34–36,40 two of these reported data separately for adults and children and are included in the 12
trials for adults and six trials for children.34,40 Two trials (O’Connell et al.35 and RealTrend36) did not report
data separately for adults and children. Therefore, the results from these trials were not used in the main
analyses. However, the data are reported in the data extraction tables in Appendix 3 and they are used in
the additional analyses for the economic model (see Additional analyses for the economic model).
Studies in adults
Twelve studies were included in the analyses for adults.32,34,37–46 Only one of these studies (Hirsch et al.34)
reported the change in HbA1c levels separately for adults. None of these studies looked at CSII or
MDI+CGM. Table 5 shows an overview of these 12 studies, their comparisons and their baseline data.
Further details are reported in Appendix 3.
TABLE 23 Ongoing studies (continued )
Study ID Year Intervention RCT Comment Age
Addenbrooke’s NHS Trust
EUCTR2005-004526-72-GB62
2006 CSII+CGM vs.
MDI+ SMBG
Yes CSII vs. MDI in preschool-aged
children with T1DM
< 18 years
Medtronic Australasia
ACTRN1260600004957263
2006 Integrated
CSII+CGM vs.
CSII+ SMBG
Yes MiniMed Paradigm REAL-Time
insulin pump and CGM system
(MMT-722 pump) vs. pre-trial
insulin pump device (no new
intervention)
13–39 years
Juvenile Diabetes
Research Foundation
ACTRN1261400051064064
2014 Veo vs. integrated
CSII+CGM
Yes CSII with real-time CGM system
and predictive LGS feature
(Medtronic’s MiniMed 640G)
vs. standard SAPT
8–20 years
The Royal Children’s
Hospital Melbourne
ACTRN1261000060509965
2010 CSII+ SMBG vs.
MDI+ SMBG
Yes CSII vs. MDIs in children and
adolescents with T1DM
9–16 years
Royal Children’s Hospital
ACTRN1261100014293266
2011 Integrated
CSII+CGM vs.
CSII+CGM
Yes Patients’ own pump vs. a new
integrated pump (unclear which
type of monitoring was used with
patients’ own pumps)
< 18 years
Alder Hey Children’s
NHS Foundation Trust
ISRCTN2925527567
2010 CSII+ SMBG vs.
MDI+ SMBG
Yes CSII vs. MDIs in children with T1DM 1–15 years
University of Schleswig-Holstein
NCT0133892268
2011 CSII+ SMBG vs.
MDI+ SMBG
Yes CSII vs. MDIs in children with T1DM 6–16 years
DAFNE, dose adjusted for normal eating; NHSFT, Sheffield Teaching Hospitals NHS Foundation Trust; Obs, observational
study; RTSA, real-time sensor augmentation.
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MiniMed Veo system versus the integrated CSII+ CGM system
Only one study (ASPIRE in-home32) with data for adults (n= 247) included the MiniMed Veo system as one
of the treatment arms. This study compared the MiniMed Veo system with an integrated CSII+CGM
system at 3-month follow-up. The results of this study showed that there was no significant difference in
change in HbA1c levels at 3-month follow-up; however, both nocturnal hypoglycaemic event rates and day
and night hypoglycaemic event rates were significantly reduced for patients using the MiniMed Veo
system. There were no significant differences in any of the other reported outcomes (BG level at follow-up,
insulin use, DKA, quality of life or adverse events). Therefore, the conclusion from this trial is that the
MiniMed Veo system reduces hypoglycaemic events in adults more than the integrated CSII+CGM system
does, without any differences in other outcomes, including the change in HbA1c levels.
MiniMed Veo system versus other treatments
Indirect evidence seems to suggest that that there are no significant differences between the MiniMed Veo
system and CSII+ SMBG or MDI+ SMBG with regard to the change in HbA1c levels at 3-month follow-up.
However, if all studies are combined (see Additional analyses for the economic model), the MiniMed Veo
system is significantly better than MDI+ SMBG in terms of the change in HbA1c levels.
The integrated CSII+ CGM system versus other treatments
Five studies compared the integrated CSII+CGM system with other treatments.34,37–40 One of these
compared the integrated CSII+CGM system with CSII+ SMBG at 6-month follow-up (Hirsch et al.34), but
this study reported only the change in HbA1c levels separately for adults. The other four studies compared
the integrated CSII+CGM system with MDI+ SMBG at 3-month follow-up (Lee et al.,38 and Peyrot and
Rubin39), at 6-month follow-up (Eurythmics37) and at 12-month follow-up (STAR-340).
The results of the trial34 comparing the integrated CSII+CGM system with CSII+ SMBG at 6-month
follow-up in adults showed no significant difference in HbA1c levels between groups. Other outcomes in
this trial were not reported separately for adults.34 An indirect comparison showed that quality of life was
significantly more improved in the integrated CSII+CGM group than in the CSII+CGM group.37,41
For the comparison of the integrated CSII+CGM system with MDI+ SMBG, the most reliable data, from
the largest trial with 12-month follow-up (STAR-340), show that there is a significant difference in the
change in HbA1c levels and in the proportion of patients achieving HbA1c levels of ≤ 7%, in favour of the
integrated CSII+CGM system. With regard to hypoglycaemic event rates, none of the studies showed a
significant difference between groups. Similarly, there were no significant differences in DKA between
groups. Insulin use was significantly lower in patients using the integrated CSII+CGM system, and quality
of life was significantly more improved in the integrated CSII+CGM group than in the CSII+ SMBG group.
Overall, the results show significant results in favour of the integrated CSII+CGM system over
MDI+ SMBG with regard to HbA1c levels and quality of life.
Continuous subcutaneous insulin infusion versus multiple daily
insulin injections
We found six trials with data for adults comparing CSII+ SMBG with MDI+ SMBG.41–46 No trials were
found with data for adults comparing the treatments CSII+CGM and MDI+CGM.
In terms of the change in HbA1c levels, only one42 of the six trials showed a significant difference between
CSII+ SMBG and MDI+ SMBG. DeVries et al.42 found a significant difference in favour of CSII+CGM: at
16 weeks, the mean HbA1c level was 0.84% lower (mean = –0.84%, 95% CI –1.31% to –0.36%) in the
CSII+ SMBG group than in the MDI+ SMBG group. Significance was not reported in the OSLO trial44 or in
Nosadini et al.,43 while the difference between groups was not significant in Bolli et al.,41 Thomas et al.45 or
Tsui et al.46
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In terms of the number of severe hypoglycaemic events, three trials found no significant differences
between groups (Bolli et al.,41 DeVries et al.42 and Thomas et al.45), while this was not reported in the other
three trials.
Studies in children
Six studies were included in the analyses for children.33,34,40,47–49 One of these studies (Hirsch et al.34)
reported only the change in HbA1c levels separately for children. None of these studies looked at CSII or
MDI+CGM. Table 15 shows an overview of these six studies, their comparisons and their baseline data.
Further details are reported in Appendix 3.
MiniMed Veo system versus the integrated CSII+ CGM system
None of the studies in children made a direct comparison between the MiniMed Veo system and the
integrated CSII+CGM system.
An indirect comparison was possible, using data at 6-month follow-up from Ly et al.33 and Hirsch et al.,34
but only for HbA1c levels, which showed no significant difference between groups.
MiniMed Veo system versus other treatments
One study compared the MiniMed Veo system with CSII+ SMBG at 6-month follow-up in a mixed
population of patients between 4 and 50 years old (Ly et al.33). No results were found for the MiniMed
Veo system versus any other treatment at 3-month or ≥ 9-month follow-up.
The only significant difference between treatment groups was the rate of moderate and severe
hypoglycaemic events, which favoured the MiniMed Veo system. All other outcomes showed no significant
differences between groups.
The integrated CSII+ CGM system versus other treatments
One study compared the integrated CSII+CGM system with CSII+ SMBG at 6-month follow-up in children
(Hirsch et al.34). This trial found no significant difference in HbA1c levels between groups.
One study (STAR-340) compared the integrated CSII+CGM system with MDI+ SMBG at 12-month
follow-up in children. This trial showed a significant difference in HbA1c change scores in favour of the
integrated CSII+CGM system, but no significant difference in the number of children achieving HbA1c
levels of ≤ 7%. The hyperglycaemic AUC was significantly lower in the integrated CSII+CGM group, but
the hypoglycaemic AUC showed no significant difference between groups. Other outcomes showed no
significant differences between groups.
Studies in pregnant women
We found one RCT that reported data for pregnant women.57 The study included 32 pregnancies in
31 different pregnant women. The number of pregnancies was the unit of analysis. The study compared
CSII+ SMBG with MDI+ SMBG; therefore, the results are not relevant for comparisons with the MiniMed
Veo system or the integrated CSII+CGM system.
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Chapter 4 Assessment of cost-effectiveness
In this chapter, we explore the cost-effectiveness of integrated insulin pump systems in the managementof T1DM in adults in the UK.
Review of the economic evaluations
Search methods
Literature searches were undertaken to identify published economic evaluations of the MiniMed Paradigm
Veo system and the Vibe and G4 PLATINUM CGM system. The search strategy for economic evaluations
included a filter designed to identify cost and economic studies in databases that are not health
economics specific.
The following databases and resources were searched for relevant economic evaluations and cost studies:
l NHS Economic Evaluation Database (Wiley Online Library): issue 3/July 2014
l Health Economic Evaluations Database (Wiley Online Library): up to 5 September 2014
l MEDLINE (via OvidSP): 1946–2014/August week 4
l MEDLINE In-Process Citations and Daily Update (via OvidSP): up to 5 September 2014
l PubMed (via National Library of Medicine): up to 5 September 2014
l EMBASE (via OvidSP): 1974–2014/week 34
l EconLit (EBSCOhost): 1969–1 August 2014
l Cost-effectiveness Analysis Registry (www.cearegistry.org): up to 5 September 2014
l Research Papers in Economics (http://repec.org/): up to 5 September 2014.
In addition, economic searches specifically for the MiniMed Paradigm Veo system, and Vibe and G4
PLATINUM CGM system were conducted using the same resources listed above.
The full search strategies are presented in Appendix 1.
Relevant studies were then identified in two stages. Titles and abstracts returned by the search strategy
were examined independently by two researchers (Maiwenn Al and Isaac Corro Ramos) and screened for
possible inclusion. Disagreements were resolved by discussion. Full texts of the identified studies were
obtained. Two researchers (Maiwenn Al and Isaac Corro Ramos) examined these independently for
inclusion or exclusion, and disagreements were resolved by discussion.
Inclusion criteria
The initial search identified a total of eight abstracts, six of which were of conference abstracts and were
thus not included. Both of the full-text papers were identified as relevant to our review. These studies were
by Kamble et al.69 and Ly et al.70 The study by Kamble et al.69 evaluated integrated CSII+CGM versus
MDI+ SMBG in the USA, whereas the study by Ly et al.70 evaluated the MiniMed Paradigm Veo system
versus CSII+ SMBG in Australia. The first evaluation69 showed that the integrated CSII+CGM system was
not cost-effective compared with MDI+ SMBG, despite taking all health effects into account through the
IMS Centre for Outcomes Research and Effectiveness diabetes model (IMS CDM) version 8.5 (IMS Health,
Danbury, CT, USA). On the other hand, the second study70 showed that the MiniMed Veo system was
cost-effective compared with CSII+ SMBG, if only the impact on the reduction of severe hypoglycaemic
events was taken into account.
The characteristics of these studies are summarised in Table 24.
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Of the six (excluded) conference abstracts, one was an abstract that was later published as a full-text
paper71 and was already included as one of the two selected full-text papers.69 While we will not formally
discuss the conference abstracts,72–76 their characteristics, as far as they can be found in these abstracts,
are presented in Table 25.
Quality assessment
A quality appraisal was carried out on the two studies,69,70 using the Drummond checklist.77 A summary of
the results are provided in Table 26.
Results
Study design
Both studies69,70 were modelling studies, each based primarily on one clinical study. As a result, one of the
studies69 did not explain why the comparator had been chosen. They both stated their research question
and the approach to economic evaluation clearly.
In one study,70 results were presented both as cost per severe hypoglycaemic events avoided (all patients) and
as costs per quality-adjusted life-year (QALY) gained (patients of ≥ 12 years of age). A clear rationale was
provided [i.e. the European Quality of Life-5 Dimensions scale (EQ-5D) was administered to parents and carers
on behalf of children aged < 12 years] with regard to why cost per QALY could only be estimated for patients
of ≥ 12 years. The outcomes per severe hypoglycaemic events avoided are unlikely to be informative for
decision makers who want to establish the cost-effectiveness from a health-care perspective.
Data
As mentioned above, both studies69,70 were based on a single clinical study. The current papers describe
the details of the study design only briefly, but refer to the papers that specifically present the clinical
results. The study69 based on the IMS CDM did not provide a rationale with regard to why the IMS CDM
was chosen. The other study70 explained the choice of model by stating that this was a trial-based
economic evaluation and so costs and effects were not extrapolated beyond the 6-month clinical trial
period. This means that the long-term impact of the changes in HbA1c levels seen during the clinical study
were not taken into consideration, and only the direct impact of avoiding severe hypoglycaemic events are
accounted for.
For the study based on the IMS CDM,69 all utilities and costs of complications were taken from literature.
Hence, in this paper, no information was available with regard to the subjects from whom valuations of
quality of life were obtained, and resources for complications were not reported separately from their unit
cost. The cost information relating to the technologies and insulin treatment did provide both resource-use
and unit costs.
For the 6-month study,70 all details regarding utilities and resource use were clearly presented. However,
once the results were presented, it became clear that an explanation for the calculation of utilities and
QALYs was lacking. For example, the paper reported a QALY accumulation of –0.00017 for the standard
pump group (CSII+ SMBG), which would only be possible if patients had a health state of worse than
death. A likely explanation is the definition of QALYs used in the paper, but this was not clarified.
Analysis and interpretation of results
Both studies69,70 were, in general, performed appropriately; however, the study by Kamble et al.69 did not
discuss any issues pertaining to generalisability.
In summary, only one study was found for the integrated CSII+CGM and one for the MiniMed Veo
system, both with different comparators and for different countries. The latter study is of limited
importance to the current diagnostic appraisal, given its short time horizon of 6 months and its very limited
model structure. The study of integrated CSII+CGM by Kamble et al.69 was better, given that all
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TABLE 26 Results of the quality assessment of studies, performed using the Drummond checklist (1996)77
Criteria Kamble et al. (2012)69 Ly et al. (2014)70
Study design
1. Was the research question stated? Yes Yes
2. Was the economic importance of the
research question stated?
Yes Yes
3. Was/were the viewpoint(s) of the analysis
clearly stated and justified?
Yes Yes
4. Was a rationale reported for the choice of
the alternative programmes or interventions
compared?
No, CEA based on clinical
trial so alternative based on
that
Yes
5. Were the alternatives being compared clearly
described?
Partially; not easy to find if
glucose monitoring is CGM
or SMBG
Yes
6. Was the form of economic evaluation stated? Yes Yes
7. Was the choice of form of economic
evaluation justified in relation to the
questions addressed?
Yes Justification was given, but doubtful if
choice is reasonable
Data collection
8. Was/were the source(s) of effectiveness
estimates used stated?
Yes Yes
9. Were details of the design and results of the
effectiveness study given (if based on a single
study)?
Yes; most details in separate
paper
Yes; most details in separate paper
10. Were details of the methods of synthesis or
meta-analysis of estimates given (if based on
an overview of a number of effectiveness
studies)?
NA NA
11. Was/were the primary outcome measure(s)
for the economic evaluation clearly stated?
Yes Yes
12. Were the methods used to value health
states and other benefits stated?
Yes Yes; however, after seeing QALY
outcomes, explanation clearly
insufficient
13. Were the details of the subjects from whom
valuations were obtained given?
NA; utilities from literature Yes
14. Were productivity changes (if included)
reported separately?
NA NA
15. Was the relevance of productivity changes to
the study question discussed?
NA NA
16. Were quantities of resources reported
separately from their unit cost?
Yes for all treatment related
costs; no for complication
costs
Yes
17. Were the methods for the estimation of
quantities and unit costs described?
Yes Yes
18. Were currency and price data recorded? Yes Yes
19. Were details of price adjustments for
inflation or currency conversion given?
Yes NA
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TABLE 26 Results of the quality assessment of studies, performed using the Drummond checklist
(1996)77 (continued )
Criteria Kamble et al. (2012)69 Ly et al. (2014)70
20. Were details of any model used given? Yes Yes
21. Was there a justification for the choice of
model used and the key parameters on
which it was based?
No justification for why IMS
CDM was used in the paper
A justification was given, i.e. the
clinical trial was modelled and
extrapolation was not considered of
interest. Unlikely that only looking at
hypoglycaemic events and not
long-term complications is of interest
for decision makers
Analysis and interpretation of results
22. Was the time horizon of cost and benefits
stated?
Yes Yes
23. Was the discount rate stated? Yes NA
24. Was the choice of rate justified? Yes NA
25. Was an explanation given if costs or benefits
were not discounted?
NA Yes
26. Were the details of statistical test(s) and CIs
given for stochastic data?
Yes Yes
27. Was the approach to sensitivity analysis
described?
Yes Yes
28. Was the choice of variables for sensitivity
analysis justified?
Yes No justification given, but choices
appear reasonable
29. Were the ranges over which the parameters
were varied stated?
Yes Yes
30. Were relevant alternatives compared?
(That is, were appropriate comparisons made
when conducting the incremental analysis?)
Yes Yes
31. Was an incremental analysis reported? Yes Yes
32. Were major outcomes presented in a
disaggregated as well as aggregated form?
Yes Yes; this highlighted the lack of face
validity: QALYs in both arms were
0.036650 and –0.00017, while
perfect health would yield 0.5 per arm
33. Was the answer to the study question given? Yes Yes
34. Did conclusions follow from the data
reported?
Yes Yes
35. Were conclusions accompanied by the
appropriate caveats?
Yes Not fully; authors did not discuss the
impact of the intervention in the trial
on HbA1c levels and how that would
impact cost-effectiveness
36. Were generalisability issues addressed? No Yes
CEA, cost-effectiveness analysis; NA, not applicable; QALY, quality-adjusted life-year.
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potentially relevant costs and effects were included. However, IMS Health has now published updated
utility values that conform with the NICE standard (i.e. based on EQ-5D)78 and has also updated the IMS
CDM several times. Thus, the value of the Kamble et al. paper69 mostly relates to its use for formulating
scenarios and presenting a benchmark against which the validity of outcomes from the de novo
cost-effectiveness analysis could be checked.
Model structure and methodology
This section describes the health economic model used to evaluate the cost-effectiveness of the MiniMed
Paradigm Veo system (an integrated CGM and insulin pump system with LGS function) and the Vibe and
G4 PLATINUM CGM system for the management of T1DM in adults in comparison with (1) CSII+CGM,
(2) CSII+ SMBG, (3) MDI+CGM and (4) MDI+ SMBG.
The IMS CDM79 was chosen to perform the cost-effectiveness analyses in this assessment. The IMS
CDM has been previously used in NICE- and NHS-related projects on T1DM. It is probably the most
commonly used model in the literature and it has been validated extensively. It was used to assess the
cost-effectiveness of CSII versus MDIs for T1DM patients in a HTA report from 2010.80 In that report, the
IMS CDM was deemed to be inappropriate for health economic outcomes in paediatric and adolescent
populations. This was confirmed by the model developers who also mentioned that the model is not
appropriate for pregnant women either. Therefore, these two subgroup populations were not included in
the cost-effectiveness analyses. The IMS CDM has also been used in the current update of the NICE
Guideline on T1DM (NG17).81 The model’s time horizon was set to 80 years. Costs were estimated from
the perspective of the NHS in England and Wales. Consequences were expressed in life-years gained and
QALYs. All costs and effects were discounted by 3.5%. The uncertainty about model input parameters and
the potential impact on the model results were explored through scenario analyses and probabilistic
sensitivity analyses.
Model structure
The IMS CDM is an internet-based, interactive simulation model that predicts the long-term health
outcomes and costs associated with the management of T1DM and T2DM. It is suitable for running cohort
(bootstrap) and individual patient-level simulations. It was first developed by the Centre for Outcomes
Research and Effectiveness and details of the first version were published by Palmer et al. in 2004.79 It is
widely used in diabetes cost-effectiveness research, both by health technology companies as well as those
who pay for such technologies, and it has also been used in previous NICE technology assessments and
clinical guidelines.14,81–85 The model has been extensively validated. Since 1999, it has been examined at
Mount Hood conferences, during which health economic models on diabetes are compared with each
other in terms of their structure, performance and validity.86–88 Two major validation papers on the IMS
CDM have been published to date.89,90 The latest one,90 from 2014, is the basis for the technical model
description provided in this report. This description is consistent with the latest version of the model
(version 8.5). Given the degree of validation of the model, and in order to be in line with the T1DM NICE
guideline,81 it was deemed important not to use an alternative model or develop a de novo cost-effectiveness
model for this evaluation.
The structure of the IMS CDM (from McEwan et al.90) is shown in Figure 10. The IMS CDM comprises
17 interdependent submodels, which represent the most common diabetes-related complications: angina
pectoris, myocardial infarction (MI), congestive heart failure (CHF), stroke, peripheral vascular disease (PVD),
diabetic retinopathy, cataracts, hypoglycaemia, DKA, nephropathy, neuropathy, foot ulcer/amputation,
macular oedema, lactic acidosis (T2DM only), (peripheral) oedema (T2DM only) and depression. A
submodel for non-specific mortality is also included. Each of these submodels is a Markov model that
includes different health states depicting the severity/stage of the complication. Transition probabilities in
between the states of a complication submodel can be dependent on time, demographics, health state,
physiological factors and diabetes type.
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In addition, the non-parametric bootstrapping approach provides additional information on the uncertainty
surrounding the long-term outcomes provided by the model. In this approach, a cohort population (with a
size that can be defined by the model user) is created. Each patient in this population is unique in the
sense of its baseline characteristics (demographics, existing baseline complications, baseline physiological
risk factors and other risk factors, e.g. the number of cigarettes smoked per day). Within the bootstrapping
simulation approach, two types of analysis are possible: deterministic and probabilistic. In the deterministic
simulation, the continuous input parameters (baseline age, diabetes duration, HbA1c levels, etc.) of each
patient in the cohort that is created (e.g. 1000 patients) will be identical, but binary variables will differ
(gender, presence of a diabetes-related complication, e.g. MI, etc.). In each iteration, one of the patients in
this cohort is sampled with replacement and entered into the simulation (i.e. the complication submodels)
until the patient dies. Applied treatment effects, utilities, costs and coefficients of cardiovascular disease
(CVD) events will then be identical in each iteration. However, results will differ per iteration because of the
differences in the binary input parameters in the baseline cohort and the way a patient progresses through
the model (random walk). In the probabilistic simulation, all variables that are subjected to random sampling
(i.e. cohort baseline parameters, treatment effects, coefficients of the CVD risk equations, health-state
utilities/adverse event disutilities and costs) are randomly assigned at the beginning of the first iteration
according to pre-defined probability distributions. Then all the patients in the cohort (e.g. 1000) are
processed through the model while the parameters assigned at the start of the iteration are held constant.
Those patients will only differ as a result of binary variables and random walk. When the model progresses
to the next iteration, parameters are resampled again and the next 1000 patients are progressed though
the model while parameters are held constant again. This process is repeated for all the bootstrap iterations.
However, it should be noted that because of computational time requirements, not all parameters in the
model are subjected to random sampling. For instance, among the baseline risk factors, cigarette and
alcohol consumption per day are not subjected to sampling. The same is true for minor and severe
hypoglycaemia/ketoacidosis rates and coefficients from non-CVD-related risk adjustment equations.
Transition probabilities within each submodel (i.e. the annual probability of a change in health state) are
dependent on baseline demographic and current physiological patient characteristics [HbA1c levels, body
mass index (BMI), etc.], and the existence of other complications and concomitant treatments (e.g.
angiotensin-converting enzyme inhibitor, statin or laser). Transition probabilities are further calculated
based on established regression or risk adjustment functions from the literature.91–93 State transitions of a
cohort occur simultaneously in each submodel. Therefore, it is possible that a patient will develop multiple
complications in 1 year. In the IMS CDM model, diabetes-specific mortality is assumed to be caused by the
following complications: MI, stroke, CHF, nephropathy, foot ulcer/amputation, hypoglycaemia, DKA and
lactic acidosis. However, non-specific mortality is based on UK life tables.94 Additional details on the
submodels of the IMS CDM are given in Appendix 5.
An important limitation of the model is that it is not suitable for modelling long-term outcomes for
children or adolescent populations, because the background risk adjustment/risk factor progression
equations (such as those based on the Framingham studies)93,95–97 are all based on adult populations.
Hence, we had to limit all our analyses to the adult population.
Model input parameters
This section describes the input parameters used in the model for the base case and how their values were
estimated. Six different input parameter databases can be distinguished in the IMS CDM: (1) cohort,
(2) economics (including management costs, costs of complications and utilities), (3) treatment effects,
(4) treatment costs, (5) other management and (6) clinical. Table 27 maps the IMS CDM input parameter
databases into the conventional model input categories.
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TABLE 27 Mapping IMS CDM input parameter databases into conventional input parameter categories
IMS CDM input database Conventional input parameter category
Cohort database Demographics (age, diabetes duration, percentage male, racial profile)
Baseline physiological risk factors (e.g. HbA1c levels, SBP, T-CHOL, BMI, etc.)
Baseline complications (proportion with MI history, proportion with cataract, etc.)
Other risk factors (proportion that smoke, alcohol consumption, etc.)
Economics database Cost and effect discount rates
Sampling settings for PSA (for costs)
Management costs (e.g. statin, aspirin, ACEI costs, screening costs for depression, foot
ulcer, eye disease, etc.)
Utilities/utility decrements for all relevant health states and adverse events
Direct costs for:
l Cardiovascular complications (year 1 and ≥ 2 costs for MI, angina, CHF, stroke, etc.)
l Renal complications (year 1 and ≥2 costs for haemodialysis, renal transplantation, etc.)
l Eye diseases/complications (year 1 and ≥ 2 costs for cataract, severe vision loss, etc.)
l Foot ulcer/amputation/neuropathy (year 1 and ≥ 2)
Acute events (severe hypoglycaemia, DKA, etc.)
Treatment database Effect of the treatment on physiological parameters:
l For the first year: change in the baseline value
l For the consecutive years: progression approach (e.g. UKPDS,91,96,98 Framingham93,95–97
or user-defined clinical tables)
Adverse events:
l Minor and severe hypoglycaemic events
l DKA events
Risk adjustments for concomitant medicines (e.g. ACEIs, statins)
Treatment cost group database Assigns treatment costs to the treatments for year 1 and afterwards
Management database Percentage of patients on concomitant medication (e.g. statins, ACEIs)
Percentage of patients on screening or patient management programmes (e.g. renal
disease screening or foot ulcer prevention programme)
Other:
l Risk reductions because of management and sensitivity/specificity of screening tests
Clinical database Risk adjustments for:
l HbA1c
l SBP
Risk multipliers for:
l MI
l Stroke
l Angina
l CHF
l Ethnicity
l Adverse events
l Other microvascular complications
l Foot ulcer/amputation
l Depression
l Others
ACEI, angiotensin-converting enzyme inhibitor; PSA, probabilistic sensitivity analysis; SBP, systolic blood pressure;
T-CHOL, total cholesterol; UKPDS, UK Prospective Diabetes Study.
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Given the degree of validation of the model, only those parameters that needed to be adapted to time
(year 2015), place (the UK), population (T1DM patients eligible for a pump) and technologies to be
compared were amended in the base case. Furthermore, for the sake of consistency, unless there was
thought to be a more appropriate value, we chose to follow the approach from the latest diabetes NICE
guideline81 (which also adopted the IMS CDM). In addition, many of the parameters were also validated by
clinical experts. Further details on specific input parameters and their probability distributions are
described below.
Baseline population characteristics
If possible, we estimated cohort baseline parameters based on the studies identified in our systematic
review to properly reflect our base-case population (i.e. T1DM patients eligible for an insulin pump). In this
case, only the study by Bergenstal et al.32 provided reliable information for some patient characteristics.
For the characteristics not reported in Bergenstal et al.,32 we used those from the general T1DM population,
as in the latest diabetes NICE guideline.81 The cohort baseline characteristics used in our base-case analysis
and their sources can be seen in Table 28. For the probabilistic sensitivity analysis (PSA) the input parameters
age, duration of diabetes and baseline risk factors, for HbA1c levels, systolic blood pressure (SBP), BMI, total
cholesterol and low-density lipoproteins, are sampled from a normal distribution; the means and SDs are
given in Table 28. Baseline triglyceride and high-density lipoprotein levels are sampled from a gamma
distribution with the following parameters: alpha=mean2/SD2 and beta=mean/SD2.
TABLE 28 Cohort baseline characteristics (base-case analysis)
Parameter Mean SD Source
Patient demographics
Start age (years) 41.6 12.8 Bergenstal et al. (2013)32
Duration of diabetes (years) 27.1 12.5
Proportion male 0.38 NA
Baseline risk factors
HbA1c (% points) 7.26 0.71 Bergenstal et al. (2013)
32
SBP (mmHg) 128.27 16.07 National Diabetes Audit99
Total cholesterol (mg/dl) 176.50 33.00 Nathan et al. (2009)100
HDL (mg/dl) 50.25 13.00
LDL (mg/dl) 109.75 29.00
Triglycerides (mg/dl) 81.50 41.00
BMI (kg/m2) 27.6 15.9 Bergenstal et al. (2013)32
eGFR (ml/min/1.73 m2) 77.50 0 Default IMS CDM value81 (not used in
our analyses)
Haemoglobin (g/dl) 14.50 0
White blood cell count (106/ml) 6.80 0
Heart rate (b.p.m.) 72 0
Proportion smoker 0.22 NA National Diabetes Audit99
Cigarettes/day 12 NA Opinions and Lifestyle Survey, Smoking
Habits Amongst Adults, 2012101
Alcohol consumption (oz/week) 9a NA The WHO’s Global Status Report on
Alcohol and Health (2011)102
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TABLE 28 Cohort baseline characteristics (base-case analysis) (continued )
Parameter Mean SD Source
Racial characteristics
Proportion white 0.92 NA National Diabetes Audit99
Proportion black 0.03 NA
Proportion Hispanic 0.05 NA
Proportion Native American 0 NA
Proportion Asian/Pacific Islander 0 NA
Baseline CVD complications
Proportion MI 0 NA Assumption
Proportion angina 0.00298b NA England Health Survey (2011)103
Proportion PVD 0 NA Assumption
Proportion stroke 0.00298c NA England Health Survey (2011)103
Proportion heart failure 0 NA Assumption
Proportion atrial fibrillation 0 NA
Proportion left ventricular hypertrophy 0 NA
Baseline renal complications
Proportion microalbuminuria 0.181 NA National Diabetes Audit99
Proportion gross proteinuria 0 NA Assumption
Proportion end-stage renal disease 0 NA
Baseline retinopathy complications
Proportion background diabetic retinopathy 0 NA Assumption
Proportion proliferative diabetic retinopathy 0 NA
Proportion severe vision loss 0 NA
Baseline macular oedema
Proportion macular oedema 0 NA Assumption
Baseline cataract
Proportion cataract 0 NA Assumption
Baseline foot ulcer complications
Proportion uninfected ulcer 0 NA Assumption
Proportion infected ulcer 0 NA
Proportion healed ulcer 0 NA
Proportion history of amputation 0 NA
Baseline neuropathy
Proportion neuropathy 0.049 NA Nathan et al. (2009)100
Baseline depression
Proportion depression 0.21 NA Hopkins et al. (2012)104
b.p.m., beats per minute; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density
lipoprotein; NA, not applicable.
a 13.37 litres per year.
b Angina in 25- to 34-year age group.
c Stroke in 25- to 34-year age group.
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Costs
The direct costs included in the model are for:
l management (for primary prevention of complications)
l diabetes-related complications
l the treatment of diabetes (this also includes the cost of the pump and/or glucose monitor)
l other hospital costs.
Indirect costs parameters were set to zero in the model as these were not included in our analyses, given
the perspective of the NHS. Treatment costs were not included in the PSA because this was not possible
using the current version of the IMS CDM, as the model developers argue that the uncertainty around the
pharmacy/treatment administration costs is very small.
All other direct costs can be included in the PSA. Although cost parameters are typically sampled from
different distributions independently in other economic evaluations, in the IMS CDM all direct costs are
multiplied by the same positive factor which is sampled from a log-normal distribution with a mean of 1 and
a user-defined coefficient of variation. In line with the latest diabetes NICE guideline,81 for our analyses we
assumed a 20% deviation from the mean as it is assumed that this would represent a reasonable range of
variation. Detailed descriptions of all four direct cost categories are given in the following sections.
Disease management unit costs
Management costs include the costs of managing chronic conditions, performing screening procedures,
administering concomitant medication, etc. All cost data were sourced from NG1781 and, if necessary,
were further inflated to 2014 prices using the 2013/14 Hospital and Community Health Services (HCHS)
index available from the Personal Social Services Research Unit (PSSRU).105 The management costs used in
our analyses can be seen in Table 29.
Costs of diabetes-related complications
Both ongoing disease complications and acute events are considered in this section. The costs of ongoing
complications are considered per year until the complication is resolved or the patient dies. The costs
of acute events are assumed to occur at only the time of the event. The costs of diabetes-related
complications were sourced from NICE Guideline NG1781 and, if necessary, were inflated to 2014 prices
using the 2013/14 HCHS index available from the PSSRU.105 These costs are shown in Table 30.
Treatment costs
Sensor-augmented pump therapy
In addition to the cost of the MiniMed Paradigm Veo System and the Vibe and G4 PLATINUM CGM
system, a number of consumables are needed. These are cannulas, reservoirs and batteries for the
insulin pump and sensors for the CGM device. The prices and expected lifetimes of these devices and
consumables were reported by the relevant manufacturers. To estimate the equipment costs associated
with these devices, the following assumptions were made:
l insulin pumps have a 4-year lifetime
l cannulas and reservoirs would be replaced every 3 days
l the MiniMed Paradigm Veo requires one Energizer® AAA alkaline battery (Energizer® Holdings, Inc.,
St Louis, MO, USA) and the battery will be replaced every 8.5 days (the lifetime of the battery is
dependent on the quality of the battery, the nature of the pump use, temperature, etc.)
l the Vibe pump operates on one AA battery (lithium batteries are recommended) and the expected
battery lifetime is 5 weeks (35 days) (continuous glucose monitor components are supplied with a
rechargeable battery and a charger)
l the MiniLink transmitter is replaced each year and the sensors are replaced every 6 days
l the G4 PLATINUM monitor is replaced every 6 months and the sensors are replaced every 7 days.
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TABLE 29 Management costs in T1DM patients
Management type
Mean cost
per year (£) Source
ACEIs 18.54a NHS drug tariff (2014)106
Statins 38.22b
Aspirin 13.70c
Screening for microalbuminuria 3.12d Lamb et al. (2009)107
Screening for gross proteinuria 2.94e
Stopping ACEIs because of adverse events 19.96f NHS drug tariff (2014)106
Eye screening 35.38 Assumption
g
Foot screening programme 42.46h NHS Reference Costs 2012–13108
Non-standard ulcer treatment [e.g. becaplermin
(Regranex®, Smith & Nephew)]
0 Default value in IMS CDM81
Antidepression treatment and management 494.44 NICE Guideline NG1781
Screening for depression 0 Assumptioni
ACEI, angiotensin-converting enzyme inhibitor.
a Average cost of five generics.
b Atorvastatin (80mg/day for 28 days).
c After an ischaemic event (75mg/day for 28 days).
d Weighted: 80% once per year; 20% three times per year; unit cost £2.16.
e Two per year; unit cost £1.42.
f Angiotensin receptor antagonist for 28 days (50mg/day of losartan potassium or 8mg/day of candesartan cilexitil).
g Based on annual national cost of £70M for 2 million diabetic screens once per year (Clinical Guideline Development
Group of the UK National Screening Committee, December 2013, personal communication).
h Podiatrist outpatient visit.
i Included in cost of antidepression treatment and management.
TABLE 30 Costs of T1DM-related complications
Type of complication Mean cost (£) Source
CVD complications
MI, first year 3731 aNICE lipids clinical guideline (CG181)109,110
MI, each subsequent year 788
Angina, first year 6406
Angina, each subsequent year 288
CHF, first year 3596
CHF, each subsequent year 2597
Stroke, fatal (within 30 days) 1174
Stroke, non-fatal first year 4170
Stroke, each subsequent year 155
PVD, first year 952
PVD, each subsequent year 529
continued
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TABLE 30 Costs of T1DM-related complications (continued )
Type of complication Mean cost (£) Source
Renal complications
Haemodialysis, each year 30,819 NICE peritoneal dialysis clinical guideline (CG125)111
Peritoneal dialysis, each year 24,793
Renal transplant, first year 20,600
Renal transplant, each subsequent year 7694
Acute events
Severe hypoglycaemic event (cost per event) 439 NICE Guideline NG1781
Minor hypoglycaemic event (cost per event) 0
DKA event (cost per event) 0
Eye disease
Laser treatment 705 NHS Reference Costs 2012–13 (BZ24D:
non-surgical ophthalmology with interventions)108
Cataract operation 1035 Weighted NHS Reference Costs 2012/13:
non-phacoemulsification cataract surgery,
with complication score 0 (BZ03A) and score 1+
(BZ03B)108
After cataract operation 81 NHS Reference Costs 2012–13 (WF01A:
non-admitted face-to-face attendance,
ophthalmology follow-up)108
Blindness, year of onset 5647 NICE glaucoma clinical guideline (CG85)112,113
Blindness, each subsequent year 5456
Neuropathy/foot ulcer/amputation
Neuropathy, each year 362 MIMS, 2014 (online version):114 60mg of duloxetine
(Cymbalta®, Elli Lilly and Co.) daily (first-line
treatment in NICE CG96)115
Amputation, event based 11,416 NICE lower limb peripheral arterial disease clinical
guideline (CG147)116,117
Amputation with prosthesis, event based 15,420
Gangrene treatment 5483 Ghatnekar et al. (2002)118
Healed ulcer 266
Infected ulcer 7410 NICE CG147116,117 and Kerr (2012)119
Uninfected ulcer 4115
Healed ulcer with history of amputation 25,577 NICE lower limb peripheral arterial disease clinical
guideline (CG147)116,117
MIMS, Monthly Index of Medical Specialties.
a It was assumed that one-third of angina episodes would be unstable and two-thirds would be stable.
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Table 31 presents the estimated yearly equipment costs for the MiniMed Paradigm Veo system and the
Vibe and G4 PLATINUM CGM system.
Continuous subcutaneous insulin infusion (stand-alone insulin pumps)
The average price of a stand-alone insulin pump in the UK was sourced from a study from the London
New Drugs Group in November 2013.120 This was inflated to 2014 prices using the 2013/14 HCHS index
available from the PSSRU105 and are shown in Table 32. An estimated market share for each brand was
calculated based on White et al.121 and data from Diabetes UK.122 Based on this information, the estimated
weighted average price for a stand-alone pump in the UK is £2173.54.
Continuous glucose monitoring (stand alone)
We followed the approach in NICE Guideline NG1781 and considered the three main CGM technologies
available in the UK: Dexcom G4 PLATINUM, Abbott (Chicago, IL) FreeStyle Navigator and Medtronic
Guardian®. The items included were receivers, transmitters and sensors. The costs of the three receivers
were sourced from NICE Guideline NG17.81 Transmitter and sensor costs, and usage for the Dexcom G4
and the Medtronic Guardian, were assumed to be the same as for integrated systems (see Table 31), since
this information was provided by the companies. For the Abbott FreeStyle Navigator, sensor costs (there is
no transmitter) and usage were assumed to be the same as reported in NICE Guideline NG17.81 Finally, a
yearly weighted average cost, equal to £3087.75, was estimated based on the estimated market share
from White et al.121 and data from Diabetes UK.122 This information is shown in Table 33.
TABLE 31 Equipment costs of MiniMed Paradigm Veo system and Vibe/G4 Platinum CGM system based on
2014 costs
Cost component MiniMed Paradigm Veo system Vibe/G4 Platinum CGM system
Insulin pump £2679 £2800
Insulin pump cannula £8.70 £9.75
Insulin pump reservoir £2.68 £2.46
Insulin pump batteries £0.49a £1.77b
Continuous glucose monitor transmitter £228.70 £335.0
Continuous glucose monitor sensor £42.05 £46.50
Total device cost £2961.62 £3195.48
Insulin pump
Years of use 4 4
Cannula, units/year (days of use) 121.67 (3) 121.67 (3)
Reservoir, units/year (days of use) 121.67 (3) 121.67 (3)
Batteries, units/year (days of use) 42.94 (8.5) 10.42 (35)
Continuous glucose monitor
Transmitter (years of use) 1 0.5
Sensor, units/year (days of use) 60.83 (6) 52.14 (7)
Total costs
Total cost per year £4862.10 £5298.65
a Energizer Classic AAA batteries (4 pack).
b Energizer Ultimate Lithium AA batteries (4 pack).
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Blood glucose tests costs
Blood glucose tests are needed in all interventions and comparators. Each time a BG test is conducted a
lancet and a test strip are consumed. The estimated cost of a single BG test (computed as the average of
all marketed lancets and test strips) is £0.29 according to NICE Guideline NG17.81 We assumed that BG
meters are supplied free of charge. The number of BG tests required for the different interventions and
comparators depend on the method of monitoring glucose, whether it is manual (SMBG) or continuous
(CGM). Our systematic review identified only two studies reporting the number of BG tests.37,40 Based on
these studies, we defined, on average, four BG tests per day for both SMBG and CGM for the base case.
Based on clinical opinion, this choice seems to be somewhat counterintuitive as a higher number of tests
would be expected for SMBG than for CGM. However, we believe that trial values are generally more valid
and consistent within our analyses, given that the estimate of effectiveness comes from the trials and there
is likely to be a correlation between frequency of monitoring and outcome. Nevertheless, since there was
some uncertainty around these values, other options were explored in scenario analyses. Yearly costs
associated with SMBG for the base case are shown in Table 34.
TABLE 32 Price and market share of stand-alone insulin pumps in the UK
Cost component
(all costs net of VAT)
Insulin pump
Accu-Chek®
Spirit (Roche,
Basel)
Dana
(SOOIL,
Seoul)
Animas
Vibe
Medtronic
Paradigm
mylife OmniPod
(Ypsomed,
Burgdorf)
Insulin pump £2523a £1972a £2831a £2882a £425a
Estimated annual
non-consumables cost
(based on 4 years of life)
£631 £493 £708 £720
Estimated annual
consumables cost
£1324 £1400 £1663 £1282 £3052
Total cost per year £1955 £1893 £2371 £2002 £3158
Estimated UK market share (%)b 30 3 23 35 9
Average cost per year (based on market shares) £2174
VAT, value-added tax.
a Quoted price from the London New Drugs Group Comparative Table of Insulin Pumps (produced for use within the
NHS),120 inflated to 2014 prices using the 2013/14 HCHS index available from the PSSRU (2014).105
b UK market share per brand derived from White et al. (2013)121,122 and Diabetes UK.
TABLE 33 Price and market share of stand-alone CGM devices in the UK in 2014
Continuous glucose monitor
component
CGM device
Dexcom G4 FreeStyle Navigator Medtronic Guardian
Receiver cost £1750 £950 £1059
Transmitter cost £335 £0 £229
Sensor cost £47 £48 £42
Total equipment cost £2132 £998 £1330
Receiver, years of use 5 5 5
Transmitter, years of use 0.5 0 1
Sensor, units/year (days of use) 52.14 (7) 60.83 (6) 60.83 (6)
Total cost/year £3445 £3110 £2999
Estimated UK market share 15% 20% 65%
Average cost per year (based on market shares) £3088
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Insulin costs
Both SAP and CSII therapies use short-acting insulin. Based on expert opinion, we assumed the same type
and amount of short-acting insulin for both technologies. Following the approach in NICE Guideline
NG17,81 only the cartridges and pre-filled pens were used to calculate the costs of short-acting insulin. For
the base case, we assumed 48 units per day of short-acting insulin for pumps, as in Bergenstal et al.32 and
NICE Guideline NG17.81 This choice was validated by clinical experts/committee members. The total insulin
costs per year for patients on insulin pumps are shown in Table 35.
Based on clinical opinion, we assumed that patients on MDIs would use a regimen with basal (long-acting)
insulin once or twice daily, and bolus (short-acting) insulin with meals, three times per day. Furthermore,
the conclusion from NICE Guideline NG1781 is that insulin detemir twice daily is the most cost-effective
long-acting insulin regimen for people with T1DM. Therefore, we assumed this for the base case. Based on
the information from our clinical experts, we also assumed that the number of insulin units would be split
50 : 50 between basal and bolus. For the base case, we also assumed 48 units per day for MDIs, as in NICE
Guideline NG17.81 Thus, we assumed 24 units per day of long-acting insulin and 24 units per day of
short-acting insulin. The unit cost of the needles was assumed to be £0.11 as in NICE Guideline NG17.81
This was calculated as a weighted average of the prices of the 10 most commonly used needles, according
to data from Prescription Cost Analysis – England, 2012.123 The annual cost of needles per patient was
then calculated based on a frequency of five injections per day (long-acting twice daily and short-acting
insulin three times per day) as mentioned above. The total insulin costs (including the costs of needles)
per year for patients on MDIs are shown in Table 36.
TABLE 34 Blood glucose test costs
Cost component CGM and SMBG
Cost of single BG test £0.29
Number of tests per day 4
Total number of tests per year 1460
Total yearly cost £423.40
TABLE 35 Sensor-augmented insulin pump and CSII (short-acting) insulin costs
Short-acting insulin Cartridges and pens Unit cost (£)
Cost per unit
of insulin (£)a
Yearly cost
per patient (£)b
Insulin aspart (NovoRapid®,
Novo Nordisk)
5 × 3-ml cartridges 28.31 0.0188 330.66
5 × 3-ml FlexPen pre-filled
(Novo Nordisk, Bagsværd, Denmark)
30.60 0.0204 357.41
5 × 3-ml FlexTouch pre-filled
(Novo Nordisk, Bagsværd, Denmark)
32.13 0.0214 375.28
Insulin glulisine (Apidra®,
Sanofi-Aventis)
5 × 3-ml cartridges 28.30 0.0188 330.54
5 × 3-ml SoloStar pre-filled
(Sanofi-Aventis, Paris, France)
28.30 0.0188 330.54
Insulin lispro (Humalog®,
Lilly)
5 × 3-ml cartridges 28.31 0.0188 330.66
5 × 3-ml KwikPen pre-filled
(Eli Lilly, Indianapolis, IN, USA)
29.46 0.0196 344.09
Average insulin costs NA 29.34 0.0196 342.74
NA, not applicable.
a Unit cost divided by 1500.
b Based on 48 units per day.
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There was some uncertainty around the assumption of equal amounts of insulin for pumps and MDIs.
Clinical experts have different opinions about this; some experts expect that a lower amount of insulin
would be used for pumps than would be used for MDIs (14% lower according to Cummins et al.80).
Therefore, we explored this in a separate scenario.
Other hospital costs
Outpatient care-related costs
Outpatient care-related costs (consultant and diabetic specialised nurse) were estimated based on clinical
expert opinion. We assumed that in the first year during pump initiation, there would be seven
appointments and three group sessions of 45 minutes each with diabetic specialist nurses in a 6-month
period. After the pump initiation period, but still during the first year, we assumed two appointments of
45 minutes with a consultant and two appointments of 45 minutes with a diabetic specialised nurse.
Therefore, in total, in the first year, we assumed that there would be nine appointments and three group
sessions of 45 minutes with a diabetic specialised nurse, and two appointments of 45 minutes with a
consultant. Each subsequent year we assumed that there would be two appointments of 45 minutes with
a consultant and two appointments of 45 minutes with a diabetic specialised nurse. For patients on MDIs,
we assumed two appointments of 45 minutes with a consultant and two appointments of 45 minutes
with a diabetic specialised nurse every year. The NHS outpatient follow-up tariff is £99.124 Total outpatient
costs for the base case are shown in Table 37.
Glycated haemoglobin tests costs
The cost and frequency of HbA1c tests were also estimated based on clinical expert opinion. We assumed
that, on average, this test would be performed three times a year. The cost of the test is dependent on the
hospital, the lab, etc., in which the test is performed. Based on the average of three hospital prices,
we assumed £3.14 as the average cost of a HbA1c test.
Summary of treatment and other hospital costs
A summary of treatment-related costs for the six technologies considered in this study is shown in Table 38.
TABLE 36 Multiple daily insulin injection (long-acting insulin detemir and short-acting insulin) costs
Cost item Unit cost (£) Cost per unit of insulin (£)a Yearly cost per patient (£)
Long-acting insulin detemir 42.00 0.0280 245.28b
Short-acting insulin 29.34 0.0196 171.35b
Needles 0.11 NA 200.75c
Total cost for MDIs 617.38
NA, not applicable.
a Unit cost divided by 1500.
b Based on 24 units per day.
c Based on five injections per day.
TABLE 37 Annual outpatient care-related costs
Year Insulin pump (£) MDIs (£)
Year 1 1386.00 396.00
Year 2 or more 396.00 396.00
Average yearly cost (based on a time horizon of 80 years) 408.38 396.00
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Utilities
Health benefits were expressed in terms of life-years and QALYs gained. If more than one complication
occurs at a time, a multiplicative approach is applied.125 For the PSA, utility and disutility values are
sampled from a beta distribution. Means and SDs are inputs for the IMS CDM; these are parameterized
into parameters a and b of the beta distribution as follows: a= ((mean2) × (1 –mean)/(SD2)); and
b= (mean × (1 –mean)/(SD2)) – ((mean2) × (1 –mean)/(SD2)). The utilities used in the model are summarised
in Table 39.
Treatment effects
We used the reduction in HbA1c baseline levels and the number of severe hypoglycaemic events as
the outcomes to characterise treatment effectiveness. We considered using the number of minor
hypoglycaemic and DKA events as well but not enough reliable data were found to make comparisons.
For HbA1c levels, a baseline value had to be established onto which the treatment effect could be applied
[i.e. the value at the start of treatment (time zero)]. The mean baseline value was 7.26% (standard error
0.71%), based on the relevant population, as shown in Table 28. Treatment effects were then estimated
as the mean reduction from the baseline value, determined from our systematic review. An indirect meta-
analysis was conducted to estimate the WMD between the MiniMed Paradigm Veo system and integrated
CSII+CGM (used to inform the Vibe and G4 PLATINUM CGM system), CSII+CGM, CSII+ SMBG,
MDI+CGM and MDI+ SMBG. Because of a lack of published clinical data, MDI+CGM had to be
excluded from the analysis (see Figure 8) and treatment effects of integrated CSII+CGM and
non-integrated CSII+CGM were assumed to be identical (see Figure 8 and Table 21). After calculating the
change in HbA1c levels from baseline in Bergenstal et al.32 as –0.02, the change in HbA1c levels for other
treatments could be found. These values are listed in Table 40.
Since there is uncertainty and there are limitations in the indirect meta-analysis (because of heterogeneity
and differences in baseline HbA1c levels), to explore the impact of different HbA1c change levels, we
analysed a hypothetical situation in which the baseline HbA1c levels do not change after the initiation of
treatment in a separate scenario. It should be noted that, in the IMS CDM, the change in HbA1c level is
assumed to occur within the first 12 months. After this, an annual progression rate is applied. For the base
case we followed the approach in NICE Guideline NG17,81 in which an annual progression of 0.045%
(derived from the DCCT)92 was used.
For severe hypoglycaemic events, it is not necessary to set a baseline value since the IMS CDM assumes that
this is a treatment-specific parameter. Treatment effects were estimated as the rate ratio of event rates per
100 patient-years obtained from our systematic review (see Figure 9 and Table 22). This was then applied to
a reference value for integrated CSII+CGM, which was derived from a weighted average (by sample size)
of the event rates observed in the CSII+CGM arms of the trials. These values are shown in Table 41.
TABLE 38 Summary of annual treatment-related costs per technology
Technology
Equipment and
consumables (£)
Blood glucose
tests (£) Insulin (£) Outpatient (£)
HbA1c
tests (£) Total (£)
MiniMed Veo system 4862.10 423.40 342.74 408.38 9.42 6046.04
Integrated CSII+CGM (Vibe) 5298.65 423.40 342.74 408.38 9.42 6482.59
CSII+CGM 5261.29 423.40 342.74 408.38 9.42 6445.22
CSII+ SMBG 2166.13 423.40 342.74 408.38 9.42 3350.07
MDI+CGM 3288.50 423.40 416.63 396.00 9.42 4533.94
MDI+ SMBG 200.75 423.40 416.63 396.00 9.42 1446.20
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TABLE 39 Utilities per health state
Health state
Mean (dis)
utility value SE Source
T1DM with no complications 0.814 0.01 Clarke et al. (2002)126
MI, event year –0.055 0.01 Beaudet et al. (2014)78
MI, after event 0.759 0.01 Equal to no complication minus event
Angina 0.695 0.01 Beaudet et al. (2014)78
Chronic heart failure 0.677 0.01
Stroke, event year –0.164 0.01
Stroke, after event 0.650 0.01 Equal to no complication minus event
PVD 0.724 0.01 Beaudet et al. (2014)78
Microalbuminuria 0.814 0.01 Equal to no complication
Gross proteinuria 0.737 0.01 Beaudet et al. (2014)78
Haemodialysis 0.621 0.03
Peritoneal dialysis 0.581 0.03
Renal transplant 0.762 0.12
Background diabetic retinopathy 0.745 0.02
Background diabetic retinopathy, wrongly treated 0.745 0.02
Proliferative diabetic retinopathy, laser treated 0.715 0.02
Proliferative diabetic retinopathy, non-laser treated 0.715 0.02
Macular oedema 0.745 0.02
Severe vision loss 0.711 0.01
Cataract 0.769 0.02
Neuropathy 0.701 0.01
Healed ulcer 0.814 0.01 Equal to no complication
Active ulcer 0.615 0.01 Beaudet et al. (2014)78
Amputation, event year –0.280 0.01
Amputation, after event 0.534 0.01 Equal to no complication minus event
Severe hypoglycaemic event –0.012 0.00 Currie et al. (2006)127
Minor hypoglycaemic event 0 0.00 Assumption
Fear of hypoglycaemic event 0 0.00 Included in the disutility for severe
hypoglycaemic event
DKA event 0 0.00 Assumption
Depression, not treated 0.6059 0.00 Goldney et al. (2004)128
Depression, treated 0.814 0.00 Equal to no complication
SE, standard error.
ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
60
For the PSA, treatment effects on HbA1c levels at baseline are sampled from a beta distribution (mean and
SD are converted into beta distribution-specific parameters, as explained in Utilities). The event rates of
severe hypoglycaemic events are fixed in the IMS CDM and therefore they are not included in the PSA. In
order to explore the uncertainty of the effects of severe hypoglycaemic episodes on long-term outcomes,
several scenarios with different treatment-specific rates were analysed (see Treatment effects part II: severe
hypoglycaemic event rates).
Disease management parameters
These parameters will determine the proportion of patients that will receive disease management
regimens, such as preventative treatments or screening programmes. These parameters and their sources
are shown in Table 42. With the exception of the proportion on the UK-specific foot ulcer prevention
programme, for which we followed the approach in NICE Guideline NG17,81 the majority of the inputs are
the default values from the IMS CDM and were also used in the latest diabetes NICE guideline.81
Disease natural history parameters
These are the parameters that will determine the natural course of the disease. These parameters are
either transition probabilities, that is the probability of each of the events (e.g. diabetic retinopathy or MI)
or the (relative) risk of an event, given a particular risk factor; risk factors are based on physiological
measures, such as HbA1c levels, BMI, SBP or characteristics like the presence of microalbuminuria. We
considered the same values as in NICE Guideline NG17,81 most of which were the same as the IMS CDM
default values. For that reason, and because the number of parameters is so large that it may distract the
reader’s attention, we have decided to show these parameters in Appendix 6.
It should be noted that one of these parameters is the probability of death from a severe hypoglycaemic
event. In line with NICE Guideline NG17,81 this was assumed to be zero for the base case. However, as
deaths due to severe hypoglycaemic events have been reported,138,139 we expect that this parameter may
have an impact on our results, as one of the key features of the MiniMed Paradigm Veo is the LGS
function, which was shown to reduce the number of severe hypoglycaemic events, and thus the number
of deaths caused by severe hypoglycaemia. Therefore, other options for this mortality rate were explored in
additional scenarios.
TABLE 40 Change in HbA1c levels with respect to baseline for all treatments included in the analysis
Treatment Mean (SE) change in HbA1c levels compared with baseline, %
MiniMed Veo system –0.02 (0.04)
Integrated CSII+CGM (Vibe) –0.06 (0.05)
CSII+ SMBG 0.05 (0.12)
MDI+ SMBG 0.64 (0.19)
CSII+CGM –0.06 (0.05)
TABLE 41 Rate per 100 patient-years of severe hypoglycaemic episodes for all treatments included in the analysis
Treatment Rate per 100 patient-years of severe hypoglycaemic episodes
MiniMed Veo system 1.9584
Integrated CSII+CGM (Vibe) 16.32
CSII+ SMBG 5.0215
MDI+ SMBG 19.584
CSII+CGM 16.32
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TABLE 42 Disease management parameters
Parameter Mean value Source
Concomitant medication
Proportion using aspirin for primary prevention 0.456 Minshall et al. (2008)129
Proportion using aspirin for secondary prevention 0.755 Gerstein et al. (2008)130
Proportion using statins for primary prevention 0.450 Minshall et al. (2008)129
Proportion using statins for secondary prevention 0.878 Gerstein et al. (2008)130
Proportion using ACEIs for primary prevention 0.500 Minshall et al. (2008)129
Proportion using ACEIs for secondary prevention 0.708 Gerstein et al. (2008)130
Screening and patient management proportions
Proportion on foot ulcer prevention programme 0.992 National Diabetes Audit99
Proportion screened for eye disease 1.000 No data
Proportion screened for renal disease 1.000 No data
Proportion receiving intensive insulin after MI 0.877 McMullin et al. (2004)131
Proportion treated with extra ulcer treatment 0.570 Lyon (2008)132
Proportion screened for depression with no complications 0.830 Jones and Doebbeling (2007)133
Proportion screened for depression with complications 0.830
Others
Reduction in incidence of foot ulcers with prevention programme 0.310 O’Meara et al. (2000)134
Improvement in ulcer healing rate with extra ulcer treatment 1.390 Kantor and Margolis (2001)135
Reduction in amputation rate with foot care 0.340 O’Meara et al. (2000)134
Sensitivity of eye screening 0.920 Lopez-Bastida et al. (2007)136
Specificity of eye screening 0.960
Sensitivity of gross proteinuria screening 0.830 Cortes-Sanabria et al. (2006)137
Sensitivity of microalbuminuria screening 0.830
Specificity of microalbuminuria screening 0.960
ACEI, angiotensin-converting enzyme inhibitor.
Sensitivity and scenario analyses
Probabilistic sensitivity analysis
Probabilistic sensitivity analysis was used to explore the impact of statistical uncertainties regarding the
model’s input parameters. PSA is an in-built feature of the IMS CDM, activated if the second order with
sampling option is selected.
Probabilistic sensitivity analysis results were presented in the cost-effectiveness plane for all the treatments
compared. Cost-effectiveness acceptability curves (CEACs) were used to describe the probability of a
treatment being considered cost-effective given a threshold incremental cost-effectiveness ratio (ICER). The
probability distributions used in the PSA are described throughout the Model input parameters section.
Scenario analyses
Scenario analyses were performed to explore the impact on costs and QALYs of using different
assumptions on the baseline population characteristics, on the number of blood tests (finger prick tests)
conducted per day, on the amount of insulin used, on the inclusion of HbA1c progression after year 1,
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on treatment effects (both in terms of HbA1c level change and in terms of the number of severe hypoglycaemic
episodes per treatment), on the inclusion of a non-zero probability of death as a result of hypoglycaemia, on
time horizon, on QALY estimation methods, on utility benefits associated with less fear of hypoglycaemia, and
on the cost of the stand-alone insulin pump and CGM devices.
Baseline population characteristics
The base case assumed baseline population characteristics, as in the Bergenstal et al.32 In this scenario, we
considered the general T1DM population, as used in NICE Guideline NG17.81 Table 43 shows the patient
characteristics that were changed for this scenario.
Number of blood glucose tests per day
In the base case, we assumed four BG tests (finger prick tests) for interventions containing CGM (the
MiniMed Paradigm Veo system, integrated CSII+CGM and stand-alone CSII+CGM) and four BG tests for
interventions containing SMBG (CSII+ SMBG and MDI+ SMBG). This assumption was based on the results
from the systematic review, in which no significant differences in the number of tests between the
CGM- and SMBG-containing treatments were observed.32,37
In the sensitivity analysis, we followed the approach in NICE Guideline NG17 (appendix P of this
guideline),81 and considered two tests per day (for calibration) for CGM-containing treatments and four
tests per day for SMBG-containing treatments, since this is considered to be current practice. Moreover,
we have included 8 (the most cost-effective frequency in the guideline) and 10 tests per day for
SMBG-containing technologies versus 2 tests per day for CGM-containing technologies as scenarios in
our analysis. Unlike the latest diabetes NICE guideline scenarios (appendix P of the guideline),81 we
assumed in our analyses that the number of blood tests per day had no impact on the treatment effect,
since such an effect (e.g. that more blood tests lead to a greater decrease in HbA1c levels) was not
observed in our systematic review. Finally, we also explored a scenario based on the observational study by
Lynch et al.,140 which reports an average number of 4.35 BG tests per day for CGM and 7.11 for SMBG.
The costs related to BG testing for the complete list of the scenarios conducted are given in Table 44.
Amount of insulin per day
For the base case, we assumed equal units of insulin per day for both MDI-containing interventions
(MDI+ SMBG) and insulin pump-containing interventions (the MiniMed Paradigm Veo system, integrated
CSII+CGM, stand-alone CSII+CGM and CSII+ SMBG). However, some of the clinical experts mentioned
that they would expect a lower amount of insulin to be used for pumps than for MDIs. In addition,
Cummins et al.80 report a 14% reduction in insulin use with pumps compared with MDIs. From the
findings of our systematic review, this seems to be a reasonable assumption.37,41,141 Thus, for this scenario,
we assumed 48 units per day of short-acting insulin for pump-containing treatments (which is the same as
TABLE 43 Baseline characteristics that change with respect to the base case
Parameter Mean base case Mean scenario SD Source
Patient demographics
Start age (years) 41.6 42.98 19.14 Nathan et al. (2009)100
Duration of diabetes (years) 27.1 16.92 13.31 National Diabetes Audit99
Proportion male 0.38 0.567 NA
Baseline risk factors
HbA1c (% points) 7.26 8.60 4.00 National Diabetes Audit
99
BMI (kg/m2) 28.27 27.09 5.77
NA, not applicable.
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the insulin use assumption in the base case given in Table 35) and 55 units of insulin per day (14% more)
for MDI+ SMBG treatments. It was also assumed that the insulin used for MDI+ SMBG is split 50 : 50
between basal and bolus (27.5 units per day of long-acting insulin and 27.5 units per day of short-acting
insulin). The costs pertaining to the insulin use for this scenario analysis are given Table 45.
Glycated haemoglobin progression
In the base-case analysis, the IMS CDM default value for the annual progression in HbA1c levels after year 1
was used (0.045%). This value was based on the DCCT.92 According to NICE Guideline NG17,81 the
Guideline Development Group expects that HbA1c levels in T1DM patients will be more stable than in
T2DM patients. Therefore, an alternative assumption of no annual progression in HbA1c levels (0%) was
tested to gain insight into the effects of HbA1c progression rate on costs and QALYs gained after year 1.
TABLE 44 Number of BG tests and test costs for the additional scenarios
Cost component CGM SMBG
Cost of single BG test81 0.29 0.29
Scenario 1
Number of tests per day81 2 4
Total number of tests per year (365 days) 730 1460
Total yearly cost (£) 212 423
Scenario 2
Number of tests per day81 2 8
Total number of tests per year (365 days) 730 2920
Total yearly cost (£) 212 847
Scenario 3
Number of tests per day81 2 10
Total number of tests per year (365 days) 730 3650
Total yearly cost (£) 212 1058
Lynch et al. (2012)140 scenario
Number of tests per day 4.35 7.11
Total number of tests per year (365 days) 1588 2595
Total yearly cost (£) 460 753
TABLE 45 Multiple daily insulin injection (long-acting insulin detemir and short-acting insulin) costs based on
55 units per day
Cost item Unit cost (£) Cost per unit of insulin (£)a Yearly cost per patient (£)
Long-acting insulin detemir 42.00 0.0280 281b
Short-acting insulin 29.34 0.0196 196b
Needles 0.11 NA 201c
Total cost for MDIs 678
NA, not applicable.
a Unit cost divided by 1500.
b Based on 27.5 units per day.
c Based on five injections per day.
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Treatment effects part I: change in glycated haemoglobin levels in the first year
As explained above (see Treatment effects), treatment effects were estimated as the mean reduction from
the baseline HbA1c value obtained from our systematic review. The baseline HbA1c value was taken from
Bergenstal et al.32 This value is lower than the average baseline HbA1c value of patients given in the
National Diabetes Audit,99 which indicates that the patients in the Bergenstal et al.32 study have better
glycaemic control. As an alternative scenario, we assumed that the baseline HbA1c value is stable for one
year and does not change with any of the treatments (0% change in HbA1c level in the first year).
Treatment effects part II: severe hypoglycaemic event rates
Treatment-specific severe hypoglycaemic event rates were derived from our systematic review, from which
it was observed that the MiniMed Paradigm Veo system had fewer reported severe hypoglycaemic events
than the other treatments. In the scenario analysis, we elaborate on this observation, and for all treatments
other than the MiniMed Paradigm Veo system, we assumed a uniform event rate for severe hypoglycaemia
(16.32 events per 100 patient-years) and applied different RR values (1, 0.5, 0.25 and 0.125) for the severe
hypoglycaemic event rate for the MiniMed Paradigm Veo system. It should be noted that the value of
16.32 events per 100 patient-years is derived from the indirect comparison, as explained above (see
Treatment effects), and is the weighted mean for the severe hypoglycaemic event rate for integrated
CSII+CGM, which is chosen as a reference treatment in this case because the number of studies (n= 8)32,34–40
that the weighted average rate was based on is highest for integrated CSII+CGM; the Bergenstal et al. trial,32
from which the baseline population characteristics were derived, is one of these eight studies.
In addition, we conducted a scenario analysis in which the higher severe hypoglycaemic episode rate from
Hirsch et al.34 was taken as the baseline rate for integrated CSII+CGM, and the RRs from the indirect
comparison in Treatment effects (base case) were applied for other treatments. Severe hypoglycaemic
episode rates (number of events per 100 patient-years) are given in Table 46 for each scenario.
Non-zero probability of death resulting from severe hypoglycaemia
In the base case, the case fatality rate for severe hypoglycaemia was taken as zero. This assumption is in
line with NICE Guideline NG1781 and systematic review results, since none of the included studies reported
a death due to severe hypoglycaemia.
As an extreme scenario, as in NG17,81 we assumed a case fatality rate of 4.9%, derived from a study by
Ben-Ami et al.142 in which five patients were reported to die among 102 patients who had drug-induced
hypoglycaemic coma.
TABLE 46 Severe hypoglycaemic episode rates for different scenarios
Intervention
Number of events per 100 patient-years
Scenario 1
(RR= 1)
Scenario 2
(RR= 0.5)
Scenario 3
(RR= 0.25)
Scenario 4
(RR= 0.125) Scenario 5a
MDI+ SMBG 16.32 16.32 16.32 16.32 38.37
CSII+ SMBG 16.32 16.32 16.32 16.32 10.20
CSII+CGM 16.32 16.32 16.32 16.32 33
MiniMed Veo system 16.32 8.16 4.08 2.04 3.96
Integrated CSII+CGM (Vibe) 16.32 16.32 16.32 16.32 33
a Scenario 5 is based on the severe hypoglycaemic event rate described by Hirsch et al.34 for integrated CSII+CGM (Vibe)
system and RRs from the indirect treatment comparison.
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Quality-adjusted life-year estimation method
In the base case, a multiplicative approach was applied for the QALY estimation. This approach, in which
the utility values of multiple events are multiplied to derive an overall utility in cases of multiple events/
complications, is considered to be appropriate for this condition because simultaneous complications often
do develop.125 As a scenario analysis, the minimum approach was used as an alternative QALY estimation
method; for this approach, the minimum of the multiple health state utility values was applied for patients
with a history of multiple events.
Different time horizons
In the base case, a lifetime analysis is achieved by selecting 80 years as the model time horizon. For
scenario analyses, a 4-year time horizon (the average lifetime of an insulin pump) was selected and the
effect of this time horizon on the results was explored.
Fear of hypoglycaemia unawareness
In the STAR-3 trial,40 patients using integrated CSII+CGM devices demonstrated more of an improvement
compared with baseline values on the ‘worry’ subscale of the Hypoglycaemia Fear Survey143 than the MDI
group. Subsequently, in Kamble et al.,69 this improvement was translated into a utility increment of 0.0329
using the EQ-5D questionnaire index. As a scenario analysis, we applied this utility increment associated
with less fear of hypoglycaemia throughout the remaining lifetimes of patients using integrated devices
(the MiniMed Paradigm Veo system and integrated CSII+CGM). This benefit was not applied to
non-integrated devices (CSII+CGM, CSII+ SMBG and MDI+ SMBG), as these devices do not give a
warning or activate/stop the release of insulin automatically in response to low BG levels.
Cost of stand-alone insulin pumps and continuous glucose monitoring devices
In the base-case analysis, the yearly device cost (equipment+ consumables) of the stand-alone CSII+CGM
(£5261.29) was estimated based on the market share obtained from White et al.121,122 As a scenario
analysis, we considered the average costs without the market-share weighting. Therefore, in this scenario,
the estimated yearly device cost is £2275.80 for the stand-alone insulin pump and £3184.39 for the
stand-alone CGM device. Thus, when the other cost items are considered (insulin, BG tests, outpatient
costs and HbA1c tests), the average yearly cost (without using any market share assumptions) of the
stand-alone CSII+CGM is £6644.13. Hence, the cost of the stand-alone CSII+CGM combination is
£198.90 higher than the base-case cost. In a similar manner, the yearly cost of CSII+ SMBG is £102.26
higher than the base-case cost. Because of these higher costs, stand-alone CSII+CGM becomes more
expensive than integrated CSII+CGM (Vibe) in this scenario. Since both technologies are assumed to have
the same efficacy, integrated CSII+CGM (Vibe) will dominate stand-alone CSII+CGM.
Model assumptions
The main assumptions made in our analyses are summarised in Box 1.
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BOX 1 Main model assumptions
General
1. For the base-case scenario, baseline population characteristics, as in Bergenstal et al.,32 were assumed.
In an additional scenario, we considered general T1DM population characteristics as in NICE
Guideline NG17.81
2. For the costs included in the PSA, 20% deviation from the mean was assumed. This is in line with NICE
Guideline NG17.81
3. Costs of initiation training for insulin pumps and CGM were covered by outpatient costs. This was based
on clinical expert opinion.
Sensor-augmented pump therapy
4. A 4-year lifetime was assumed for insulin pumps.
5. Cannulas and reservoirs would be replaced every 3 days.
6. The MiniMed Paradigm Veo system requires one Energizer AAA alkaline battery. An estimated replacement
time of 8.5 days was assumed.
7. The Vibe system pump operates on one AA lithium battery. The expected battery lifetime is 5 weeks
(35 days) when used with CGM and 8 weeks when used without CGM.
8. We assumed the same percentage of increase in battery lifetime for the MiniMed Paradigm Veo system
when used without CGM.
9. The MiniLink transmitter is replaced each year and the sensors are replaced every 6 days.
10. The G4 PLATINUM monitor is replaced every 6 months and the sensors are replaced every 7 days.
Stand-alone insulin pumps
11. The assumptions made for integrated insulin pumps are also valid for stand-alone insulin pumps.
Stand-alone continuous glucose monitoring
12. Transmitter and sensor costs, and usage for the Dexcom G4 and the Medtronic Guardian were assumed to
be the same as for integrated systems. This was mentioned by the relevant companies.
13. For the Abbott FreeStyle Navigator, sensor costs and usage were assumed to be the same as reported in
NICE Guideline NG17.81
Blood glucose tests
14. For the base case, we assumed, on average, four BG tests per day for both SMBG and CGM.
15. In the sensitivity analysis, we followed the approach in NICE Guideline NG1781 and considered two tests
per day (for calibration) for CGM and four tests per day for SMBG, since this is considered current practice.
Moreover, we have included eight tests per day (the most cost-effective frequency according to the
guideline) and 10 tests per day for SMBG-containing technologies vs. two tests per day for
CGM-containing technologies, as scenarios in our analysis.
16. We also explored a scenario based on the observational study by Lynch et al.140 which reports an average
number of 4.35 BG tests per day for CGM and 7.11 for SMBG.
17. We assumed that BG meters are supplied free of charge.
DOI: 10.3310/hta20170 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 17
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Riemsma et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
67
Insulin
18. We assumed the same type and amount of short-acting insulin for both integrated and stand-alone insulin
pumps. This was based on expert opinion.
19. For the base case, we assumed 48 units per day of short-acting for insulin pumps. This was based on
Bergenstal et al.32 and NICE Guideline NG17,81 and it was validated by clinical experts.
20. Based on clinical opinion, we assumed that patients on MDIs would use a regimen with basal (long-acting)
insulin once or twice daily, and bolus (short-acting) insulin with meals, three times per day.
21. NICE Guideline NG1781 concluded that it is likely that insulin detemir twice daily is the most cost-effective
long-acting insulin regimen for people with T1DM. Therefore, we assumed this for the base case.
22. Based on clinical opinion, we also assumed that the amount of daily insulin would split 50 : 50 between
basal and bolus.
23. For the base case, we assumed 48 units per day for MDIs, as in NICE Guideline NG17.81
24. In an additional scenario, we assumed 48 units per day of short-acting insulin for pumps, as in the base
case, and 55 units per day (14% increase as reported in Cummins et al.80) for MDIs.
Multiple daily insulin injections
25. The unit cost of the needles was assumed to be £0.11 as in NICE Guideline NG17.81
26. The annual cost of needles per patient was then calculated based on a frequency of 5 injections per day
(long-acting twice daily and short-acting insulin three times per day).
Outpatient care
27. We assumed that, in the first year of pump initiation, there would be seven appointments and three group
sessions of 45 minutes each with diabetic specialist nurses in a 6-month period.
28. After the pump initiation period, but still during the first year, we assumed two appointments of
45 minutes with a consultant and two appointments of 45 minutes with a diabetic specialised nurse.
29. Each subsequent year we assumed two appointments of 45 minutes with a consultant and two
appointments of 45 minutes with a diabetic specialised nurse.
30. For patients on MDIs, we assumed two appointments of 45 minutes with a consultant and two
appointments of 45 minutes with a diabetic specialised nurse every year.
Glycated haemoglobin tests
31. We assumed that, on average, this test would be performed three times a year.
32. The cost of this test depends on the hospital, lab, etc., in which they are performed. Based on the average
of three hospital prices, we assumed that the average price for a HbA1c test would be £3.14.
Treatment effects
33. Treatment effects are estimated as the mean reduction from the baseline value from our systematic review.
This reduction is assumed to occur for up to 12 months. After this, annual progression occurs. In the base
case, we followed NICE Guideline NG17,81 which chose a T1DM trial, DCCT (annual progression of
0.045%), for the base case and no progression in sensitivity analysis.
34. In the absence of data, treatment effects of integrated CSII+CGM and non-integrated CSII+CGM were
assumed to be identical.
Disease natural history
35. The probability of death from severe hypoglycaemic events was assumed to be zero for the base case.81
Other values were explored in separate scenarios.
BOX 1 Main model assumptions (continued)
ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
68
Results of cost-effectiveness analyses
Base-case results
The base-case results from the full incremental analysis reported as cost per QALY gained (ICER) per
technology for adult T1DM patients are summarised in Table 47.
First, it should be noted that since the same treatment effects were assumed for stand-alone and
integrated CSII+CGM, the latter is dominated by the former (i.e. effectiveness is the same for the
integrated as for the stand-alone technology, but the integrated technology is more expensive, as shown
in Table 38). As expected, MDI+ SMBG is the cheapest treatment but also the one that provides the
lowest number of QALYs. The ICER of CSII+ SMBG compared with MDI+ SMBG is £52,381. MiniMed
Paradigm Veo is extendedly dominated by stand-alone CSII+CGM. Essentially, this means that, in a full
incremental analysis, where all the interventions and comparators are considered, CSII+CGM is better
value for money than MiniMed Veo. This is because, from our systematic review, the decrease in HbA1c
levels with respect to baseline was highest for stand-alone CSII+CGM; this decrease in HbA1c levels leads
to a decrease in the number of complications that occur over a lifetime to such an extent that it
compensates for the higher number of hypoglycaemic events. In any case, the ICER of stand-alone
CSII+CGM compared with CSII+ SMBG is £660,376. Thus, given the common threshold ICER of £30,000,
it is clear that stand-alone CSII+CGM is not cost-effective.
Alternatively, we present the base-case ICERs for the two interventions against every comparator in
Table 48. Integrated CSII+CGM (Vibe) is dominated by stand-alone CSII+CGM. It should be noted that
when the MiniMed Veo system is compared with stand-alone CSII+CGM, the ICER obtained is high
(£422,849) but that this results from both negative incremental QALYs and incremental costs (i.e. the ICER
is in the south-west quadrant of the cost-effectiveness plane). In this case, the cost savings outweigh the
loss in QALYs and therefore the MiniMed Veo system is more cost-effective than stand-alone CSII+CGM.
TABLE 47 Base-case model results (all technologies) probabilistic simulation
Intervention QALYs Cost (£) Incremental QALY Incremental cost (£) ICER (£)
MDI+ SMBG 11.4146 61,050 – – –
CSII+ SMBG 11.9756 90,436 0.561 29,386 52,381
MiniMed Veo system 12.0412 138,357 Extendedly dominateda by stand-alone CSII+CGM
CSII+CGM 12.0604 146,476 0.0849 56,039 660,376
Integrated CSII+CGM (Vibe) 12.0604 147,150 Dominated by stand-alone CSII+CGM
a An extendedly dominated strategy has an ICER higher than that of the next most effective strategy.
TABLE 48 Base-case model results (intervention vs. comparator only) probabilistic simulation
Intervention Comparator Incremental QALY Incremental cost (£) ICER (£)
MiniMed Veo system MDI+ SMBG 0.6266 77,307 123,375
MiniMed Veo system CSII+ SMBG 0.0656 47,921 730,501
MiniMed Veo system CSII+CGM –0.0192 8119 422,849
Integrated CSII+CGM (Vibe) MDI+ SMBG 0.6458 86,100 133,323
Integrated CSII+CGM (Vibe) CSII+ SMBG 0.0849 56,713 668,789
Integrated CSII+CGM (Vibe) CSII+CGM 0 674 Undefined
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This might not be immediately apparent when looking at the full incremental results in Table 47 because,
in this table, the MiniMed Veo system is in position of extended dominance. The lowest ICERs are obtained
when the interventions are compared with MDI+ SMBG, but these are above £100,000 in the north-east
quadrant of the cost-effectiveness plane. When the interventions are compared with CSII+ SMBG, the
highest ICERs are obtained (around £700,000 in the north-east quadrant of the cost-effectiveness plane).
Thus, given the common threshold ICER of £30,000, the interventions are not cost-effective.
In the deterministic simulation, the cost-effectiveness results are very similar except that, in this simulation,
MiniMed Veo is not extendedly dominated by stand-alone CSII+CGM. These results are shown in
Table 24. Although overall cost and QALY estimates are higher than in the probabilistic simulation, the
ICERs and the main conclusions from the simulation presented in Table 49 are similar to the conclusions
drawn from the simulation presented in Table 47.
The base-case ICERs for the two interventions compared with every comparator in the deterministic
simulation are shown in Table 50. These results are similar to those presented in Table 48 and so are the
conclusions drawn.
When we looked at the breakdown of the total costs, we observed that treatment costs always represent
the largest proportion of the total costs, independently of the treatment chosen. In Figure 11, the
treatment costs constitute 79% of the total direct costs for the MiniMed Paradigm Veo system, and
integrated and stand-alone CSII+CGM. For CSII+ SMBG, treatment costs represent 66% of the total costs
and for MDI+ SMBG this is 41%. For each treatment, the foot ulcer/amputation/neuropathy cost category
is the second largest, and eye diseases and renal diseases are the third and fourth largest cost categories,
respectively. MDI+ SMBG has higher complication incidences (CVD, ulcer, eye disease, etc.), whereas for
the other four treatments these complication incidences are similar. Lifetime hypoglycaemic events were
least reported for the MiniMed Paradigm Veo system (0.622 severe hypoglycaemic events per patient), and
were most reported for MDI+ SMBG (5.412 severe hypoglycaemic events per patient).
TABLE 50 Base-case model results (intervention vs. comparator only) deterministic simulation
Intervention Comparator Incremental QALY Incremental cost (£) ICER (£)
MiniMed Veo system MDI+ SMBG 0.6637 80,382 121,112
MiniMed Veo system CSII+ SMBG 0.0829 49,876 601,639
MiniMed Veo system CSII+CGM –0.0136 –8363 614,910
Integrated CSII+CGM (Vibe) MDI+ SMBG 0.6773 89,445 132,061
Integrated CSII+CGM (Vibe) CSII+ SMBG 0.0965 58,939 610,772
Integrated CSII+CGM (Vibe) CSII+CGM 0 701 Undefined
TABLE 49 Base-case model results (all technologies) deterministic simulation
Intervention QALYs Cost (£) Incremental QALY Incremental cost (£) ICER (£)
MDI+ SMBG 12.1450 62,927 – – –
CSII+ SMBG 12.7258 93,433 0.5808 30,506 52,524
MiniMed Veo system 12.8087 143,309 0.0829 49,876 601,641
CSII+CGM 12.8223 151,671 0.0136 8,363 614,910
Integrated CSII+CGM (Vibe) 12.8223 152,372 Dominated by CSII+CGM
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(a)
(b)
(c) Treatment
Management
CVD
Renal
Ulcer/amputation/neuropathy
Eye
Hypoglycaemia
Keto/lactic acidosis
Antidepression treatment
(d)
(e)
FIGURE 11 Breakdown of costs per treatment: (a) breakdown of MiniMed Veo system costs; (b) breakdown of
integrated CSII+CGM costs; (c) breakdown of stand-alone CSII+CGM costs; (d) breakdown of CSII+ SMBG costs;
and (e) breakdown of MDI+ SMBG costs.
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Results of the probabilistic sensitivity analyses
Statistical uncertainties in the model were investigated in the PSA. Since we compared five treatments
simultaneously, the scatterplot of the PSA outcomes in the cost-effectiveness plane was not very
informative (Figure 12). Nevertheless, we can observe a clear positive correlation between costs and QALYs
and that the treatments including CGM are similarly scattered, showing that they are more expensive but
also provide more QALYs.
The CEACs for each treatment are shown in Figure 13. These CEACs confirm that only the treatments
including SMBG are considered cost-effective. At ceiling ratio values of < £52,381, MDI+ SMBG was the
treatment with the highest probability of being cost-effective. When that threshold is exceeded, then
CSII+ SMBG was the treatment with the highest probability of being cost-effective. It should be noted
that, for all three treatments including CGM, the cost-effectiveness probability was zero for all the ceiling
ratios considered in the analysis. This was expected as the difference in costs between CGM treatments
and SMBG treatments was too large to outweigh the additional QALYs gained by using CGM.
Multiple daily insulin injection-unsuitable subgroup
As mentioned in Chapter 1 (see Comparators), insulin pumps are recommended for people with T1DM for
whom MDIs are not suitable. Therefore, we questioned the extent to which insulin pumps (especially
modern pumps such as the integrated systems) and MDIs are used in similar populations. This seemed a
reasonable question in light of the lack of studies found by our systematic review that compared these two
treatments. If MDI+ SMBG is not considered in the analysis, the ICERs from the full incremental analysis
were the same as those reported in Table 47, but excluding the first row. It appears that CSII+ SMBG is
the strategy most likely to be cost-effective, independent of the ceiling ratio value (up to £100,000 per
QALY), as shown in Figure 14.
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FIGURE 12 Cost-effectiveness plane with PSA outcomes for all treatments in T1DM patients.
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Continuous glucose monitoring-indicated/self-monitoring of blood
glucose-unsuitable subgroup
In the analysis for the CGM-indicated/SMBG-unsuitable subgroup, we excluded SMBG-based treatment
options from the analysis on the presumption that the most relevant population comprises those who find
it difficult to perform SMBG often or adequately enough. In this situation, integrated CSII+CGM (Vibe) is
dominated by stand-alone CSII+CGM, as shown in Table 47 and the only relevant comparison is the
MiniMed Veo system with stand-alone CSII+CGM. The ICER is £422,849 (in the south-west quadrant of
the cost-effectiveness plane), as shown in Table 48. The corresponding CEACs are shown in Figure 15.
These CEACs indicate that the MiniMed Veo system is the CGM treatment most likely to be cost-effective
for all the ceiling ratios considered in the analysis. However, as the ceiling ratio increases, the CEACs for
the MiniMed Paradigm Veo system and stand-alone CSII+CGM seem to converge. As expected, the CEAC
for integrated CSII+CGM was always zero for all the ceiling ratios considered in the analysis, since this
was dominated by the stand-alone combination of CSII and CGM.
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FIGURE 14 Cost-effectiveness acceptability curves for all non-MDI treatments in T1DM patients.
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Results of scenario analyses
In the scenarios presented below, only the ICERs from the full incremental analysis are discussed. The
ICERs for the two interventions against every comparator are shown in Appendix 7.
Baseline population characteristics
In the scenario analysis, in which the baseline population characteristics have been updated in accordance
with NICE Guideline NG17,81 the main results are similar to the base-case results, as shown in Table 51.
The intervention with the lowest costs and the lowest gain in QALYs is MDI+ SMBG. CSII+ SMBG and
stand-alone CSII+CGM are on the efficient frontier, with ICERs of £53,588 per QALY and £738,593 per
QALY, respectively. Thus, given the common threshold ICER of £30,000, they are not cost-effective. The
MiniMed Veo system and integrated CSII+CGM are extendedly dominated and dominated, respectively,
by stand-alone CSII+CGM.
Number of blood glucose tests per day
All of the scenarios listed in Table 44 gave similar results. Compared with the base case, costs were lower
in the scenarios for treatments that require fewer than four BG tests per day and, otherwise, were higher.
Since all results were similar, in Table 52 we present only the full incremental cost-effectiveness results of
the scenarios with two BG tests per day for CGM-containing treatments and eight BG tests per day for
SMBG. Eight tests per day for SMBG represent the most cost-effective frequency, as was shown in NICE
Guideline NG17.81
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FIGURE 15 Cost-effectiveness acceptability curves for CGM treatments in T1DM patients.
TABLE 51 Model results (all technologies) for scenarios with different baseline population characteristics
Interventions QALYs Cost (£) Incremental QALY Incremental cost (£) ICER (£)
MDI+ SMBG 9.6117 65,070 – – –
CSII+ SMBG 10.0991 91,189 0.4874 26,119 53,588
MiniMed Veo system 10.1474 132,149 Extendedly dominated by stand-alone CSII+CGM
CSII+CGM 10.164 139,157 0.0649 47,967 738,593
Integrated CSII+CGM (Vibe) 10.164 139,733 Dominated by stand-alone CSII+CGM
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The intervention with the lowest costs and the lowest gain in QALYs is MDI+ SMBG. CSII+ SMBG and
stand-alone CSII+CGM are on the efficient frontier, with ICERs of £52,717 per QALY and £570,844 per
QALY, respectively. Therefore, given the common threshold ICER of £30,000, they are not cost-effective.
The MiniMed Veo system and integrated CSII+CGM are extendedly dominated and dominated,
respectively, by stand-alone CSII+CGM.
Amount of insulin per day
In this scenario, the costs for MDI+ SMBG were higher than in the base case; however, this had a very
small impact on the cost-effectiveness results because all QALYs and the costs of the other treatments
remained unchanged. Since the main conclusions of the cost-effectiveness analyses were the same in this
scenario as in the base case, we have not presented these results in a separate table in this chapter, but
these results are shown in Appendix 7.
Glycated haemoglobin progression
In this scenario, no HbA1c progression after year 1 was assumed for each treatment. Table 53 summarises
the model results.
The intervention with the lowest costs and the lowest gain in QALYs is MDI+ SMBG. CSII+ SMBG and
stand-alone CSII+CGM are on the efficient frontier, with ICERs of £51,615 per QALY and £683,889 per
QALY, respectively. Therefore, they are not cost-effective given the common threshold ICER of £30,000.
The MiniMed Veo system and integrated CSII+CGM (Vibe) are extendedly dominated and dominated,
respectively, by stand-alone CSII+CGM.
Treatment effects part I: change in glycated haemoglobin levels in the first year
In this scenario analysis, we assumed that the baseline HbA1c value is stabilised for 1 year and that it does
not change in any of the treatments (i.e. 0% change in HbA1c levels in the first year). The model results for
this scenario are shown in Table 54.
The QALY expectations for all treatments are very similar. The minor differences in QALYs can be explained
by the differences in severe hypoglycaemic episode rates. It should be noted that although the rate of
severe hypoglycaemic events for MDI+ SMBG was estimated to be higher than the rate for integrated
TABLE 52 Model results (all technologies) for scenario with two (CGM) vs. eight (SMBG) BG tests per day
Intervention QALYs Cost (£) Incremental QALY Incremental cost (£) ICER (£)
MDI+ SMBG 11.4146 68,460 – – –
CSII+ SMBG 11.9756 98,034 0.5610 29,574 £52,717
MiniMed Veo system 12.0412 138,357 Extendedly dominated by CSII+CGM
CSII+CGM 12.0604 146,476 0.0849 48,441 570,844
Integrated CSII+CGM (Vibe) 12.0604 147,150 Dominated by CSII+CGM
TABLE 53 Model results (all technologies) for scenario with no HbA1c progression
Intervention QALYs Cost (£) Incremental QALY Incremental cost (£) ICER (£)
MDI+ SMBG 11.8715 58,520 – – –
CSII+ SMBG 12.4558 88,663 0.5843 30,143 51,615
MiniMed Veo system 12.5228 137,739 Extendedly dominated by CSII+CGM
CSII+CGM 12.5398 146,076 0.0840 57,414 683,889
Integrated CSII+CGM (Vibe) 12.5398 146,767 Dominated by CSII+CGM
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CSII+CGM (see Treatment effects), MDI+ SMBG resulted in a slightly higher gain in QALYs which could
be due to randomness. CSII+CGM systems were dominated by MDI+ SMBG. Furthermore, CSII+ SMBG
and the MiniMed Veo system are on the efficient frontier but with extremely high ICER values. As can be
seen in the resulting CEACs in Figure 16, MDI+ SMBG was the most cost-effective treatment for all the
values of the ceiling ratio considered in the analysis.
Treatment effects part II: severe hypoglycaemic event rates
When we used different RRs (0.125, 0.25, 0.5 and 1) for the severe hypoglycaemic episode rates for the
MiniMed Veo system, the results did not deviate significantly from the base case. In all of the scenarios,
MDI+ SMBG was the lowest cost intervention, the MiniMed Veo system was extendedly dominated by
stand-alone CSII+CGM and integrated CSII+CGM was dominated. Table 55 shows the results for the
most extreme scenario, which is obtained if the RR value is 0.125. For this RR, the severe hypoglycaemia
rates per 100 patient-years for all interventions are shown in Table 46.
Non-zero probability of death caused by severe hypoglycaemia
In this scenario, we assumed a mortality due to severe hypoglycaemia of 4.9%, as derived from
Ben-Ami et al.142 The model results are shown in Table 56.
TABLE 54 Cost-effectiveness results when no treatment effect (in terms of change in HbA1c levels) is assumed in the
first year (for all technologies)
Intervention QALYs Cost (£) Incremental QALY Incremental cost (£) ICER (£)
CSII+CGM 12.0006 146,632 Dominated by MDI+ SMBG
Integrated CSII+CGM (Vibe) 12.0006 147,304 Dominated by MDI+ SMBG
MDI+ SMBG 12.0016 56,928 – – –
CSII+ SMBG 12.0160 90,178 0.0144 33,250 2,309,028
MiniMed Veo system 12.0260 138,538 0.0099 48,360 4,871,356
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FIGURE 16 Cost-effectiveness acceptability curves for all treatments when there is no HbA1c treatment effect.
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In this scenario, both integrated and stand-alone CSII+CGM were dominated by CSII+ SMBG. The ICER
of CSII+ SMBG compared with MDI+ SMBG was £40,006, and the ICER of MiniMed Veo compared with
CSII+ SMBG was £374,531. Thus, these treatments are not cost-effective given the common threshold
ICER of £30,000. Both cost-effectiveness plane scatterplots and CEACs are similar to those for the
base-case scenario and therefore they are not shown here. If only the CGM treatments were considered,
the probability of the MiniMed Paradigm Veo system being cost-effective was equal to 1 for almost all the
values of the ceiling ratio considered in the analysis; this is shown in Figure 17.
TABLE 55 Cost-effectiveness results if a RR of 0.125 is used for the MiniMed Veo system severe hypoglycaemic rate
(all technologies)
Intervention QALYs Cost (£) Incremental QALY Incremental cost (£) ICER (£)
MDI+ SMBG 11.4120 60,812 – – –
CSII+ SMBG 11.9597 91,195 0.5477 30,383 55,474
MiniMed Veo system 12.0453 138,333 Extendedly dominated by CSII+CGM
CSII+CGM 12.0604 146,476 0.1007 55,281 549,080
Integrated CSII+CGM (Vibe) 12.0604 147,150 Dominated by CSII+CGM
TABLE 56 Cost-effectiveness results for the mortality due to severe hypoglycaemia scenario (all technologies)
Intervention QALYs Cost (£) Incremental QALY Incremental cost (£) ICER (£)
MDI+ SMBG 11.1041 58,510 – – –
CSII+CGM 11.7701 142,215 Dominated by CSII+ SMBG
Integrated CSII+CGM (Vibe) 11.7701 142,872 Dominated by CSII+ SMBG
CSII+ SMBG 11.8781 89,475 0.774 30,965 40,006
MiniMed Veo system 12.0071 137,801 0.129 8326 374,531
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FIGURE 17 Cost-effectiveness acceptability curves for only CGM treatments for the non-zero mortality due to
severe hypoglycaemia scenario.
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Quality-adjusted life-year estimation method
In this scenario, we assumed the minimum approach as an alternative QALY estimation method, in which
the minimum of the multiple health-state utility values was applied for patients with a history of multiple
events. The results of this scenario are shown in Table 57.
These results are similar to those obtained using the base-case scenario; however, in this scenario, the
MiniMed Paradigm Veo system is not extendedly dominated by stand-alone CSII+CGM. All the ICERs are
larger than £50,000 and therefore the different treatments are not cost-effective given the common
threshold ICER of £30,000.
Different time horizon
In this scenario, we assumed a 4-year time horizon, which corresponds to the average lifetime of an insulin
pump. These results are shown in Table 58.
We observed that both stand-alone and integrated CSII+CGM are dominated by CSII+ SMBG. Although
the MiniMed Paradigm Veo system is the treatment with the highest number of QALYs gained, its high
cost when compared with CSII+ SMBG does not outweigh this gain in QALYs, and results in an ICER of
£4,461,063. Therefore, for this scenario also, it is very unlikely that MiniMed Paradigm Veo will be deemed
cost-effective, as illustrated by the corresponding CEACs in Figure 18.
If only the CGM treatments are considered, the MiniMed Paradigm Veo system is clearly the treatment
with the highest probability of being cost-effective, as shown in Figure 19.
Fear of hypoglycaemia unawareness
Table 59 shows the results obtained when the utility increment (0.0329) from Kamble et al.69 was used to
represent the reduced fear of hypoglycaemia. We applied this utility increment throughout the remaining
lifetimes of patients using integrated devices (the MiniMed Paradigm Veo system and integrated
CSII+CGM). This benefit was not applied to non-integrated devices (stand-alone CSII+CGM, CSII+ SMBG
and MDI+ SMBG), as these non-integrated devices do not give a warning or activate/stop the release of
insulin automatically in response to low BG levels.
TABLE 57 Cost-effectiveness results using the minimum QALY estimation method scenario (all technologies)
Intervention QALYs Cost (£) Incremental QALY Incremental cost (£) ICER (£)
MDI+ SMBG 12.1327 61,050 – – –
CSII+ SMBG 12.5861 90,436 0.4534 29,386 64,813
MiniMed Veo system 12.6408 138,357 0.0546 47,920 876,987
CSII+CGM 12.6462 146,476 0.0601 56,039 932,305
Integrated CSII+CGM (Vibe) 12.6462 147,150 Dominated by CSII+CGM
TABLE 58 The 4-year time horizon scenario (all technologies)
Intervention QALYs Cost (£) Incremental QALY Incremental cost (£) ICER (£)
MDI+ SMBG 2.7718 6706 – – –
CSII+CGM 2.7882 24,803 Dominated by CSII+ SMBG
Integrated CSII+CGM (Vibe) 2.7886 24,939 Dominated by CSII+ SMBG
CSII+ SMBG 2.7906 13,365 0.0188 6659 354,202
MiniMed Paradigm Veo 2.7928 23,144 0.0022 9778 4,461,063
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FIGURE 18 Cost-effectiveness acceptability curves for all treatments for the 4-year time horizon scenario.
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FIGURE 19 Cost-effectiveness acceptability curves for CGM treatments only: 4-year time horizon scenario.
TABLE 59 Cost-effectiveness results for the fear of hypoglycaemia scenario (all technologies)
Intervention QALYs Cost (£) Incremental QALY Incremental cost (£) ICER (£)
MDI+ SMBG 11.4146 61,050 – – –
CSII+ SMBG 11.9756 90,436 0.5610 259,386 52,381
CSII+CGM 12.0604 146,476 Extendedly dominated by MiniMed Veo system
MiniMed Veo system 12.6224 138,357 0.6468 47,920 74,088
Integrated CSII+CGM (Vibe) 12.6429 147,150 0.0205 8792 428,595
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For this scenario, the main difference with respect to the base-case scenario is that stand-alone CSII and
stand-alone CGM devices is extendedly dominated by the MiniMed Paradigm Veo system, which has an
ICER compared with CSII+ SMBG of £74,088. Moreover, in this scenario, integrated CSII+CGM is not
dominated by the corresponding stand-alone combination, as the utility increment for the integrated
system led to a larger number of QALYs accumulated than the non-integrated options. Nevertheless,
the ICER of integrated CSII+CGM compared with the MiniMed Paradigm Veo system is still very
large (£428,595).
The scatterplot of the PSA outcomes in the CE plane is very similar to the one in the base-case scenario
and therefore we decided not to show it here. The CEACs for each treatment are shown in Figure 20.
These CEACs demonstrate that, compared with the base-case scenario, the probability of being
cost-effective for CSII+ SMBG starts decreasing at approximately £60,000. As the ceiling ratio increases,
the probability of being cost-effective for the MiniMed Paradigm Veo system and integrated CSII+CGM
systems also increases. At ceiling ratio values larger than (approximately) £75,000, the MiniMed Paradigm
Veo system is the treatment with the highest probability of being cost-effective, followed by integrated
CSII+CGM systems, at ceiling ratio values of more than (approximately) £90,000. It should be noted that
for stand-alone CSII+CGM, the cost-effectiveness probability was zero for all of the ceiling ratios
considered in the analysis.
If only the CGM treatments were considered, we observed similar CEACs (Figure 21) to those observed for
the base case (see Figure 14), but in this scenario the role of integrated and stand-alone CSII+CGM was
interchanged in the CEAC.
Cost of stand-alone insulin pumps and continuous glucose
monitoring devices
In this scenario, we assumed that the yearly cost of stand-alone CSII+CGM could be estimated from the
average costs of the different stand-alone devices, as shown in Tables 32 and 33, but without the
weighting for market share from White et al.121,122 Therefore, in this scenario, the estimated yearly cost of
stand-alone CSII+CGM was £5460. The results from this scenario are shown in Table 60.
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FIGURE 20 Cost-effectiveness acceptability curves for reduced fear of hypoglycaemia scenario.
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The main difference in these results, with respect to the base-case scenario, was that, as expected,
stand-alone CSII+CGM was more expensive than integrated CSII+CGM (Vibe). Since both technologies
are assumed to have the same efficacy, integrated CSII+CGM (Vibe) dominated stand-alone CSII+CGM.
The CEACs for each treatment are shown in Figure 22. These are very similar to those for the base-case
scenario. The higher cost of stand-alone CSII+CGM had almost no impact on the cost-effectiveness
probability since MDI+ SMBG and CSII+ SMBG are the only strategies that are considered cost-effective.
If only the CGM treatments were considered, we observed similar CEACs (Figure 23) as those observed for
the base-case scenario (see Figure 15) but, as expected, in this scenario the role of integrated CSII+CGM
(Vibe) and stand-alone CSII+CGM was interchanged in the CEAC.
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FIGURE 21 Cost-effectiveness acceptability curves for only CGM treatments for the fear of hypoglycaemia scenario.
TABLE 60 Cost-effectiveness results for cost of stand-alone CSII+CGM without market share scenario
(all technologies)
Intervention QALYs Cost (£) Incremental QALY Incremental cost (£) ICER (£)
MDI+ SMBG 11.4146 61,050 – – –
CSII+ SMBG 11.9756 92,272 0.5610 31,222 55,654
MiniMed Veo system 12.0412 138,357 Extendedly dominated by integrated CSII+CGM
Integrated CSII+CGM (Vibe) 12.0604 147,150 0.0849 54,878 646,692
CSII+CGM 12.0604 150,063 Dominated by integrated CSII+CGM
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FIGURE 23 Cost-effectiveness acceptability curves for CGM treatments only for the cost of stand-alone CSII and
stand-alone CGM devices without market share scenario.
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FIGURE 22 Cost-effectiveness acceptability curves for cost of stand-alone CSII and stand-alone CGM devices CGM
without market share scenario.
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Extension of the health economic analysis to children
and adolescents
In addition to the clinical effectiveness limitations with regard to the evidence for children and adolescent
patients mentioned in Chapter 3 (see Effectiveness of interventions in children), the model employed to
conduct the cost-effectiveness analyses, the IMS CDM, is not suitable for modelling long-term outcomes
for children/adolescent populations, mostly because the background risk adjustment/risk factor progression
equations are all based on adult populations.
Based on these limitations, it was deemed that there are too many crucial parameters with essentially no
evidence specifically for these subgroups. This makes the reliability and validity of the results of conducting
an economic evaluation for children and adolescents in this diagnostics assessment programme
questionable. An overview of these parameters and reasons for the extreme uncertainty related to children
and young adolescent patients is given in the following sections.
We have also reviewed the latest NICE guidelines (see Health economic analyses of type 1 diabetes for
children and adolescent patients in other National Institute for Health and Care Excellence guidelines/
assessment reports) in order to summarise how they have modelled with regard to children and further
emphasise the limitations resulting from a lack of evidence.
Parameters subject to extreme uncertainty in the clinical effectiveness
evidence for child and adolescent patients
These are all parameters for treatment effects on both HbA1c levels and hypoglycaemic event rates for all
six treatment options (i.e. essentially 12 different parameters).
For the MiniMed Veo system, our systematic review identified only one study in children: Ly et al.33
This study included patients between 4 and 50 years old, 70% of whom were children (4–18 years old).
However, data were not reported separately by age group; therefore, we could use only the data for the
total population and assume that it would apply to children.
However, our clinical experts advised us not to use this study as a study in children for two main reasons:
(1) children behave differently to adults and, therefore, results for children are not the same as those for
adults; and (2) pre-teen children behave differently from teenagers and, therefore, the 4- to 12-year-old age
group would be different from a 12- to 18-year-old age group and the influence of parents on younger
children would have to be taken into account. Indeed, this further subdivision of children essentially implies
a doubling of the number of parameters for which there is no evidence of any treatment effect.
The only reason that we presented the data from this study in Chapter 3 (see Assessment of clinical
effectiveness) is that, without it, there would have been no evidence at all with regard to the effectiveness of
the MiniMed Veo system in children. Therefore, for the MiniMed Veo system (and the assessment of severe
hypoglycaemic events), we have data from only one study and this does not properly apply to children.
In addition, we found two trials presenting evidence for the integrated CSII+CGM system versus
CSII+ SMBG34 and versus MDI+ SMBG,40 and three trials comparing CSII+ SMBG with MDI+ SMBG.47–49
However, these studies differed with regard to the age groups included (12–17 years,34 7–18 years,40
8–14 years,47 8–18 years48 and 8–21 years49), whether or not patients had pump experience, baseline
HbA1c levels (8–11.5%), follow-up times (3, 6 and 12months), hypoglycaemic status at baseline (in one
study, patients with hypoglycaemia unawareness were excluded;40 in another study, only patients with
impaired awareness of hypoglycaemia were included;33 and other studies had no exclusions34 or no
information47–49), and country (Israel,47 the USA,34,48,49 and the USA and Canada40). None of the studies was
performed in the UK. Therefore, there is considerable heterogeneity between the studies, which makes any
pooling of results invalid.
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Uncertainties around the parameters for disease progression and treatment
within the IMS CDM for child and adolescent patients
Several additional modelling uncertainties with regard to using the IMS CDM for children and adolescents
have been identified. Indeed, the CDM structure is limited in that it lacks crucial parameters to inform the
long-term effects of hypoglycaemia. These uncertainties have been summarised in Table 61, along with
those regarding the treatment effects on HbA1c levels and hypoglycaemic event rate.
TABLE 61 Uncertainties regarding modelling a children and adolescent population with the IMS CDM
Category of
parameter Parameter
Possibility to include
parameter in the current
version of IMS CDM Impact on CE results
Treatment-related
adverse events
Long-term consequences of
hypoglycaemia in young children
are not included in the model,
despite them being potentially
relevant. Couper et al.,144 for
example, indicate that there is
greater concern about the
consequences of hypoglycaemia in
young children, given the rapid
growth and development of the
brain from birth to 7 years. In
children who develop diabetes
before 5 years of age,
hypoglycaemia-related long-term
adverse effects have been found,
such as cognitive deficits,
particularly in visuospatial tasks and
lower IQ scores. In children who
develop diabetes after 5 years, this
impairment has not been found145
No. The model structure is
fixed
Long-term costs and
QALYs associated with
these complications would
change. It is not possible to
predict in which direction
the CE results would
change
Costs 1. Disease management costs:
whether or not disease
management is the same for
children and adults is uncertain.
Some additional disease
management categories can be
relevant for children/
adolescents, such as screening/
management of eating disorders
and anxiety
2. BG test costs: the frequency of
BG tests differs for adults
and children
3. Insulin costs: the amount of
insulin used differs for adults
and children
4. Outpatient care-related costs:
unclear how these costs would
differ for children. We anticipate
additional costs associated with
special training for parents
5. HbA1c tests: unclear how these
costs would differ for children
Partially (except for
categories that only apply
to children, if any). These
costs could be averaged
(together with the costs for
the adult population) over
the simulation time horizon
Costs 1, 2 and 5: no
change in base-case
incremental results, as
these costs are the same
for all treatments (unless
there are categories that
apply only to children)
Cost 3: results would be
more favourable towards
CSII technologies, as the
difference in insulin costs
with respect to MDI
technologies would
increase
Cost 4: it is not possible to
predict in which direction
the CE results would
change
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TABLE 61 Uncertainties regarding modelling a children and adolescent population with the IMS CDM (continued )
Category of
parameter Parameter
Possibility to include
parameter in the current
version of IMS CDM Impact on CE results
Utilities It is uncertain how the different
complications can affect quality of
life in children compared with
adults. If this differs, then at least
two different utility values would
be needed for each complication
No. The model only
accepts one value per
health state as input. Note
also that the consequences
of hypoglycaemic events in
young children are not
modelled
It is not possible to predict
in which direction the CE
results would change
We anticipate that utilities
associated with severe
hypoglycaemic events (including
the fear of experiencing it) may be
different, in particular for younger
children, as hypoglycaemic events
can cause serious long-term
adverse events (e.g. brain damage)
Treatment effects:
reduction in baseline
HbA1c levels in the first
12 months
In the IMS CDM, the change in
HbA1c levels is assumed to occur
within the first 12 months. It is
uncertain whether or not this is
also applicable to children. It may
take longer to observe the
treatment benefits in children
Partially. The change in
HbA1c levels can be an
input in the model
regardless of age.
However, extending the
treatment effect beyond
12 months is not possible
It is not possible to predict
in which direction the CE
results would change
Treatment effects:
rate per 100 patient-
years of severe
hypoglycaemic
episodes
The rate of severe hypoglycaemic
events differs between children and
adults146
No. The model only
accepts one value as input
which is carried over the
simulation time horizon
It is not possible to predict
in which direction the CE
results would change
HbA1c progression
after year 1
Annual HbA1c progression in
children and adults is different;146
progression in children has been
reported in the literature147
Yes. This can be modelled,
for example, as in NICE
Guideline NG18 for
children148
It is not possible to predict
in which direction the CE
results would change
Disease management
parameters
It is uncertain whether or not these
parameters are the same for adults
and children. If these are different
then at least two values would be
needed for each parameter
No. The model only
accepts one value as input
It is not possible to predict
in which direction the CE
results would change
Disease natural history
parameters
It is uncertain whether or not these
parameters are the same for adults
and children. If these are different
then at least two values would be
needed for each parameter
No. The model only
accepts one value as input
It is not possible to predict
in which direction the CE
results would change
Transition
probabilities/risk
equations
All of these probabilities/equations
are based on adult data. Therefore,
it is uncertain to what extent these
parameters are appropriate for
modelling child populations. We
anticipate that, for example, the
reduction of the risk of MI or
nephropathy for every 1%
reduction in HbA1c levels or every
10mmHg reduction in SBP would
be different for children/younger
patients than for adults because of
differences in the accumulation of
any depreciation with disease
duration
No. The model only
accepts one value as input
It is not possible to predict
in which direction the CE
results would change
CE, cost-effectiveness; IQ, intelligence quotient.
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Health economic analyses of type 1 diabetes for children and adolescent
patients in other National Institute for Health and Care Excellence
guidelines/assessment reports
CG15 (2004)148 Type 1 Diabetes: Diagnosis and Management of
Type 1 Diabetes in Children and Young People
This guideline was developed for the diagnosis and management of T1DM in adults and children/younger
patients. In this guideline, no economic analysis was carried out for children or younger patients.148 No
explicit reasons for not conducting such economic analyses were mentioned in the guideline. In the
introduction section of this guideline, it is stated that it was accepted that economic models utilising
literature review data should be considered when there are resource implications with recommendations
from guidelines, or when clinical effectiveness data from well-conducted studies were presented, or when
guideline recommendations signified a policy amendment.
TA151 (2011)14 Continuous Subcutaneous Insulin Infusion for the Treatment
of Diabetes Mellitus
No economic analysis was conducted for children in this assessment, because in the technology assessment
report, it was stated that the IMS CDM (online software applied for the adult economic analysis) was not
created to run with children and could not replicate childrens’ long-term outcomes. Therefore, the
cost-effectiveness results for children/younger adults for CSII are not modelled in TA151.80
NG18 (2015)148 Diabetes (Type 1 and Type 2) in Children and Young People:
Diagnosis and Management
This guideline focuses on children and younger patients with T1DM as well as with T2DM.
In this guideline, two cost-effectiveness analyses for T1DM were conducted using the IMS CDM. The first
analysis compared MDIs (four or more injections of insulin per day, matching insulin to food – also known
as a basal–bolus regimen) with mixed insulin injections (less than four injections of insulin per day and no
matching of insulin to food). The second analysis is a ‘what if’ analysis in which the intervention effects
were based on an observational study and explored the possible cost-effectiveness of different frequencies
of capillary BG monitoring.
For these analyses, a newly diagnosed cohort (i.e. with a disease duration of 0 years) with a baseline age
of 12 years and an average baseline HbA1c value of 11.4% was used. Among the physical risk factors,
only HbA1c progression was tailored by the Guideline Development Group (based on clinical advice) to
represent progression in children. However, we anticipate that other risk factors and the risk adjustments
for children/younger patients should also be adjusted: for example, the reduction of the risk of MI or
nephropathy for every 1% reduction in HbA1c levels, or every 10mmHg reduction in SBP would be
different for children/younger patients than for adults because of differences in the accumulation of any
depreciation with disease duration. In conclusion, some input parameters of the IMS CDM (such as the
baseline HbA1c value and HbA1c progression) were adapted for the child population, but there are many
other parameters that cannot be adjusted (see Table 61). It should be noted that it is not possible to
predict the extent to which these non-adjusted parameters will affect the cost-effectiveness results;
therefore, the use of the IMS CDM for these analyses of children/younger populations is questionable.
No explicit discussion regarding the use of the IMS CDM in children/adolescents was given in this
draft guideline.
Finally, it should also be noted that, in this draft guideline, it was mentioned that the clinical evidence was
not sufficiently robust to support a recommendation for the routine use of CGM as a glucose monitoring
strategy and therefore modelling was not used to aid recommendations.81 In this regard, the conclusions
of this draft guideline81 on the lack of clinical evidence are similar to those of our report, which are
summarised in Parameters subject to extreme uncertainty in the clinical effectiveness evidence for children
and adolescent patients.
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Conclusion
The limited clinical effectiveness evidence (as discussed in Chapter 3, Effectiveness of interventions in
children and Parameters subject to extreme uncertainty in the clinical effectiveness evidence for children
and adolescent patients), the limitations of the model (summarised in Table 61), and the approaches
followed in previous NICE clinical guidelines and assessment reports support our conclusion that it is not
possible to conduct a reliable and valid economic evaluation for children/adolescent populations using the
IMS CDM.
DOI: 10.3310/hta20170 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 17
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Riemsma et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
87

Chapter 5 Discussion
Statement of principal findings
Clinical effectiveness
Nineteen trials were included, 12 reported data for adults,32,34,37–46 six reported data for children33,34,40,47–49 and
one trial reported data for pregnant women.50 Four trials were in mixed populations (adults and children); two
of these reported data separately for adults and children and are included in both the 12 trials for adults and
the six trials for children.34,40 Two trials did not report data separately for adults and children (O’Connell et al.35
and RealTrend36). Therefore, the results from these trials were not used in the main analyses.
Twelve studies were included in the analyses for adults.32,34,37–46 The main conclusion from these trials is
that the MiniMed Paradigm Veo system reduces hypoglycaemic events in adults in comparison with the
integrated CSII+CGM system, without any differences in other outcomes, including change in HbA1c
levels. Nocturnal hypoglycemic events occurred 31.8% less frequently in the MiniMed Veo group than in
the integrated CSII+CGM group [1.5 events (SD 1.0 event) vs. 2.2 events (SD 1.3 events) per patient per
week; p< 0.001]. Similarly, the MiniMed Veo group had significantly lower weekly rates of combined
daytime and night-time events than the integrated CSII+CGM group (p< 0.001). Indirect evidence seems
to suggest that that there are no significant differences between the MiniMed Paradigm Veo system and
CSII+ SMBG or MDI+ SMBG with regard to the change in HbA1c levels at 3-month follow-up. However,
if all studies are combined (combining different follow-up times and including mixed populations), the
MiniMed Paradigm Veo system is significantly better than MDI+ SMBG in terms of HbA1c levels.
For the integrated CSII+CGM system (MiniMed Paradigm REAL-Time 722 System) versus other treatments,
the results suggest a significant effect in favour of the integrated CSII+CGM system over MDI+ SMBG for
HbA1c levels, but not if compared with CSII+ SMBG, and a significant effect in favour of the integrated
CSII+CGM system over MDI+ SMBG and CSII+ SMBG with regard to quality of life.
With regard to comparisons of CSII and MDIs, only one of the six trials41–46 showed a significant difference
between CSII+ SMBG and MDI+ SMBG in terms of change in HbA1c levels. DeVries et al.42 found a
significant difference in favour of CSII+CGM: at 16 weeks, mean HbA1c levels were 0.84% lower
(mean= –0.84%, 95% CI –1.31% to –0.36%) in the CSII+ SMBG group than the MDI+ SMBG group.
No differences were found in any trial with regard to the number of severe hypoglycaemic events.
Six studies were included in the analyses for children.33,34,40,47–49 None of the studies in children made a
direct comparison between the MiniMed Paradigm Veo system and the integrated CSII+CGM system.
An indirect comparison was possible, using data from Ly et al.33 and Hirsch et al.34 at 6-month follow-up,
but only for HbA1c levels, which showed no significant difference between groups.
One study33 compared the MiniMed Paradigm Veo system with CSII+ SMBG. The only significant
difference between treatment groups was the rate of moderate and severe hypoglycaemic events, which
favoured the MiniMed Paradigm Veo system.
One study34 compared the integrated CSII+CGM system with CSII+ SMBG; this trial found no significant
difference in HbA1c levels between groups. One study40 compared the integrated CSII+CGM system with
MDI+ SMBG; this trial found a significant difference in HbA1c change scores in favour of the integrated
CSII+CGM system, but no significant difference in the number of children achieving HbA1c levels of
≤ 7%. The hyperglycaemic AUC was significantly lower in the integrated CSII+CGM group, but the
hypoglycaemic AUC showed no significant difference. Other outcomes showed no significant differences
between groups.
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For pregnant women, we found only one trial50 comparing CSII+ SMBG with MDI+ SMBG, which is not
relevant to the decision problem.
Cost-effectiveness
We assessed the cost-effectiveness of the MiniMed Paradigm Veo system and the Vibe and G4 PLATINUM
CGM system compared with stand-alone CSII+CGM, CSII+ SMBG, MDI+CGM and MDI+ SMBG for the
management of T1DM in adults.
In addition to the literature limitations regarding the population subgroups of interest (i.e. children and
pregnant women) mentioned above, the model employed to conduct the cost-effectiveness analyses,
the IMS CDM, is not suitable for modelling long-term outcomes for child/adolescent or pregnant woman
populations, because all of the background risk adjustment/risk factor progression equations are based on
adult populations.
The comparator MDI+CGM was not included in the cost-effectiveness analyses as no relevant evidence
for this comparator was found in the systematic review. Moreover, in the absence of data comparing the
clinical effectiveness of integrated CSII+CGM systems with stand-alone CSII+CGM systems, we assumed,
in our analyses, that both technologies would be equally effective, which seems to be plausible. The
immediate consequence of this assumption was that stand-alone CSII+CGM systems dominated the
integrated CSII+CGM systems since the stand-alone system was cheaper, according to our estimated cost,
while being equally effective.
Overall, the cost-effectiveness results suggest that the technologies using SMBG (either with CSII or MDIs)
are more likely to be cost-effective, since the higher quality of life provided by the technologies that use
CGM does not outweigh their higher costs. This is in line with the findings in the currently updated
T1DM guideline,81 in which CGM was compared with several SMBG setups and was found not to be
cost-effective. In particular, the base-case results show that MDI+ SMBG is the cheapest treatment, but
also the one that provides the lowest number of QALYs. The ICER of CSII+ SMBG compared with
MDI+ SMBG is £52,381. The MiniMed Paradigm Veo system is extendedly dominated by stand-alone
CSII+CGM. This is mainly because, according to our systematic review, the decrease in HbA1c levels with
respect to baseline was highest for integrated CSII+CGM, and this decrease in HbA1c leads to a decrease
in the number of complications that occur over a lifetime to such an extent that it compensates for the
higher number of severe hypoglycaemic events. In any case, the ICER of stand-alone CSII+CGM compared
with CSII+ SMBG was £660,376. Thus, given the common threshold ICER of £30,000, it is clear that
stand-alone CSII+CGM would not be cost-effective.
We also considered two additional base-case analyses. Since insulin pumps are recommended for people
with T1DM for whom MDIs are not suitable, we excluded MDI-containing technologies from the analysis.
In this scenario, the CSII+ SMBG appeared to be the strategy most likely to be cost-effective, with a
cost-effectiveness probability equal to almost 1 for all of the ceiling ratios considered in the analysis.
Following this, we also excluded SMBG treatments from the analysis in order to capture the effect of the
LGS function of the MiniMed Paradigm Veo system, which is expected to have an influence on reducing
the number of severe hypoglycaemic events, and thus on the number of QALYs gained. In this situation,
the only relevant comparison was the MiniMed Veo system versus stand-alone CSII+CGM, since the Vibe
and G4 PLATINUM CGM system was dominated by the stand-alone combination of CSII and CGM. The
corresponding results showed that when the MiniMed Veo system was compared with stand-alone
CSII+CGM, the ICER obtained was high (£422,849). However, this results from both negative incremental
QALYs and incremental costs (i.e. the ICER is in the south-west quadrant of the cost-effectiveness plane).
In this case, the higher the ICER, the better (i.e. any cost saving could be used on other patients in order to
generate QALYs that could ‘outweigh’ the loss in QALYs). Therefore, at a ceiling ratio of £30,000 per
QALY, the MiniMed Veo system would be more cost-effective than stand-alone CSII+CGM. This is
demonstrated by the corresponding CEACs, since the MiniMed Paradigm Veo system is the CGM
treatment most likely to be cost-effective for all of the ceiling ratios considered in the analysis.
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However, as the ceiling ratio increases, the CEACs for the MiniMed Paradigm Veo system and stand-alone
CSII+CGM seem to converge. As expected, the PSA showed that, for the Vibe and G4 PLATINUM CGM
system, the probability of this system being cost-effective is always zero for all of the ceiling ratios
considered in the analysis.
The results of these different scenario analyses did not differ much from the base-case results. The scenario
that was most favourable with regard to the MiniMed Paradigm Veo system was the one that considered
an additional utility decrement associated with the fear of hypoglycaemia. In this scenario, the ICER of the
MiniMed Paradigm Veo system compared with CSII+ SMBG was equal to £74,088 (the lowest found in all
analyses). However, given the common threshold ICER of £30,000, the MiniMed Paradigm Veo system
would not be considered cost-effective. For the Vibe and G4 PLATINUM CGM system, when it was not
(extendedly) dominated by other strategies, the lowest ICER obtained was £428,595 when compared with
the MiniMed Paradigm Veo system. This was also the case for the scenario in which a utility increment
associated with reducing the fear of hypoglycaemia was considered.
Strengths and limitations of the assessment
Clinical effectiveness
Overall, the evidence seems to suggest that the MiniMed Paradigm Veo system reduces hypoglycaemic
events in comparison with other treatments, without any differences in other outcomes, including change
in HbA1c levels. In addition, we found significant results in favour of the integrated CSII+CGM system in
comparison with MDI+ SMBG with regard to HbA1c levels and quality of life. However, the evidence base
was poor. The quality of included studies was generally low and often there was only one study that
compared treatments in a specific population and at a specific follow-up time. In particular, the evidence
for the two interventions of interest was limited, with only one study comparing the MiniMed Paradigm
Veo system with an integrated CSII+CGM system,32 and only one study, in a mixed population,
comparing the MiniMed Paradigm Veo system with CSII+ SMBG.33 In addition, although several studies
included the integrated CSII+CGM system as a treatment arm, it is important to note that none of these
studies looked at the Vibe and G4 PLATINUM CGM system; in the included studies, the integrated
CSII+CGM system was always a MiniMed Paradigm pump with integrated CGM system (MiniMed
Paradigm REAL-Time 722 System). This also means that all of the studies that assessed the effectiveness of
the integrated CSII+CGM system were performed in the USA. Overall, only 337,41,45 out of the 19 included
studies included patients from the UK, and only one of these was completely performed in the UK
(Thomas et al.).45 Interactions between patients and health-care providers may show considerable
differences in different countries, which will affect patients’ behaviour and therefore the effectiveness of
insulin pumps and monitors. Therefore, the results from the included studies may not be representative
of the UK situation.
Unfortunately, many studies had to be excluded because they compared CSII with MDIs, without
specifying the type of monitoring, or CGM with SMBG, without specifying the type of insulin delivery. Two
studies149,150 with 2 × 2 factorial design, including CSII+CGM, CSII+ SMBG, MDI+CGM and MDI+ SMBG,
had to be excluded because the results were reported for only CSII versus MDIs and CGM versus SMBG.
One of these studies was in children (Mauras et al.149) and one was in adults [Little et al. (HypoCOMPaSS
trial.150)] These studies were excluded because they could not be classified as one of the relevant
comparators defined by NICE and they could not be compared with the MiniMed Paradigm Veo system or
an integrated CSII+CGM system.
In addition, we had problems differentiating stand-alone and integrated CSII+CGM interventions because
the interventions were often poorly described, making it difficult to be sure which type of intervention was
used. Sometimes researchers indicated no differences between these two types of treatments and provided
patients in the same treatment arm with stand-alone and integrated CSII+CGM systems (see Beck151).
DOI: 10.3310/hta20170 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 17
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Riemsma et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
91
Four of the included studies were in mixed populations (Ly et al.33 used 65 children and 30 adults with
an age range of 4–50 years; O’Connell et al.35 used 32 children and 30 adults with an age range of
13–40 years; RealTrend36 used 51 children and 81 adults with an age range of 2–65 years; and Hirsch
et al.34 used 40 children and 98 adults with an age range of 12–72 years). The advice from clinical experts
was not to combine results from adults and children and vice versa. Therefore, these studies were, in the
first instance, excluded from our analyses. Only if results were reported separately for adults and children
were results included in the analyses or if there would have been no data without using a mixed adult/
child population study, as in the case of Ly et al.,33 which was used as a study in children to make a
comparison between the MiniMed Paradigm Veo system and other treatments.
As reported in Chapter 1 of this report (see Comparators), there is a problem with the comparability of
populations in studies evaluating insulin pumps and MDIs. NICE recommended CSII as a potential
treatment for children ≥ 12 years and adults, who have disabling hypoglycaemia (including anxiety about
hypoglycaemia) when trying to attain HbA1c < 7.5%, or HbA1c is constantly > 8.5%, while undergoing
MDIT.14 In other words, insulin pumps are recommended for people with T1DM for whom MDIs are not
suitable. Therefore, it was anticipated that it would be problematic finding studies comparing insulin
pumps (especially modern pumps such as the integrated systems) with MDIs in similar populations.
Most studies comparing CSII with MDIs show no difference with regard to HbA1c levels. One trial found a
significant difference in the change in HbA1c levels at follow-up (DeVries et al.42). In this trial, patients with
persistent poor control, defined as a mean of all HbA1c levels of ≥ 8.5% in the 6 months before the trial,
were included. Partly based on this trial, NICE14 concluded that CSII would most likely be cost-effective in
patients with poorly controlled diabetes. Our current systematic review shows that nothing has changed
in the evidence base with regard to CSII versus MDIs. The trial by DeVries et al.42 is still the only trial
showing significant differences in HbA1c levels at follow-up between CSII+ SMBG and MDI+ SMBG. This
highlights the problem with identifying the correct population for comparisons between the interventions
relevant to this appraisal. For the comparison of the MiniMed Paradigm Veo system with the integrated
CSII+CGM system, we have included a general population of T1DM patients. However, if we compare
these interventions with CSII+ SMBG or MDI+ SMBG in general populations, we will obscure the
differences that exist between CSII and MDIs in diabetes patients with poor control at baseline.
For the comparison of CSII with MDIs, it is important to differentiate between populations with good
HbA1c control at baseline and populations with poor control. However, if we compare the MiniMed
Paradigm Veo system with the integrated CSII+CGM system and with CSII+ SMBG, all patients will be
using a pump and, in most studies comparing different types of pumps, patients will have been using a
pump for > 6 months. In such studies, baseline HbA1c levels will be relatively low because of long-term
pump use. Therefore, it is difficult to assess how valid comparisons are between those patients and
patients involved in trials comparing pump use with MDIs.
Given these problems resulting from the heterogeneity among RCT populations, we did not consider
including any further observational studies, as these problems would be even more apparent if results from
observational studies were compared.
For pregnant women, we found no studies looking at the MiniMed Paradigm Veo system or the integrated
CSII+CGM system.
Cost-effectiveness
An important strength of the current cost-effectiveness evaluation is that we used a well-validated diabetes
model (IMS CDM) that has been used for many assessments, including submissions for NICE.14,81–85 In
particular, this model was used to assess the cost-effectiveness of CSII versus MDIs for T1DM patients in a
2010 HTA report80 and in the current update of the NICE Guideline on T1DM (NG17).81 Since 1999, the
model has been used at Mount Hood conferences, during which health economic models on diabetes are
compared with each other in terms of their structure, performance and validity.86–88 Two major validation
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papers on the IMS CDM have been published to date.89,90 The latest one,90 from 2014, is the basis for the
technical model description provided in this report. This description is consistent with the latest version of
the model (version 8.5). Given the degree of validation of the model, and in order to be in line with the
currently updated T1DM guideline81 from which we sourced many input parameters, it was deemed
important not to use an alternative model or develop a de novo cost-effectiveness model for this
evaluation. The most recent unit cost data were obtained for the analyses, including detailed data on
equipment costs obtained from the relevant companies.
Although many of our input parameters are the same as those described in NICE Guideline NG17,81
we have also considered interventions that were not assessed in the guideline. Furthermore, we have
considered a large variety of scenarios and performed PSAs for all of them.
A major limitation of the model is that the IMS CDM is not appropriate for analysing health economic
outcomes for paediatric/adolescent populations. This was reported in the 2010 assessment of CSII versus
MDIs for T1DM patients80 and confirmed by the model developers, who also mentioned that the model is
not appropriate for pregnant women either. Therefore, these two subgroup populations were not included
in the cost-effectiveness analyses.
Another limitation of the IMS CDM is that not all input parameters can be included in a PSA because of
the technical constraints of the model. It is likely that the most important parameter not included in
the PSA was the rate of severe hypoglycaemic events, as this is considered to be one of the key drivers
of the model results, especially with regard to the MiniMed Paradigm Veo system. As a consequence,
the uncertainty regarding the ICERs is currently somewhat underestimated. However, the ICERs themselves
are not influenced by this limitation.
Another major limitation is the lack of comparability of treatments and clinical trials to estimate the
treatment effect for stand-alone CSII+CGM. In the current analysis, we had to assume equal effectiveness
of integrated and stand-alone CSII+CGM, thus assuring that stand-alone CSII+CGM would always
dominate integrated CSII+CGM. Moreover, it was difficult to determine the extent to which the effect of
the LGS function of the MiniMed Paradigm Veo system was captured in the model results. Furthermore,
we found no reliable data on minor hypoglycaemic events and DKA events. The impact of these
parameters on the cost-effectiveness results is difficult to predict, but we expect them to have less of an
impact than the other treatment effect parameters (e.g. reduction in HbA1c levels and rate of severe
hypoglycaemic events).
Finally, information was limited for the estimation of the cost of the stand-alone insulin pump. Although
we do not expect a large difference in our estimated costs, it may have a major implication for the
comparison of stand-alone CSII+CGM versus the integrated Vibe and G4 PLATINUM CGM system,
as both are equally effective. Thus, depending on the price, one of these two options will dominate
the other.
Uncertainties
Clinical effectiveness
The main uncertainties with regard to clinical effectiveness are the general lack of data (especially for
children and pregnant women) and the poor quality of the available data. In addition, there were problems
with differentiating interventions (in particular integrated and stand-alone CSII+CGM systems) and with
interpreting results from mixed populations (adults and children).
Because of inherent differences in patient characteristics at baseline, it was difficult to compare
MDI+ SMBG with any of the other interventions in this assessment.
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Cost-effectiveness
The uncertainties described for clinical effectiveness also apply to the assessment of cost-effectiveness. In
addition, it is uncertain how realistic it is to assume a continuous increase in HbA1c levels over the first year
of treatment. It seems likely that, in clinical practice, efforts would be made to keep HbA1c levels as low as
possible, so periods of increase may be followed by decreases. It is unclear at this moment what the most
realistic scenario will be in the long term.
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Chapter 6 Conclusions
Implications for service provision
Overall, the limited evidence seems to suggest that the MiniMed Paradigm Veo system reduces
hypoglycaemic events in comparison with other treatments, without any differences in other outcomes,
including change in HbA1c levels. In addition, we found significant results in favour of the integrated
CSII+CGM system over MDI+ SMBG with regard to HbA1c levels and quality of life. However, the
evidence base was poor. The quality of included studies was generally low and there was often only one
study to compare treatments in a specific population and at a specific follow-up time. In particular, the
evidence for the two interventions of interest was limited, with only one study comparing the MiniMed
Paradigm Veo system with an integrated CSII+CGM system, and only one study, in a mixed population,
comparing the MiniMed Paradigm Veo system with CSII+ SMBG.
Cost-effectiveness analyses indicated that MDI+ SMBG is the option most likely to be cost-effective, given
the current threshold of £30,000 per QALY gained, whereas integrated CSII+CGM systems and MiniMed
Paradigm Veo are dominated and extendedly dominated, respectively, by stand-alone CSII+CGM.
Scenario analyses, used to assess the potential impact of changing various input parameters, did not alter
these conclusions. No cost-effectiveness modelling was conducted for children and pregnant women.
Suggested research priorities
In adults, a trial comparing the MiniMed Paradigm Veo system with CSII+ SMBG is warranted. Similarly,
a trial comparing the integrated CSII+CGM system with CSII+ SMBG is warranted.
In children, a trial comparing the MiniMed Paradigm Veo system with the integrated CSII+CGM system is
warranted. Similarly, a trial comparing the integrated CSII+CGM system with CSII+ SMBG is warranted.
For pregnant women, trials comparing the MiniMed Paradigm Veo system and the integrated CSII+CGM
system with other interventions are warranted.
Future trials should include longer-term follow-up and include EQ-5D (besides more disease-specific
quality-of-life questionnaires) at various time points with a view to informing improved
cost-effectiveness modelling.
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Appendix 1 Literature search strategies
Clinical effectiveness searches
EMBASE (via OvidSP)
Date range searched: 1974–2014/week 34.
Date searched: 5 September 2014.
Search strategy
1. insulin dependent diabetes mellitus/ (78,607)
2. exp diabetic ketoacidosis/ (7787)
3. (diabet$ adj3 (typ$ 1 or typ$ i or type1 or typei or typ$ one)).ti,ab,ot,hw. (49,088)
4. (diabet$ adj3 (britt$ or juvenil$ or pediatric or paediatric or early or keto$ or labil$ or acidos$ or
autoimmun$ or auto immun$ or sudden onset)).ti,ab,ot,hw. (29,355)
5. ((insulin$ adj2 depend$) or insulindepend$).ti,ab,ot,hw. (217,259)
6. (dm1 or dm 1 or dmt1 or dm t1 or t1dm or t1 dm or t1d or iddm).ti,ab,ot,hw. (20,038)
7. (ketoacidosis or acidoketosis or keto acidosis or ketoacidemia or ketosis).ti,ab,ot,hw. (14,231)
8. hypoglycemia/ or hyperglycemia/ (108,615)
9. (hyperglyc?em$ or hypoglyc?em$).ti,ab,ot. (104,051)
10. ((high or higher or low or lower or increas$ or decreas$ or deficien$ or sufficien$ or insufficien$ or
reduce$ or reduction$ or fluctuat$ or fallen or falling or threshold or safe) adj3 (glucose$ or sugar$ or
hba1c or hb a1 or hba1 or a1c or h?emoglob$ or glycoh?emoglob$)).ti,ab,ot,hw. (126,603)
11. or/1-10 (436,900)
12. (sensor$ adj3 (augment$ or pump$)).ti,ab,hw,ot. (598)
13. SAPT.ti,ab,ot,hw. (114)
14. (minimed or paradigmveo).ti,ab,ot,hw,dm,dv. (727)
15. (paradigm$ adj3 (veo or pump$)).ti,ab,hw,ot,dm,dv. (127)
16. (veo adj3 pump$).ti,ab,ot,hw,dm,dv. (38)
17. ((animas or vibe) adj3 (pump$ or infus$ or system$)).ti,ab,ot,hw,dm,dv. (25)
18. (g4 adj3 platinum).ti,ab,ot,hw,dm,dv. (27)
19. dexcom.ti,ab,ot,hw,dm,dv. (298)
20. or/12-19 (1674)
21. 11 and 20 (1105)
22. insulin pump/ (3425)
23. insulin infusion/ (5096)
24. artificial pancreas/ (1433)
25. (insulin$ adj3 (pump$ or infus$ or deliver$ or catheter$)).ti,ab,ot,hw. (17,265)
26. (pump$ adj2 (therap$ or treatment$)).ti,ab,ot,hw. (3171)
27. ((subcutaneous adj2 insulin$) or CSII).ti,ab,ot,hw. (4218)
28. (artificial adj3 (pancreas or beta cell$)).ti,ab,ot,hw. (2050)
29. (closed loop adj3 (pump$ or deliver$ or infus$ or therap$ or treatment$ or system$)).ti,ab,ot,hw. (1941)
30. (accu-chek or cellnovo or dana diabecare or omnipod).ti,ab,ot,hw,dm,dv. (529)
31. ((integrat$ or dual or combined or unified) adj3 (system$ or device$)).ti,ab,ot,hw. (39,256)
32. or/22-31 (62,055)
33. insulin/ and exp injection/ (3392)
34. (multiple daily adj3 (inject$ or insulin$ or regime$ or routine$)).ti,ab,ot,hw. (1188)
35. (multiple dose adj3 (inject$ or insulin$ or regime$ or routine$)).ti,ab,ot,hw. (561)
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36. (multiple adj3 (inject$ or insulin$ or regime$ or routine$)).ti,ab,ot,hw. (9358)
37. MDI.ti,ab,hw,ot. (3791)
38. (injection adj3 therapy).ti,ab,ot,hw. (4157)
39. ((basal$ and bolus) adj3 (injection$ or regime$ or routine$ or system$)).ti,ab,hw,ot. (1491)
40. (short acting adj3 insulin).ti,ab,hw,ot. (1038)
41. rapid acting adj3 insulin).ti,ab,hw,ot. (864)
42. or/33-41 (22,079)
43. 32 or 42 (81,787)
44. crossover-procedure/ or double-blind procedure/ or randomized controlled trial/ or single-blind
procedure/ (397,683)
45. (random$ or factorial$ or crossover$ or cross over$ or cross-over$ or placebo$ or (doubl$ adj blind$)
or (singl$ adj blind$) or assign$ or allocat$ or volunteer$).ti,ab,ot,hw. (1,636,591)
46. 44 or 45 (1,636,591)
47. 11 and 43 and 46 (3628)
48. 21 or 47 (4491)
49. animal/ (1,574,788)
50. animal experiment/ (1,795,287)
51. (rat or rats or mouse or mice or murine or rodent or rodents or hamster or hamsters or pig or pigs or
porcine or rabbit or rabbits or animal or animals or dogs or dog or cats or cow or bovine or sheep or
ovine or monkey or monkeys).ti,ab,ot,hw. (5,694,449)
52. or/49-51 (5,694,449)
53. exp human/ (15,050,997)
54. human experiment/ (328,369)
55. 53 or 54 (15,052,426)
56. 52 not (52 and 55) (4,552,229)
57. (letter or editorial or note).pt. (1,874,995)
58. 48 not (56 or 57) (4185)
The trials filter was based on terms suggested in chapter 6 of the Cochrane Handbook.152
MEDLINE (via OvidSP)
Date range searched: 1946–2014/August week 4.
Date searched: 5 September 2014.
Search strategy
1. Diabetes Mellitus, Type 1/ (62,323)
2. Diabetic Ketoacidosis/ (5178)
3. (diabet$ adj3 (typ$ 1 or typ$ i or type1 or typei or typ$ one)).ti,ab,ot,hw. (69,580)
4. (diabet$ adj3 (britt$ or juvenil$ or pediatric or paediatric or early or keto$ or labil$ or acidos$ or
autoimmun$ or auto immun$ or sudden onset)).ti,ab,ot,hw. (20,273)
5. ((insulin$ adj2 depend$) or insulindepend$).ti,ab,ot,hw. (30,469)
6. (dm1 or dm 1 or dmt1 or dm t1 or t1dm or t1 dm or t1d or iddm).ti,ab,ot,hw. (13,085)
7. (ketoacidosis or acidoketosis or keto acidosis or ketoacidemia or ketosis).ti,ab,ot,hw. (9331)
8. Hyperglycemia/ (20,833)
9. Hypoglycemia/ (21,743)
10. (hyperglyc?em$ or hypoglyc?em$).ti,ab,ot. (72,656)
11. ((high or higher or low or lower or increas$ or decreas$ or deficien$ or sufficien$ or insufficien$ or
reduce$ or reduction$ or fluctuat$ or fallen or falling or threshold or safe) adj3 (glucose$ or sugar$ or
hba1c or hb a1 or hba1 or a1c or h?emoglob$ or glycoh?emoglob$)).ti,ab,ot,hw. (94,623)
12. or/1-11 (24,5714)
13. (sensor$ adj3 (augment$ or pump$)).ti,ab,hw,ot. (312)
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
116
14. SAPT.ti,ab,ot,hw. (93)
15. (minimed or paradigmveo).ti,ab,ot,hw. (197)
16. (paradigm$ adj3 (veo or pump$)).ti,ab,hw,ot. (34)
17. (veo adj3 pump$).ti,ab,ot,hw. (5)
18. ((animas or vibe) adj3 (pump$ or infus$ or system$)).ti,ab,ot,hw. (7)
19. (g4 adj3 platinum).ti,ab,ot,hw. (3)
20. dexcom.ti,ab,ot,hw. (44)
21. or/13-20 (645)
22. 12 and 21 (297)
23. Insulin Infusion Systems/ (3988)
24. Pancreas, Artificial/ (402)
25. (insulin$ adj3 (pump$ or infus$ or deliver$ or catheter$)).ti,ab,ot,hw. (11,972)
26. (pump$ adj2 (therap$ or treatment$)).ti,ab,ot,hw. (1810)
27. ((subcutaneous adj2 insulin$) or CSII).ti,ab,ot,hw. (2474)
28. (artificial adj3 (pancreas or beta cell$)).ti,ab,ot,hw. (1203)
29. (closed loop adj3 (pump$ or deliver$ or infus$ or therap$ or treatment$ or system$)).ti,ab,ot,hw. (1310)
30. (accu-chek or cellnovo or dana diabecare or omnipod).ti,ab,ot,hw. (150)
31. ((integrat$ or dual or combined or unified) adj3 (system$ or device$)).ti,ab,ot,hw. (32,573)
32. or/23-31 (47,787)
33. Insulin/ and Injections, Subcutaneous/ (2134)
34. (multiple daily adj3 (inject$ or insulin$ or regime$ or routine$)).ti,ab,ot,hw. (624)
35. (multiple dose adj3 (inject$ or insulin$ or regime$ or routine$)).ti,ab,ot,hw. (452)
36. (multiple adj3 (inject$ or insulin$ or regime$ or routine$)).ti,ab,ot,hw. (6795)
37. MDI.ti,ab,hw,ot. (2372)
38. (injection adj3 therapy).ti,ab,ot,hw. (2858)
39. ((basal$ and bolus) adj3 (injection$ or regime$ or routine$ or system$)).ti,ab,hw,ot. (1015)
40. (short acting adj3 insulin).ti,ab,hw,ot. (466)
41. (rapid acting adj3 insulin).ti,ab,hw,ot. (468)
42. or/33-41 (15,196)
43. 32 or 42 (61,325)
44. randomized controlled trial.pt. (387,461)
45. controlled clinical trial.pt. (89,748)
46. randomized.ab. (283,558)
47. placebo.ab. (150,467)
48. randomly.ab. (200,457)
49. trial.ab. (294,684)
50. groups.ab. (1,279,172)
51. or/44-50 (1,878,983)
52. exp Animals/ not (exp Animals/ and Humans/) (4,007,023)
53. 51 not 52 (1,535,840)
54. 12 and 43 and 53 (2750)
55. 22 not 52 (291)
56. 54 or 55 (2966)
Based on trials filter from box 6.4.c of the Cochrane Handbook.152
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MEDLINE In-Process & Other Non-Indexed Citations, MEDLINE Daily Update
(via OvidSP)
Date searched: 5 September 2014.
Search strategy
1. Diabetes Mellitus, Type 1/ (36)
2. Diabetic Ketoacidosis/ (3)
3. (diabet$ adj3 (typ$ 1 or typ$ i or type1 or typei or typ$ one)).ti,ab,ot,hw. (2614)
4. (diabet$ adj3 (britt$ or juvenil$ or pediatric or paediatric or early or keto$ or labil$ or acidos$ or
autoimmun$ or auto immun$ or sudden onset)).ti,ab,ot,hw. (1105)
5. ((insulin$ adj2 depend$) or insulindepend$).ti,ab,ot,hw. (701)
6. (dm1 or dm 1 or dmt1 or dm t1 or t1dm or t1 dm or t1d or iddm).ti,ab,ot,hw. (884)
7. (ketoacidosis or acidoketosis or keto acidosis or ketoacidemia or ketosis).ti,ab,ot,hw. (430)
8. Hyperglycemia/ (20)
9. Hypoglycemia/ (10)
10. (hyperglyc?em$ or hypoglyc?em$).ti,ab,ot. (5462)
11. ((high or higher or low or lower or increas$ or decreas$ or deficien$ or sufficien$ or insufficien$ or
reduce$ or reduction$ or fluctuat$ or fallen or falling or threshold or safe) adj3 (glucose$ or sugar$ or
hba1c or hb a1 or hba1 or a1c or h?emoglob$ or glycoh?emoglob$)).ti,ab,ot,hw. (7457)
12. or/1-11 (14909)
13. (sensor$ adj3 (augment$ or pump$)).ti,ab,hw,ot. (59)
14. SAPT.ti,ab,ot,hw. (83)
15. (minimed or paradigmveo).ti,ab,ot,hw. (13)
16. (paradigm$ adj3 (veo or pump$)).ti,ab,hw,ot. (4)
17. (veo adj3 pump$).ti,ab,ot,hw. (1)
18. ((animas or vibe) adj3 (pump$ or infus$ or system$)).ti,ab,ot,hw. (0)
19. (g4 adj3 platinum).ti,ab,ot,hw. (3)
20. dexcom.ti,ab,ot,hw. (7)
21. or/13-20 (164)
22. 12 and 21 (40)
23. Insulin Infusion Systems/ (2)
24. Pancreas, Artificial/ (2)
25. (insulin$ adj3 (pump$ or infus$ or deliver$ or catheter$)).ti,ab,ot,hw. (504)
26. (pump$ adj2 (therap$ or treatment$)).ti,ab,ot,hw. (189)
27. ((subcutaneous adj2 insulin$) or CSII).ti,ab,ot,hw. (172)
28. (artificial adj3 (pancreas or beta cell$)).ti,ab,ot,hw. (61)
29. (closed loop adj3 (pump$ or deliver$ or infus$ or therap$ or treatment$ or system$)).ti,ab,ot,hw. (343)
30. (accu-chek or cellnovo or dana diabecare or omnipod).ti,ab,ot,hw. (16)
31. ((integrat$ or dual or combined or unified) adj3 (system$ or device$)).ti,ab,ot,hw. (4137)
32. or/23-31 (5154)
33. Insulin/ and Injections, Subcutaneous/ (3)
34. (multiple daily adj3 (inject$ or insulin$ or regime$ or routine$)).ti,ab,ot,hw. (66)
35. (multiple dose adj3 (inject$ or insulin$ or regime$ or routine$)).ti,ab,ot,hw. (9)
36. (multiple adj3 (inject$ or insulin$ or regime$ or routine$)).ti,ab,ot,hw. (492)
37. MDI.ti,ab,hw,ot. (161)
38. (injection adj3 therapy).ti,ab,ot,hw. (206)
39. ((basal$ and bolus) adj3 (injection$ or regime$ or routine$ or system$)).ti,ab,hw,ot. (51)
40. (short acting adj3 insulin).ti,ab,hw,ot. (29)
41. (rapid acting adj3 insulin).ti,ab,hw,ot. (59)
42. or/33-41 (937)
43. 32 or 42 (6014)
44. randomized controlled trial.pt. (809)
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
118
45. controlled clinical trial.pt. (53)
46. randomized.ab. (24,330)
47. placebo.ab. (8979)
48. randomly.ab. (21,647)
49. trial.ab. (25,986)
50. groups.ab. (122,705)
51. or/44-50 (163,158)
52. exp Animals/ not (exp Animals/ and Humans/) (1565)
53. 51 not 52 (162,926)
54. 12 and 43 and 53 (178)
55. 22 not 52 (40)
56. 54 or 55 (203)
Based on trials filter from box 6.4.c of the Cochrane Handbook.152
PubMed (via the National Library of Medicine)
URL: www.ncbi.nlm.nih.gov/pubmed/
Date range searched: from inception until 5 September 2014.
Date searched: 5 September 2014.
Search strategy
#63 Search (#61 and #62) (99)
#62 Search (pubstatusaheadofprint OR publisher[sb] OR pubmednotmedline[sb]) (1,815,003)
#61 Search (#57 not #60) (1862)
#60 Search ((#58 not (#58 and #59))) (2,730,690)
#59 Search human*[tiab] (2,017,079)
#58 Search (rat[tiab] or rats[tiab] or mouse[tiab] or mice[tiab] or murine[tiab] or rodent[tiab] or rodents
[tiab] or hamster[tiab] or hamsters[tiab] or pig[tiab] or pigs[tiab] or porcine[tiab] or rabbit[tiab] or rabbits
[tiab] or animal[tiab] or animals[tiab] or dogs[tiab] or dog[tiab] or cats[tiab] or cow[tiab] or bovine[tiab] or
sheep[tiab] or ovine[tiab] or monkey[tiab] or monkeys[tiab]) (3,335,539)
#57 Search (#30 or #56) (1967)
#56 Search (#20 and #54 and #55) (1778)
#55 Search (#38 or #46) (19531)
#54 Search (#47 or #48 or #49 or #50 or #51 or #52 or #53) (2,074,509)
#53 Search groups [tiab] (1,413,274)
#52 Search trial [tiab] (369,610)
#51 Search randomly [tiab] (219,790)
#50 Search placebo [tiab] (160,018)
#49 Search randomized [tiab] (324,067)
#48 Search controlled clinical trial [pt] (87,768)
#47 Search randomized controlled trial [pt] (371,691)
#46 Search (#39 or #40 or #41 or #42 or #43 or #44 or #45) (9426)
#45 Search (“short acting insulin”[tiab] OR “rapid acting insulin”[tiab]) (810)
#44 Search (basal*[tiab] AND bolus[tiab] AND (injection*[tiab] OR regime*[tiab] OR routine*[tiab] OR
system*[tiab])) (1549)
#43 Search “injection therapy”[tiab] (2098)
#42 Search MDI[tiab] (2524)
#41 Search “multiple injection”[tiab] or “multiple injections”[tiab] or “multiple insulin”[tiab] or “multiple
regime”[tiab] or “multiple regimes”[tiab] or “multiple routine”[tiab] or “multiple routines”[tiab] (2414)
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#40 Search “multiple dose injection”[tiab] or “multiple dose injections”[tiab] or “multiple dose
insulin”[tiab] or “multiple dose regime”[tiab] or “multiple dose regimes”[tiab] or “multiple dose
routine”[tiab] or “multiple dose routines”[tiab] (48)
#39 Search “multiple daily injection”[tiab] or “multiple daily injections”[tiab] or “multiple daily
insulin”[tiab] or “multiple daily regime”[tiab] or “multiple daily regimes”[tiab] or “multiple daily
routine”[tiab] or “multiple daily routines”[tiab] (603)
#38 Search (#31 or #32 or #33 or #34 or #35 or #36 or #37) (10,964)
#37 Search “integrated system”[tiab] or “integrated systems”[tiab] “integrated device”[tiab] or
“integrated devices”[tiab] or “dual system”[tiab] or “dual systems”[tiab] or “dual device”[tiab] or “dual
devices”[tiab] or “combined system”[tiab] or “combined systems”[tiab] or “combined device”[tiab] or
“combined devices”[tiab] or “unified system”[tiab] or “unified systems”[tiab] or “unified device”[tiab] or
“unified devices”[tiab] (1317)
#36 Search (accu-chek[tiab] or cellnovo[tiab] or “dana diabecare”[tiab] or omnipod[tiab]) (159)
#35 Search “closed loop pump”[tiab] or “closed loop pumps”[tiab] or “closed loop delivery”[tiab] or
“closed loop infusion”[tiab] or “closed loop infusions”[tiab] or “closed loop therapy”[tiab] or “closed loop
treatment”[tiab] or “closed loop treatments”[tiab] or “closed loop system”[tiab] or “closed
loop systems”[tiab] (812)
#34 Search “artificial pancreas”[tiab] or “artificial beta cell”[tiab] (822)
#33 Search “subcutaneous insulin”[tiab] or CSII[tiab] (2385)
#32 Search “pump therapy”[tiab] or “pump therapies”[tiab] or “pump treatment”[tiab] or
“pump treatments”[tiab] (920)
#31 Search “insulin pump”[tiab] or “insulin pumps”[tiab] or “insulin infusion”[tiab] or “insulin
infuse”[tiab] or “insulin infused”[tiab] or “insulin deliver”[tiab] or “insulin delivery”[tiab] (7485)
#30 Search (#20 and #29) (273)
#29 Search (#21 or #22 or #23 or #25 or #26 or #27 or #28) (928)
#28 Search dexcom (54)
#27 Search (animas or vibe) AND (pump* or infus* or system*) (81)
#26 Search “veo pump” or “veo pumps” (15)
#25 Search (paradigm* AND (veo or pump*)) (350)
#23 Search minimed or paradigmveo (216)
#22 Search SAPT[tiab] (184)
#21 Search “sensor augmented”[tiab] or “sensor augment”[tiab] or “sensor pump”[tiab] or “pump
sensor”[tiab] or “sensor pumps”[tiab] (91)
#20 Search (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or
#15 or #16 or #17 or #18 or #19) (126,788)
#19 Search “high glycohemoglobin”[tiab] or “higher glycohemoglobin”[tiab] or “low
glycohemoglobin”[tiab] or “lower glycohemoglobin”[tiab] or “increase glycohemoglobin”[tiab]
or “increased glycohemoglobin”[tiab] or “increases glycohemoglobin”[tiab] or “decrease
glycohemoglobin”[tiab] or “decreasedcglycohemoglobin”[tiab] or “decreases glycohemoglobin”[tiab]
or “deficient glycohemoglobin”[tiab] or “sufficient glycohemoglobin”[tiab] or “insufficient
glycohemoglobin”[tiab] or “reduce glycohemoglobin”[tiab] or “reduced glycohemoglobin”[tiab] or
“glycohemoglobin reduction”[tiab] or “fallen glycohemoglobin”[tiab] or “falling glycohemoglobin”[tiab]
or “glycohemoglobin threshold”[tiab] or “safe glycohemoglobin”[tiab] (17)
#18 Search “high haemoglobin”[tiab] or “higher haemoglobin”[tiab] or “low haemoglobin”[tiab] or
“lower haemoglobin”[tiab] or “increase haemoglobin”[tiab] or “increased haemoglobin”[tiab] or
“increases haemoglobin”[tiab] or “decrease haemoglobin”[tiab] or “decreasedchaemoglobin”[tiab] or
“decreases haemoglobin”[tiab] or “deficient haemoglobin”[tiab] or “sufficient haemoglobin”[tiab] or
“insufficient haemoglobin”[tiab] or “reduce haemoglobin”[tiab] or “reduced haemoglobin”[tiab] or
“haemoglobin reduction”[tiab] or “fallen haemoglobin”[tiab] or “falling haemoglobin”[tiab] or
“haemoglobin threshold”[tiab] or “safe haemoglobin”[tiab] (1110)
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#17 Search “high hemoglobin”[tiab] or “higher hemoglobin”[tiab] or “low hemoglobin”[tiab] or “lower
hemoglobin”[tiab] or “increase hemoglobin”[tiab] or “increased hemoglobin”[tiab] or “increases
hemoglobin”[tiab] or “decrease hemoglobin”[tiab] or “decreasedchemoglobin”[tiab] or “decreases
hemoglobin”[tiab] or “deficient hemoglobin”[tiab] or “sufficient hemoglobin”[tiab] or “insufficient
hemoglobin”[tiab] or “reduce hemoglobin”[tiab] or “reduced hemoglobin”[tiab] or “hemoglobin
reduction”[tiab] or “fallen hemoglobin”[tiab] or “falling hemoglobin”[tiab] or “hemoglobin
threshold”[tiab] or “safe hemoglobin”[tiab] (3476)
#16 Search “high a1c”[tiab] or “higher a1c”[tiab] or “low a1c”[tiab] or “lower a1c”[tiab] or “increase
a1c”[tiab] or “increased a1c”[tiab] or “increases a1c”[tiab] or “decrease a1c”[tiab] or
“decreasedca1c”[tiab] or “decreases a1c”[tiab] or “deficient a1c”[tiab] or “sufficient a1c”[tiab] or
“insufficient a1c”[tiab] or “reduce a1c”[tiab] or “reduced a1c”[tiab] or “a1c reduction”[tiab] or “fallen
a1c”[tiab] or “falling a1c”[tiab] or “a1c threshold”[tiab] or “safe a1c”[tiab] (291)
#15 Search ((“high hba1”[tiab] or “higher hba1”[tiab] or “low hba1”[tiab] or “lower hba1”[tiab] or
“increase hba1”[tiab] or “increased hba1”[tiab] or “increases hba1”[tiab] or “decrease hba1”[tiab] or
“decreasedchba1”[tiab] or “decreases hba1”[tiab] or “deficient hba1”[tiab] or “sufficient hba1”[tiab] or
“insufficient hba1”[tiab] or “reduce hba1”[tiab] or “reduced hba1”[tiab] or “hba1 reduction”[tiab] or
“fallen hba1”[tiab] or “falling hba1”[tiab] or “hba1 threshold”[tiab] or “safe hba1”[tiab])) (76)
#14 Search “high hb a1”[tiab] or “higher hb a1”[tiab] or “low hb a1”[tiab] or “lower hb a1”[tiab] or
“increase hb a1”[tiab] or “increased hb a1”[tiab] or “increases hb a1”[tiab] or “decrease hb a1”[tiab] or
“decreasedchb a1”[tiab] or “decreases hb a1”[tiab] or “deficient hb a1”[tiab] or “sufficient hb a1”[tiab] or
“insufficient hb a1”[tiab] or “reduce hb a1”[tiab] or “reduced hb a1”[tiab] or “hb a1 reduction”[tiab] or
“fallen hb a1”[tiab] or “falling hb a1”[tiab] or “hb a1 threshold”[tiab] or “safe hb a1”[tiab] (0)
#13 Search “high hba1c”[tiab] or “higher hba1c”[tiab] or “low hba1c”[tiab] or “lower hba1c”[tiab] or
“increase hba1c”[tiab] or “increased hba1c”[tiab] or “increases hba1c”[tiab] or “decrease hba1c”[tiab] or
“decreasedchba1c”[tiab] or “decreases hba1c”[tiab] or “deficient hba1c”[tiab] or “sufficient hba1c”[tiab]
or “insufficient hba1c”[tiab] or “reduce hba1c”[tiab] or “reduced hba1c”[tiab] or “hba1c reduction”[tiab]
or “fallen hba1c”[tiab] or “falling hba1c”[tiab] or “hba1c threshold”[tiab] or “safe hba1c”[tiab] (1271)
#12 Search “high sugar”[tiab] or “higher sugar”[tiab] or “low sugar”[tiab] or “lower sugar”[tiab] or
“increase sugar”[tiab] or “increased sugar”[tiab] or “increases sugar”[tiab] or “decrease sugar”[tiab] or
“decreasedcsugar”[tiab] or “decreases sugar”[tiab] or “deficient sugar”[tiab] or “sufficient sugar”[tiab] or
“insufficient sugar”[tiab] or “reduce sugar”[tiab] or “reduced sugar”[tiab] or “sugar reduction”[tiab] or
“fallen sugar”[tiab] or “falling sugar”[tiab] or “sugar threshold”[tiab] or “safe sugar”[tiab] (1539)
#11 Search (“high glucose”[tiab] or “higher glucose”[tiab] or “low glucose”[tiab] or “lower
glucose”[tiab] or “increase glucose”[tiab] or “increased glucose”[tiab] or “increases glucose”[tiab] or
“decrease glucose”[tiab] or “decreasedcglucose”[tiab] or “decreases glucose”[tiab] or “deficient
glucose”[tiab] or “sufficient glucose”[tiab] or “insufficient glucose”[tiab] or “reduce glucose”[tiab] or
“reduced glucose”[tiab] or “glucose reduction”[tiab] or “fallen glucose”[tiab] or “falling glucose”[tiab] or
“glucose threshold”[tiab] or “safe glucose”[tiab]) (16,645)
#10 Search (hyperglycemia[tiab] or hypoglycaemia[tiab] or hyperglycemic[tiab] or
hypoglycaemic[tiab]) (44,267)
#9 Search ketoacidosis[tiab] or acidoketosis[tiab] or “keto acidosis”[tiab] or ketoacidemia[tiab] or
ketosis[tiab] (7293)
#8 Search dm1[tiab] or “dm 1”[tiab] or t1dm[tiab] or “t1 dm”[tiab] or t1d[tiab] or iddm[tiab] (13,131)
#7 Search “insulin dependent”[tiab] or insulindepend*[tiab] (27,550)
#6 Search “brittle diabetic”[tiab] or “diabetic juvenile”[tiab] or “diabetic pediatric”[tiab] or “diabetic
paediatric”[tiab] or “diabetic early”[tiab] or “diabetic labile”[tiab] or “diabetic acidosis”[tiab] or “diabetic
sudden onset”[tiab] (348)
#5 Search “diabetic brittle”[tiab] or “juvenile diabetic”[tiab] or “pediatric diabetic”[tiab] or “paediatric
diabetic”[tiab] or “early diabetic”[tiab] or “labile diabetic”[tiab] or “acidosis diabetic”[tiab] or “sudden
onset diabetic”[tiab] (1122)
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#4 Search “brittle diabetes”[tiab] or “diabetes juvenile”[tiab] or “diabetes pediatric”[tiab] or “diabetes
paediatric”[tiab] or “diabetes early”[tiab] or “diabetes ketosis”[tiab] or “diabetes labile”[tiab] or “diabetes
acidosis”[tiab] or “diabetes sudden onset”[tiab] (264)
#3 Search “diabetes brittle”[tiab] or “juvenile diabetes”[tiab] or “pediatric diabetes”[tiab] or “paediatric
diabetes”[tiab] or “early diabetes”[tiab] or “ketosis diabetes”[tiab] or “labile diabetes”[tiab] or “acidosis
diabetes”[tiab] or “sudden onset diabetes”[tiab] (2238)
#2 Search “diabetic type 1”[tiab] OR “type 1 diabetic”[tiab] OR “diabetic type i”[tiab] OR “type i
diabetic”[tiab] OR “diabetic type1”[tiab] OR “type1 diabetic”[tiab] OR “diabetic typei”[tiab] OR
“typei diabetic”[tiab] (6044)
#1 Search ((“diabetes type 1”[tiab] OR “type 1 diabetes”[tiab] OR “diabetes type i”[tiab] OR “type i
diabetes”[tiab] OR “diabetes type1”[tiab] OR “type1 diabetes”[tiab] OR “diabetes typei”[tiab] OR
“typei diabetes”[tiab])) (28,884)
Cochrane Database of Systematic Reviews (via Wiley Online Library),
Cochrane Central Register of Controlled Trials (via Wiley Online Library),
Database of Abstracts of Reviews of Effects (via Wiley Online Library) and
Health Technology Assessment Database (via Wiley Online Library)
Cochrane Database of Systematic Reviews: issue 9 of 12, September 2014.
Cochrane Central Register of Controlled Trials: issue 8 of 12, August 2014.
Database of Abstracts of Reviews of Effects: issue 3 of 4, July 2014.
Health Technology Assessment Database: issue 3 of 4, July 2014.
Date searched: 5 September 2014.
Search strategy
#1 MeSH descriptor: [Diabetic Mellitus, Type 1] this term only
#2 MeSH descriptor: [Diabetic Ketoacidosis] this term only
#3 (diabet* near/3 (typ* next 1 or typ* next i or type1 or typei or typ* next one)):ti,ab,kw
#4 (diabet* near/3 (britt* or juvenil* or pediatric or paediatric or early or keto* or labil* or acidos* or
autoimmun* or auto next immun* or sudden next onset)):ti,ab,kw
#5 ((insulin* near/2 depend*) or insulindepend*):ti,ab,kw
#6 (dm1 or dm next 1 or dmt1 or dm next t1 or t1dm or t1 next dm or t1d or iddm):ti,ab,kw
#7 (ketoacidosis or acidoketosis or keto next acidosis or ketoacidemia or ketosis):ti,ab,kw
#8 MeSH descriptor: [Hyperglycemia] this term only
#9 MeSH descriptor: [Hypoglycemia] this term only
#10 (hyperglyc?em* or hypoglyc?em*):ti,ab,kw
#11 ((high or higher or low or lower or increas* or decreas* or deficien* or sufficien* or insufficien* or
reduce* or reduction* or fluctuat* or fallen or falling or threshold or safe) near/3 (glucose* or sugar* or
hba1c or hb next a1 or hba1 or a1c or h?emoglob* or glycoh?emoglob*)):ti,ab,kw
#12 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11
#13 (sensor* near/3 (augment* or pump*))
#14 SAPT:ti,ab,kw
#15 minimed or paradigmveo
#16 (paradigm* near/3 (veo or pump*))
#17 (veo near/3 pump*)
#18 ((animas or vibe) near/3 (pump* or infus* or system*))
#19 dexcom
#20 #13 or #14 or #15 or #16 or #17 or #18 or #19
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#21 MeSH descriptor: [Insulin Infusion Systems] this term only
#22 MeSH descriptor: [Pancreas, Artificial] this term only
#23 (insulin* near/3 (pump* or infus* or deliver* or catheter*)):ti,ab,kw
#24 (pump* near/2 (therap* or treatment*)):ti,ab,kw
#25 ((subcutaneous near/2 insulin*) or CSII):ti,ab,kw
#26 (artificial near/3 (pancreas or beta next cell*)):ti,ab,kw
#27 (closed next loop near/3 (pump* or deliver* or infus* or therap* or treatment* or system*)):ti,ab,kw
#28 accu-chek or cellnovo or dana next diabecare or omnipod
#29 ((integrat* or dual or combined or unified) near/3 (system* or device*)):ti,ab,kw
#30 #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29
#31 MeSH descriptor: [Insulin] this term only
#32 MeSH descriptor: [Injections, Subcutaneous] this term only
#33 #31 and #32
#34 “multiple daily” near/3 (inject* or insulin* or regime* or routine*):ti,ab,kw
#35 “multiple dose” near/3 (inject* or insulin* or regime* or routine*):ti,ab,kw
#36 multiple near/3 (inject* or insulin* or regime* or routine*):ti,ab,kw
#37 MDI:ti,ab,kw
#38 injection near/3 therapy:ti,ab,kw
#39 (basal* and bolus) near/3 (inject* or regime* or routine* or system*):ti,ab,kw
#40 (“short acting” near/3 insulin) or (“rapid acting” near/3 insulin):ti,ab,kw
#41 #34 or #35 or #36 or #37 or #38 or #39 or #40
#42 #12 and (#20 or #30 or #41)
Cochrane Database of Systematic Reviews: 14.
Database of Abstracts of Reviews of Effects: 25.
Cochrane Central Register of Controlled Trials: 1910.
HTA: 19.
Science Citation Index Expanded (Web of Science)
Date range searched: 1988–29 August 2014.
Date searched: 5 September 2014.
Search strategy
# 40 4,012 #38 not #39
# 39 3,123,359 TS=(rat or rats or mouse or mice or murine or hamster or hamsters or animal or
animals or dogs or dog or pig or pigs or cats or bovine or cow or sheep or ovine or porcine or monkey)
# 38 5,027 #37 OR #18
# 37 4,914 #36 AND #33 AND #8
# 36 4,219,275 #35 OR #34
# 35 4,185,460 TS=((clinic* SAME trial*) OR (placebo* OR random* OR control* OR prospectiv*))
# 34 194,182 TS=((singl* or doubl* or trebl* or tripl*) SAME (blind* or mask*))
# 33 126,955 #32 OR #26
# 32 11,323 #31 OR #30 OR #29 OR #28 OR #27
# 31 837 TS=(“short acting” NEAR/3 insulin) or TS=(“rapid acting” NEAR/3 insulin)
# 30 5,207 TS=(injection NEAR/3 therapy)
# 29 4,652 TS=MDI
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# 28 332 TS=(“multiple dose” NEAR/3 (inject* or insulin* or regime* or routine*))
# 27 774 TS=(“multiple daily” NEAR/3 (inject* or insulin* or regime* or routine*))
# 26 116,578 #19 or #20 or #21 or #22 or #23 or #24 or #25
# 25 91,258 TS=((integrat* or dual or combined or unified) NEAR/3 (system* or device*))
# 24 165 TS=(accu-chek or cellnovo or “dana diabecare” or omnipod)
# 23 11,130 TS=(“closed loop” NEAR/3 (pump* or deliver* or infus* or therap* or treatment*
or system*))
# 22 851 TS=(artificial NEAR/3 (pancreas or “beta cell*”))
# 21 3,017 TS=((subcutaneous NEAR/2 insulin*) or CSII)
# 20 3,696 TS=(pump* NEAR/2 (therap* or treatment*))
# 19 10,301 TS=(insulin* NEAR/3 (pump* or infus* or deliver* or catheter*))
# 18 260 #8 and #17
# 17 1,375 #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
# 16 38 TS=dexcom
# 15 7 TS=(g4 NEAR/3 platinum)
# 14 13 TS=((animas or vibe) NEAR/3 (pump* or infus* or system*))
# 13 4 TS=(veo NEAR/3 pump*)
# 12 38 TS=(paradigm* NEAR/3 (veo or pump*))
# 11 154 TS=(minimed or paradigmveo)
# 10 396 TS=SAPT
# 9 765 TS=(sensor* NEAR/3 (augment* or pump*))
# 8 226,312 #1 or #2 or #3 or #4 or #5 or #6 or #7
# 7 109,659 TS=((high or higher or low or lower or increas* or decreas* or deficien* or sufficien* or
insufficien* or reduce* or reduction* or fluctuat* or fallen or falling or threshold or safe) NEAR/3 (glucose*
or sugar* or hba1c or “hb a1” or hba1 or a1c or hemoglob* or glycohemoglob* or haemoglob*
or glycohaemoglob*))
# 6 68,183 TS=(hyperglycem* or hypoglycem* or hyperglycaem* or hypoglycaem*)
# 5 5,944 TS=(ketoacidosis or acidoketosis or “keto acidosis” or ketoacidemia or ketosis)
# 4 17,145 TS=(dm1 or “dm 1” or dmt1 or “dm t1” or t1dm or “t1 dm” or t1d or iddm)
# 3 25,575 TS=((insulin* NEAR/2 depend*) or insulindepend*)
# 2 17,654 TS=(diabet* NEAR/3 (britt* or juvenil* or pediatric or paediatric or early or keto* or labil*
or acidos* or autoimmun* or “auto immun*” or “sudden onset”))
# 1 40,584 TS=(diabet* NEAR/3 (“typ* 1” or “typ* i” or type1 or typei or “typ* one”))
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Latin American and Caribbean Health Sciences Literature (LILACS)
URL: http://lilacs.bvsalud.org/en/
Date range searched: 1982–5 September 2014.
Date searched: 5 September 2014.
Search strategy
((MH:C18.452.394.750.124 or MH:C18.452.076.176.652.500 or MH:C18.452.394.952 or MH:
C18.452.394.984 or “diabetes type 1” or “diabetes type i” or “diabetes type1” or “diabetes typei” or
“diabetes type one” or “type 1 diabetes” or “type I diabetes” or “type1 diabetes” or “typei diabetes” or
“type one diabetes” or “diabetes tipo 1” or “diabetes tipo i” or “diabetes tipo1” or “diabetes tipoi” or
“tipo 1 diabetes” or “tipo I diabetes” or “tipo1 diabetes” or “tipoi diabetes” or “brittle diabetes” or
“juvenile diabetes” or “pediatric diabetes” or “paediatric diabetes” or “early diabetes” or “labile
diabetes” or “autoimmune diabetes” or “auto immune diabetes” or “sudden onset diabetes” or
“diabetes autoimune” or “diabetes inestable” or “diabetes instável” or “insulin dependent” or
insulindependent or “insulin dependiente” or insulinodependiente or “insulin dependente” or
insulinodependente or dm1 or “dm 1” or dmt1 or “dm t1” or t1dm or “t1 dm” or t1d or iddm or dmid or
ketoacidosis or acidoketosis or “keto acidosis” or ketoacidemia or ketosis or cetoacidosis or cetoacidose or
hyperglycem$ or hyperglycaem$ or hiperglucem$ or hiperglicem$ or hypoglycem$ or hypoglycaem$ or
hipoglucem$ or hipoglicem$) AND (MH:E02.319.300.508 or “insulin pump” or “insulin pumps” or
“insulin infusion” or “insulin infusions” or “insulin delivery” or “insulin catheter” or “insulin catheters” or
“pump therapy” or “pump therapies” or “pump treatment” or “pump treatments” or “insulina sistemas”
or “sistemas insulina” or “insulina infusion” or “infusion insulina” or “insulina infusions” or “infusion
insulinas” or “infusão de insulina” or “subcutaneous insulin” or CSII or “artificial pancreas” or “artificial
beta cell” or “célula beta artificial” or “páncreas endocrino artificial” or “integrated system” or
“integrated systems” or “integrated devices” or “dual system” or “dual systems” or “dual devices” or
“combined system” or “combined systems” or “combined devices” or “unified system” or “unified
systems” or “unified devices” or (MH: D06.472.699.587.200.500.625 and MH; E02.319.267.530.620) or
“multiple daily injection” or “multiple daily injections” or “multiple daily insulin” or “multiple dose
injection” or “multiple dose injections” or “multiple injection” or “multiple injections” or MDI or
“injection therapy” or “inyecciones terapia” or “injeções terapia” or “short acting insulin” or “rapid acting
insulin”)) or (“sensor augmented pump” or “sensor augmented pumps” or “sensor augmented insulin” or
SAPT or minimed or paradigmveo or “paradigm veo” or “paradigm pump” or “veo pump” or “veo
pumps” or “animas pump” or “animas pumps” “animas system” or “vibe pump” or “vibe pumps” or
“vibe system” or dexcom)
Retrieved: 58.
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NIHR Project Portfolio and NIHR Journals Library
NIHR Project Portfolio URL: www.nets.nihr.ac.uk/projects/
NIHR Journals Library URL: www.journalslibrary.nihr.ac.uk/
Date range searched: from inception until 5 September 2014.
Date searched: 5 September 2014.
Search terms NIHR Project Portfolio NIHR Journals Library
“sensor augmented pump” 0 0
“sensor augmented pumps” 0 0
“sensor augmented insulin” 0 0
SAPT 0 0
minimed 1 6
paradigmveo 0 0
“paradigm veo” 0 0
“veo pump” 0 0
“veo pumps” 0 0
animas 0 4
vibe 0 0
dexcom 0 1
“insulin pump” 5 14
“insulin pumps” 5 12
“continuous subcutaneous insulin infusion”
[Journals Library limit: ICD-10; E10-E14 Diabetes mellitus*]
4 17*
“artificial pancreas” 0 2
“multiple daily injection” 3 7
“multiple daily injections” 3 11
Total 21 (14 duplicates) 72 (47 duplicates)
Total after removal of duplicates 32 (61 duplicates)
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PROSPERO
URL: www.crd.york.ac.uk/prospero/
Date range searched: up to 5 September 2014.
Date searched: 5 September 2014.
Search: combine phrase/terms with ‘OR’; five search boxes in ‘All fields’.
Terms searched Records
sensor augmented pump* OR sensor augmented insulin* OR SAPT OR minimed OR paradigmveo 2
paradigm veo OR veo pump* OR animas OR vibe OR dexcom 0
insulin pump* OR insulin infusion* OR insulin therapy OR subcutaneous insulin OR CSII 14 (1 duplicate)
artificial pancreas 0
multiple daily injection* OR multiple daily insulin* 1
MDI [review title] 0
Total 17 (2 duplicates)
Total after removal of duplicates 15
US Food and Drug Administration
URL: www.fda.gov/ (includes links to approval/summary of safety and effectiveness).
Date range searched: from inception up to 5 September 2014.
Date searched: 5 September 2014.
Search strategy for medical devices
Search terms Records
minimed 6
animas 5
Vibe 0
“g4 platinum” 3
“multiple daily injection” 0
“multiple daily injections” 0
“multiple daily insulin” 1
Total 15
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Medicines and Healthcare Products Regulatory Agency
URL: www.mhra.gov.uk
Date range searched: from inception up to 5 September 2014.
Date searched: 5 September 2014.
Search strategy
Search terms Records
minimed 7
Animas+ insulin+ pump 16
Animas+ vibe 5
“g4 platinum” 2
“multiple daily injection” 0
“multiple daily injections” 0
“multiple daily insulin” 0
Total 30a
a Results almost entirely field safety notices.
National Institutes of Health (US) ClinicalTrials.gov
URL: http://clinicaltrials.gov/ct2/search/advanced
Date range searched: from inception up to 2 September 2014.
Date searched: 2 September 2014.
Advanced search option.
Search strategy
Search terms Results
Search terms: (“sensor augmented pump” OR “sensor augmented insulin” OR SAPT OR minimed or
paradigmveo OR paradigm* OR veo OR animas OR vibe OR dexcom OR “G4 platinum”)
Conditions: Type 1 Diabetes Mellitus OR Hyperglycemia OR Hypoglycemia
84
Search terms: “insulin pump” OR “insulin pumps” OR “insulin infusion” OR “insulin delivery” OR “pump
therapy” OR “subcutaneous insulin” OR CSII OR “artificial pancreas” OR “artificial beta cell”
Conditions: Type 1 Diabetes Mellitus OR Hyperglycemia OR Hypoglycemia
454
Search terms: “closed loop” OR accu-chek OR cellnovo OR “dana diabecare” OR omnipod
Conditions: Type 1 Diabetes Mellitus OR Hyperglycemia OR Hypoglycemia
136
Search terms: “integrated system” OR “integrated device” OR “integrated systems” OR “integrated devices”
OR “dual system” OR “dual device” OR “dual systems” OR “dual devices” OR “combined system” OR
“combined device” OR “combined systems” OR “combined devices”
Conditions: Type 1 Diabetes Mellitus OR Hyperglycemia OR Hypoglycemia
1
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Search terms Results
Search terms: “multiple daily injection” OR “multiple daily injections” OR “multiple daily insulin” OR
“multiple dose injection” OR “multiple dose injections”
Conditions: Type 1 Diabetes Mellitus OR Hyperglycemia OR Hypoglycemia
42
Search terms: MDI OR “multiple dose insulin” OR “multiple injection” OR “multiple injections” OR “multiple
insulin” OR “injection therapy”
Conditions: Type 1 Diabetes Mellitus OR Hyperglycemia OR Hypoglycemia
46
Total 763
Total after removal of duplicates 496
metaRegister of Controlled Trials
URL: www.controlled-trials.com/
Date range searched: from inception up to 5 September 2014.
Date searched: 5 September 2014.
National Institutes of Health (US) Clinical Trials register option not ticked as already searched separately.
Search strategy
Search terms Results
(“sensor augmented pump” OR “sensor augmented insulin” OR SAPT OR minimed or paradigmveo OR
paradigm* OR veo OR animas OR vibe OR dexcom OR “G4 platinum”) AND (Diabetes OR Hyperglycemia OR
Hypoglycemia)
2
(“insulin pump” OR “insulin pumps” OR “insulin infusion” OR “insulin delivery” OR “pump therapy” OR
“subcutaneous insulin” OR CSII OR “artificial pancreas” OR “artificial beta cell”) AND (Diabetes OR
Hyperglycemia OR Hypoglycemia)
4
(“closed loop” OR accu-chek OR cellnovo OR “dana diabecare” OR omnipod) AND (Diabetes OR
Hyperglycemia OR Hypoglycemia)
0
(“integrated system” OR “integrated device” OR “integrated systems” OR “integrated devices”) AND
(Diabetes OR Hyperglycemia OR Hypoglycemia)
0
(“dual system” OR “dual device” OR “dual systems” OR “dual devices” OR “combined system” OR
“combined device” OR “combined systems” OR “combined devices”) AND (Diabetes OR Hyperglycemia OR
Hypoglycemia)
0
(“multiple daily injection” OR “multiple daily injections” OR “multiple daily insulin” OR “multiple dose
injection” OR “multiple dose injections”) AND (Diabetes OR Hyperglycemia OR Hypoglycemia)
0
(MDI OR “multiple dose insulin” OR “multiple injection” OR “multiple injections” OR “multiple insulin” OR
“injection therapy”) AND (Diabetes OR Hyperglycemia OR Hypoglycemia)
3
Total 9
Total after removal of duplicates 7
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WHO International Clinical Trials Register Platform
URL: www.who.int/ictrp/en/
Date range searched: from inception up to 5 September 2014.
Date searched: 5 September 2014.
Standard search option.
Search strategy
Search terms Results
sensor augmented pump* OR SAPT OR minimed OR paradigmveo OR paradigm veo OR animas vibe
OR dexcom OR G4 platinum
70 for 65 trials
type 1 diabetes mellitus AND insulin pump* OR insulin infusion* OR pump therapy OR subcutaneous
insulin* OR CSII OR artificial pancreas
317 for 297 trials
type 1 diabetes mellitus AND closed loop* OR accu-chek OR cellnovo OR dana diabecare OR omnipod 115 for 115 trials
type 1 diabetes mellitus AND integrated system* OR integrated device* OR dual system* OR dual
device*
1
type 1 diabetes mellitus AND multiple daily injection* OR multiple dose injection* OR multiple daily
insulin* OR multiple injection*
75 for 50 trials
type 1 diabetes mellitus AND MDI OR multiple insulin OR injection therapy 95 for 78 trials
Total 606
Total after removal of duplicates 475
Diabetes UK Professional Conference
URL: www.diabetes.org.uk/diabetes-uk-professional-conference/
Date range searched: 2010–14.
Date searched: 10 September 2014.
Abstracts were not available from the Diabetes UK website; proceedings were published in the journal
Diabetic Medicine. It was not possible to search the proceedings from the Diabetic Medicine search screen.
Available PDFs were scanned for 2014 and 2013. Previous conference proceedings (2010, 2011 and 2012)
were only available for purchase online, so could not be scanned.
Abstracts of the Diabetes UK Professional Conference 2014
Abstracts of the Diabetes UK Professional Conference 2014, Arena and Convention Centre, Liverpool, UK,
5–7 March 2014. Diabet Med 2014;31(Suppl. 1):1–184. URL: http://onlinelibrary.wiley.com/doi/10.1111/
dme.2014.31.issue-s1/issuetoc (accessed 10 September 2014).
Basic and clinical science posters.
Clinical care and other categories posters.
Hypoglycaemia.
Children, young people and emerging adulthood.
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Abstracts of the Diabetes UK Professional Conference 2013
Abstracts of the Diabetes UK Professional Conference 2013. Manchester, UK, 13–15 March 2013. Diabet
Med 2013;30(Suppl. 1):1–213, E1–10. URL: http://onlinelibrary.wiley.com/doi/10.1111/dme.2013.30.
issue-s1/issuetoc (accessed 10 September 2014).
Basic and clinical science posters.
Clinical care and other categories posters.
Abstracts of Diabetes UK Professional Conference 2012
Abstracts of Diabetes UK Professional Conference 2012. Glasgow, UK, 7–9 March 2012. Diabet Med
2012;29(Suppl. 1):1–187. URL: http://onlinelibrary.wiley.com/doi/10.1111/dme.2012.29.issue-s1/issuetoc
(accessed 10 September 2014).
Not available online. Purchase access only.
Abstracts of Diabetes UK Professional Conference 2011
Abstracts of Diabetes UK Annual Professional Conference 2011. London, UK, 30 March 30–1 April 2011.
Diabet Med 2011;28(Suppl. 1):1–214. URL: http://onlinelibrary.wiley.com/doi/10.1111/dme.2012.29.
issue-s1/issuetoc (accessed 10 September 2014).
Not available online. Purchase access only.
Abstracts of Diabetes UK Professional Conference 2010
Abstracts of Diabetes UK Annual Professional Conference. Liverpool, UK. 3–5 March 2010. Diabet Med
2010;27(Suppl. 1):1–188. URL: http://onlinelibrary.wiley.com/doi/10.1111/dme.2010.27.issue-s1/issuetoc
(accessed 10 September 2014).
Not available online. Purchase access only.
Search results
Terms scanned Abstracts identified
sensor augmented 2014= 0
2013= 1
SAPT 2014= 0
2013= 0
minimed 2014= 0
2013= 0
paradigmveo 2014= 0
2013= 0
paradigm veo 2014= 0
2013= 0
animas 2014= 0
2013= 0
dexcom 2014= 0
2013= 0
Total 1
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European Association for the Study of Diabetes annual meeting
URL: www.easd.org
Date searched: 10 September 2014.
Advanced search
Session type=ALL Keyword=ALL.
Searched in presentation title and abstract body.
Meetings searched
The 50th European Association for the Study of Diabetes (EASD) Annual Meeting, 15–19 September 2014,
Vienna, Austria.
The 49th EASD Annual Meeting, 23–27 September 2013, Barcelona, Spain (URL: www.abstractsonline.
com/plan/start.aspx?mkey={7E87E03A-5554-4497-B245-98ADF263043C}).
The 48th EASD Annual Meeting, 1–5 October 2012, Berlin, Germany (URL: www.abstractsonline.com/plan/
ViewSession.aspx?mID=1668&skey=8e40db00-2d48-40da-891e-e4c9db8d9378&mKey={2DBFCAF7-1539-
42D5-8DDA-0A94ABB089E8}).
The 47th EASD Annual Meeting, 12–16 September 2011, Lisbon, Portugal (URL: www.abstractsonline.
com/plan/start.aspx?mkey={BAFB2746-B0DD-4110-8588-E385FAF957B7}).
The 46th EASD Meeting. 20–24 September 2010, Stockholm, Sweden (URL: www.abstractsonline.com/
plan/AdvancedSearch.aspx?mkey={10A86782-07E4-4A2D-9100-F660E5D752A9}).
The 45th EASD Meeting. 29 September-2 October 2009, Vienna, Austria (URL: www.abstractsonline.com/
plan/start.aspx?mkey={B3E385FB-2CC7-4F7C-8766-2F743C19F069}).
Search results
Terms Hits in title Hits in abstract body
“sensor augmented pump” 2013= 0
2012= 0
2011= 1
2010= 0
2009= 1
2013= 0
2012= 1
2011= 0
2010= 2
“sensor augmented pumps” 2013= 0
2012= 0
2011= 0
2010= 0
2009= 0
2013= 0
2012= 0
2011= 0
2010= 0
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Terms Hits in title Hits in abstract body
SAPT 2013= 0
2012= 0
2011= 0
2010= 0
2009= 0
2013= 0
2012= 0
2011= 0
2010= 0
minimed 2013= 0
2012= 0
2011= 0
2010= 0
2009= 0
2013= 5
2012= 5
2011= 2
2010= 5
paradigmveo 2013= 0
2012= 0
2011= 0
2010= 0
2009= 0
2013= 0
2012= 0
2011= 0
2010= 0
“paradigm veo” 2013= 0
2012= 0
2011= 0
2010= 0
2009= 0
2013= 0
2012= 0
2011= 2
2010= 0
“veo pump” 2013= 0
2012= 0
2011= 0
2010= 0
2009= 0
2013= 0
2012= 0
2011= 0
2010= 0
animas 2013= 0
2012= 0
2011= 0
2010= 0
2009= 0
2013= 0
2012= 1
2011= 2
2010= 3
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Terms Hits in title Hits in abstract body
vibe 2013= 0
2012= 0
2011= 0
2010= 0
2009= 0
2013= 0
2012= 0
2011= 1
2010= 0
dexcom 2013= 0
2012= 1
2011= 0
2010= 0
2009= 0
2013= 4
2012= 7
2011= 1
2010= 2
“insulin pump” 2013= 7
2012= 8
2011= 8
2010= 5
2009= 3
2013= 18
2012= 20
2011= 18
2010= 16
“insulin pumps” 2013= 4
2012= 0
2011= 0
2010= 0
2009= 2
2013= 8
2012= 6
2011= 6
2010= 5
“continuous subcutaneous insulin infusion” 2013= 3
2012= 1
2011= 4
2010= 7
2009= 6
2013= 8
2012= 8
2011= 11
2010= 13
CSII 2013= 3
2012= 2
2011= 2
2010= 3
2009= 4
2013= 15
2012= 23
2011= 17
2010= 20
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Terms Hits in title Hits in abstract body
“artificial pancreas” 2013= 2
2012= 3
2011= 0
2010= 0
2009= 0
2013= 5
2012= 7
2011= 3
2010= 1
“multiple daily injection” 2013= 1
2012= 0
2011= 0
2010= 4
2009= 0
2013= 6
2012= 1
2011= 2
2010= 6
“multiple daily injections” 2013= 0
2012= 0
2011= 0
2010= 2
2009= 3
2013= 7
2012= 2
2011= 6
2010= 7
MDI 2013= 0
2012= 2
2011= 1
2010= 0
2009= 1
2013= 13
2012= 12
2011= 8
2010= 13
Total 94 354
Overall total 448
Overall total after removal of duplicates 196
American Diabetes Association Scientific Sessions
URL: www.diabetes.org/
Date searched: 10 September 2014.
Sessions searched
74th American Diabetes Association Scientific Sessions, 13–17 June 2014, San Francisco, CA (URL: www.
abstractsonline.com/plan/start.aspx?mkey={40FC5C61-819A-4D1B-AABA-3705F7D0EA76}).
73rd American Diabetes Association Scientific Sessions, 21–25 June 2013, Chicago, IL (URL: www.
abstractsonline.com/plan/start.aspx?mkey={89918D6D-3018-4EA9-9D4F-711F98A7AE5D}).
72nd American Diabetes Association Scientific Sessions, 8–12 June 2012, Philadelphia, PA (URL: www.
abstractsonline.com/plan/start.aspx?mkey={0F70410F-8DF3-49F5-A63D-3165359F5371}).
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Search results
Terms Hits in abstract title
“sensor augmented pump” 2014= 0
2013= 0
2012= 0
“sensor augmented pumps” 2014= 0
2013= 0
2012= 0
SAPT 2014= 0
2013= 0
2012= 0
minimed 2014= 0
2013= 2
2012= 0
paradigmveo 2014= 0
2013= 0
2012= 0
“paradigm veo” 2014= 0
2013= 0
2012= 0
“veo pump” 2014= 0
2013= 0
2012= 0
animas 2014= 0
2013= 0
2012= 0
vibe 2014= 0
2013= 0
2012= 0
dexcom 2014= 1
2013= 0
2012= 1
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Terms Hits in abstract title
“insulin pump” 2014= 16
2013= 7
2012= 12
“insulin pumps” 2014= 6
2013= 0
2012= 1
“continuous subcutaneous insulin infusion” 2014= 5
2013= 6
2012= 3
CSII 2014= 8
2013= 7
2012= 5
“artificial pancreas” 2014= 13
2013= 7
2012= 4
“multiple daily injection” 2014= 1
2013= 0
2012= 0
“multiple daily injections” 2014= 1
2013= 0
2012= 0
MDI 2014= 2
2013= 6
2012= 1
Total 115
Total after removal of duplicates 91
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Cost-effectiveness searches
NHS Economic Evaluation Database (via Wiley Online Library)
Issue searched: 3 of 4, July 2014.
Date searched: 5 September 2014.
Search strategy
#1 MeSH descriptor: [Diabetes Mellitus, Type 1] this term only
#2 MeSH descriptor: [Diabetic Ketoacidosis] this term only
#3 (diabet* near/3 (typ* next 1 or typ* next i or type1 or typei or typ* next one)):ti,ab,kw
#4 (diabet* near/3 (britt* or juvenil* or pediatric or paediatric or early or keto* or labil* or acidos* or
autoimmun* or auto next immun* or sudden next onset)):ti,ab,kw
#5 ((insulin* near/2 depend*) or insulindepend*):ti,ab,kw
#6 (dm1 or dm next 1 or dmt1 or dm next t1 or t1dm or t1 next dm or t1d or iddm):ti,ab,kw
#7 (ketoacidosis or acidoketosis or keto next acidosis or ketoacidemia or ketosis):ti,ab,kw
#8 MeSH descriptor: [Hyperglycemia] this term only
#9 MeSH descriptor: [Hypoglycemia] this term only
#10 (hyperglyc?em* or hypoglyc?em*):ti,ab,kw
#11 ((high or higher or low or lower or increas* or decreas* or deficien* or sufficien* or insufficien* or
reduce* or reduction* or fluctuat* or fallen or falling or threshold or safe) near/3 (glucose* or sugar* or
hba1c or hb next a1 or hba1 or a1c or h?emoglob* or glycoh?emoglob*)):ti,ab,kw
#12 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11
#13 (sensor* near/3 (augment* or pump*))
#14 SAPT:ti,ab,kw
#15 minimed or paradigmveo
#16 (paradigm* near/3 (veo or pump*))
#17 (veo near/3 pump*)
#18 ((animas or vibe) near/3 (pump* or infus* or system*))
#19 dexcom
#20 #13 or #14 or #15 or #16 or #17 or #18 or #19
#21 MeSH descriptor: [Insulin Infusion Systems] this term only
#22 MeSH descriptor: [Pancreas, Artificial] this term only
#23 (insulin* near/3 (pump* or infus* or deliver* or catheter*)):ti,ab,kw
#24 (pump* near/2 (therap* or treatment*)):ti,ab,kw
#25 ((subcutaneous near/2 insulin*) or CSII):ti,ab,kw
#26 (artificial near/3 (pancreas or beta next cell*)):ti,ab,kw
#27 (closed next loop near/3 (pump* or deliver* or infus* or therap* or treatment* or system*)):ti,ab,kw
#28 accu-chek or cellnovo or dana next diabecare or omnipod
#29 ((integrat* or dual or combined or unified) near/3 (system* or device*)):ti,ab,kw
#30 #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29
#31 MeSH descriptor: [Insulin] this term only
#32 MeSH descriptor: [Injections, Subcutaneous] this term only
#33 #31 and #32
#34 “multiple daily” near/3 (inject* or insulin* or regime* or routine*):ti,ab,kw
#35 “multiple dose” near/3 (inject* or insulin* or regime* or routine*):ti,ab,kw
#36 multiple near/3 (inject* or insulin* or regime* or routine*):ti,ab,kw
#37 MDI:ti,ab,kw
#38 injection near/3 therapy:ti,ab,kw
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#39 (basal* and bolus) near/3 (inject* or regime* or routine* or system*):ti,ab,kw
#40 (“short acting” near/3 insulin) or (“rapid acting” near/3 insulin):ti,ab,kw
#41 #34 or #35 or #36 or #37 or #38 or #39 or #40
#42 #12 and (#20 or #30 or #41)
NHS Economic Evaluation Database (NHS EED) records retrieved: 16 records.
Health Economic Evaluations Database (via Wiley Online Library)
Date range searched: from inception up to 5 September 2014.
Date searched: 5 September 2014.
Search strategy
AX=‘sensor augmented’ or sensor-augmented or SAPT (1)
AX=minimed or paradigmveo or ‘paradigm veo’ or ‘paradigm pump’ or ‘veo pump’ or ‘animas pump’ or
‘animas infusion’ or ‘vibe pump’ or ‘vibe infusion’ or ‘g4 platinum’ or dexcom (0)
CS=1 or 2 (1)
AX=diabetes or dm1 or ‘dm 1’ or dmt1 or ‘dm t1’ or t1dm or ‘t1 dm’ or t1d or iddm (2289)
AX=ketoacidosis or acidoketosis or ‘keto acidosis’ or ketoacidemia or ketosis (28)
AX=hyperglycemia or hypoglycemia or hyperglycaemia or hypoglycaemia (146)
CS=4 or 5 or 6 (2321)
AX=‘insulin pump’ or ‘insulin pumps’ or ‘insulin infusion’ or ‘insulin infusions’ or ‘insulin delivery’ (46)
AX=‘pump therapy’ or ‘subcutaneous insulin’ or CSII or ‘artificial pancreas’ or ‘artificial beta-cell’ (41)
AX=‘closed loop’ or accu-chek or cellnovo or ‘dana diabecare’ or omnipod (1)
AX=‘integrated system’ or ‘integrated systems’ or ‘integrated device’ or ‘integrated devices’ or ‘dual
system’ or ‘dual systems’ or ‘dual device’ or ‘dual devices’ (7)
AX=‘multiple daily injection’ or ‘multiple daily injections’ or ‘multiple daily insulin’ or ‘multiple dose
injection’ or ‘multiple dose injections’ or ‘multiple dose insulin’ or AX=‘multiple injection’ or ‘multiple
injections’ or ‘multiple insulin’ OR MDI (45)
CS=8 or 9 or 10 or 11 or 12 (86)
CS=7 and 12 (52)
CS=3 or 14 (52)
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EMBASE (via OvidSP)
Date range searched: 1974–2014/week 34.
Date searched: 5 September 2014.
Search strategy
1. insulin dependent diabetes mellitus/ (78,607)
2. exp diabetic ketoacidosis/ (7787)
3. (diabet$ adj3 (typ$ 1 or typ$ i or type1 or typei or typ$ one)).ti,ab,ot,hw. (49,088)
4. (diabet$ adj3 (britt$ or juvenil$ or pediatric or paediatric or early or keto$ or labil$ or acidos$ or
autoimmun$ or auto immun$ or sudden onset)).ti,ab,ot,hw. (29,355)
5. ((insulin$ adj2 depend$) or insulindepend$).ti,ab,ot,hw. (217,259)
6. (dm1 or dm 1 or dmt1 or dm t1 or t1dm or t1 dm or t1d or iddm).ti,ab,ot,hw. (20,038)
7. (ketoacidosis or acidoketosis or keto acidosis or ketoacidemia or ketosis).ti,ab,ot,hw. (14,231)
8. hypoglycemia/ or hyperglycemia/ (108,615)
9. (hyperglyc?em$ or hypoglyc?em$).ti,ab,ot. (104,051)
10. ((high or higher or low or lower or increas$ or decreas$ or deficien$ or sufficien$ or insufficien$ or
reduce$ or reduction$ or fluctuat$ or fallen or falling or threshold or safe) adj3 (glucose$ or sugar$ or
hba1c or hb a1 or hba1 or a1c or h?emoglob$ or glycoh?emoglob$)).ti,ab,ot,hw. (126,603)
11. or/1-10 (436,900)
12. (sensor$ adj3 (augment$ or pump$)).ti,ab,hw,ot. (598)
13. SAPT.ti,ab,ot,hw. (114)
14. (minimed or paradigmveo).ti,ab,ot,hw,dm,dv. (727)
15. (paradigm$ adj3 (veo or pump$)).ti,ab,hw,ot,dm,dv. (127)
16. (veo adj3 pump$).ti,ab,ot,hw,dm,dv. (38)
17. ((animas or vibe) adj3 (pump$ or infus$ or system$)).ti,ab,ot,hw,dm,dv. (25)
18. (g4 adj3 platinum).ti,ab,ot,hw,dm,dv. (27)
19. dexcom.ti,ab,ot,hw,dm,dv. (298)
20. or/12-19 (1674)
21. insulin pump/ (3425)
22. insulin infusion/ (5096)
23. artificial pancreas/ (1433)
24. (insulin$ adj3 (pump$ or infus$ or deliver$ or catheter$)).ti,ab,ot,hw. (17,265)
25. (pump$ adj2 (therap$ or treatment$)).ti,ab,ot,hw. (3171)
26. ((subcutaneous adj2 insulin$) or CSII).ti,ab,ot,hw. (4218)
27. (artificial adj3 (pancreas or beta cell$)).ti,ab,ot,hw. (2050)
28. (closed loop adj3 (pump$ or deliver$ or infus$ or therap$ or treatment$ or system$)).ti,ab,ot,hw. (1941)
29. (accu-chek or cellnovo or dana diabecare or omnipod).ti,ab,ot,hw,dm,dv. (529)
30. ((integrat$ or dual or combined or unified) adj3 (system$ or device$)).ti,ab,ot,hw. (39,256)
31. or/21-30 (62,055)
32. insulin/ and exp injection/ (3392)
33. (multiple daily adj3 (inject$ or insulin$ or regime$ or routine$)).ti,ab,ot,hw. (1188)
34. (multiple dose adj3 (inject$ or insulin$ or regime$ or routine$)).ti,ab,ot,hw. (561)
35. (multiple adj3 (inject$ or insulin$ or regime$ or routine$)).ti,ab,ot,hw. (9358)
36. MDI.ti,ab,hw,ot. (3791)
37. (injection adj3 therapy).ti,ab,ot,hw. (4157)
38. ((basal$ and bolus) adj3 (injection$ or regime$ or routine$ or system$)).ti,ab,hw,ot. (1491)
39. (short acting adj3 insulin).ti,ab,hw,ot. (1038)
40. (rapid acting adj3 insulin).ti,ab,hw,ot. (864)
41. or/32-40 (22,079)
42. 20 or 31 or 41 (82,594)
43. 11 and 42 (18,536)
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44. health-economics/ (33,789)
45. exp economic-evaluation/ (214,699)
46. exp health-care-cost/ (207,493)
47. exp pharmacoeconomics/ (168,062)
48. or/44-47 (484,055)
49. (econom$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab.
(620,526)
50. (expenditure$ not energy).ti,ab. (24,446)
51. (value adj2 money).ti,ab. (1422)
52. budget$.ti,ab. (24,740)
53. or/49-52 (645,088)
54. 48 or 53 (918,375)
55. letter.pt. (853,934)
56. editorial.pt. (454,769)
57. note.pt. (566,292)
58. or/55-57 (1,874,995)
59. 54 not 58 (830,092)
60. (metabolic adj cost).ti,ab. (913)
61. ((energy or oxygen) adj cost).ti,ab. (3189)
62. ((energy or oxygen) adj expenditure).ti,ab. (20,605)
63. or/60-62 (23,877)
64. 59 not 63 (824,949)
65. exp animal/ (19,314,568)
66. exp animal-experiment/ (1,798,176)
67. nonhuman/ (4,359,920)
68. (rat or rats or mouse or mice or hamster or hamsters or animal or animals or dog or dogs or cat or
cats or bovine or sheep).ti,ab,sh. (4,850,843)
69. or/65-68 (20,707,342)
70. exp human/ (15,050,997)
71. exp human-experiment/ (328,369)
72. 70 or 71 (15,052,426)
73. 69 not (69 and 72) (5,655,873)
74. 64 not 73 (761,307)
75. 43 and 74 (1027)
The economics terms were based on the following costs filter:
Centre for Reviews and Dissemination. Search strategies: NHS EED EMBASE using OvidSP (economics
filter). York: Centre for Reviews and Dissemination; 2014. URL: www.crd.york.ac.uk/crdweb/
searchstrategies.asp#nhseedembase (accessed 2 June 2014).
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MEDLINE (via OvidSP)
Date range searched: 1946–2014/August week 4.
Date searched: 5 September 2014.
1. Diabetes Mellitus, Type 1/ (62,323)
2. Diabetic Ketoacidosis/ (5178)
3. (diabet$ adj3 (typ$ 1 or typ$ i or type1 or typei or typ$ one)).ti,ab,ot,hw. (69,580)
4. (diabet$ adj3 (britt$ or juvenil$ or pediatric or paediatric or early or keto$ or labil$ or acidos$ or
autoimmun$ or auto immun$ or sudden onset)).ti,ab,ot,hw. (20,273)
5. ((insulin$ adj2 depend$) or insulindepend$).ti,ab,ot,hw. (30469)
6. (dm1 or dm 1 or dmt1 or dm t1 or t1dm or t1 dm or t1d or iddm).ti,ab,ot,hw. (13,085)
7. (ketoacidosis or acidoketosis or keto acidosis or ketoacidemia or ketosis).ti,ab,ot,hw. (9331)
8. Hyperglycemia/ (20,833)
9. Hypoglycemia/ (21,743)
10. (hyperglyc?em$ or hypoglyc?em$).ti,ab,ot. (72,656)
11. ((high or higher or low or lower or increas$ or decreas$ or deficien$ or sufficien$ or insufficien$ or
reduce$ or reduction$ or fluctuat$ or fallen or falling or threshold or safe) adj3 (glucose$ or sugar$ or
hba1c or hb a1 or hba1 or a1c or h?emoglob$ or glycoh?emoglob$)).ti,ab,ot,hw. (94,623)
12. or/1-11 (245,714)
13. (sensor$ adj3 (augment$ or pump$)).ti,ab,hw,ot. (312)
14. SAPT.ti,ab,ot,hw. (93)
15. (minimed or paradigmveo).ti,ab,ot,hw. (197)
16. (paradigm$ adj3 (veo or pump$)).ti,ab,hw,ot. (34)
17. (veo adj3 pump$).ti,ab,ot,hw. (5)
18. ((animas or vibe) adj3 (pump$ or infus$ or system$)).ti,ab,ot,hw. (7)
19. (g4 adj3 platinum).ti,ab,ot,hw. (3)
20. dexcom.ti,ab,ot,hw. (44)
21. or/13-20 (645)
22. Insulin Infusion Systems/ (3988)
23. Pancreas, Artificial/ (402)
24. (insulin$ adj3 (pump$ or infus$ or deliver$ or catheter$)).ti,ab,ot,hw. (11,972)
25. (pump$ adj2 (therap$ or treatment$)).ti,ab,ot,hw. (1810)
26. ((subcutaneous adj2 insulin$) or CSII).ti,ab,ot,hw. (2474)
27. (artificial adj3 (pancreas or beta cell$)).ti,ab,ot,hw. (1203)
28. (closed loop adj3 (pump$ or deliver$ or infus$ or therap$ or treatment$ or system$)).ti,ab,ot,hw. (1310)
29. (accu-chek or cellnovo or dana diabecare or omnipod).ti,ab,ot,hw. (150)
30. ((integrat$ or dual or combined or unified) adj3 (system$ or device$)).ti,ab,ot,hw. (32,573)
31. or/22-30 (47,787)
32. Insulin/ and Injections, Subcutaneous/ (2134)
33. (multiple daily adj3 (inject$ or insulin$ or regime$ or routine$)).ti,ab,ot,hw. (624)
34. (multiple dose adj3 (inject$ or insulin$ or regime$ or routine$)).ti,ab,ot,hw. (452)
35. (multiple adj3 (inject$ or insulin$ or regime$ or routine$)).ti,ab,ot,hw. (6795)
36. MDI.ti,ab,hw,ot. (2372)
37. (injection adj3 therapy).ti,ab,ot,hw. (2858)
38. ((basal$ and bolus) adj3 (injection$ or regime$ or routine$ or system$)).ti,ab,hw,ot. (1015)
39. (short acting adj3 insulin).ti,ab,hw,ot. (466)
40. (rapid acting adj3 insulin).ti,ab,hw,ot. (468)
41. or/32-40 (15,196)
42. 21 or 31 or 41 (61,753)
43. 12 and 42 (10,730)
44. economics/ (27,125)
45. exp “costs and cost analysis”/ (184,746)
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46. economics, dental/ (1867)
47. exp “economics, hospital”/ (19,806)
48. economics, medical/ (8680)
49. economics, nursing/ (3985)
50. economics, pharmaceutical/ (2574)
51. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab.
(431,861)
52. (expenditure$ not energy).ti,ab. (17,649)
53. (value adj1 money).ti,ab. (23)
54. budget$.ti,ab. (17,373)
55. or/44-54 (557,969)
56. ((energy or oxygen) adj cost).ti,ab. (2704)
57. (metabolic adj cost).ti,ab. (788)
58. ((energy or oxygen) adj expenditure).ti,ab. (16,809)
59. or/56-58 (19,580)
60. 55 not 59 (553,698)
61. letter.pt. (826,900)
62. editorial.pt. (346,911)
63. historical article.pt. (306,574)
64. or/61-63 (1,465,388)
65. 60 not 64 (525,046)
66. 43 and 65 (327)
The economics terms were based on the following costs filter:
Centre for Reviews and Dissemination. Search strategies: NHS EED MEDLINE using OvidSP (economics
filter). York: Centre for Reviews and Dissemination; 2014. URL: www.crd.york.ac.uk/crdweb/
searchstrategies.asp#nhseedmedline (accessed 2 June 2014).
MEDLINE In-Process & Other Non-Indexed Citations, MEDLINE Daily Update
(via OvidSP); 4 September 2014
Date searched: 5 September 2014.
Search strategy
1. Diabetes Mellitus, Type 1/ (36)
2. Diabetic Ketoacidosis/ (3)
3. (diabet$ adj3 (typ$ 1 or typ$ i or type1 or typei or typ$ one)).ti,ab,ot,hw. (2614)
4. (diabet$ adj3 (britt$ or juvenil$ or pediatric or paediatric or early or keto$ or labil$ or acidos$ or
autoimmun$ or auto immun$ or sudden onset)).ti,ab,ot,hw. (1105)
5. ((insulin$ adj2 depend$) or insulindepend$).ti,ab,ot,hw. (701)
6. (dm1 or dm 1 or dmt1 or dm t1 or t1dm or t1 dm or t1d or iddm).ti,ab,ot,hw. (884)
7. (ketoacidosis or acidoketosis or keto acidosis or ketoacidemia or ketosis).ti,ab,ot,hw. (430)
8. Hyperglycemia/ (20)
9. Hypoglycemia/ (10)
10. (hyperglyc?em$ or hypoglyc?em$).ti,ab,ot. (5462)
11. ((high or higher or low or lower or increas$ or decreas$ or deficien$ or sufficien$ or insufficien$ or
reduce$ or reduction$ or fluctuat$ or fallen or falling or threshold or safe) adj3 (glucose$ or sugar$ or
hba1c or hb a1 or hba1 or a1c or h?emoglob$ or glycoh?emoglob$)).ti,ab,ot,hw. (7457)
12. or/1-11 (14909)
13. (sensor$ adj3 (augment$ or pump$)).ti,ab,hw,ot. (59)
14. SAPT.ti,ab,ot,hw. (83)
15. (minimed or paradigmveo).ti,ab,ot,hw. (13)
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16. (paradigm$ adj3 (veo or pump$)).ti,ab,hw,ot. (4)
17. (veo adj3 pump$).ti,ab,ot,hw. (1)
18. ((animas or vibe) adj3 (pump$ or infus$ or system$)).ti,ab,ot,hw. (0)
19. (g4 adj3 platinum).ti,ab,ot,hw. (3)
20. dexcom.ti,ab,ot,hw. (7)
21. or/13-20 (164)
22. Insulin Infusion Systems/ (2)
23. Pancreas, Artificial/ (2)
24. (insulin$ adj3 (pump$ or infus$ or deliver$ or catheter$)).ti,ab,ot,hw. (504)
25. (pump$ adj2 (therap$ or treatment$)).ti,ab,ot,hw. (189)
26. ((subcutaneous adj2 insulin$) or CSII).ti,ab,ot,hw. (172)
27. (artificial adj3 (pancreas or beta cell$)).ti,ab,ot,hw. (61)
28. (closed loop adj3 (pump$ or deliver$ or infus$ or therap$ or treatment$ or system$)).ti,ab,ot,hw. (343)
29. (accu-chek or cellnovo or dana diabecare or omnipod).ti,ab,ot,hw. (16)
30. ((integrat$ or dual or combined or unified) adj3 (system$ or device$)).ti,ab,ot,hw. (4137)
31. or/22-30 (5154)
32. Insulin/ and Injections, Subcutaneous/ (3)
33. (multiple daily adj3 (inject$ or insulin$ or regime$ or routine$)).ti,ab,ot,hw. (66)
34. (multiple dose adj3 (inject$ or insulin$ or regime$ or routine$)).ti,ab,ot,hw. (9)
35. (multiple adj3 (inject$ or insulin$ or regime$ or routine$)).ti,ab,ot,hw. (492)
36. MDI.ti,ab,hw,ot. (161)
37. (injection adj3 therapy).ti,ab,ot,hw. (206)
38. ((basal$ and bolus) adj3 (injection$ or regime$ or routine$ or system$)).ti,ab,hw,ot. (51)
39. (short acting adj3 insulin).ti,ab,hw,ot. (29)
40. (rapid acting adj3 insulin).ti,ab,hw,ot. (59)
41. or/32-40 (937)
42. 21 or 31 or 41 (6140)
43. 12 and 42 (543)
44. economics/ (0)
45. exp “costs and cost analysis”/ (103)
46. economics, dental/ (0)
47. exp “economics, hospital”/ (10)
48. economics, medical/ (0)
49. economics, nursing/ (0)
50. economics, pharmaceutical/ (0)
51. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab.
(51,540)
52. (expenditure$ not energy).ti,ab. (1501)
53. (value adj1 money).ti,ab. (5)
54. budget$.ti,ab. (2211)
55. or/44-54 (53,783)
56. ((energy or oxygen) adj cost).ti,ab. (294)
57. (metabolic adj cost).ti,ab. (80)
58. ((energy or oxygen) adj expenditure).ti,ab. (1183)
59. or/56-58 (1507)
60. 55 not 59 (53,348)
61. letter.pt. (30,310)
62. editorial.pt. (18,730)
63. historical article.pt. (112)
64. or/61-63 (49,132)
65. 60 not 64 (52,805)
66. 43 and 65 (35)
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The economics terms were based on the following costs filter:
Centre for Reviews and Dissemination. Search strategies: NHS EED MEDLINE using OvidSP (economics
filter). York: Centre for Reviews and Dissemination; 2014. URL: www.crd.york.ac.uk/crdweb/
searchstrategies.asp#nhseedmedline (accessed 2 June 2014).
PubMed (via the National Library of Medicine)
URL: www.ncbi.nlm.nih.gov/pubmed/
Date range searched: from inception up to 5 September 2014.
Date searched: 5 September 2014.
Search strategy
#59 Search (#57 and #58) 20
#58 Search (pubstatusaheadofprint OR publisher[sb] OR pubmednotmedline[sb]) 18,150,03
#57 Search (#46 and #56) 188
#56 Search (#51 not #55) 498,516
#55 Search (#52 or #53 or #54) 20,445
#54 Search “energy expenditure”[tiab] or “oxygen expenditure”[tiab] 17,356
#53 Search “metabolic cost”[tiab] 879
#52 Search “energy cost”[tiab] or “oxygen cost”[tiab] 2972
#51 Search (#47 or #48 or #49 or #50) 503,197
#50 Search budget*[tiab] 19,728
#49 Search “value for money” 928
#48 Search (expenditure*[tiab] not energy[tiab]) 19,130
#47 Search (economic*[tiab] or cost[tiab] or costs[tiab] or costly[tiab] or costing[tiab] or price[tiab] or prices
[tiab] or pricing[tiab] or pharmacoeconomic*[tiab])
482,242
#46 Search (#20 and #45) 5237
#45 Search (#28 or #36 or #44) 20,242
#44 Search (#37 or #38 or #39 or #40 or #41 or #42 or #43) 9426
#43 Search (“short acting insulin”[tiab] OR “rapid acting insulin”[tiab]) 810
#42 Search (basal*[tiab] AND bolus[tiab] AND (injection*[tiab] OR regime*[tiab] OR routine*[tiab] OR
system*[tiab]))
1549
#41 Search “injection therapy”[tiab] 2098
#40 Search MDI[tiab] 2524
#39 Search “multiple injection”[tiab] or “multiple injections”[tiab] or “multiple insulin”[tiab] or “multiple
regime”[tiab] or “multiple regimes”[tiab] or “multiple routine”[tiab] or “multiple routines”[tiab]
2414
#38 Search “multiple dose injection”[tiab] or “multiple dose injections”[tiab] or “multiple dose
insulin”[tiab] or “multiple dose regime”[tiab] or “multiple dose regimes”[tiab] or “multiple dose
routine”[tiab] or “multiple dose routines”[tiab]
48
#37 Search “multiple daily injection”[tiab] or “multiple daily injections”[tiab] or “multiple daily insulin”[tiab]
or “multiple daily regime”[tiab] or “multiple daily regimes”[tiab] or “multiple daily routine”[tiab] or
“multiple daily routines”[tiab]
603
#36 Search (#29 or #30 or #31 or #32 or #33 or #34 or #35) 10,964
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#35 Search “integrated system”[tiab] or “integrated systems”[tiab] “integrated device”[tiab] or “integrated
devices”[tiab] or “dual system”[tiab] or “dual systems”[tiab] or “dual device”[tiab] or “dual
devices”[tiab] or “combined system”[tiab] or “combined systems”[tiab] or “combined device”[tiab] or
“combined devices”[tiab] or “unified system”[tiab] or “unified systems”[tiab] or “unified device”[tiab]
or “unified devices”[tiab]
1317
#34 Search (accu-chek[tiab] or cellnovo[tiab] or “dana diabecare”[tiab] or omnipod[tiab]) 159
#33 Search “closed loop pump”[tiab] or “closed loop pumps”[tiab] or “closed loop delivery”[tiab] or
“closed loop infusion”[tiab] or “closed loop infusions”[tiab] or “closed loop therapy”[tiab] or “closed
loop treatment”[tiab] or “closed loop treatments”[tiab] or “closed loop system”[tiab] or “closed loop
systems”[tiab]
812
#32 Search “artificial pancreas”[tiab] or “artificial beta cell”[tiab] 822
#31 Search “subcutaneous insulin”[tiab] or CSII[tiab] 2385
#30 Search “pump therapy”[tiab] or “pump therapies”[tiab] or “pump treatment”[tiab] or “pump
treatments”[tiab]
920
#29 Search “insulin pump”[tiab] or “insulin pumps”[tiab] or “insulin infusion”[tiab] or “insulin infuse”[tiab]
or “insulin infused”[tiab] or “insulin deliver”[tiab] or “insulin delivery”[tiab]
7485
#28 Search (#21 or #22 or #23 or #24 or #25 or #26 or #27) 928
#27 Search dexcom 54
#26 Search (animas or vibe) AND (pump* or infus* or system*) 81
#25 Search “veo pump” or “veo pumps” 15
#24 Search ((paradigm* AND (veo or pump*))) 350
#23 Search minimed or paradigmveo 216
#22 Search SAPT[tiab] 184
#21 Search “sensor augmented”[tiab] or “sensor augment”[tiab] or “sensor pump”[tiab] or “pump
sensor”[tiab] or “sensor pumps”[tiab]
91
#20 Search (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or
#15 or #16 or #17 or #18 or #19)
126,838
#19 Search “high glycohemoglobin”[tiab] or “higher glycohemoglobin”[tiab] or “low
glycohemoglobin”[tiab] or “lower glycohemoglobin”[tiab] or “increase glycohemoglobin”[tiab] or
“increased glycohemoglobin”[tiab] or “increases glycohemoglobin”[tiab] or “decrease
glycohemoglobin”[tiab] or “decreased glycohemoglobin”[tiab] or “decreases glycohemoglobin”[tiab]
or “deficient glycohemoglobin”[tiab] or “sufficient glycohemoglobin”[tiab] or “insufficient
glycohemoglobin”[tiab] or “reduce glycohemoglobin”[tiab] or “reduced glycohemoglobin”[tiab] or
“glycohemoglobin reduction”[tiab] or “fallen glycohemoglobin”[tiab] or “falling
glycohemoglobin”[tiab] or “glycohemoglobin threshold”[tiab] or “safe glycohemoglobin”[tiab]
17
#18 Search (“high haemoglobin”[tiab] or “higher haemoglobin”[tiab] or “low haemoglobin”[tiab] or
“lower haemoglobin”[tiab] or “increase haemoglobin”[tiab] or “increased haemoglobin”[tiab] or
“increases haemoglobin”[tiab] or “decrease haemoglobin”[tiab] or “decreased haemoglobin”[tiab] or
“decreases haemoglobin”[tiab] or “deficient haemoglobin”[tiab] or “sufficient haemoglobin”[tiab] or
“insufficient haemoglobin”[tiab] or “reduce haemoglobin”[tiab] or “reduced haemoglobin”[tiab] or
“haemoglobin reduction”[tiab] or “fallen haemoglobin”[tiab] or “falling haemoglobin”[tiab] or
“haemoglobin threshold”[tiab] or “safe haemoglobin”[tiab])
1161
#17 Search “high hemoglobin”[tiab] or “higher hemoglobin”[tiab] or “low hemoglobin”[tiab] or “lower
hemoglobin”[tiab] or “increase hemoglobin”[tiab] or “increased hemoglobin”[tiab] or “increases
hemoglobin”[tiab] or “decrease hemoglobin”[tiab] or “decreasedchemoglobin”[tiab] or “decreases
hemoglobin”[tiab] or “deficient hemoglobin”[tiab] or “sufficient hemoglobin”[tiab] or “insufficient
hemoglobin”[tiab] or “reduce hemoglobin”[tiab] or “reduced hemoglobin”[tiab] or “hemoglobin
reduction”[tiab] or “fallen hemoglobin”[tiab] or “falling hemoglobin”[tiab] or “hemoglobin
threshold”[tiab] or “safe hemoglobin”[tiab]
3476
#16 Search “high a1c”[tiab] or “higher a1c”[tiab] or “low a1c”[tiab] or “lower a1c”[tiab] or “increase
a1c”[tiab] or “increased a1c”[tiab] or “increases a1c”[tiab] or “decrease a1c”[tiab] or
“decreasedca1c”[tiab] or “decreases a1c”[tiab] or “deficient a1c”[tiab] or “sufficient a1c”[tiab] or
“insufficient a1c”[tiab] or “reduce a1c”[tiab] or “reduced a1c”[tiab] or “a1c reduction”[tiab] or “fallen
a1c”[tiab] or “falling a1c”[tiab] or “a1c threshold”[tiab] or “safe a1c”[tiab]
291
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#15 Search (((“high hba1”[tiab] or “higher hba1”[tiab] or “low hba1”[tiab] or “lower hba1”[tiab] or
“increase hba1”[tiab] or “increased hba1”[tiab] or “increases hba1”[tiab] or “decrease hba1”[tiab] or
“decreasedchba1”[tiab] or “decreases hba1”[tiab] or “deficient hba1”[tiab] or “sufficient hba1”[tiab]
or “insufficient hba1”[tiab] or “reduce hba1”[tiab] or “reduced hba1”[tiab] or “hba1 reduction”[tiab]
or “fallen hba1”[tiab] or “falling hba1”[tiab] or “hba1 threshold”[tiab] or “safe hba1”[tiab])))
76
#14 Search “high hb a1”[tiab] or “higher hb a1”[tiab] or “low hb a1”[tiab] or “lower hb a1”[tiab] or
“increase hb a1”[tiab] or “increased hb a1”[tiab] or “increases hb a1”[tiab] or “decrease hb a1”[tiab]
or “decreasedchb a1”[tiab] or “decreases hb a1”[tiab] or “deficient hb a1”[tiab] or “sufficient hb
a1”[tiab] or “insufficient hb a1”[tiab] or “reduce hb a1”[tiab] or “reduced hb a1”[tiab] or “hb a1
reduction”[tiab] or “fallen hb a1”[tiab] or “falling hb a1”[tiab] or “hb a1 threshold”[tiab] or “safe hb
a1”[tiab]
0
#13 Search “high hba1c”[tiab] or “higher hba1c”[tiab] or “low hba1c”[tiab] or “lower hba1c”[tiab] or
“increase hba1c”[tiab] or “increased hba1c”[tiab] or “increases hba1c”[tiab] or “decrease
hba1c”[tiab] or “decreasedchba1c”[tiab] or “decreases hba1c”[tiab] or “deficient hba1c”[tiab] or
“sufficient hba1c”[tiab] or “insufficient hba1c”[tiab] or “reduce hba1c”[tiab] or “reduced hba1c”[tiab]
or “hba1c reduction”[tiab] or “fallen hba1c”[tiab] or “falling hba1c”[tiab] or “hba1c threshold”[tiab]
or “safe hba1c”[tiab]
1271
#12 Search “high sugar”[tiab] or “higher sugar”[tiab] or “low sugar”[tiab] or “lower sugar”[tiab] or
“increase sugar”[tiab] or “increased sugar”[tiab] or “increases sugar”[tiab] or “decrease sugar”[tiab]
or “decreasedcsugar”[tiab] or “decreases sugar”[tiab] or “deficient sugar”[tiab] or “sufficient
sugar”[tiab] or “insufficient sugar”[tiab] or “reduce sugar”[tiab] or “reduced sugar”[tiab] or “sugar
reduction”[tiab] or “fallen sugar”[tiab] or “falling sugar”[tiab] or “sugar threshold”[tiab] or “safe
sugar”[tiab]
1539
#11 Search (“high glucose”[tiab] or “higher glucose”[tiab] or “low glucose”[tiab] or “lower glucose”[tiab]
or “increase glucose”[tiab] or “increased glucose”[tiab] or “increases glucose”[tiab] or “decrease
glucose”[tiab] or “decreasedcglucose”[tiab] or “decreases glucose”[tiab] or “deficient glucose”[tiab] or
“sufficient glucose”[tiab] or “insufficient glucose”[tiab] or “reduce glucose”[tiab] or “reduced
glucose”[tiab] or “glucose reduction”[tiab] or “fallen glucose”[tiab] or “falling glucose”[tiab] or
“glucose threshold”[tiab] or “safe glucose”[tiab])
16,645
#10 Search (hyperglycemia[tiab] or hypoglycaemia[tiab] or hyperglycemic[tiab] or hypoglycaemic[tiab]) 44,267
#9 Search ketoacidosis[tiab] or acidoketosis[tiab] or “keto acidosis”[tiab] or ketoacidemia[tiab] or ketosis
[tiab]
7293
#8 Search dm1[tiab] or “dm 1”[tiab] or t1dm[tiab] or “t1 dm”[tiab] or t1d[tiab] or iddm[tiab] 13,131
#7 Search “insulin dependent”[tiab] or insulindepend*[tiab] 27,550
#6 Search “brittle diabetic”[tiab] or “diabetic juvenile”[tiab] or “diabetic pediatric”[tiab] or “diabetic
paediatric”[tiab] or “diabetic early”[tiab] or “diabetic labile”[tiab] or “diabetic acidosis”[tiab] or
“diabetic sudden onset”[tiab]
348
#5 Search “diabetic brittle”[tiab] or “juvenile diabetic”[tiab] or “pediatric diabetic”[tiab] or “paediatric
diabetic”[tiab] or “early diabetic”[tiab] or “labile diabetic”[tiab] or “acidosis diabetic”[tiab] or “sudden
onset diabetic”[tiab]
1122
#4 Search “brittle diabetes”[tiab] or “diabetes juvenile”[tiab] or “diabetes pediatric”[tiab] or “diabetes
paediatric”[tiab] or “diabetes early”[tiab] or “diabetes ketosis”[tiab] or “diabetes labile”[tiab] or
“diabetes acidosis”[tiab] or “diabetes sudden onset”[tiab]
264
#3 Search “diabetes brittle”[tiab] or “juvenile diabetes”[tiab] or “pediatric diabetes”[tiab] or “paediatric
diabetes”[tiab] or “early diabetes”[tiab] or “ketosis diabetes”[tiab] or “labile diabetes”[tiab] or
“acidosis diabetes”[tiab] or “sudden onset diabetes”[tiab]
2238
#2 Search “diabetic type 1”[tiab] OR “type 1 diabetic”[tiab] OR “diabetic type i”[tiab] OR “type i
diabetic”[tiab] OR “diabetic type1”[tiab] OR “type1 diabetic”[tiab] OR “diabetic typei”[tiab] OR “typei
diabetic”[tiab]
6044
#1 Search (((“diabetes type 1”[tiab] OR “type 1 diabetes”[tiab] OR “diabetes type i”[tiab] OR “type i
diabetes”[tiab] OR “diabetes type1”[tiab] OR “type1 diabetes”[tiab] OR “diabetes typei”[tiab] OR
“typei diabetes”[tiab])))
28,884
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The economics terms were based on the following costs filter:
Centre for Reviews and Dissemination. Search strategies: NHS EED MEDLINE using OvidSP (economics
filter). York: Centre for Reviews and Dissemination; 2014. URL: www.crd.york.ac.uk/crdweb/
searchstrategies.asp#nhseedmedline (accessed 2 June 2014).
American Economic Association’s electronic bibliography EconLit
(via EBSCOhost)
Date range searched: 1969 to 1 August 2014.
Date searched: 5 September 2014.
Search strategy
S28 S7 AND S27 (1)
S27 (S11 OR S19 OR S26) (2379)
S26 S20 OR S21 OR S22 OR S23 OR S24 OR S25 (174)
S25 TI (“short acting” N3 insulin or “rapid acting” N3 insulin) or AB (“short acting” N3 insulin or “rapid
acting” N3 insulin (0)
S24 TI (((basal* and bolus) N3 injection*) or ((basal* and bolus) N3 regime*) or ((basal* and bolus) N3
routine*) or ((basal* and bolus) N3 system*)) or AB (((basal* and bolus) N3 injection*) or ((basal* and
bolus) N3 regime*) or ((basal* and bolus) N3 routine*) or ((basal* and bolus) N3 system*)) (0)
S23 TI (MDI or injection N3 therapy) or AB (MDI or injection N3 therapy) (11)
S22 TI (multiple N3 inject* or multiple N3 insulin* or multiple N3 regime* or multiple N3 routine*) or AB
(multiple N3 inject* or multiple N3 insulin* or multiple N3 regime* or multiple N3 routine*) (163)
S21 TI (“multiple dose” N3 inject* or “multiple dose” N3 insulin* or “multiple dose” N3 regime* or
“multiple dose” N3 routine*) or AB (“multiple dose” N3 inject* or “multiple dose” N3 insulin* or
“multiple dose” N3 regime* or “multiple dose” N3 routine*) (0)
S20 TI (“multiple daily” N3 inject* or “multiple daily” N3 insulin* or “multiple daily” N3 regime* or
“multiple daily” N3 routine*) or AB (“multiple daily” N3 inject* or “multiple daily” N3 insulin* or
“multiple daily” N3 regime* or “multiple daily” N3 routine*) (0)
S19 S12 or S13 or S14 or S15 or S16 or S17 or S18 (2,206)
S18 TI (integrat* N3 system* or integrat* N3 device* or dual N3 system* or dual N3 device* or
combined N3 system* or combined N3 device* or unified N3 system* or unified N3 device) or AB
(integrat* N3 system* or integrat* N3 device* or dual N3 system* or dual N3 device* or combined N3
system* or combined N3 device* or unified N3 system* or unified N3 device) (2,187)
S17 TI (accu-chek or cellnovo or “dana diabecare” or omnipod) or AB (accu-chek or cellnovo or “dana
diabecare” or omnipod) (0)
S16 TI (“closed loop” N3 pump* or “closed loop” N3 deliver* or “closed loop” N3 infus* or “closed
loop” N3 therap* or “closed loop” N3 treatment* or “closed loop” N3 system*) or AB (“closed loop” N3
pump* or “closed loop” N3 deliver* or “closed loop” N3 infus* or “closed loop” N3 therap* or “closed
loop” N3 treatment* or “closed loop” N3 system*) (18)
S15 TI (artificial N3 pancreas or artificial N3 “beta cell*” or artificial N2 beta-cell*) or AB (artificial N3
pancreas or artificial N3 “beta cell*” or artificial N3 beta-cell*) (0)
S14 TI (subcutaneous N2 insulin* or CSII) or AB (subcutaneous N2 insulin* or CSII (2)
S13 TI (pump* N3 therap* or pump* N3 treatment*) or AB (pump* N3 therap* or pump* N3
treatment*) (1)
S12 TI (insulin* N3 pump* or insulin* N3 infus* or insulin* N3 deliver* or insulin N3 catheter*) or AB
(insulin* N3 pump* or insulin* N3 infus* or insulin* N3 deliver* or insulin N3 catheter*) (1)
S11 S8 or S9 or S10 (0)
S10 TI (animas N3 pump* or animas N3 infus* or animas N3 system* or vibe N3 pump* or vibe N3
infus* or vibe N3 system* or g4 N3 platinum or dexcom) or AB (animas N3 pump* or animas N3 infus* or
animas N3 system* or vibe N3 pump* or vibe N3 infus* or vibe N3 system* or g4 N3 platinum or
dexcom) (0)
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S9 TI (minimed or paradigmveo or paradigm* N3 veo or paradigm* N3 pump* or veo N3 pump*) or AB
(minimed or paradigmveo or paradigm* N3 veo or paradigm* N3 pump* or veo N3 pump*) (0)
S8 TI (sensor* N3 augment* or sensor* N3 pump* or sensor-augment* or SAPT) or AB (sensor* N3
augment* or sensor* N3 pump* or sensor-augment* or SAPT) (0)
S7 S1 or S2 or S3 or S4 or S5 or S6 (26)
S6 TI (hyperglycem* or hypoglycem* or hyperglycaem* or hypoglycaem*) or AB (hyperglycem* or
hypoglycem* or hyperglycaem* or hypoglycaem*) (5)
S5 TI (ketoacidosis or acidoketosis or “keto acidosis” or ketoacidemia or ketosis) or AB (ketoacidosis or
acidoketosis or “keto acidosis” or ketoacidemia or ketosis) (0)
S4 TI (dm1 or “dm 1” or dmt1 or “dm t1” or t1dm or “t1 dm” or t1d or iddm) or AB (dm1 or “dm 1”
or dmt1 or “dm t1” or t1dm or “t1 dm” or t1d or iddm) (2)
S3 TI (insulin* N2 depend* or insulindepend*) or AB (insulin* N2 depend* or insulindepend*) (5)
S2 TI (diabet* N3 britt* or diabet* N3 juvenil* or diabet* N3 pediatric or diabet* N3 paediatric or
diabet* N3 early or diabet* N3 keto* or diabet* N3 labil* or diabet* N3 acidos* or diabet* N3
autoimmun* or diabet* N3 “auto immune*” or diabet* N3 “sudden onset”) or AB (diabet* N3 britt* or
diabet* N3 juvenil* or diabet* N3 pediatric or diabet* N3 paediatric or diabet* N3 early or diabet* N3
keto* or diabet* N3 labil* or diabet* N3 acidos* or diabet* N3 autoimmun* or diabet* N3 “auto
immune*” or di ... (2)
S1 TI (diabet* N3 “typ* 1” or diabet* N3 “typ* i” or diabet* N3 type1 or diabet* N3 typei or diabet*
N3 “typ* one”) or AB (diabet* N3 “typ* 1” or diabet* N3 “typ* i” or diabet* N3 type1 or diabet* N3
typei or diabet* N3 “typ* one”) (14)
Cost-effectiveness Analysis Registry
URL: www.cearegistry.org
Date range searched: from inception up to 5 September 2014.
Date searched: 5 September 2014.
Seven records retrieved.
Search strategy
sensor augmented
sensor-augmented
SAPT
minimed
paradigmveo
paradigm veo
paradigm-veo
veo pump
animas
vibe pump
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vibe infusion
vibe system
vibe systems
g4 platinum
dexcom
insulin pump
insulin pumps
insulin infusion
insulin delivery
pump therapy
pump treatment
pump treatments
subcutaneous insulin
CSII
artificial pancreas
artificial beta cell
artificial beta-cell
closed loop
integrated system
integrated systems
integrated device
integrated devices
multiple daily injection
multiple daily injections
multiple dose injection
multiple dose injections
multiple daily insulin
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multiple dose insulin
multiple injection
multiple injections
MDI
injection therapy
basal bolus
short acting insulin
rapid acting insulin
RePEc Research Papers in Economics
URL: http://repec.org/
Date range searched: from inception up to 5 September 2014.
Date searched: 5 September 2014.
IDEAS search interface.
Search strategy
(“diabetes mellitus type 1” | “diabetes type 1” | “diabetes mellitus type1” | “diabetes type1” | “diabetes
mellitus type I” | “diabetes type I” | “diabetes mellitus typeI” | “diabetes typeI” | “diabetes mellitus
type one” | “diabetes type one” | dm1 | “dm 1” | dmt1 | “dm t1” | t1dm | “t1 dm” | t1d | iddm |
ketoacidosis)+ (“sensor augmented” | sensor-augmented | SAPT | minimed | paradigmveo | “paradigm
veo” | “paradigm pump” | “veo pump” | animas | vibe | “g4 platinum” | dexcom)
Records retrieved: 0.
(“brittle diabetes” | “juvenile diabetes” | “pediatric diabetes” | “paediatric diabetes” | “early diabetes” |
“autoimmune diabetes” | “auto immune diabetes” | “sudden onset diabetes”)+ (“sensor augmented” |
sensor-augmented | SAPT | minimed | paradigmveo | “paradigm veo” | “paradigm pump” | “veo pump” |
animas | vibe | “g4 platinum” | dexcom)
Records retrieved: 0.
(hyperglycemia | hypoglycemia | hyperglycaemia | hypoglycaemia)+ (“sensor augmented” | sensor-
augmented | SAPT | minimed | paradigmveo | “paradigm veo” | “paradigm pump” | “veo pump” | animas
| vibe | “g4 platinum” | dexcom)
Records retrieved: 0.
(“diabetes mellitus type 1” | “diabetes type 1” | “diabetes mellitus type1” | “diabetes type1” | “diabetes
mellitus type I” | “diabetes type I” | “diabetes mellitus typeI” | “diabetes typeI” | “diabetes mellitus
type one” | “diabetes type one” | dm1 | “dm 1” | dmt1 | “dm t1” | t1dm | “t1 dm” | t1d | iddm |
ketoacidosis)+ (“insulin pump” | “insulin pumps” | “insulin infusion” | “insulin delivery” | “pump therapy”
| “pump treatment” | “pump treatments”)
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Records retrieved: 1.
(“diabetes mellitus type 1” | “diabetes type 1” | “diabetes mellitus type1” | “diabetes type1” | “diabetes
mellitus type I” | “diabetes type I” | “diabetes mellitus typeI” | “diabetes typeI” | “diabetes mellitus
type one” | “diabetes type one” | dm1 | “dm 1” | dmt1 | “dm t1” | t1dm | “t1 dm” | t1d | iddm |
ketoacidosis)+ (“subcutaneous insulin” | CSII | “artificial pancreas” | “artificial beta cell” | “artificial
beta-cell” | “artificial beta cells” | “artificial beta-cells” | “closed loop” | closed-loop | “integrated system” |
“integrated systems | “dual system” | “dual systems” | “integrated device” | “integrated devices | “dual
device” | “dual devices”)
Records retrieved: 11.
(“brittle diabetes” | “juvenile diabetes” | “pediatric diabetes” | “paediatric diabetes” | “early diabetes” |
“autoimmune diabetes” | “auto immune diabetes” | “sudden onset diabetes”)+ (“insulin pump” | “insulin
pumps” | “insulin infusion” | “insulin delivery” | “pump therapy” | “pump treatment” | “pump treatments”)
Records retrieved: 0.
(“brittle diabetes” | “juvenile diabetes” | “pediatric diabetes” | “paediatric diabetes” | “early diabetes” |
“autoimmune diabetes” | “auto immune diabetes” | “sudden onset diabetes”)+ (“subcutaneous insulin” |
CSII | “artificial pancreas” | “artificial beta cell” | “artificial beta-cell” | “artificial beta cells” | “artificial
beta-cells” | “closed loop” | closed-loop | “integrated system” | “integrated systems | “dual system” |
“dual systems” | “integrated device” | “integrated devices | “dual device” | “dual devices”)
Records retrieved: 0.
(hyperglycemia | hypoglycemia | hyperglycaemia | hypoglycaemia)+ (“insulin pump” | “insulin pumps” |
“insulin infusion” | “insulin delivery” | “pump therapy” | “pump treatment” | “pump treatments”)
Records retrieved: 0.
(hyperglycemia | hypoglycemia | hyperglycaemia | hypoglycaemia)+ (“subcutaneous insulin” | CSII |
“artificial pancreas” | “artificial beta cell” | “artificial beta-cell” | “artificial beta cells” | “artificial beta-cells”
| “closed loop” | closed-loop | “integrated system” | “integrated systems | “dual system” | “dual systems” |
“integrated device” | “integrated devices | “dual device” | “dual devices”)
Records retrieved: 0.
(“diabetes mellitus type 1” | “diabetes type 1” | “diabetes mellitus type1” | “diabetes type1” | “diabetes
mellitus type I” | “diabetes type I” | “diabetes mellitus typeI” | “diabetes typeI” | “diabetes mellitus
type one” | “diabetes type one” | dm1 | “dm 1” | dmt1 | “dm t1” | t1dm | “t1 dm” | t1d | iddm |
ketoacidosis)+ (“multiple daily injection” | “multiple daily injections” | “multiple dose injection” | “multiple
dose injections” | “multiple daily insulin” | “multiple dose insulin” | “multiple injection” | “multiple
injections” | MDI | “injection therapy” | “basal bolus” | basal-bolus | basalbolus | “short acting insulin” |
“rapid acting insulin”)
Records retrieved: 11.
(“brittle diabetes” | “juvenile diabetes” | “pediatric diabetes” | “paediatric diabetes” | “early diabetes” |
“autoimmune diabetes” | “auto immune diabetes” | “sudden onset diabetes”)+ (“multiple daily injection”
| “multiple daily injections” | “multiple dose injection” | “multiple dose injections” | “multiple daily insulin”
| “multiple dose insulin” | “multiple injection” | “multiple injections” | MDI | “injection therapy” | “basal
bolus” | basal-bolus | basalbolus | “short acting insulin” | “rapid acting insulin”)
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Records retrieved: 0.
(hyperglycemia | hypoglycemia | hyperglycaemia | hypoglycaemia)+ (“multiple daily injection” | “multiple
daily injections” | “multiple dose injection” | “multiple dose injections” | “multiple daily insulin” | “multiple
dose insulin” | “multiple injection” | “multiple injections” | MDI | “injection therapy” | “basal bolus” |
basal-bolus | basalbolus | “short acting insulin” | “rapid acting insulin”)
Records retrieved: 1.
Records retrieved in total: 24.
Records retrieved after removal of duplicates: 11.
Key:
| OR
+ AND
” “ phrase search
Specific economic searches (MiniMed and Animas Vibe only)
NHS Economic Evaluation Database (via Wiley Online Library)
Issue searched: 3 of 4, July 2014.
Date searched: 2 October 2014.
Search strategy
#1 (sensor* near/3 (augment* or pump*))
#2 SAPT:ti,ab,kw
#3 minimed or paradigmveo
#4 (paradigm* near/3 (veo or pump*))
#5 (veo near/3 pump*)
#6 ((animas or vibe) near/3 (pump* or infus* or system*))
#7 dexcom
#8 #1 or #2 or #3 or #4 or #5 or #6 or #7
NHS EED: 4.
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Health Economic Evaluations Database (via Wiley Online Library)
Date range searched: from inception up to 2 October 2014.
Date searched: 2 October 2014.
Search strategy
AX=‘sensor augmented’ or sensor-augmented or SAPT (1)
AX=minimed or paradigmveo or ‘paradigm veo’ or ‘paradigm pump’ or ‘veo pump’ or ‘animas pump’ or
‘animas infusion’ or ‘vibe pump’ or ‘vibe infusion’ or ‘g4 platinum’ or dexcom (0)
CS=1 or 2 (1)
EMBASE (via OvidSP)
Date range searched: 1974–2014/week 39.
Date searched: 2 October 2014.
Search strategy
1. insulin dependent diabetes mellitus/ (79,725)
2. exp diabetic ketoacidosis/ (7880)
3. (diabet$ adj3 (typ$ 1 or typ$ i or type1 or typei or typ$ one)).ti,ab,ot,hw. (50,200)
4. (diabet$ adj3 (britt$ or juvenil$ or pediatric or paediatric or early or keto$ or labil$ or acidos$ or
autoimmun$ or auto immun$ or sudden onset)).ti,ab,ot,hw. (29,720)
5. ((insulin$ adj2 depend$) or insulindepend$).ti,ab,ot,hw. (221,115)
6. (dm1 or dm 1 or dmt1 or dm t1 or t1dm or t1 dm or t1d or iddm).ti,ab,ot,hw. (20,641)
7. (ketoacidosis or acidoketosis or keto acidosis or ketoacidemia or ketosis).ti,ab,ot,hw. (14,385)
8. hypoglycemia/ or hyperglycemia/ (110,120)
9. (hyperglyc?em$ or hypoglyc?em$).ti,ab,ot. (105,704)
10. ((high or higher or low or lower or increas$ or decreas$ or deficien$ or sufficien$ or insufficien$ or
reduce$ or reduction$ or fluctuat$ or fallen or falling or threshold or safe) adj3 (glucose$ or sugar$ or
hba1c or hb a1 or hba1 or a1c or h?emoglob$ or glycoh?emoglob$)).ti,ab,ot,hw. (128,520)
11. or/1-10 (442,805)
12. (sensor$ adj3 (augment$ or pump$)).ti,ab,hw,ot. (611)
13. SAPT.ti,ab,ot,hw. (114)
14. (minimed or paradigmveo).ti,ab,ot,hw,dm,dv. (746)
15. (paradigm$ adj3 (veo or pump$)).ti,ab,hw,ot,dm,dv. (134)
16. (veo adj3 pump$).ti,ab,ot,hw,dm,dv. (41)
17. ((animas or vibe) adj3 (pump$ or infus$ or system$)).ti,ab,ot,hw,dm,dv. (29)
18. (g4 adj3 platinum).ti,ab,ot,hw,dm,dv. (29)
19. dexcom.ti,ab,ot,hw,dm,dv. (314)
20. or/12-19 (1730)
21. 11 and 20 (1156)
22. health-economics/ (33,844)
23. exp economic-evaluation/ (215,823)
24. exp health-care-cost/ (208,556)
25. exp pharmacoeconomics/ (168,747)
26. or/22-25 (486,347)
27. (econom$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab.
(625,347)
28. (expenditure$ not energy).ti,ab. (24,608)
29. (value adj2 money).ti,ab. (1430)
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30. budget$.ti,ab. (24,869)
31. or/27-30 (650,042)
32. 26 or 31 (924,348)
33. letter.pt. (856,710)
34. editorial.pt. (456,641)
35. note.pt. (570,035)
36. or/33-35 (1,883,386)
37. 32 not 36 (835,648)
38. (metabolic adj cost).ti,ab. (924)
39. ((energy or oxygen) adj cost).ti,ab. (3207)
40. ((energy or oxygen) adj expenditure).ti,ab. (20,769)
41. or/38-40 (24,065)
42. 37 not 41 (830,473)
43. exp animal/ (19,415,638)
44. exp animal-experiment/ (1,804,426)
45. nonhuman/ (4,376,931)
46. (rat or rats or mouse or mice or hamster or hamsters or animal or animals or dog or dogs or cat or
cats or bovine or sheep).ti,ab,sh. (4,869,940)
47. or/43-46 (20,812,704)
48. exp human/ (15,138,243)
49. exp human-experiment/ (329,281)
50. 48 or 49 (15,139,672)
51. 47 not (47 and 50) (5,673,989)
52. 42 not 51 (766,321)
53. 21 and 52 (73)
The economics terms were based on the following costs filter:
Centre for Reviews and Dissemination. Search strategies: NHS EED EMBASE using OvidSP (economics
filter). York: Centre for Reviews and Dissemination; 2014. URL: www.crd.york.ac.uk/crdweb/
searchstrategies.asp#nhseedembase (accessed 2 June 2014).
MEDLINE (via OvidSP)
Date range searched: 1946–2014/September week 4.
Date searched: 2 October 2014.
Search strategy
1. Diabetes Mellitus, Type 1/ (62,498)
2. Diabetic Ketoacidosis/ (5186)
3. (diabet$ adj3 (typ$ 1 or typ$ i or type1 or typei or typ$ one)).ti,ab,ot,hw. (69,786)
4. (diabet$ adj3 (britt$ or juvenil$ or pediatric or paediatric or early or keto$ or labil$ or acidos$ or
autoimmun$ or auto immun$ or sudden onset)).ti,ab,ot,hw. (20,339)
5. ((insulin$ adj2 depend$) or insulindepend$).ti,ab,ot,hw. (30,496)
6. (dm1 or dm 1 or dmt1 or dm t1 or t1dm or t1 dm or t1d or iddm).ti,ab,ot,hw. (13,154)
7. (ketoacidosis or acidoketosis or keto acidosis or ketoacidemia or ketosis).ti,ab,ot,hw. (9345)
8. Hyperglycemia/ (20,917)
9. Hypoglycemia/ (21,796)
10. (hyperglyc?em$ or hypoglyc?em$).ti,ab,ot. (72,929)
11. ((high or higher or low or lower or increas$ or decreas$ or deficien$ or sufficien$ or insufficien$ or
reduce$ or reduction$ or fluctuat$ or fallen or falling or threshold or safe) adj3 (glucose$ or sugar$ or
hba1c or hb a1 or hba1 or a1c or h?emoglob$ or glycoh?emoglob$)).ti,ab,ot,hw. (95,034)
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12. or/1-11 (246,558)
13. (sensor$ adj3 (augment$ or pump$)).ti,ab,hw,ot. (313)
14. SAPT.ti,ab,ot,hw. (93)
15. (minimed or paradigmveo).ti,ab,ot,hw. (198)
16. (paradigm$ adj3 (veo or pump$)).ti,ab,hw,ot. (34)
17. (veo adj3 pump$).ti,ab,ot,hw. (5)
18. ((animas or vibe) adj3 (pump$ or infus$ or system$)).ti,ab,ot,hw. (7)
19. (g4 adj3 platinum).ti,ab,ot,hw. (4)
20. dexcom.ti,ab,ot,hw. (45)
21. or/13-20 (648)
22. 12 and 21 (300)
23. economics/ (27,132)
24. exp “costs and cost analysis”/ (185,352)
25. economics, dental/ (1867)
26. exp “economics, hospital”/ (19,852)
27. economics, medical/ (8682)
28. economics, nursing/ (3987)
29. economics, pharmaceutical/ (2577)
30. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab.
(434,246)
31. (expenditure$ not energy).ti,ab. (17,736)
32. (value adj1 money).ti,ab. (23)
33. budget$.ti,ab. (17,453)
34. or/23-33 (560,640)
35. ((energy or oxygen) adj cost).ti,ab. (2713)
36. (metabolic adj cost).ti,ab. (793)
37. ((energy or oxygen) adj expenditure).ti,ab. (16,876)
38. or/35-37 (19,659)
39. 34 not 38 (556,354)
40. letter.pt. (829,485)
41. editorial.pt. (348,438)
42. historical article.pt. (307,377)
43. or/40-42 (1,470,234)
44. 39 not 43 (527,602)
45. 22 and 44 (8)
The economics terms were based on the following costs filter:
Centre for Reviews and Dissemination. Search strategies: NHS EED MEDLINE using OvidSP (economics
filter). York: Centre for Reviews and Dissemination; 2014. URL: www.crd.york.ac.uk/crdweb/
searchstrategies.asp#nhseedmedline (accessed 2 June 2014).
MEDLINE In-Process & Other Non-Indexed Citations, MEDLINE Daily Update
(via OvidSP)
Date searched: 2 October 2014.
Search strategy
1. Diabetes Mellitus, Type 1/ (64)
2. Diabetic Ketoacidosis/ (5)
3. (diabet$ adj3 (typ$ 1 or typ$ i or type1 or typei or typ$ one)).ti,ab,ot,hw. (2660)
4. (diabet$ adj3 (britt$ or juvenil$ or pediatric or paediatric or early or keto$ or labil$ or acidos$ or
autoimmun$ or auto immun$ or sudden onset)).ti,ab,ot,hw. (1112)
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5. ((insulin$ adj2 depend$) or insulindepend$).ti,ab,ot,hw. (712)
6. (dm1 or dm 1 or dmt1 or dm t1 or t1dm or t1 dm or t1d or iddm).ti,ab,ot,hw. (879)
7. (ketoacidosis or acidoketosis or keto acidosis or ketoacidemia or ketosis).ti,ab,ot,hw. (440)
8. Hyperglycemia/ (32)
9. Hypoglycemia/ (27)
10. (hyperglyc?em$ or hypoglyc?em$).ti,ab,ot. (5503)
11. ((high or higher or low or lower or increas$ or decreas$ or deficien$ or sufficien$ or insufficien$ or
reduce$ or reduction$ or fluctuat$ or fallen or falling or threshold or safe) adj3 (glucose$ or sugar$ or
hba1c or hb a1 or hba1 or a1c or h?emoglob$ or glycoh?emoglob$)).ti,ab,ot,hw. (7549)
12. or/1-11 (15,088)
13. (sensor$ adj3 (augment$ or pump$)).ti,ab,hw,ot. (61)
14. SAPT.ti,ab,ot,hw. (86)
15. (minimed or paradigmveo).ti,ab,ot,hw. (12)
16. (paradigm$ adj3 (veo or pump$)).ti,ab,hw,ot. (4)
17. (veo adj3 pump$).ti,ab,ot,hw. (1)
18. ((animas or vibe) adj3 (pump$ or infus$ or system$)).ti,ab,ot,hw. (0)
19. (g4 adj3 platinum).ti,ab,ot,hw. (3)
20. dexcom.ti,ab,ot,hw. (7)
21. or/13-20 (167)
22. 12 and 21 (39)
23. economics/ (3)
24. exp “costs and cost analysis”/ (243)
25. economics, dental/ (0)
26. exp “economics, hospital”/ (22)
27. economics, medical/ (3)
28. economics, nursing/ (3)
29. economics, pharmaceutical/ (1)
30. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab.
(52,040)
31. (expenditure$ not energy).ti,ab. (1513)
32. (value adj1 money).ti,ab. (5)
33. budget$.ti,ab. (2216)
34. or/23-33 (54,328)
35. ((energy or oxygen) adj cost).ti,ab. (303)
36. (metabolic adj cost).ti,ab. (83)
37. ((energy or oxygen) adj expenditure).ti,ab. (1206)
38. or/35-37 (1538)
39. 34 not 38 (53,879)
40. letter.pt. (30,601)
41. editorial.pt. (18,927)
42. historical article.pt. (188)
43. or/40-42 (49,699)
44. 39 not 43 (53,316)
45. 22 and 44 (3)
The economics terms were based on the following costs filter:
Centre for Reviews and Dissemination. Search strategies: NHS EED MEDLINE using OvidSP (economics
filter). York: Centre for Reviews and Dissemination; 2014. URL: www.crd.york.ac.uk/crdweb/
searchstrategies.asp#nhseedmedline (accessed 2 June 2014).
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PubMed (via National Library of Medicine)
URL: www.ncbi.nlm.nih.gov/pubmed/
Date range searched: from inception up to 5 September 2014.
Date searched: 5 September 2014.
Search strategy
#42 Search (#41 and #42) 0
#41 Search (pubstatusaheadofprint OR publisher[sb] OR pubmednotmedline[sb]) 18,267,75
#40 Search (#35 not #39) 501,673
#39 Search ((#36 or #37 or #38)) 20,549
#38 Search “energy expenditure”[tiab] or “oxygen expenditure”[tiab] 17,441
#37 Search “metabolic cost”[tiab] 888
#36 Search “energy cost”[tiab] or “oxygen cost”[tiab] 2986
#35 Search ((#31 or #32 or #33 or #34)) 506,382
#34 Search budget*[tiab] 19,827
#33 Search “value for money” 934
#32 Search (expenditure*[tiab] not energy[tiab]) 19,227
#31 Search (economic*[tiab] or cost[tiab] or costs[tiab] or costly[tiab] or costing[tiab] or price[tiab] or prices
[tiab] or pricing[tiab] or pharmacoeconomic*[tiab])
485,328
#30 Search (#20 and #29) 276
#29 Search (#21 or #22 or #23 or #24 or #25 or #26 or #27 or #28) 937
#28 Search “g4 platinum” 10
#27 Search dexcom 56
#26 Search (animas or vibe) AND (pump* or infus* or system*) 81
#25 Search “veo pump” or “veo pumps” 15
#24 Search ((paradigm* AND (veo or pump*))) 354
#23 Search minimed or paradigmveo 217
#22 Search SAPT[tiab] 187
#21 Search “sensor augmented”[tiab] or “sensor augment”[tiab] or “sensor pump”[tiab] or “pump
sensor”[tiab] or “sensor pumps”[tiab]
92
#20 Search ((#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or
#15 or #16 or #17 or #18 or #19))
127,385
#19 Search “high glycohemoglobin”[tiab] or “higher glycohemoglobin”[tiab] or “low
glycohemoglobin”[tiab] or “lower glycohemoglobin”[tiab] or “increase glycohemoglobin”[tiab]
or “increased glycohemoglobin”[tiab] or “increases glycohemoglobin”[tiab] or “decrease
glycohemoglobin”[tiab] or “decreased glycohemoglobin”[tiab] or “decreases glycohemoglobin”[tiab]
or “deficient glycohemoglobin”[tiab] or “sufficient glycohemoglobin”[tiab] or “insufficient
glycohemoglobin”[tiab] or “reduce glycohemoglobin”[tiab] or “reduced glycohemoglobin”[tiab]
or “glycohemoglobin reduction”[tiab] or “fallen glycohemoglobin”[tiab] or “falling
glycohemoglobin”[tiab] or “glycohemoglobin threshold”[tiab] or “safe glycohemoglobin”[tiab]
17
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#18 Search (“high haemoglobin”[tiab] or “higher haemoglobin”[tiab] or “low haemoglobin”[tiab] or
“lower haemoglobin”[tiab] or “increase haemoglobin”[tiab] or “increased haemoglobin”[tiab] or
“increases haemoglobin”[tiab] or “decrease haemoglobin”[tiab] or “decreased haemoglobin”[tiab] or
“decreases haemoglobin”[tiab] or “deficient haemoglobin”[tiab] or “sufficient haemoglobin”[tiab] or
“insufficient haemoglobin”[tiab] or “reduce haemoglobin”[tiab] or “reduced haemoglobin”[tiab] or
“haemoglobin reduction”[tiab] or “fallen haemoglobin”[tiab] or “falling haemoglobin”[tiab] or
“haemoglobin threshold”[tiab] or “safe haemoglobin”[tiab])
1167
#17 Search “high hemoglobin”[tiab] or “higher hemoglobin”[tiab] or “low hemoglobin”[tiab] or “lower
hemoglobin”[tiab] or “increase hemoglobin”[tiab] or “increased hemoglobin”[tiab] or “increases
hemoglobin”[tiab] or “decrease hemoglobin”[tiab] or “decreasedchemoglobin”[tiab] or “decreases
hemoglobin”[tiab] or “deficient hemoglobin”[tiab] or “sufficient hemoglobin”[tiab] or “insufficient
hemoglobin”[tiab] or “reduce hemoglobin”[tiab] or “reduced hemoglobin”[tiab] or “hemoglobin
reduction”[tiab] or “fallen hemoglobin”[tiab] or “falling hemoglobin”[tiab] or “hemoglobin
threshold”[tiab] or “safe hemoglobin”[tiab]
3497
#16 Search “high a1c”[tiab] or “higher a1c”[tiab] or “low a1c”[tiab] or “lower a1c”[tiab] or “increase
a1c”[tiab] or “increased a1c”[tiab] or “increases a1c”[tiab] or “decrease a1c”[tiab] or
“decreasedca1c”[tiab] or “decreases a1c”[tiab] or “deficient a1c”[tiab] or “sufficient a1c”[tiab] or
“insufficient a1c”[tiab] or “reduce a1c”[tiab] or “reduced a1c”[tiab] or “a1c reduction”[tiab] or “fallen
a1c”[tiab] or “falling a1c”[tiab] or “a1c threshold”[tiab] or “safe a1c”[tiab]
294
#15 Search ((((“high hba1”[tiab] or “higher hba1”[tiab] or “low hba1”[tiab] or “lower hba1”[tiab] or
“increase hba1”[tiab] or “increased hba1”[tiab] or “increases hba1”[tiab] or “decrease hba1”[tiab] or
“decreasedchba1”[tiab] or “decreases hba1”[tiab] or “deficient hba1”[tiab] or “sufficient hba1”[tiab]
or “insufficient hba1”[tiab] or “reduce hba1”[tiab] or “reduced hba1”[tiab] or “hba1 reduction”[tiab]
or “fallen hba1”[tiab] or “falling hba1”[tiab] or “hba1 threshold”[tiab] or “safe hba1”[tiab]))))
76
#14 Search “high hb a1”[tiab] or “higher hb a1”[tiab] or “low hb a1”[tiab] or “lower hb a1”[tiab] or
“increase hb a1”[tiab] or “increased hb a1”[tiab] or “increases hb a1”[tiab] or “decrease hb a1”[tiab]
or “decreasedchb a1”[tiab] or “decreases hb a1”[tiab] or “deficient hb a1”[tiab] or “sufficient hb
a1”[tiab] or “insufficient hb a1”[tiab] or “reduce hb a1”[tiab] or “reduced hb a1”[tiab] or “hb a1
reduction”[tiab] or “fallen hb a1”[tiab] or “falling hb a1”[tiab] or “hb a1 threshold”[tiab] or “safe hb
a1”[tiab]
0
#13 Search “high hba1c”[tiab] or “higher hba1c”[tiab] or “low hba1c”[tiab] or “lower hba1c”[tiab] or
“increase hba1c”[tiab] or “increased hba1c”[tiab] or “increases hba1c”[tiab] or “decrease
hba1c”[tiab] or “decreasedchba1c”[tiab] or “decreases hba1c”[tiab] or “deficient hba1c”[tiab] or
“sufficient hba1c”[tiab] or “insufficient hba1c”[tiab] or “reduce hba1c”[tiab] or “reduced hba1c”[tiab]
or “hba1c reduction”[tiab] or “fallen hba1c”[tiab] or “falling hba1c”[tiab] or “hba1c threshold”[tiab]
or “safe hba1c”[tiab]
1287
#12 Search “high sugar”[tiab] or “higher sugar”[tiab] or “low sugar”[tiab] or “lower sugar”[tiab] or
“increase sugar”[tiab] or “increased sugar”[tiab] or “increases sugar”[tiab] or “decrease sugar”[tiab]
or “decreasedcsugar”[tiab] or “decreases sugar”[tiab] or “deficient sugar”[tiab] or “sufficient
sugar”[tiab] or “insufficient sugar”[tiab] or “reduce sugar”[tiab] or “reduced sugar”[tiab] or “sugar
reduction”[tiab] or “fallen sugar”[tiab] or “falling sugar”[tiab] or “sugar threshold”[tiab] or “safe
sugar”[tiab]
1551
#11 Search (“high glucose”[tiab] or “higher glucose”[tiab] or “low glucose”[tiab] or “lower glucose”[tiab]
or “increase glucose”[tiab] or “increased glucose”[tiab] or “increases glucose”[tiab] or “decrease
glucose”[tiab] or “decreasedcglucose”[tiab] or “decreases glucose”[tiab] or “deficient glucose”[tiab] or
“sufficient glucose”[tiab] or “insufficient glucose”[tiab] or “reduce glucose”[tiab] or “reduced
glucose”[tiab] or “glucose reduction”[tiab] or “fallen glucose”[tiab] or “falling glucose”[tiab] or
“glucose threshold”[tiab] or “safe glucose”[tiab])
16,743
#10 Search (hyperglycemia[tiab] or hypoglycaemia[tiab] or hyperglycemic[tiab] or hypoglycaemic[tiab]) 44,476
#9 Search ketoacidosis[tiab] or acidoketosis[tiab] or “keto acidosis”[tiab] or ketoacidemia[tiab] or ketosis
[tiab]
7314
#8 Search dm1[tiab] or “dm 1”[tiab] or t1dm[tiab] or “t1 dm”[tiab] or t1d[tiab] or iddm[tiab] 13,200
#7 Search “insulin dependent”[tiab] or insulindepend*[tiab] 27,576
#6 Search “brittle diabetic”[tiab] or “diabetic juvenile”[tiab] or “diabetic pediatric”[tiab] or “diabetic
paediatric”[tiab] or “diabetic early”[tiab] or “diabetic labile”[tiab] or “diabetic acidosis”[tiab] or
“diabetic sudden onset”[tiab]
348
#5 Search “diabetic brittle”[tiab] or “juvenile diabetic”[tiab] or “pediatric diabetic”[tiab] or “paediatric
diabetic”[tiab] or “early diabetic”[tiab] or “labile diabetic”[tiab] or “acidosis diabetic”[tiab] or “sudden
onset diabetic”[tiab]
1125
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#4 Search “brittle diabetes”[tiab] or “diabetes juvenile”[tiab] or “diabetes pediatric”[tiab] or “diabetes
paediatric”[tiab] or “diabetes early”[tiab] or “diabetes ketosis”[tiab] or “diabetes labile”[tiab] or
“diabetes acidosis”[tiab] or “diabetes sudden onset”[tiab]
264
#3 Search “diabetes brittle”[tiab] or “juvenile diabetes”[tiab] or “pediatric diabetes”[tiab] or “paediatric
diabetes”[tiab] or “early diabetes”[tiab] or “ketosis diabetes”[tiab] or “labile diabetes”[tiab] or
“acidosis diabetes”[tiab] or “sudden onset diabetes”[tiab]
2243
#2 Search “diabetic type 1”[tiab] OR “type 1 diabetic”[tiab] OR “diabetic type i”[tiab] OR “type i
diabetic”[tiab] OR “diabetic type1”[tiab] OR “type1 diabetic”[tiab] OR “diabetic typei”[tiab] OR “typei
diabetic”[tiab]
6061
#1 Search ((((“diabetes type 1”[tiab] OR “type 1 diabetes”[tiab] OR “diabetes type i”[tiab] OR “type i
diabetes”[tiab] OR “diabetes type1”[tiab] OR “type1 diabetes”[tiab] OR “diabetes typei”[tiab] OR
“typei diabetes”[tiab]))))
29,036
The economics terms were based on the following costs filter:
Centre for Reviews and Dissemination. Search strategies: NHS EED MEDLINE using OvidSP (economics
filter). York: Centre for Reviews and Dissemination; 2014. URL: www.crd.york.ac.uk/crdweb/
searchstrategies.asp#nhseedmedline (accessed 2 June 2014).
American Economic Association’s electronic bibliography EconLit
(via EBSCOhost)
Date range searched: 1969–2014.
Date searched: 2 October 2014.
Search strategy
S4 S1 or S2 or S3 (0)
S3 TI (animas N3 pump* or animas N3 infus* or animas N3 system* or vibe N3 pump* or vibe N3
infus* or vibe N3 system* or g4 N3 platinum or dexcom) or AB (animas N3 pump* or animas N3 infus* or
animas N3 system* or vibe N3 pump* or vibe N3 infus* or vibe N3 system* or g4 N3 platinum or
dexcom) (0)
S2 TI (minimed or paradigmveo or paradigm* N3 veo or paradigm* N3 pump* or veo N3 pump*) or AB
(minimed or paradigmveo or paradigm* N3 veo or paradigm* N3 pump* or veo N3 pump*) (0)
S1 TI (sensor* N3 augment* or sensor* N3 pump* or sensor-augment* or SAPT) or AB (sensor* N3
augment* or sensor* N3 pump* or sensor-augment* or SAPT) (0)
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Cost-effectiveness Analysis Registry
URL: www.cearegistry.org
Date range searched: from inception up to 5 September 2014.
Date searched: 2 October 2014.
1 record retrieved.
Search strategy
sensor augmented
sensor-augmented
SAPT
minimed
paradigmveo
paradigm veo
paradigm-veo
veo pump
animas
vibe pump
vibe infusion
vibe system
vibe systems
g4 platinum
dexcom
DOI: 10.3310/hta20170 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 17
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Riemsma et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
161
RePEc:Research Papers in Economics
URL: http://repec.org/
Date range searched: from inception up to 2 October 2014.
Date searched: 2 October 2014.
IDEAS search interface.
Search strategy
(“diabetes mellitus type 1” | “diabetes type 1” | “diabetes mellitus type1” | “diabetes type1” | “diabetes
mellitus type I” | “diabetes type I” | “diabetes mellitus typeI” | “diabetes typeI” | “diabetes mellitus
type one” | “diabetes type one” | dm1 | “dm 1” | dmt1 | “dm t1” | t1dm | “t1 dm” | t1d | iddm |
ketoacidosis)+ (“sensor augmented” | sensor-augmented | SAPT | minimed | paradigmveo | “paradigm
veo” | “paradigm pump” | “veo pump” | animas | vibe | “g4 platinum” | dexcom)
Records retrieved: 0.
(“brittle diabetes” | “juvenile diabetes” | “pediatric diabetes” | “paediatric diabetes” | “early diabetes” |
“autoimmune diabetes” | “auto immune diabetes” | “sudden onset diabetes”)+ (“sensor augmented”
| sensor-augmented | SAPT | minimed | paradigmveo | “paradigm veo” | “paradigm pump” | “veo pump” |
animas | vibe | “g4 platinum” | dexcom)
Records retrieved: 0.
(hyperglycemia | hypoglycemia | hyperglycaemia | hypoglycaemia)+ (“sensor augmented” | sensor-
augmented | SAPT | minimed | paradigmveo | “paradigm veo” | “paradigm pump” | “veo pump” | animas
| vibe | “g4 platinum” | dexcom)
Records retrieved: 0.
Records retrieved in total: 0.
Key:
| OR
+ AND
” “ phrase search
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Appendix 2 List of excluded studies with
rationale
The following table lists the studies that were excluded at the full-paper screening stage of the review,along with the reasons for their exclusion.
TABLE 62 Summary of reasons for exclusion of excluded studies at full-paper screening stage
Reason for exclusion
Number of excluded
studies
Population 8
Intervention 86
Outcomes 109
Study design 206
Systematic review/meta-analysis 36
Background 3
Duplicate 5
Not found 29
Total 482
TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion
Excluded study Reason for exclusion
Conference: 11th Annual Diabetes Technology Meeting San Francisco, CA, USA,
27–29 October 2011. J Diabetes Sci Technol 2012;6:453–A202
Study design
Conference: 4th International Conference on Advanced Technologies and Treatments for
Diabetes (ATTD). London, UK, 16–19 February 2011. Diabetes Technol Ther 2011;13:S1–108
Study design
Abraham M, Davey R, Paramalingam N, Keenan B, Ambler G, Fairchild J, et al. Prevention of
hypoglycaemia with predictive low glucose management system: comparison of hypoglyclaemia
induction with exercise and subcutaneous bolus. Diabetes Technol Ther 2014;16:A43.
Conference: 7th International Conference on Advanced Technologies and Treatments for
Diabetes, (ATTD). Vienna, Austria, 5–8 February 2014
Study design
Conference: 7th International Conference on Advanced Technologies and Treatments for
Diabetes (ATTD). Vienna, Austria, 5–8 February 2014. Diabetes Technol Ther 2014;16:A1–162
Study design
ACTRN12607000198426. The Australian Sensor-Augmented Pump Algorithm Study. 2007.
URL: www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12607000198426
(accessed 11 January 2016)
Study design
ACTRN12614000035628. The Performance of an Artificial Pancreas at Home in People with
Type 1 Diabetes. 2014. URL: https://anzctr.org.au/Trial/Registration/TrialReview.aspx?
ACTRN=12614000035628 (accessed 11 January 2016)
Study design
ACTRN12614000482662. Closed Loop Insulin Delivery and Glucose Control for Type 1 Diabetes,
Seven Days and Nights, Hospital to Home. 2014. URL: www.anzctr.org.au/Trial/Registration/
TrialReview.aspx?id=366247 (accessed 11 January 2016)
Study design
Agrawal P, Kannard B, Shin J, Huang S, Welsh JB, Kaufman FR. Improvement in glycemic
parameters with use of the low glucose suspend feature of the veo insulin pump. Diabetes
2012;61:A229–30. Conference: 72nd Scientific Sessions of the American Diabetes Association.
Philadelphia, PA, USA, 8–12 June 2012
Study design
continued
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Agrawal P, Welsh JB, Kannard B, Askari S, Yang Q, Kaufman FR. Usage and effectiveness of the
low glucose suspend feature of the Medtronic Paradigm Veo insulin pump. J Diabetes Sci
Technol 2011;5:1137–41
Outcomes
Agrawal P, Welsh JB, Kaufman FR. Use of the low glucose suspend (LGS) feature results in
significant reduction in hypoglycemia in pediatric and adult patients with type 1 diabetes.
Pediatr Diabetes 2012;13:116. Conference: 38th Annual Meeting of the International Society
for Pediatric and Adolescent Diabetes (ISPAD). Istanbul, Turkey, 10–13 October 2012
Study design
Alemzadeh R, Palma-Sisto P, Parton E, Holzum M, Kichler J. Insulin pump therapy attenuated
glycemic instability without improving glycemic control in a one-year study of preschool children
with type 1 diabetes. Diabetes 2006;55:A97. Paper presented at 66th Annual Meeting of the
American Diabetes Association. Washington, DC, USA, 9–13 June 2006
Not found
Alemzadeh R, Palma-Sisto P, Parton EA, Holzum MK. Continuous subcutaneous insulin infusion
and multiple dose of insulin regimen display similar patterns of blood glucose excursions in
pediatric type 1 diabetes. Diabetes Technol Ther 2005;7:587–96
Study design
Allen TJ, Cao Z, Youssef S, Hulthen UL, Cooper ME. High-dose intravenous insulin infusion versus
intensive insulin treatment in newly diagnosed IDDM. Diabetes 1997;46:1612–18
Population
Ambrosino JM, Weinzimer SA, Steffen AT, Ruedy K. Short-term psychosocial impact of
sensor-augmented pump therapy within three months of diagnosis of type 1 diabetes. Diabetes
2012;61:A586. Conference: 72nd Scientific Sessions of the American Diabetes Association
Philadelphia, PA, USA, 8–12 June 2012
Outcomes
Conference: 72nd Scientific Sessions of the American Diabetes Association Philadelphia, PA, USA,
8–12 June 2012. Diabetes 2012;61:A1–722
Study design
Arias P, Kerner W, Zier H, Navascues I, Pfeiffer EF. Incidence of hypoglycemic episodes in diabetic
patients under continuous subcutaneous insulin infusion and intensified conventional insulin
treatment: assessment by means of semiambulatory 24-hour continuous blood glucose
monitoring. Diabetes Care 1985;8:134–40
Study design
Bailey TS, Weiss R, Bode BW, Garg S, Ahmann AJ, Welsh JB, et al. Hypoglycemia reduction
and changes in A1C in the aspire in-home study. Diabetes 2014;63:A60. Conference:
74th Scientific Sessions of the American Diabetes Association San Francisco, CA, USA,
13–17 June 2014
Outcomes
Bak JF, Nielsen OH, Pedersen O, Beck-Nielsen H. Multiple insulin injections using a pen injector
versus insulin pump treatment in young diabetic patients. Diabetes Res 1987;6:155–8
Outcomes
Bangstad HJ, Kofoed-Enevoldsen A, Dahl-Jorgensen K, Hanssen KF. Glomerular charge selectivity
and the influence of improved blood glucose control in type 1 (insulin-dependent) diabetic
patients with microalbuminuria. Diabetologia 1992;35:1165–9
Population
Bangstad HJ, Osterby R, Dahl-Jorgensen K, Berg KJ, Hartmann A, Hanssen KF. Improvement of
blood glucose control in IDDM patients retards the progression of morphological changes in early
diabetic nephropathy. Diabetologia 1994;37:483–90
Study design
Barcelo-Rico F, Luis Diez J, Vehi J, Ampudia-Blasco FJ, Rossetti P, Bondia J. Evaluation of a
local-model-based calibration algorithm for continuous glucose monitoring in subjects with
type 1 diabetes. J Diabetes Sci Technol 2013;7:A5. Conference: 12th Annual Diabetes
Technology Meeting. Bethesda, MD, USA, 8–10 November 2012
Study design
Battelino T, Conget I, Olsen B, Schutz-Fuhrmann I, Hommel E, Hoogma R, et al. The use and
efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy:
a randomised controlled trial. Diabetologia 2012;55:3155–62
Outcomes
Battelino T, Conget I, Olsen B, Schutz-Fuhrmann I, Hommel E, Hoogma R, et al. The SWITCH
study: continuous glucose monitoring in type 1 diabetes. Pediatr Diabetes 2011;12:30.
Conference: 37th Annual Meeting of the International Society for Pediatric and Adolescent
Diabetes (ISPAD). Miami Beach, FL, USA, 19–22 October 2011
Outcomes
Battelino T, Phillip M, Bratina N, Nimri R, Oskarsson P, Bolinder J. Effect of continuous glucose
monitoring on hypoglycemia in type 1 diabetes. Diabetes Care 2011;34:795–800
Study design
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Beck RW, Raghinaru D, Wadwa RP, Chase HP, Maahs DM, Buckingham BA, In Home Closed
Loop Study Group. Frequency of morning ketosis after overnight insulin suspension using an
automated nocturnal predictive low glucose suspend system. Diabetes Care 2014;37:1224–9
Study design
Beck RW. The effect of continuous glucose monitoring in well-controlled type 1 diabetes.
Diabetes Care 2009;32:1378–83
Intervention
Bell PM, Hayes JR, Hadden DR. A comparison of continuous subcutaneous insulin infusion (CSII)
and conventional therapy in insulin dependent diabetes mellitus (IDDM). Ir J Med Sci
1984;153:116
Intervention
Berg TJ, Nourooz-Zadeh J, Wolff SP, Tritschler HJ, Bangstad HJ, Hanssen KF. Hydroperoxides in
plasma are reduced by intensified insulin treatment. A randomized controlled study of IDDM
patients with microalbuminuria. Diabetes Care 1998;21:1295–300
Intervention
Bergenstal RM, Dupre J, Lawson PM, Rizza RA, Rubenstein AH. Observations on C-peptide and
free insulin in the blood during continuous subcutaneous insulin infusion and conventional
insulin therapy. Diabetes 1985;34(Suppl. 3):31–6
Intervention
Bergenstal RM, Lee SW, Welsh JB, Shin J, Kaufman FR. Prevention of hypoglycemia in the
aspire in-home study. Diabetes Technol Ther 2014;16:A107. Conference: 7th International
Conference on Advanced Technologies and Treatments for Diabetes (ATTD). Vienna, Austria,
5–8 February 2014
Outcomes
Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, et al. Sensor-
augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month
continuation phase. Diabetes Care 2011;34:2403–5
Study design
Bergenstal RM. Sensor-augmented insulin-pump therapy in type 1 diabetes. REPLY. N Engl J Med
2010;363:2071
Study design
Berhe T, Innocenti M. Insulin pump therapy as a routine care for children with type 1 diabetes:
improvement in glycemic control using insulin pump therapy with intermittent higher basal rate
in adolescents with type 1 diabetes who have a previous history of poor glyaemic control
(HbA1c > 10%). Diabetes 2008;57:A748. Paper presented at 68th Annual Meeting of the
American Diabetes Association. San Francisco, USA, 6–10 June 2008
Not found
Blair J, Gregory JW, Peak M. Insulin delivery by multiple daily injections or continuous
subcutaneous insulin infusion in childhood: addressing the evidence gap. Practical Diabetes
2012;29:47–8
Study design
Blue Cross Blue Shield Association. Artificial pancreas device systems. Technol Eval Cent Assess
Program 2014;28:122
Systematic
review/meta-analysis
Bode B, Gross K, Rikalo N, Schwartz S, Wahl T, Page C, et al. Alarms based on real-time sensor
glucose values alert patients to hypo- and hyperglycemia: the guardian continuous monitoring
system. Diabetes Technol Ther 2004;6:105–13
Study design
Bode B, Lee SW, Kaufman FR. Predictors of hypoglycemia during the run-in period of the
aspire-2 study. Diabetes Technol Ther 2013;15:A35. Conference: 6th International Conference
on Advanced Technologies and Treatments for Diabetes (ATTD). Paris, France,
27 February–2 March 2013
Outcomes
Bode B, Shelmet J, Gooch B, Hassman DR, Liang J, Smedegaard JK, et al. Patient perception and
use of an insulin injector/glucose monitor combined device. Diabetes Educ 2004;30:301–9
Outcomes
Bode BW, Lee SW, Kaufman FR. Predictors of nocturnal hypoglycemia during the run-in period
of the ASPIRE-2 study. Diabetes 2013;62:A252. Conference: 73rd Scientific Sessions of the
American Diabetes Association. Chicago, IL USA, 21–25 June 2013
Outcomes
Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous
subcutaneous insulin infusion in type I diabetes. Diabetes Care 1996;19:324–7
Study design
Bode BW, Steed RD, Schleusener DS, Strange P. Switch to multiple daily injections with insulin
glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro:
a randomized, open-label study using a continuous glucose monitoring system. Endocr Pract
2005;11:157–64
Study design
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Bolli GB, Capani F, Home PD, Kerr D, Thomas R, Torlone E, et al. Comparison of a multiple daily
injection regimen with once-daily insulin glargine basal insulin and mealtime lispro, to continuous
subcutaneous insulin infusion: a randomised, open, parallel study. Diabetes 2004;53:A107–8.
Paper presented at 64th Annual Meeting of the American Diabetes Association. Orlando, USA,
4–8 June 2004
Intervention
Bonfanti R, Meschi F, Viscardi M, Rigamonti A, Biffi V, Frontino G, et al. Insulin pump therapy
versus multiple injections in young children with diabetes: comparison of long-term efficacy.
Pediatr Diabetes 2010;11:100. Conference: 36th Annual Meeting of the International Society for
Pediatric and Adolescent Diabetes (ISPAD). Buenos Aires, Argentina, 27–30 October 2010
Study design
Bonfanti R, Meschi F, Viscardi M, Rigamonti A, Biffi V, Frontino G, et al. Long-term efficacy of
insulin pump therapy in young children with diabetes. Diabetologia 2010;53:S372. Conference:
46th Annual Meeting of the European Association for the Study of Diabetes (EASD). Stockholm,
Sweden, 20–24 September 2010
Study design
Bonnemaison E, Hasselmann C, Dieckmann K, Perdereau S, Marques C, Faure N, et al.
Observational study: continuous glucose monitoring in children under 7 years old.
Pediatr Diabetes 2011;12:132. Conference: 37th Annual Meeting of the International Society
for Pediatric and Adolescent Diabetes (ISPAD). Miami Beach, FL, USA, 19–22 October 2011
Study design
Boston University, Massachusetts General Hospital, Juvenile Diabetes Research Foundation.
Closed-loop Glucose Control for Automated Management of Type 1 Diabetes. NCT00811317
2010. URL: https://clinicaltrials.gov/ct2/show/NCT00811317 (accessed 12 November 2015)
Intervention
Botta RM, Sinagra D, Angelico MC, Bompiani GD. [Comparison of intensified traditional insulin
therapy and micropump therapy in pregnant women with type 1 diabetes mellitus.] Minerva Med
1986;77:657–61
Not found
Bragd J, Adamson U, Lins PE, Von Dobeln A, Oskarsson P. Basal insulin substitution with glargine
or CSII in adult type I diabetes patients: a randomized controlled trial. Diabetes 2009;58:A60–1.
Paper presented at 69th Annual Meeting of the American Diabetes Association. New Orleans,
USA, 5–9 June 2009
Not found
Bratina N. The switch study: the impact of continuous glucose monitoring on health care
resource utilization. Diabetes Technol Ther 2013;15:A3. Conference: 6th International
Conference on Advanced Technologies and Treatments for Diabetes (ATTD). Paris, France,
27 February 2013–2 March 2013
Outcomes
Brazg R, Garg S, Bailey T, Buckingham B, Slover R, Klonoff D, et al. Interim analysis of an in-clinic,
randomized, crossover study to assess efficacy of the low glucose suspend feature of the
Paradigm Veo system with hypoglycemic induction from exercise. J Diabetes Sci Technol
2012;6:A19. Conference: 11th Annual Diabetes Technology Meeting. San Francisco, CA, USA,
27–29 October 2011
Study design
Brazg RL, Bailey TS, Garg S, Buckingham BA, Slover RH, Klonoff DC, et al. The ASPIRE study:
design and methods of an in-clinic crossover trial on the efficacy of automatic insulin pump
suspension in exercise-induced hypoglycemia. J Diabetes Sci Technol 2011;5:1466–71
Study design
Brinchmann-Hansen O, Dahl-Jorgensen K, Hanssen KF, Sandvik L. The response of diabetic
retinopathy to 41 months of multiple insulin injections, insulin pumps, and conventional insulin
therapy. Arch Ophthalmol 1988;106:1242–6
Outcomes
Bruttomesso D, Bonomo M, Costa S, Dal Pos M, Di Cianni G, Pellicano F, et al. Type 1 diabetes
control and pregnancy outcomes in women treated with continuous subcutaneous insulin
infusion (CSII) or with insulin glargine and multiple daily injections of rapid-acting insulin
analogues (glargine-MDI). Diabetes Metab 2011;37:426–31
Study design
Bruttomesso D, Crazzolara D, Maran A, Costa S, Dal Pos M, Girelli A, et al. In type 1 diabetic
patients with good glycaemic control, blood glucose variability is lower during continuous
subcutaneous insulin infusion than during multiple daily injections with insulin glargine.
Diabet Med 2008;25:326–32
Intervention
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Buckingham B, Beck RW, Ruedy KJ, Cheng P, Kollman C, Weinzimer SA, et al. Effectiveness of
early intensive therapy on beta-cell preservation in type 1 diabetes. Diabetes Care 2013;36:4030–5
Intervention
Buckingham B, Nakamura K, Benassi K, Realsen J, Liljenquist D, Chase P. Effectiveness and safety
study of the prototype 4th generation seven day continuous glucose monitoring system in youth
with type 1 diabetes mellitus. Paper presented at 47th Annual Meeting of the European
Association for the Study of Diabetes (EASD). Lisbon, Portugal, 12–16 September 2011
Study design
Buckingham B, Ruedy K, Chase HP, Weinzimer S, DiMeglio L, Russell W, et al. Does intensive
metabolic control at the onset of diabetes followed by one year of sensor augmented pump
therapy improve C-peptide levels one year post diagnosis? Diabetes Technol Ther 2013;15:A137.
Conference: 6th International Conference on Advanced Technologies and Treatments for
Diabetes (ATTD). Paris, France, 27 February–2 March 2013
Study design
Buckingham BA, Cameron F, Calhoun P, Maahs DM, Wilson DM, Chase HP, et al. Outpatient
safety assessment of an in-home predictive low-glucose suspend system with type 1 diabetes
subjects at elevated risk of nocturnal hypoglycemia. Diabetes Technol Ther 2013;15:622–7
Study design
Buckingham BA, Cheng P, Beck RW, Kollman C, Ruedy K, Weinzimer SA, et al. Relationship
of glycemic control and c-peptide levels 2 years following diagnosis of T1D. Diabetes
2014;63:A392. Conference: 74th Scientific Sessions of the American Diabetes Association
San Francisco, CA, USA, 13–17 June 2014
Outcomes
Buckingham BA, Tanner JP. Factors predictive of continuous glucose monitoring (CGM) use and
benefit in the JDRF CGM RCT. Diabetes 2009;58. Conference: 69th Annual Meeting of the
American Diabetes Association. New Orleans, LA, USA, 5–9 June 2009
Study design
Bukara-Radujkovic G, Zdravkovic D, Lakic S. Short-term use of continuous glucose monitoring
system adds to glycemic control in young type 1 diabetes mellitus patients in the long run:
a clinical trial. Vojnosanit Pregl 2011;68:650–4
Study design
Burkart W, Hanker JP, Schneider HP. Complications and fetal outcome in diabetic pregnancy.
Intensified conventional versus insulin pump therapy. Gynecol Obstet Invest 1988;26:104–12
Population
Buse JB, Kudva YC, Guthrie RA, Laffel L, Battelino T, Shin J, et al. Assessment of glycemic
variability and CD40 ligand in the STAR 3 study. Diabetes 2011;60:A252. Conference:
71st Scientific Sessions of the American Diabetes Association. San Diego, CA, USA,
24–28 June 2011
Outcomes
Butcher B, Jones T. Safety, Efficacy and Quality of Life Associated with Continuous Glucose
Monitoring in People with Diabetes. PROSPERO: CRD42014013270; 2014. URL: www.crd.york.
ac.uk/PROSPERO/display_record.asp?ID=CRD42014013270 (accessed 16 November 2015)
Systematic review/
meta-analysis
Callaghan BC, Little AA, Feldman EL, Hughes RAC. Enhanced glucose control for preventing
and treating diabetic neuropathy. Cochrane Database Syst Rev 2012;6:CD007543
Study design
Cander S, Oz Gul O, Deligonul A, Un OK, Kiyici S, Tuncel E, et al. Weight gain in type 1 diabetic
patients with insulin pump therapy. Obesity Rev 2011;12:214. Conference: 18th European
Congress on Obesity (ECO). Istanbul, Turkey, 25–28 May 2011
Outcomes
Capel I, Rigla M, Garcia-Saez G, Rodriguez-Herrero A, Pons B, Subias D, et al. Artificial pancreas
using a personalized rule-based controller achieves overnight normoglycemia in patients with
type 1 diabetes. Diabetes Technol Ther 2014;16:172–9
Study design
Carta Q, Meriggi E, Trossarelli GF, Catella G, Dal Molin V, Menato G, et al. Continuous
subcutaneous insulin infusion versus intensive conventional insulin therapy in type I and type II
diabetic pregnancy. Diabetes Metab 1986;12:121–9
Not found
Centre d’Etudes et de Recherche pour l’Intensification du Traitement du D, Abbott. Are the
Continuous Glucose Monitoring Systems Able to Improve Long Term Glycaemic Control in Type 1
Diabetic Patients? NCT00726440 2012. URL: https://clinicaltrials.gov/ct2/show/NCT00726440
(accessed 12 November 2015)
Outcomes
Chase HP, Beck R, Tamborlane W, Buckingham B, Mauras N, Tsalikian E, et al. A randomized
multicenter trial comparing the GlucoWatch Biographer with standard glucose monitoring in
children with type 1 diabetes. Diabetes Care 2005;28:1101–6
Study design
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Chase HP, Beck RW, Xing D, Tamborlane WV, Coffey J, Fox LA, et al. Continuous glucose
monitoring in youth with type 1 diabetes: 12-month follow-up of the juvenile diabetes research
foundation continuous glucose monitoring randomized trial. Diabetes Technol Ther
2010;12:507–15
Intervention
Chase HP, Kim LM, Owen SL, MacKenzie TA, Klingensmith GJ, Murtfeldt R, et al. Continuous
subcutaneous glucose monitoring in children with type 1 diabetes. Pediatrics 2001;107:222–6
Intervention
Chase HP. A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1
diabetes. Diabetes Technol Ther 2014;16:A2. Conference: 7th International Conference on
Advanced Technologies and Treatments for Diabetes (ATTD). Vienna, Austria, 5–8 February 2014
Study design
Chatelais L, Voinot C, Robine A, Gatelais F, Dufresne S, Bouhours-Nouet N, et al. Continuous
subcutaneous insulin infusion in type 1 diabetic adolescents with poor glycemic control under
multiple daily injections: 1-year evaluation of HbA1c and acceptability. Horm Res 2009;72:182.
Paper presented at LWPES/ESPE 8th Joint Meeting Global Care in Pediatric Endocrinology in
collaboration with APEG, APPES, JSPE and SLEP. New York, NY, USA, 9–12 September 2009
Study design
Chen R, Yogev Y, Weissman-Brenner A, Ben-Haroush A, Hod M. Level of glycemic control and
pregnancy outcome in type-1 diabetes: a comparison between multiple daily injections (MDI) and
continuous subcutaneous insulin infusions (CSII). Diabetes 2007;56:A703. Paper presented at
67th Annual Meeting of the American Diabetes Association. Chicago, USA, 22–26 June 2007
Not found
Chen R, Yogev Y, Weissman-Brenner A, Haroush AB, Hod M. Level of glycemic control and
pregnancy outcome in type-1 diabetes: a comparison between multiple daily injections (MDI) and
continuous subcutaneous insulin infusions (CSII). Am J Obstet Gynecol 2006;195:S132. Paper
presented at 27th Annual Meeting of the Society of Maternal Fetal Medicine. San Francisco,
USA, 5–10 February 2007
Study design
Chen Y, Ben-Haroush A, Weismann-Brenner A, Melamed N, Hod M, Yogev Y. Level of glycemic
control and pregnancy outcome in type 1 diabetes: a comparison between multiple daily insulin
injections and continuous subcutaneous insulin infusions. Am J Obstet Gynecol 2007;197:e1–5.
[Erratum published in Am J Obstet Gynecol 2008;198:610]
Study design
Chevremont A, Collet-Gaudillat C, Duvezin-Caubet P, Franc S, Gouet D, Jan P, et al. [Insulin
pump Paradigm Veo with automated insulin suspension function: results of a pilot study in type 1
diabetic patients at high hypoglycemic risk.] Medecine des Maladies Metaboliques 2012;6:531–8
Study design
Chiasson JL, Ducros F, Poliquin-Hamet M, Lopez D, Lecavalier L, Hamet P. Continuous
subcutaneous insulin infusion (Mill-Hill Infuser) versus multiple injections (Medi-Jector) in the
treatment of insulin-dependent diabetes mellitus and the effect of metabolic control on
microangiopathy. Diabetes Care 1984;7:331–7
Study design
Chico A, Saigi I, Garcia-Patterson A, Santos MD, Adelantado JM, Ginovart G, et al. Glycemic
control and perinatal outcomes of pregnancies complicated by type 1 diabetes: influence of
continuous subcutaneous insulin infusion and lispro insulin. Diabetes Technol Ther
2010;12:937–45
Study design
Chico A, Vidal-Rios P, Subira M, Novials A. The continuous glucose monitoring system is useful
for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not
better than frequent capillary glucose measurements for improving metabolic control. Diabetes
Care 2003;26:1153–7
Population
Choudhary P, Shin J, Wang Y, Evans ML, Hammond PJ, Kerr D, et al. Insulin pump therapy with
automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia
in those at greatest risk. Diabetes Care 2011;34:2023–5
Study design
Christensen CK, Christiansen JS, Christensen T, Hermansen K, Mogensen CE. The effect of
six months continuous subcutaneous insulin infusion on kidney function and size in
insulin-dependent diabetics. Diabet Med 1986;3:29–32
Not found
Christensen CK, Christiansen JS, Schmitz A, Christensen T, Hermansen K, Mogensen CE. Effect of
continuous subcutaneous insulin infusion on kidney function and size in IDDM patients: a 2 year
controlled study. J Diabet Complications 1987;1:91–5
Intervention
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Christiansen JS, Ingerslev J, Bernvil SS, Christensen CK, Hermansen K, Schmitz A. Near
normoglycemia for 1 year has no effect on platelet reactivity, factor VIII, and von Willebrand
factor in insulin-dependent diabetes mellitus: a controlled trial. J Diabet Complications
1987;1:100–6
Intervention
Churchill JN, Ruppe RL, Smaldone A. Use of continuous insulin infusion pumps in young children
with type 1 diabetes: a systematic review. J Pediatr Health Care 2009;23:173–9
Systematic review/
meta-analysis
Ciavarella A, Vannini P, Flammini M, Bacci L, Forlani G, Borgnino LC. Effect of long-term
near-normoglycemia on the progression of diabetic nephropathy. Diabetes Metab 1985;11:3–8
Not found
Cinar A, Turksoy K, Quinn L, Littlejohn E. An integrated hypoglycemia early alarm and adaptive
control system for artificial pancreas. Diabetes Technol Ther 2014;16:A103. Paper presented at
7th International Conference on Advanced Technologies & Treatments for Diabetes. Vienna,
Austria, 5–8 February 2014
Study design
Clarke WL, Anderson S, Breton M, Patek S, Kashmer L, Kovatchev B. Closed-loop artificial
pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control
algorithm: the Virginia experience. J Diabetes Sci Technol 2009;3:1031–8
Study design
Cobry E, Chase HP, Burdick P, McFann K, Yetzer H, Scrimgeour L. Use of CoZmonitor in youth
with type 1 diabetes. Pediatr Diabetes 2008;9:148–51
Study design
Cohen D, Weintrob N, Benzaquen H, Galatzer A, Fayman G, Phillip M. Continuous subcutaneous
insulin infusion versus multiple daily injections in adolescents with type I diabetes mellitus:
a randomized open crossover trial. J Pediatr Endocrinol 2003;16:1047–50
Intervention
Cohen N, Minshall ME, Sharon-Nash L, Zakrzewska K, Valentine WJ, Palmer AJ. Continuous
subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in
adult and adolescent type 1 diabetes mellitus in Australia. Pharmacoeconomics 2007;25:881–97
Outcomes
Colquitt JL, Green C, Sidhu MK, Hartwell D, Waugh N. Clinical and cost-effectiveness of
continuous subcutaneous insulin infusion for diabetes. Health Technol Assess 2004;8(43)
Systematic review/
meta-analysis
Conget I, Battelino T, Gimenez M, Gough H, Castaneda J, Bolinder J, et al. The SWITCH study
(sensing with insulin pump therapy to control HbA(1c)): design and methods of a randomized
controlled crossover trial on sensor-augmented insulin pump efficacy in type 1 diabetes
suboptimally controlled with pump therapy. Diabetes Technol Ther 2011;13:49–54
Study design
Conget I, Battelino T, Gimenez M, Gough H, Castaneda J, Bolinder J. The SWITCH study
(Sensing with insulin pump therapy to control HbA1c). Design and methods of a randomized
controlled cross-over trial on sensor-augmented insulin pump efficacy in type 1 diabetes
suboptimally controlled with pump therapy. Pediatr Diabetes 2010;11:105. Conference:
36th Annual Meeting of the International Society for Pediatric and Adolescent Diabetes (ISPAD).
Buenos Aires, Argentina, 27–30 October 2010
Outcomes
Cooke D, Hurel SJ, Casbard A, Steed L, Walker S, Meredith S, et al. Randomized controlled trial
to assess the impact of continuous glucose monitoring on HbA(1c) in insulin-treated diabetes
(MITRE Study). Diabet Med 2009;26:540–7
Study design
Corabian P, Guo B, Harstall C, Chuck A, Yan C. Insulin Pump Therapy for Type 1 Diabetes.
Edmonton, AB: Institute of Health Economics, 2012
Systematic review/
meta-analysis
Cordua S, Secher AL, Ringholm L, Damm P, Mathiesen ER. Real-time continuous glucose
monitoring during labour and delivery in women with type 1 diabetes – observations from a
randomized controlled trial. Diabet Med 2013;30:1374–81
Intervention
Cosson E, Hamo Tchatchouang E, Dufaitre Patouraux L, Attali JR, Pariès J, Schaepelynck-Bélicar P.
Multicentre, randomised, controlled study of the impact of continuous sub cutaneous glucose
monitoring (GlucoDay) on glycaemic control in type 1 and type 2 diabetes patients. Diabetes
Metab 2009;35:312–18
Study design
Coustan DR, Reece EA, Sherwin RS, Rudolf MC, Bates SE, Sockin SM, et al. A randomized clinical
trial of the insulin pump vs intensive conventional therapy in diabetic pregnancies. JAMA
1986;255:631–6
Intervention
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Crepaldi C, Nosadini R, Bruttomesso D, Fioretto P, Fedele D, Segato T, et al. The effect of
continuous insulin infusion as compared with conventional insulin therapy in the evolution
of diabetic retinal ischaemia. Two years report. Diabetes Nutr Metab Clin Exp 1989;2:209–18
Intervention
Cummins E, Royle P, Snaith A, Greene A, Robertson L, McIntyre L, et al. Clinical and
Cost-effectiveness of Continuous Subcutaneous Infusion for Diabetes: Updating Review.
A Technology Assessment Report Commissioned by the HTA Programme on behalf of NICE.
HTA reference 06/61. London: NICE; 2007. URL: www.nice.org.uk/guidance/ta151/resources/
diabetes-insulin-pump-therapy-assessment-report2 (accessed 8 July 2014)
Systematic review/
meta-analysis
Cummins E, Royle P, Snaith A, Greene A, Robertson L, McIntyre L, et al. Clinical effectiveness and
cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review
and economic evaluation. Health Technol Assess 2010;14(11)
Systematic review/
meta-analysis
Cyganek K, Hebda-Szydło A, Katra B, Klupa T, Kaim I, Skupien J, et al. Efficacy and safety of
continuous subcutaneous insulin infusion therapy in pregnancy complicated by type 1 diabetes.
Paper presented at 45th Annual Meeting of the European Association for the Study of Diabetes
(EASD). Vienna, Austria, 30 September–2 October 2009
Study design
Cyganek K, Hebda-Szydlo A, Katra B, Skupien J, Klupa T, Janas I, et al. Glycemic control and
selected pregnancy outcomes in type 1 diabetes women on continuous subcutaneous insulin
infusion and multiple daily injections: the significance of pregnancy planning. Diabetes Technol
Ther 2010;12:41–7
Outcomes
Cyganek K, Hebda-Szydlo A, Katra B, Skupien J, Klupa T, Janas I, et al. Pregnancy planning
improves glycemic control and pregnancy outcomes in type 1 diabetes women on CSII and MDI.
Eur J Clin Invest 2010;40:8. Paper presented at 44th Annual Scientific Meeting of the European
Society for Clinical Investigation. Bari, Italy, 24–27 February 2010
Study design
Cypryk K, Kosinski M, Kaminska P, Kozdraj T, Lewinski A. Diabetes control and pregnancy
outcomes in women with type 1 diabetes treated during pregnancy with continuous
subcutaneous insulin infusion or multiple daily insulin injections. Pol Arch Med Wewn
2008;118:339–44
Study design
Dahl-Jorgensen K, Hanssen KF, Aagenaes O, Larsen S. [New methods for subcutaneous insulin
administration. A year’s experience with the insulin pump and multiple insulin injection therapy.]
Tidsskr Nor Laegeforen 1984;104:856–61
Not found
Dahl-Jorgensen K, Hanssen KF, Kierulf P, Bjoro T, Sandvik L, Aagenaes O. Reduction of urinary
albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin-dependent
diabetes mellitus. The Oslo Study. Acta Endocrinol 1988;117:19–25
Outcomes
Dahl-Jorgensen K. Blood glucose control and progression of diabetic neuropathy: eight years
results from the Oslo study. Diabetologia 1992;35:A15. Paper presented at 28th Annual Meeting
of the European Association for the Study of Diabetes (EASD). Prague, Czech Republic,
8–11 September 1992
Not found
Dahl-Jorgensen K. Near-normoglycemia and late diabetic complications. The Oslo Study.
Acta Endocrinol 1987;284:1–38
Not found
Damiano ER, McKeon K, El-Khatib FH, Zheng H, Nathan DM, Russell SJ. A comparative
effectiveness analysis of three continuous glucose monitors: the Navigator, G4 Platinum,
and Enlite [published online ahead of print 21 April 2014]. J Diabetes Sci Technol 2014
Intervention
Danne T, Kordonouri O, Holder M, Haberland H, Golembowski S, Remus K, et al. [LGS system
cuts hypoglycaemia excursion frequency in children on SAP therapy.] Diabetes Stoffwechsel Herz
2012;21:157–63
Study design
Danne T, Kordonouri O, Holder M, Haberland H, Golembowski S, Remus K, et al. Prevention of
hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy.
Diabetes Technol Ther 2011;13:1129–34
Study design
Danne T, Kordonouri O, Remus K, Blasig S, Holder M, Wadien T, et al. The Low Glucose Suspend
(LGS) function in sensor-augmented pump therapy prevents hypoglycaemia in children. Diabetes
2011;60:A41. Conference: 71st Scientific Sessions of the American Diabetes Association.
San Diego, CA, USA, 24–28 June 2011
Study design
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Danne T, Kordonouri O, Remus K, Holder M, Wadien T, Haberland H, et al. Prevention of
hypoglycaemia by using low glucose suspend (LGS) function in sensor-augmented pump therapy.
Diabetes Technol Ther 2011;13:217. Conference: 4th International Conference on Advanced
Technologies and Treatments for Diabetes (ATTD). London, UK, 16–19 February 2011
Study design
Danne T. Predictive low glucose management with sensor augmented CSII in response to
exercise. Diabetes Technol Ther 2014;16:A2. Conference: 7th International Conference on
Advanced Technologies and Treatments for Diabetes (ATTD). Vienna, Austria, 5–8 February 2014
Study design
Daskalaki E, Norgaard K, Prountzou A, Zuger T, Diem P, Mougiakakou S. Alarm system for the
early warning of hypo- and hyperglycemic events based on online adaptive models. Diabetes
Technol Ther 2013;15:A77–8. Conference: 6th International Conference on Advanced
Technologies and Treatments for Diabetes (ATTD). Paris, France, 27 February–2 March 2013
Study design
Dauber A, Corcia L, Safer J, Agus MSD, Einis S, Steil GM. Closed-loop insulin therapy improves
glycemic control in children aged > 7 years. Diabetes Technol Ther 2014;16(Suppl. 1):23–4
Study design
Davies AG, Price DA, Houlton CA, Burn JL, Fielding BA, Postlethwaite RJ. Continuous
subcutaneous insulin infusion in diabetes mellitus. A year’s prospective trial. Arch Dis Child
1984;59:1027–33
Intervention
Davis EA, Siafarikas A, Ratnam N, Loveday J, Baker V, Marangou D, et al. The initiation of
intensive pump therapy at diagnosis of type 1 diabetes mellitus in adolescents: a randomised
trial. Diabetes 2007;56:A53. Paper presented at the 67th Annual Meeting of the American
Diabetes Association. Chicago, IL, USA, 22–26 June 2007
Intervention
de Beaufort CE, Bruining GJ, Aarsen RS, den Boer NC, Grose WF. Does continuous subcutaneous
insulin infusion (CSII) prolong the remission phase of insulin-dependent diabetic children?
Preliminary findings of a randomized prospective study. Neth J Med 1985;28(Suppl. 1):53–4
Not found
de Beaufort CE, Houtzagers CM, Bruining GJ, Aarsen RS, den Boer NC, Grose WF, et al.
Continuous subcutaneous insulin infusion (CSII) versus conventional injection therapy in newly
diagnosed diabetic children: two-year follow-up of a randomized, prospective trial. Diabet Med
1989;6:766–71
Not found
De Bock MI, Dart J, George CE, Abraham M, Cooper M, Paramalingam N, et al. Performance of
a predictive insulin pump suspension algorithm for prevention of overnight hypoglycaemia.
Diabetes 2014;63:A240–1. Conference: 74th Scientific Sessions of the American Diabetes
Association. San Francisco, CA, USA, 13–17 June 2014
Study design
De Portu S, Castaneda J, Hommel E, Olsen BS, Battelino T, Conget I, et al. The switch study:
the impact of continuous glucose monitoring on health care resource utilization. Value Health
2012;15:A357. Conference: ISPOR 15th Annual European Congress. Berlin, Germany,
3–7 November 2012
Outcomes
Deiss D, Bolinder J, Riveline JP, Battelino T, Bosi E, Tubiana-Rufi N, Kerr D, Phillip M. Improved
glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous
glucose monitoring. Diabetes Care 2006;29:2730–2
Intervention
Deiss D, Hartmann R, Schmidt J, Kordonouri O. Results of a randomized controlled cross-over trial
on the effect of continuous subcutaneous glucose monitoring (CGMS) on glycemic control in
children and adolescents with type 1 diabetes. Exp Clin Endocrinol Diabetes 2006;114:63–7
Intervention
DeLuca FC, Timoshin A, Bamji N, Ferraro G, Himel A, Noto J, et al. The effect of insulin pump
therapy on the diabetes control of children and adolescents with IDDM-1. Pediatr Res
2004;55:136A. Paper presented at the Annual Meeting of the Pediatric Academic Societies,
4 May 2004, San Francisco, USA.
Study design
Derosa G, Maffioli P, D’Angelo A, Salvadeo SAT, Ferrari I, Fogari E, et al. Effects of insulin therapy
with continuous subcutaneous insulin infusion (CSII) in diabetic patients: comparison with
multi-daily insulin injections therapy (MDI). Endocr J 2009;56:571–8
Population
DeSalvo DJ, Keith-Hynes P, Peyser T, Place J, Caswell K, Wilson DM, et al. Remote glucose
monitoring in cAMP setting reduces the risk of prolonged nocturnal hypoglycemia. Diabetes
Technol Ther 2014;16:1–7
Study design
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
DeVries JH. Health-economic comparison of continuous subcutaneous insulin infusion with
multiple daily injection for the treatment of type 1 diabetes in the UK (letter). Diabet Med
2006;23:709
Outcomes
DexCom Inc. Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose
Monitoring System in Children and Adolescents With Type 1 Diabetes Mellitus. NCT01185496
2011. URL: https://clinicaltrials.gov/ct2/show/NCT01185496 (accessed 12 November 2015)
Outcomes
DexCom Inc. Efficacy of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes
Mellitus on Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII)
Therapy. NCT01104142 2010. URL: https://clinicaltrials.gov/ct2/show/NCT01104142
(accessed 12 November 2015)
Study design
Diabetes Research in Children Network Study Group, Weinzimer S, Xing D, Tansey M,
Fiallo-Scharer R, Mauras N, et al. Prolonged use of continuous glucose monitors in children
with type 1 diabetes on continuous subcutaneous insulin infusion or intensive multiple-daily
injection therapy. Pediatr Diabetes 2009;10:91–6
Study design
The Kroc Collaborative Study Group. Diabetic retinopathy after two years of intensified insulin
treatment. Follow-up of the Kroc Collaborative Study. JAMA 1988;260:37–41
Intervention
DiMeglio LA, Pottorff TM, Boyd SR, France L, Fineberg N, Eugster EA. A randomized, controlled
study of insulin pump therapy in diabetic preschoolers. J Pediatr 2004;145:380–4
Intervention
Edelmann E, Walter H, Biermann E, Schleicher E, Bachmann W, Mehnert H. Sustained
normoglycemia and remission phase in newly diagnosed type I diabetic subjects. Comparison
between continuous subcutaneous insulin infusion and conventional therapy during a one year
follow-up. Horm Metab Res 1987;19:419–21
Intervention
Elleri D, Allen JM, Nodale M, Wilinska ME, Acerini CL, Dunger DB, et al. Suspended insulin
infusion during overnight closed-loop glucose control in children and adolescents with type 1
diabetes. Diabet Med 2010;27:480–4
Study design
Ellery B, Mundy L, Hiller JE. Closed-Loop Insulin Delivery System (‘Artificial Pancreas’) for
Management of Hypoglycaemia in Type 1 Diabetics. Adelaide, SA: Adelaide Health Technology
Assessment on behalf of National Horizon Scanning Unit; 2010
Systematic review/
meta-analysis
Emelyanov A, Kuraeva T, Peterkova V. CSII with real time continuous glucose monitoring versus
traditional CSII: the comparative results. Pediatr Diabetes 2009;10:101. Conference: 35th Annual
Meeting of the International Society for Pediatric and Adolescent Diabetes (ISPAD). Ljubljana,
Slovenia, 2–5 September 2009
Study design
Emelyanov A, Kuraeva T, Peterkova V. CSII with real time continuous glucose monitoring vs.
traditional CSII: two year comparative results. Hormone Res Paediatr 2010;74:57. Conference:
49th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE). Prague, Czech
Republic, 22–25 September 2010
Study design
Enander R, Adolfsson P, Bergdahl T, Forsander G, Gundevall C, Karlsson AK, et al. Intensive
subcutaneous insulin therapy and intravenous insulin infusion at onset of T1DM preserve
beta-cell function equally well in children. Diabetes 2011;60:A336. Conference: 71st Scientific
Sessions of the American Diabetes Association San Diego, CA, USA. 24–28 June 2011
Intervention
Enander R, Bergdahl T, Adolfsson P, Forsander G, Gundevall C, Karlsson AK, et al. Intensive
subcutaneous insulin therapy and intravenous insulin infusion at onset of diabetes preserve
beta-cell function equally well in children. Pediatr Diabetes 2011;12:69–70. Conference: 37th
Annual Meeting of the International Society for Pediatric and Adolescent Diabetes, ISPAD Miami
Beach, FL, USA, 19–22 October 2011
Intervention
Erasmus Medical Center. Comparison Between Insulin Pump Treatment and Multiple Daily Insulin
Injections in Diabetic Type 1 Children. NCT00462371 2007. URL: https://clinicaltrials.gov/ct2/
show/NCT00462371 (accessed 12 November 2015)
Outcomes
Esvant A, Guilhem I, Jouve A, Leguerrier AM, Poirier JY. Real-time continuous monitoring in
brittle diabetes: a 6-month observational study. Diabetes Technol Ther 2013;15:A61. Conference:
6th International Conference on Advanced Technologies and Treatments for Diabetes, ATTD
2013 Paris, France 27 February–2 March 2013
Study design
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
Randomized Trial to Assess Efficacy and Safety of Continuous Glucose Monitoring in Children
4-< 10 Years With T1DM. NCT00760526 2014. URL: https://clinicaltrials.gov/ct2/show/
NCT00760526 (accessed 12 November 2015)
Outcomes
Farrar D, Tuffnell DJ, West J. Continuous subcutaneous insulin infusion versus multiple daily
injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev
2007;3:CD005542
Systematic review/
meta-analysis
Fatourechi MM, Kudva YC, Murad MH, Elamin MB, Tabini CC, Montori VM. Clinical review:
hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of
randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections.
J Clin Endocrinol Metab 2009;94:729–40
Systematic review/
meta-analysis
Feldt-Rasmussen B, Mathiesen ER, Jensen T, Lauritzen T, Deckert T. Effect of improved metabolic
control on loss of kidney function in type 1 (insulin-dependent) diabetic patients: an update of
the Steno studies. Diabetologia 1991;34:164–70
Intervention
Fendler W, Baranowska AI, Mianowska B, Szadkowska A, Mlynarski W. Three-year comparison of
subcutaneous insulin pump treatment with multi-daily injections on HbA1c, its variability and
hospital burden of children with type 1 diabetes. Acta Diabetol 2012;49:363–70
Intervention
Fiallo-Scharer R. Eight-point glucose testing versus the continuous glucose monitoring system in
evaluation of glycemic control in type 1 diabetes. J Clin Endocrinol Metab 2005;90:3387–91
Intervention
Flores d’Arcais A, Morandi F, Beccaria L, Meschi F, Chiumello G. Metabolic control in newly
diagnosed type 1 diabetic children. Effect of continuous subcutaneous infusion. Horm Res
1984;19:65–9
Intervention
Fortwaengler K, Rautenberg T, Caruso A. Short term health-economic outcomes of continuous
subcutaneous insulin infusion (CSII) in type 1 diabetes: a cost comparison analysis. Value Health
2012;15:A350. Conference: ISPOR 15th Annual European Congress. Berlin, Germany,
3–7 November 2012
Outcomes
Fox L, Englert K, Mauras N. Effects of continuous subcutaneous insulin infusion (CSII) in
adolescents with newly-diagnosed type 1 diabetes (T1D) on insulin resistance and s-cell function:
a pilot study. Diabetes 2009;58:S1–700. Conference: 69th Annual Meeting of the American
Diabetes Association. New Orleans, LA, USA, 5–9 June 2009
Intervention
Fox LA, Buckloh LM, Smith S, Wysocki T, Mauras N. A randomized trial of insulin pump therapy
in toddlers and preschool age children with type 1 diabetes (DM1). Pediatr Res 2004;55:136A.
Paper presented at the Annual Meeting of the Pediatric Academic Societies. San Francisco, USA,
4 May 2004
Intervention
Fox LA, Buckloh LM, Smith SD, Wysocki T, Mauras N. A randomized controlled trial of insulin
pump therapy in young children with type 1 diabetes. Diabetes Care 2005;28:1277–81
Study design
Fox LA, Wilkinson K, Buckloh L, Wysocki T, Mauras N. A randomized trial of insulin pump
therapy in preschool age children with type 1 diabetes mellitus: preliminary results. Diabetes
2002;51(Suppl. 2):A426. Paper presented at the 62nd Annual Meeting of the American
Diabetes Association. San Francisco, CA, USA, 14–18 June 2002
Outcomes
Frandsen CSS, Kristensen PL, Beck-Nielsen H, Nørgaard K, Perrild H, Christiansen JS, et al.
Patients with Type 1 Diabetes Treated with Insulin Pumps do not Experience a Reduced Risk
of Severe Hypoglycaemia in a Real Life Setting. Paper presented at the 49th Annual Meeting
of the European Association for the Study of Diabetes (EASD). Barcelona, Spain,
23–27 September 2013
Study design
Frias JP, Gottlieb PA, Mackenzie T, Chillara B, Ashley M, Garg SK. Better glycemic control and
less severe hypoglycemia in pregnant women with type 1 diabetes treated with continuous
subcutaneous insulin infusion. Diabetes 2002;51(Suppl. 2):A431. Paper presented at the
62nd Annual Meeting of the American Diabetes Association. San Francisco, CA, USA,
14–18 June 2002
Study design
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Gane J, White B, Christie D, Viner R. Systematic review and meta-analysis of insulin pump
therapy in children and adolescents with type 1 diabetes. Arch Dis in Child 2010;95:A94.
Conference: Royal College of Paediatrics and Child Health Annual Conference (RCPCH).
Coventry, UK, 20–22 April 2010
Systematic review/
meta-analysis
Garg S, Bode BW, Bergenstal R, Klonoff DC, Mao M, Weiss R, et al. Characteristics and
predictors of nocturnal hypoglycemia in the run-in phase of the aspire in-home study. Diabetes
2014;63:A242. Conference: 74th Scientific Sessions of the American Diabetes Association.
San Francisco, CA, USA, 13–17 June 2014
Outcomes
Garg S, Brazg RL, Bailey TS, Buckingham BA, Klonoff DC, Shin J, et al. Automatic insulin pump
suspension for induced hypoglycemia: the ASPIRE study. Diabetes 2012;61:A59. Conference:
72nd Scientific Sessions of the American Diabetes Association. Philadelphia, PA, USA,
8–12 June 2012
Study design
Garg S, Brazg RL, Bailey TS, Buckingham BA, Klonoff DC, Shin J, et al. The order effect of
the in-clinic ASPIRE study: hypoglycemia begets hypoglycemia. Diabetes 2012;61:A58–9.
Conference: 72nd Scientific Sessions of the American Diabetes Association. Philadelphia, PA,
USA, 8–12 June 2012
Study design
Garg S, Brazg RL, Bailey TS, Buckingham BA, Slover RH, Klonoff DC, et al. Reduction in duration
of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study. Diabetes
Technol Ther 2012;14:205–9
Outcomes
Garg S, Brazg RL, Bailey TS, Buckingham BA, Slover RH, Klonoff DC, et al. Reduction in duration
of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study. Diabetes
Technol Ther 2013;15(Suppl. 1):17–18
Study design
Garg S, Ellis SL, Beatson C, Gottlieb P, Gutin R, Bookout T, et al. Improved glycaemic control in
intensively treated subjects with type 1 diabetes using Accu-Chek* advisor insulin guidance
software. Diabetologia 2007;50(Suppl. 1):116–17. Paper presented at the 43rd Annual Meeting
of the European Association for the Study of Diabetes (EASD). Amsterdam, the Netherlands,
18–21 September 2007
Intervention
Garg SK, Brazg RL, Bailey TS, Buckingham BA, Klonoff DC, Shin J, et al. Reduction of
hypoglycaemia with insulin pump suspension and role of antecedent hypoglycaemia on future
hypoglycaemic inductions: ASPIRE study. Diabetologia 2012;55:S258–9. Conference:
48th Annual Meeting of the European Association for the Study of Diabetes (EASD). Berlin,
Germany, 1–5 October 2012
Study design
Garg SK, Brazg RL, Bailey TS, Buckingham BA, Slover RH, Klonoff DC, et al. Hypoglycemia begets
hypoglycemia: the order effect in the ASPIRE in-clinic study. Diabetes Technol Ther 2014;16:125–30
Study design
Garg SK, Crew LB, Moser EG, Voelmle MK, Beatson CR. Effect of continuous glucose monitoring
on glycemic control in subjects with type 1 diabetes (T1D) delivering insulin via pump or multiple
daily injections (MDI): a prospective study. Diabetes 2010;59:A33–4. Paper presented at the
70th Annual Meeting of the American Diabetes Association. Orlando, USA, 25–29 June 2010
Study design
Garg SK, Voelmle MK, Beatson CR, Miller HA, Crew LB, Freson BJ, et al. Use of continuous
glucose monitoring in subjects with type 1 diabetes on multiple daily injections versus
continuous subcutaneous insulin infusion therapy: a prospective 6-month study. Diabetes Care
2011;34:574–9
Study design
Garg SK, Weiss R, Shah A, Mao M, Kaufman FR. Change in A1c and reduction in hypoglycemia
with threshold suspend in the aspire in-home study. Diabetes Technol Ther 2014;16:A107.
Conference: 7th International Conference on Advanced Technologies and Treatments for
Diabetes (ATTD). Vienna, Austria, 5–8 February 2014
Outcomes
Giacomet AC. [Efficacy of the monitoring of the glycemias and insulin pump in the control of
diabetes mellitus type I.] Rev AMRIGS 1984;28:303–9
Not found
Gimenez M, Conget I, Nicolau J, Pericot A, Levy I. Outcome of pregnancy in women with type 1
diabetes intensively treated with continuous subcutaneous insulin infusion or conventional
therapy. A case–control study. Acta Diabetol 2007;44:34–7
Study design
Goicolea I, Hernández I, Fombellida J, Vázquez JA. Evolution of GFR and other renal function
parameters in insulin-dependent diabetic patients treated with subcutaneous insulin infusion.
Comparison against an optimized standard therapy: 1 year follow-up effects. An Med Internal
1988;5:169–72
Not found
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Goicolea Opacua I, Hernandez Colau I, Vazquez Garcia JA. [Comparative study between the
subcutaneous continuous insulin infusion pump and optimized conventional treatment. Effects at
6 months.] Rev Clin Esp 1986;179:3–7
Intervention
Golden SH, Brown T, Yeh HC, Maruthur N, Ranasinghe P, Berger Z, et al. Methods for Insulin
Delivery and Glucose Monitoring: Comparative Effectiveness. Rockville, MD: Agency for
Healthcare Research and Quality (US); 2012. Report No: 12-EHC036-EF. URL: www.ncbi.nlm.nih.
gov/books/NBK99217/ (accessed 16 November 2015)
Systematic review/
meta-analysis
Gomez A, Alfonso-Cristancho R, Prieto-Salamanca D, Valencia JE, Lynch P, Roze S. Health
economic benefits of sensor augmented insulin pump therapy in Colombia. Value Health
2013;16:A690. Conference: ISPOR 4th Latin America Conference. Buenos Aires, Argentina,
12–14 September 2013
Outcomes
Gonzalez-Romero S, Gonzalez-Molero I, Fernandez-Abellan M, Dominguez-Lopez ME,
Ruiz-de-Adana S, Olveira G, et al. Continuous subcutaneous insulin infusion versus multiple daily
injections in pregnant women with type 1 diabetes. Diabetes Technol Ther 2010;12:263–9
Study design
Gottlieb PA, Crew LB, Moser EG, Voelmle MK, Beatson CR, Gutin RS, et al. Effects of continuous
glucose monitoring on glycaemic control in subjects with type 1 diabetes delivering insulin via
pump or multiple daily injections: a prospective study. Diabetologia 2010;53:S25. Conference:
46th Annual Meeting of the European Association for the Study of Diabetes (EASD). Stockholm,
Sweden, 20–24 September 2010
Study design
Gough H, Castaneda J, Hommel E, Olsen BS, Battelino T, Conget I, et al. The switch study: the
impact of continuous glucose monitoring on quality of life and treatment satisfaction. Value
Health 2012;15:A359. Conference: ISPOR 15th Annual European Congress. Berlin, Germany,
3–7 November 2012
Outcomes
Greene SA, Smith MA, Baum JD. Clinical application of insulin pumps in the management of
insulin dependent diabetes. Arch Dis Child 1983;58:578–81
Study design
Guerci B, Meyer L, Delbachian I, Kolopp M, Ziegler O, Drouin P. Blood glucose control on Sunday
in IDDM patients: intensified conventional insulin therapy versus continuous subcutaneous insulin
infusion. Diabetes Res Clin Pract 1998;40:175–80
Outcomes
Guilmin-Crepon S, Scornet E, Couque N, Sulmont V, Salmon AS, Le Tallec C, et al. Could clinical
parameters at initiation of continuous glucose monitoring (CGM) predict efficacy on HbA1c in
type 1 diabetes (T1D) pediatric patients at 3 months? Preliminary results in a prospective study
of 141 patients (Start-In!). Pediatr Diabetes 2012;13:117. Conference: 38th Annual Meeting of
the International Society for Pediatric and Adolescent Diabetes (ISPAD). Istanbul, Turkey,
10–13 October 2012
Study design
Haakens K, Hanssen KF, Dahl-Jorgensen K, Vaaler S, Aagenaes O, Mosand R. Continuous
subcutaneous insulin infusion (CSII), multiple injections (MI) and conventional insulin therapy (CT)
in self-selecting insulin-dependent diabetic patients. A comparison of metabolic control, acute
complications and patient preferences. J Intern Med 1990;228:457–64
Study design
Haardt MJ, Selam JL, Slama G, Bethoux JP, Dorange C, Mace B, et al. A cost–benefit comparison
of intensive diabetes management with implantable pumps versus multiple subcutaneous
injections in patients with type I diabetes. Diabetes Care 1994;17:847–51
Study design
Haidar A, Legault L, Dallaire M, Alkhateeb A, Coriati A, Messier V, et al. Glucose-responsive
insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes:
a randomized crossover controlled trial. CMAJ 2013;185:297–305
Study design
Halvorson M, Carpenter S, Kaiserman K, Kaufman FR. A pilot trial in pediatrics with the
sensor-augmented pump: combining real-time continuous glucose monitoring with the insulin
pump. J Pediatr 2007;150:103–5
Study design
Hanaire-Broutin H, Melki V, Bessieres-Lacombe S, Tauber JP. Comparison of continuous
subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1
diabetic patients on intensified treatment: a randomized study. The Study Group for the
Development of Pump Therapy in Diabetes. Diabetes Care 2000;23:1232–5
Outcomes
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Hanas R, Lindholm Olinder A, Olsson PO, Johansson UB, Jacobson S, Heintz E, et al. CSII and SAP
valuable tools in the treatment of diabetes; a Swedish health technology assesment. Diabetes
Technol Ther 2014;16:A56. Conference: 7th International Conference on Advanced Technologies
and Treatments for Diabetes (ATTD). Vienna, Austria, 5–8 February 2014
Systematic review/
meta-analysis
Hanssen KF, Dahl-Jorgensen K, Brinchmann-Hansen O. The influence of strict control on diabetic
complications. Acta Endocrinol 1985;272(Suppl.):57–60
Not found
Haugstvedt A, Wentzel-Larsen T, Graue M, Sovik O, Rokne B. Fear of hypoglycaemia in mothers
and fathers of children with type 1 diabetes is associated with poor glycaemic control and
parental emotional distress: a population-based study. Diabet Med 2010;27:72–8
Study design
Hayes Inc.MiniMed paradigm REAL-Time Closed-Loop Continuous Insulin Infusion and Blood
Glucose Monitoring System (Medtronic MiniMed Inc.). Hayes, Inc; 2010. URL: www.crd.york.ac.uk/
crdweb/ShowRecord.asp?LinkFrom=OAI&ID=32010000975 (accessed 2 February 2015)
Systematic review/
meta-analysis
Health Quality Ontario. Continuous glucose monitoring for patients with diabetes: an
evidence-based analysis. Ont Health Technol Assess Ser 2011;11:1–29
Systematic review/
meta-analysis
Health Quality Ontario. Continuous subcutaneous insulin infusion (CSII) pumps for type 1 and
type 2 adult diabetic populations: an evidence-based analysis. Ont Health Technol Assess Ser
2009;9:1–58
Systematic review/
meta-analysis
Helve E, Koivisto VA, Lehtonen A, Pelkonen R, Huttunen JK, Nikkila EA. A crossover comparison
of continuous insulin infusion and conventional injection treatment of type I diabetes. Acta Med
Scand 1987;221:385–93
Intervention
Helve E, Laatikainen L, Merenmies L, Koivisto VA. Continuous insulin infusion therapy and
retinopathy in patients with type I diabetes. Acta Endocrinol 1987;115:313–19
Not found
Hermanides J, DeVries JH. Sensor-augmented insulin pump more effective than multiple daily
insulin injections for reducing HbA1c in people with poorly controlled type 1 diabetes.
Evid Based Med 2011;16:46–8
Study design
Hermanides J, Norgaard K, Bruttomesso D, Mathieu C, Frid A, Dayan CM, et al. Sensor
augmented pump therapy substantially lowers HbA1c; a randomized controlled trial. Diabetologia
2009;52:S43. Conference: 45th EASD Annual Meeting of the European Association for the Study
of Diabetes. Vienna, Austria, 30 September–2 October 2009
Study design
Hermanns N, Kulzer B, Gulde C, Eberle H, Pradler E, Patzelt-Bath A, et al. Short-term effects on
patient satisfaction of continuous glucose monitoring with the glucoday with real-time and
retrospective access to glucose values: a crossover study. Diabetes Technol Ther 2009;11:275–81
Study design
Hermansen K, Moller A, Christensen CK, Christiansen JS, Schmitz O, Orskov H, et al. Diurnal
plasma profiles of metabolite and hormone concentration in insulin-dependent diabetic patients
during conventional insulin treatment and continuous subcutaneous insulin infusion. A controlled
study. Acta Endocrinol 1987;114:433–9
Not found
Hermansen K, Schmitz O, Boye N, Christensen CK, Christiansen JS, Alberti KG, et al. Glucagon
responses to intravenous arginine and oral glucose in insulin-dependent diabetic patients
during six months conventional or continuous subcutaneous insulin infusion. Metabolism
1988;37:640–4
Intervention
Hiéronimus S, Cupelli C, Bongain A, Durand-Réville M, Berthier F, Fénichel P. [Pregnancy in
type 1 diabetes: insulin pump versus intensified conventional therapy.] Gynecol Obstet Fertil
2005;33:389–94
Study design
Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P, et al. Continuous subcutaneous insulin
infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in
type 1 diabetic patients previously treated with CSII. Diabetes Care 2005;28:533–8
Study design
Hoeks L, Greven WL, de Valk HW. Real-time continuous glucose monitoring system for treatment
of diabetes: a systematic review. Diabet Med 2011;28:386–94
Systematic review/
meta-analysis
Hoffmann-La R. A Study Comparing Continuous Subcutaneous Insulin Infusion With Multiple
Daily Injections With Insulin Lispro and Glargine. NCT00468754; 2014. URL: https://clinicaltrials.
gov/ct2/show/NCT00468754 (accessed 12 November 2015)
Outcomes
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
176
TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Hoffmann-La R. European, Open-label, Prospective, Multinational, Multicenter Study in Adult
Subjects With Type 1 or Type 2 Diabetes Previously on MDI or CSII Therapy. Subjects Home
Setting is Considered Routine Practice. NCT02105103; 2014. URL: https://clinicaltrials.gov/ct2/
show/NCT02105103 (accessed 12 November 2015)
Study design
Holder M, Kordonouri O, Haberland H, Golembowski S, Zierow S, Remus K, et al. The low
glucose suspend function in sensor-augmented pump therapy prevents hypoglycaemia in
children. Diabetologia 2011;54:S400. Conference: 47th Annual Meeting of the European
Association for the Study of Diabetes (EASD). Lisbon, Portugal, 12–16 September 2011
Study design
Hollander AS, White NH. Continuous subcutaneous insulin infusion (CSII) reduces severe
hypoglycemia (SH) in children with type 1 diabetes mellitus (T1DM) without compromising overall
glycemic control. Pediatr Res 2000;47:132A. Paper presented at the Pediatric Academic Societies
and the American Academy of Pediatrics joint meeting. Boston, USA, 12–16 May 2000
Study design
Home PD, Capaldo B, Burrin JM, Worth R, Alberti KG. A crossover comparison of continuous
subcutaneous insulin infusion (CSII) against multiple insulin injections in insulin-dependent
diabetic subjects: improved control with CSII. Diabetes Care 1982;5:466–71
Study design
Hommel E, Olsen B, Battelino T, Conget I, Schutz-Fuhrmann I, Hoogma R, et al. Impact of
continuous glucose monitoring on quality of life, treatment satisfaction, and use of medical care
resources: analyses from the SWITCH study. Acta Diabetol 2014;51:845–51
Outcomes
Hoogma R, Hoekstra JB, Michels BP, Levi M. Comparison between multiple daily insulin injection
therapy (MDI) and continuous subcutaneous insulin infusion therapy (CSII), results of the five
nations study. Diabetes Res Clin Pract 2006;74:S144–7. Paper presented at International
Symposium on New Technologies for Insulin Replacement. Assisi, Italy, 28 April–1 May 2005
Study design
Hoogma R, Spijker AJM, van Doorn-Scheele M, van Doorn TT, Michels RPJ, van Doorn RG, et al.
Quality of life and metabolic control in patients with diabetes mellitus type I treated by
continuous subcutaneous insulin infusion or multiple daily insulin injections. Neth J Med
2004;62:383–7
Study design
Hoogma RP, Hammond PJ, Gomis R, Kerr D, Bruttomesso D, Bouter KP, et al. Comparison of the
effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin
injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabet Med
2006;23:141–7
Intervention
Hovorka R, Allen JM, Elleri D, Chassin LJ, Harris J, Xing D, et al. Manual closed-loop insulin
delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial.
Lancet 2010;375:743–51
Study design
Hovorka R, Elleri D, Thabit H, Allen JM, Leelarathna L, El-Khairi R, et al. Overnight closed-loop
insulin delivery in young people with type 1 diabetes: a free-living, randomized clinical trial.
Diabetes Care 2014;37:1204–11
Study design
Huang ES, O’Grady M, Basu A, Winn A, John P, Lee J, et al. The cost-effectiveness of continuous
glucose monitoring in type 1 diabetes. Diabetes Care 2010;33:1269–74
Outcomes
Husted SE, Nielsen HK, Bak JF, Beck-Nielsen H. Antithrombin III activity, von Willebrand factor
antigen and platelet function in young diabetic patients treated with multiple insulin injections
versus insulin pump treatment. Eur J Clin Invest 1989;19:90–4
Outcomes
Ignatova N, Arbatskaya N, Melnikova E. Continuous subcutaneous insulin infusion (CSII)
reduces the rate of hypoglycaemic episodes throughout pregnancy. Diabetologia
2007;50(Suppl. 1):383–4
Outcomes
In Home Closed Loop Study Group. Outpatient Reduction of Nocturnal Hypoglycemia by
Using Predictive Algorithms and Pump Suspension in Children. NCT01823341; 2014.
URL: https://clinicaltrials.gov/ct2/show/NCT01823341 (accessed 12 November 2015)
Study design
In Home Closed Loop Study Group. An Outpatient Pump Shutoff Pilot Feasibility and Safety
Study. NCT01736930; 2014. URL: https://clinicaltrials.gov/ct2/show/NCT01736930 (accessed
12 November 2015)
Study design
In Home Closed Loop Study Group. Outpatient Pump Shutoff Pilot Feasibility and Efficacy
Study. NCT01591681; 2014. URL: https://clinicaltrials.gov/ct2/show/NCT01591681 (accessed
12 November 2015)
Study design
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Indiana University, Juvenile Diabetes Research Foundation. Prospective Study of the Impact
of Insulin Pump Therapy in Young Children With Type 1 Diabetes. NCT00727220; 2012.
URL: https://clinicaltrials.gov/ct2/show/NCT00727220 (accessed 12 November 2015)
Study design
ISRCTN01687353. Standardized Procedure for the Assessment of New-to-Market Continuous
Glucose Monitoring Systems. 2012. URL: www.controlled-trials.com/ISRCTN01687353
(accessed 11 January 2016)
Study design
ISRCTN05450731. Paediatric Onset Study to Assess the Efficacy of Insulin Pump Therapy using
the MiniMed Paradigm® REAL-Time System during the First Year of Diabetes in Children and
Adolescents with Type 1 Diabetes. 2008. URL: www.controlled-trials.com/ISRCTN05450731
(accessed 11 January 2016)
Study design
ISRCTN28387915. Utility of Continuous Glucose Monitoring (CGMS) in Children with Type 1
Diabetes on Intensive Treatment Regimens. URL: www.controlled-trials.com/ISRCTN28387915
(accessed 11 January 2016)
Outcomes
ISRCTN33678610. A Randomised Controlled Trial (RCT) to Compare Minimally Invasive Glucose
Monitoring Devices to Conventional Monitoring in the Management of Insulin Treated Diabetes
Mellitus. URL: www.controlled-trials.com/ISRCTN33678610 (accessed 11 January 2016)
Study design
ISRCTN33678610. A Randomised Controlled Trial (RCT) to Compare Minimally Invasive Glucose
Monitoring Devices to Conventional Monitoring in the Management of Insulin Treated Diabetes
Mellitus. 2003. URL: www.controlled-trials.com/ISRCTN33678610 (accessed 11 January 2016)
Intervention
ISRCTN37153662. Comparison Between Continuous Subcutaneous Insulin Infusion with Multiple
Basal Lispro Infusion Rates and Multiple Daily Insulin Injection with Lispro And Glargine. 2007.
URL: www.controlled-trials.com/ISRCTN37153662 (accessed 11 January 2016)
Intervention
ISRCTN52164803. Prevention of Recurrent Severe Hypoglycaemia: Optimised Multiple Daily
Insulin Injection (MDI) versus Continuous Subcutaneous Insulin Infusion (CSII) with or without
Adjunctive Real-Time Continuous Glucose Monitoring. 2009. URL: www.controlled-trials.com/
ISRCTN52164803 (accessed 11 January 2016)
Outcomes
ISRCTN62034905. Comparison of Two Artificial Pancreas Systems for Closed Loop Blood Glucose
Control Versus Open Loop Control in Patients with Type 1 Diabetes. 2011. URL: www.controlled-
trials.com/ISRCTN62034905 (accessed 11 January 2016)
Study design
ISRCTN64351161. Comparison in Metabolic Control and Treatment Satisfaction with Continuous
Subcutaneous Insulin Infusion and Multiple Daily Injections in Children at Onset of Type 1
Diabetes Mellitus. 2007. URL: www.controlled-trials.com/ISRCTN64351161 (accessed 11 January
2016)
Outcomes
ISRCTN77773974. A Randomised Study of Continuous Subcutaneous Insulin Infusion (CSII)
Therapy Compared to Conventional Bolus Insulin Treatment in Preschool Aged Children with
Type 1 Diabetes. URL: www.controlled-trials.com/ISRCTN77773974 (accessed 11 January 2016)
Outcomes
Jakisch BI, Wagner VM, Heidtmann B, Lepler R, Holterhus PM, Kapellen TM, et al. Comparison of
continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) in paediatric
type 1 diabetes: a multicentre matched-pair cohort analysis over 3 years. Diabet Med
2008;25:80–5
Study design
JDRF Artificial Pancreas Project. Randomized Study of Real-Time Continuous Glucose Monitors
(RT-CGM) in the Management of Type 1 Diabetes. NCT00406133; 2010. URL: https://clinicaltrials.
gov/ct2/show/NCT00406133 (accessed 12 November 2015)
Outcomes
Jeha GS, Karaviti LP, Anderson B, Smith EOB, Donaldson S, McGirk TS, et al. Insulin pump
therapy in preschool children with type 1 diabetes mellitus improves glycemic control
and decreases glucose excursions and the risk of hypoglycemia. Diabetes Technol Ther
2005;7:876–84
Study design
Jeitler K, Horvath K, Berghold A, Gratzer TW, Neeser K, Pieber TR, et al. Continuous
subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes
mellitus: systematic review and meta-analysis. Diabetologia 2008;51:941–51
Systematic review/
meta-analysis
Jenkins AJ, Krishnamurthy B, Best JD, Cameron FJ, Colman PG, Hamblin PS, et al. An algorithm
guiding patient responses to real-time-continuous glucose monitoring improves quality of life.
Diabetes Technol Ther 2011;13:105–9
Intervention
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
178
TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Jennings AM, Lewis KS, Murdoch S, Talbot JF, Bradley C, Ward JD. Randomized trial comparing
continuous subcutaneous insulin infusion and conventional insulin therapy in type II diabetic
patients poorly controlled with sulfonylureas. Diabetes Care 1991;14:738–44
Population
Jiang L, Jiang S, Ma Y, Zhang M, Feng X. Real-time Continuous Glucose Monitoring vs.
Conventional Glucose Monitoring in Critically Ill Patients. PROSPERO: CRD42014013488; 2014.
URL: www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014013488 (accessed
16 November 2015)
Systematic review/
meta-analysis
Jimenez M, Hernaez R, Conget I, Alonso A, Yago G, Pericot A, et al. Metabolic control,
maternal and perinatal outcomes in type 1 diabetic pregnancies intensively treated with
conventional insulin therapy vs. continuous subcutaneous insulin infusion. Diabetologia
2005;48(Suppl. 1):A315. Paper presented at 41st Annual Meeting of the European Association
for the Study of Diabetes (EASD). Athens, Greece, 10–15 September 2005
Study design
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Group, Beck RW,
Lawrence JM, Laffel L, Wysocki T, Xing D, et al. Quality-of-life measures in children and adults
with type 1 diabetes: Juvenile Diabetes Research Foundation Continuous Glucose Monitoring
randomized trial. Diabetes Care 2010;33:2175–7
Intervention
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group,
Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, et al. Continuous glucose
monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359:1464–76
Intervention
Kamble S, Perry BM, Shafiroff J, Schulman KA, Reed SD. The cost-effectiveness of initiating
sensor-augmented pump therapy versus multiple daily injections of insulin in adults with type 1
diabetes: evaluating a technology in evolution. Value Health 2011;14:A82. Conference:
16th Annual International Meeting of the International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Baltimore, MD, USA, 21–25 May 2011
Outcomes
Kamble S, Schulman KA, Reed SD. Cost-effectiveness of sensor-augmented pump therapy in
adults with type 1 diabetes in the USA. Value Health 2012;15:632–8
Outcomes
Kamble S, Weinfurt KP, Perry BM, Schulman KA, Reed SD. Patient time and indirect costs
associated with sensor-augmented insulin pump therapy in type 1 diabetes. Value Health
2011;14:A824. Conference: 16th Annual International Meeting of the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR). Baltimore, MD, USA, 21–25 May 2011
Outcomes
Kamble S, Weinfurt KP, Schulman KA, Reed SD. Patient time costs associated with
sensor-augmented insulin pump therapy for type 1 diabetes: results from the STAR 3
randomized trial. Med Decis Making 2013;33:215–24
Outcomes
Kapellen T, Kordonouri O, Pankowska E, Rami B, Coutant R, Hartmann R, et al.
Sensor-augmented pump therapy from the onset of type 1 diabetes in children and
adolescents – results of the Pediatric ONSET Study after 12 months of treatment. Horm Res
Paediatr 2010;74:58. Conference: 49th Annual Meeting of the European Society for Paediatric
Endocrinology (ESPE). Prague, Czech Republic, 22–25 September 2010
Study design
Kaufman F, Shin J, Yang Q. Differences in measures of glycemic variability between the multiple
daily injection therapy and sensor-augmented pump therapy groups in the star 3 study. Diabetes
Technol Ther 2011;13:186. Conference: 4th International Conference on Advanced Technologies
and Treatments for Diabetes (ATTD). London, UK, 16–19 February 2011
Outcomes
Kaufman FR, Agrawal P, Askari S, Kannard B, Welsh JB. Effectiveness of the low glucose suspend
feature of the medtronic paradigm Veo insulin pump in children and adolescents. Pediatr
Diabetes 2011;12:30–31. Conference: 37th Annual Meeting of the International Society for
Pediatric and Adolescent Diabetes (ISPAD). Miami Beach, FL, USA, 19–22 October 2011
Study design
Kaufman FR, Agrawal P, Lee SW, Kannard B. Characterization of the low glucose suspend
feature of the medtronic minimed paradigm veo insulin pump system and events preceding its
activation. Diabetes 2011;60:A249. Conference: 71st Scientific Sessions of the American
Diabetes Association. San Diego, CA, USA, 24–28 June 2011
Study design
Kaufman FR, Austin J, Neinstein A, Jeng L, Halvorson M, Devoe DJ, et al. Nocturnal hypoglycemia
detected with the continuous glucose monitoring system in pediatric patients with type 1
diabetes. J Pediatr 2002;141:625–30
Study design
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Kaufman FR, Gibson LC, Halvorson M, Carpenter S, Fisher LK, Pitukcheewanont P. A pilot study
of the continuous glucose monitoring system: clinical decisions and glycemic control after its use
in pediatric type 1 diabetic subjects. Diabetes Care 2001;24:2030–4
Study design
Kaufman FR, Halvorson M, Kim C, Pitukcheewanont P. Use of insulin pump therapy at nighttime
only for children 7–10 years of age with type 1 diabetes. Diabetes Care 2000;23:579–82
Study design
Keenan DB, Cartaya R, Mastrototaro JJ. Accuracy of a new real-time continuous glucose
monitoring algorithm. J Diabetes Sci Technol 2010;4:111–18
Study design
Keenan DB, Mastrototaro JJ, Zisser H, Cooper KA, Raghavendhar G, Lee SW, et al. Accuracy of
the Enlite 6-day glucose sensor with guardian and Veo calibration algorithms. Diabetes Technol
Ther 2012;14:225–31
Study design
Kernaghan D, Farrell T, Hammond P, Owen P. Fetal growth in women managed with insulin
pump therapy compared to conventional insulin. Eur J Obstet Gynecol Reprod Biol
2008;137:47–9
Intervention
Khalil S, Wright T, Field A, Hand J, Dyer P, Karamat MA. Does continuous subcutaneous insulin
infusion (CSII) provide an effective method of controlling diabetes in pregnant women with
type 1 diabetes? Diabet Med 2013;30(Suppl. 1):170. Paper presented at Diabetes UK Professional
Conference. Manchester, UK, 13–15 March 2013
Study design
King Abdullah International Medical Research Centre. Incidence of Hypoglycemia During
Ramadan in Patients With Type 1 Diabetes on Insulin Pump Versus Multi Dose Injection.
NCT01941238; 2013. URL: https://clinicaltrials.gov/ct2/show/NCT01941238
(accessed 12 November 2015)
Study design
Kordonouri O, Hartmann R, Lauterborn R, Barnekow C, Hoeffe J, Deiss D. Age-specific
advantages of continuous subcutaneous insulin infusion as compared with multiple daily
injections in pediatric patients: one-year follow-up comparison by matched-pair analysis.
Diabetes Care 2006;29:133–4
Intervention
Kordonouri O, Hartmann R, Pankowska E, Rami B, Kapellen T, Coutant R, et al. Follow-up
of patients with sensor-augmented pump therapy during the first year of diabetes-pediatric
onset study. Pediatr Diabetes 2011;12:29. Conference: 37th Annual Meeting of the
International Society for Pediatric and Adolescent Diabetes (ISPAD). Miami Beach, FL, USA,
19–22 October 2011
Study design
Kordonouri O, Hartmann R, Pankowska E, Rami B, Kapellen T, Coutant R, et al. Sensor
augmented pump therapy from onset of type 1 diabetes: late follow-up results of the Pediatric
ONSET Study. Diabetologia 2011;54:S41. Conference: 47th Annual Meeting of the European
Association for the Study of Diabetes (EASD). Lisbon, Portugal, 12–16 September 2011
Study design
Kordonouri O, Hartmann R, Pankowska E, Rami B, Kapellen T, Coutant R, et al. Sensor
augmented pump therapy from onset of type 1 diabetes: late follow-up results of the Pediatric
Onset Study. Pediatr Diabetes 2012;13:515–18
Study design
Kordonouri O, Pankowska E, Rami B, Kapellen T, Coutant R, Hartmann R, et al. Sensor-augmented
pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study
(ONSET) after 12 months of treatment. Diabetologia 2010;53:2487–95
Study design
Kordonouri O. Pumps and sensors from the onset of diabetes. Pediatr Diabetes 2010;11:6.
Conference: 36th Annual Meeting of the International Society for Pediatric and Adolescent
Diabetes (ISPAD). Buenos Aires, Argentina, 27–30 October 2010
Study design
Kovatchev BP. Safety and efficacy of outpatient closed-loop control – results from randomized
crossover trials of a wearable artificial pancreas. Paper presented at 74th Scientific Sessions of the
American Diabetes Association. San Francisco, CA, USA, 13–17 June 2014
Study design
Kracht T, Kordonouri O, Datz N, Scarabello C, Walte K, Blaesig S, et al. Reducing glycaemic
variability and HbA1c with the Dexcom Seven.2 continuous glucose monitoring system in children
and young adults with type 1 diabetes (T1D). Pediatr Diabetes 2009;10:104. Conference:
35th Annual Meeting of the International Society for Pediatric and Adolescent Diabetes (ISPAD).
Ljubljana, Slovenia, 2–5 September 2009
Intervention
Kruger J, Brennan A. The cost of type 1 diabetes mellitus in the United Kingdom: a review of
cost-of-illness studies. Eur J Health Econ 2013;14:887–99
Outcomes
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Laatikainen L, Teramo K, Hieta-Heikurainen H, Koivisto V, Pelkonen R. A controlled study of the
influence of continuous subcutaneous insulin infusion treatment on diabetic retinopathy during
pregnancy. Acta Med Scand 1987;221:367–76
Intervention
Laffel L, Buckingham B, Chase P, Bailey T, Liljenquist D, Daniels M, et al. Performance of
a continuous glucose monitoring system (CGM) and CGM glucose ranges in youth ages
2–17 yr old. Pediatr Diabetes 2013;14:47–48. Conference: 39th Annual Conference of the
International Society for Pediatric and Adolescent Diabetes (ISPAD). Gothenburg, Sweden,
16–19 October 2013
Intervention
Lagarde WH, Barrows FP, Davenport ML, Kang M, Guess HA, Calikoglu AS. Continuous
subtaneous glucose monitoring in children with type 1 diabetes mellitus: a single-blind,
randomized, controlled trial. Pediatr Diabetes 2006;7:159–64
Outcomes
Laguna AJ, Rossetti P, Ampudia-Blasco FJ, Vehi J, Bondia J. Postprandial performance of Dexcom
SEVEN PLUS and Medtronic Paradigm Veo: modeling and statistical analysis. Biomed Signal
Process Control 2014;10:322–31
Study design
Lange K, Coutant R, Danne T, Kapellen T, Pankowska E, Rami B, et al. High quality of life in
children and psychological wellbeing in mothers 12 month after diabetes onset: results of the
paediatric onset-trial of sensor-enhanced CSII. Pediatr Diabetes 2010;11:101. Conference:
36th Annual Meeting of the International Society for Pediatric and Adolescent Diabetes (ISPAD).
Buenos Aires, Argentina, 27–30 October 2010
Study design
Langeland LB, Salvesen O, Selle H, Carlsen SM, Fougner KJ. Short-term continuous glucose
monitoring: effects on glucose and treatment satisfaction in patients with type 1 diabetes
mellitus; a randomized controlled trial. Int J Clin Pract 2012;66:741–7
Study design
Langendam M, Luijf YM, Hooft L, DeVries JH, Mudde AH, Scholten RJPM. Continuous glucose
monitoring systems for type 1 diabetes mellitus. Cochrane Database Syst Rev 2012; 1:CD008101
Systematic review/
meta-analysis
Lapolla A, Dalfra MG, Masin M, Bruttomesso D, Piva I, Crepaldi C, et al. Analysis of outcome
of pregnancy in type 1 diabetics treated with insulin pump or conventional insulin therapy.
Acta Diabetol 2003;40:143–9
Study design
Lauritzen T, Frost-Larsen K, Larsen HW, Deckert T. Two-year experience with continuous
subcutaneous insulin infusion in relation to retinopathy and neuropathy. Diabetes
1985;34(Suppl. 3):74–9
Intervention
Lawson ML, Bradley B, McAssey K, Clarson C, Kirsch S, Curtis JR, et al. Timing of initiation of
continuous glucose monitoring in established pediatric diabetes: recruitment and baseline
characteristics in the CGM time trial. Diabetes Technol Ther 2014;16:A73–4. Conference:
7th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD).
Vienna, Austria, 5–8 February 2014
Outcomes
Lawson ML, Olivier P, Huot C, Richardson C, Nakhla M, Romain J. Simultaneous vs. delayed
initiation of Real-Time Continuous Glucose Monitoring (RT-CGM) in children and adolescents
with established type 1 diabetes starting insulin pump therapy: a pilot study. Pediatr Diabetes
2011;12:126–7. Conference: 37th Annual Meeting of the International Society for Pediatric and
Adolescent Diabetes (ISPAD). Miami Beach, FL, USA, 19–22 October 2011
Outcomes
Lawson ML, Richardson C, Muileboom J, Evans K, Landry A, Cormack L. Development of a
standardized approach to initiating continuous glucose monitoring in amulticentre pediatric
study. Diabetes Technol Ther 2014;16:A73. Conference: 7th International Conference on
Advanced Technologies and Treatments for Diabetes (ATTD). Vienna, Austria, 5–8 February 2014
Outcomes
Lawson P, Home PD, Bergenstal R. Observations on blood lipid and intermediary metabolite
concentrations during conventional insulin treatment or CSII. Diabetes 1985;34(Suppl. 3):27–30
Intervention
Lebenthal Y, Lazar L, Benzaquen H, Shalitin S, Phillip M. Patient perceptions of using OmniPod
System compared with conventional insulin pumps in young adults with type 1 diabetes. Pediatr
Diabetes 2011;12:131–2. Conference: 37th Annual Meeting of the International Society for
Pediatric and Adolescent Diabetes (ISPAD). Miami Beach, FL, USA, 19–22 October 2011
Intervention
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Lebenthal Y, Lazar L, Benzaquen H, Shalitin S, Phillip M. Patient perceptions of using the
OmniPod system compared with conventional insulin pumps in young adults with type 1
diabetes. Diabetes Technol Ther 2012;14:411–17
Intervention
Lecavalier L, Havrankova J, Hamet P, Chiasson JL. Effects of continuous subcutaneous insulin
infusion versus multiple injections on insulin receptors in insulin-dependent diabetics. Diabetes
Care 1987;10:300–5
Study design
Lee SW, Welsh JB, Green JB, Joyce C, Tamborlane WV, Kaufman FR. Successful transitions from
MDI therapy to sensor-augmented pump therapy in the STAR 3 study: system settings and
behaviours. Diabetologia 2011;54:S395–6. Conference: 47th Annual Meeting of the European
Association for the Study of Diabetes (EASD). Lisbon, Portugal, 12–16 September 2011
Outcomes
Leelarathna L, Little SA, Walkinshaw E, Tan HK, Lubina-Solomon A, Kumareswaran K, et al.
Restoration of self-awareness of hypoglycemia in adults with long-standing type 1 diabetes:
hyperinsulinemic-hypoglycemic clamp substudy results from the HypoCOMPaSS trial.
Diabetes Care 2013;36:4063–70
Study design
Legacy Health System, Juvenile Diabetes Research Foundation. Sensor-Augmented Insulin
Delivery: Insulin Plus Glucagon Versus Insulin Alone. 2011. URL: http://ClinicalTrials.gov/show/
NCT00797823 (accessed 23 February 2016)
Study design
Lepore G, Dodesini AR, Nosari I, Trevisan R. Both continuous subcutaneous insulin infusion and a
multiple daily insulin injection regimen with glargine as basal insulin are equally better than
traditional multiple daily insulin injection treatment. Diabetes Care 2003;26:1321–2
Study design
Lepore G, Dodesini AR, Nosari I, Trevisan R. Effect of continuous subcutaneous insulin infusion vs.
multiple daily insulin injection with glargine as basal insulin: an open parallel long-term study.
Diabetes Nutr Metab 2004;17:84–9
Not found
Leveno KJ, Fortunato SJ, Raskin P, Williams ML, Whalley PJ. Continuous subcutaneous insulin
infusion during pregnancy. Diabetes Res Clin Pract 1988;4:257–68
Intervention
Li A, Tsang CH. The Effectiveness of Continuous Subcutaneous Insulin Infusion on Quality of Life
of Families and Glycaemic Control Among Children with Type 1 Diabetes: A Systematic Review.
PROSPERO: CRD42012002029; 2012. URL: www.crd.york.ac.uk/PROSPERO/display_record.asp?
ID=CRD42012002029 (accessed 16 November 2015)
Systematic review/
meta-analysis
Li XL. Multiple daily injections versus insulin pump therapy in patients with type 1 diabetes
mellitus: a meta analysis. J Clin Rehabil Tissue Engineering Res 2010;14:8722–5
Systematic review/
meta-analysis
Lindholm Olinder A, Hanas R, Heintz E, Jacobson S, Johansson UB, Olsson PO, et al. CGM and
SAP are valuable tools in the treatment of diabetes; a swedish health technology assessment.
Diabetes Technol Ther 2014;16:A74. Conference: 7th International Conference on Advanced
Technologies and Treatments for Diabetes (ATTD). Vienna, Austria, 5–8 February 2014
Systematic review/
meta-analysis
Liouri E, Koutsovasilis A, Kounenou K, Kamaratos A, Koukouli M-P, Nikolaou A, et al. Intensified
insulin therapy vs CSII: the influence on family cohesion and adaptability of type 1 diabetics.
Paper presented at 45th EASD Annual Meeting of the European Association for the Study of
Diabetes. Vienna, Austria, 30 September–2 October 2009
Outcomes
Little S, Chadwick T, Choudhary P, Brennand C, Stickland J, Barendse S, et al. Comparison of
Optimised MDI versus Pumps with or without Sensors in Severe Hypoglycaemia (the Hypo
COMPaSS trial). BMC Endocr Disord 2012;12:33
Outcomes
Little SA, Leelarathna L, Walkinshaw E, Kai Tan H, Chapple O, Barendse S, et al. A definitive
multicenter RCT to restore hypoglycemia awareness and prevent recurrent severe hypoglycemia
in adults with long- standing type 1 diabetes: Results from the hypocompass trial. Diabetes
2013;62:A98. Conference: 73rd Scientific Sessions of the American Diabetes Association.
Chicago, IL, USA, 21–25 June 2013
Outcomes
Little SA, Leelarathna L, Walkinshaw E, Tan HK, Chapple O, Lubina-Solomon A, et al. Recovery
of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2 × 2 factorial
randomized controlled trial comparing insulin pump with multiple daily injections and continuous
with conventional glucose self-monitoring (HypoCOMPaSS). Diabetes Care 2014;37:2114–22
Outcomes
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Littlejohn E, Turksoy K, Quinn LT, Cinar A. Integrated multivariable artificial pancreas control
systems work as well as operator controlled systems. Paper presented at 74th Scientific Sessions
of the American Diabetes Association. San Francisco, CA, USA, 13–17 June 2014
Intervention
Litton J, Rice A, Friedman N, Oden J, Lee MM, Freemark M. Insulin pump therapy in toddlers and
preschool children with type 1 diabetes mellitus. J Pediatr 2002;141:490–5
Study design
Logtenberg SJ, Kleefstra N, Groenier KH, Gans RO, Bilo HJ. Use of short-term real-time
continuous glucose monitoring in type 1 diabetes patients on continuous intraperitoneal insulin
infusion: a feasibility study. Diabetes Technol Ther 2009;11:293–9
Intervention
Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic
control in pediatric patients with type 1 diabetes: a controlled crossover study. Pediatrics
2003;111:933–8
Intervention
Luijf YM, De Vries JH, Mader JK, Doll W, Place J, Renard E, et al. Accuracy and reliability of
current continuous glucose monitoring systems: a direct comparison. J Diabetes Sci Technol
2013;7:A83. Conference: 12th Annual Diabetes Technology Meeting. Bethesda, MD, USA,
8–10 November 2012
Outcomes
Luijf YM, DeVries JH, Mader JK, Doll W, Place J, Renard E, et al. Accuracy and reliability of current
CGM systems: a direct comparison. Diabetes Technol Ther 2013;15:A13–14. Conference:
6th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD).
Paris, France, 27 February–2 March 2013
Outcomes
Luijf YM, DeVries JH, Zwinderman K, Leelarathna L, Nodale M, Caldwell K, et al. Day and night
closed-loop control in adults with type 1 diabetes: a comparison of two closed-loop algorithms
driving continuous subcutaneous insulin infusion versus patient self-management. Diabetes Care
2013;36:3882–7
Study design
Luijf YM, Mader JK, Doll W, Pieber T, Farret A, Place J, et al. Accuracy and reliability of
continuous glucose monitoring systems: a head-to-head comparison. Diabetes Technol Ther
2013;15:721–6
Study design
Ly TT, Keenan DB, Spital G, Roy A, Grosman B, Cantwell M, et al. Portable glucose control
with daytime treat-to-range and overnight proportionalintegral-derivative control in adolescents
with type 1 diabetes. Diabetes Technol Ther 2013;15:A14. Conference: 6th International
Conference on Advanced Technologies and Treatments for Diabetes (ATTD). Paris, France,
27 February–2 March 2013
Outcomes
Ly TT, Nicholas JA, Davis EA, Jones TW. Initial experience of automated low glucose insulin
suspension using the medtronic paradigm veo system. Diabetes 2011;60:A112. Conference:
71st Scientific Sessions of the American Diabetes Association. San Diego, CA, USA,
24–28 June 2011
Study design
Ly TT, Nicholas JA, Retterath A, Davis EA, Jones TW. Analysis of glucose responses to automated
insulin suspension with sensor-augmented pump therapy. Diabetes Care 2012;35:1462–5
Outcomes
Maahs DM, Calhoun P, Buckingham BA, Chase HP, Hramiak I, Lum J, et al. A randomized trial
of a home system to reduce nocturnal hypoglycemia in type 1 diabetes. Diabetes Care
2014;37:1885–91
Study design
Maahs DM, Chase HP, Westfall E, Slover R, Huang S, Shin JJ, et al. The effects of lowering
nighttime and breakfast glucose levels with sensor-augmented pump therapy on hemoglobin
A1c levels in type 1 diabetes. Diabetes Technol Ther 2014;16:284–91
Study design
Maiorino MI, Bellastella G, Petrizzo M, Improta MR, Brancario C, Castaldo F, et al. Treatment
satisfaction and glycemic control in young type 1 diabetic patients in transition from pediatric
health care: CSII versus MDI. Endocrine 2014;46:256–62
Study design
Manfrini S, Crino A, Fredrickson L, Pozzilli P. CSII versus intensive insulin therapy at onset of type
1 diabetes: the IMDIAB 8 two-year randomised trial. Diabetes 2002;51(Suppl. 2):A4. Paper
presented at 62nd Annual Meeting of the American Diabetes Association. San Francisco, CA,
USA, 14–18 Jun 2002
Study design
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Maran A, Crazzolara D, Nicoletti M, Costa S, dal Pos M, Tiengo A, et al. A randomized
crossover study to compare continuous subcutaneous insulin infusion (CSII) with multiple
daily injection (MDI) in type 1 diabetic patients previously treated with CSII. Diabetologia
2005;48(Suppl. 1):A328. Paper presented at 41st Annual Meeting of the European Association
for the Study of Diabetes (EASD). Athens, Greece, 10–15 September 2005
Outcomes
Mauras N, Beck R, Xing D, Ruedy K, Buckingham B, Tansey M, et al. A randomized controlled
trial (RCT) to assess the efficacy and safety of real-time continuous glucose monitoring (CGM) in
the management of type 1 diabetes (T1D) in young children. Pediatr Diabetes 2011;12:30.
Conference: 37th Annual Meeting of the International Society for Pediatric and Adolescent
Diabetes (ISPAD). Miami Beach, FL, USA, 19–22 October 2011
Intervention
Mauras N, Beck R, Xing D, Ruedy K, Buckingham B, Tansey M, et al. A randomized clinical
trial to assess the efficacy and safety of real-time continuous glucose monitoring in the
management of type 1 diabetes in young children aged 4 to < 10 years. Diabetes Technol Ther
2013;15(Suppl. 1):S14–15
Study design
Mauras N, Beck R, Xing DY, Ruedy K, Buckingham B, Tansey M, et al. A randomized clinical trial
to assess the efficacy and safety of real-time continuous glucose monitoring in the management
of type 1 diabetes in young children aged 4 to < 10 years. Diabetes Care 2012;35:204–10
Study design
McCoy R, Smith S. Insulin pumps with a sensor and threshold-suspend reduced nocturnal
hypoglycemia in type 1 diabetes. Ann Intern Med 2013;159:JC7
Study design
McCoy R. Insulin pumps with a sensor and threshold-suspend reduced nocturnal hypoglycemia in
type 1 diabetes. Ann Intern Med 2013;159:JC7
Study design
Medtronic Diabetes. Feasibility Study for Training Pump Naive Subjects To Use The Paradigm®
System And Evaluate Effectiveness. NCT00530023; 2011. URL: https://clinicaltrials.gov/ct2/show/
NCT00530023 (accessed 12 November 2015)
Intervention
Medtronic. SWITCH – Sensing With Insulin Pump Therapy to Control HbA1c. 2010.
URL: http://ClinicalTrials.gov/show/NCT00598663 (accessed 16 November 2015)
Study design
Melki V, Hanaire-Broutin H, Bessieres-Lacombe S, Tauber JP. CSII versus MDI in IDDM
patients treated with insulin lispro: results of a randomised, cross-over trial. Diabetologia
1999;42(Suppl. 1):A17. Paper presented at 35th Annual meeting of the European Association
for the Study of Diabetes. Brussels, Belgium, 28 September–2 October 1999
Outcomes
Mello G, Biagioni S, Ottanelli S, Nardini C, Tredici Z, Serena C, et al. Continuous subcutaneous
insulin infusion (CSII) versus multiple daily injections (MDI) of rapid-acting insulin analogues
and detemir in type 1 diabetic (T1D) pregnant women. J Matern Fetal Neonatal Med
2014;28:276–80
Study design
Mello G, Parretti E, Tondi F, Riviello C, Borri P, Scarselli G. Impact of two treatment regimens with
insulin lispro in post-prandial glucose excursion patterns and fetal fat mass growth in type 1
diabetic pregnant women. Am J Obstet Gynecol 2005;193(Suppl. 6):S36. Paper presented at
26th Annual Meeting of the Society for Maternal–Fetal Medicine: the Pregnancy Meeting,
30 January–4 February 2006, Miami, FL, USA
Outcomes
Meschi F, Beccaria L, Vanini R, Szulc M, Chiumello G. Short-term subcutaneous insulin infusion
in diabetic children. Comparison with three daily insulin injections. Acta Diabetol Lat
1982;19(4371–5)
Not found
Meyer L, Boullu-Sanchis S, Boeckler P, Sibenaler A, Treger M, Pinget M, et al. Comparison of
glycemic control in 3 groups of type 1 diabetic patients treated with multiinjections and lispro
(MDI), continuous subcutaneous insulin infusion with lispro (CSII) or continuous peritoneal
insulin infusion (CPII): data of continuous subcutaneous glucose sensing (CGMS). Diabetes
2002;51(Suppl. 2):A124–5. Paper presented at 62nd Annual Meeting of the American Diabetes
Association. San Francisco, CA, USA, 14–18 June 2002
Study design
Micossi P, Raggi U, Dosio F. Open-loop device microjet MC 2 improves unstable diabetes, lowers
the daily insulin requirement and reduces the excursions of plasma free insulin levels: comparison
with a traditional intensive treatment. J Endocrinol Invest 1983;6:189–94
Intervention
Misso ML, Egberts KJ, Page M, O’Connor D, Shaw J. Continuous subcutaneous insulin infusion
(CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev
2010; 1:CD005103
Systematic review/
meta-analysis
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Moller A, Rasmussen L, Ledet T, Christiansen JS, Christensen CK, Mogensen CE, et al.
Lipoprotein changes during continuous subcutaneous insulin infusion in insulin-dependent
diabetic patients. Scand J Clin Lab Invest 1986;46:471–5
Intervention
Monami M, Lamanna C, Marchionni N, Mannucci E. Continuous subcutaneous insulin infusion
versus multiple daily insulin injections in type 1 diabetes: a meta-analysis. Acta Diabetol
2010;47(Suppl. 1):77–81
Systematic
review/meta-analysis
Monnier LH, Rodier M, Gancel A, Crastes de Paulet P, Colette C, Piperno M, et al. Plasma lipid
fatty acids and platelet function during continuous subcutaneous insulin infusion in type I
diabetes. Diabetes Metab 1987;13:210–16
Intervention
Moreno-Fernandez J, Gomez FJ, Gazquez M, Pedroche M, Garcia-Manzanares A, Tenias JM,
et al. Real-time continuous glucose monitoring or continuous subcutaneous insulin infusion,
what goes first? Results of a pilot study. Diabetes Technol Ther 2013;15:596–600
Study design
Mukhopadhyay A, Farrell T, Fraser RB, Ola B. Continuous subcutaneous insulin infusion vs.
intensive conventional insulin therapy in pregnant diabetic women: a systematic review and
metaanalysis of randomized, controlled trials. Am J Obstet Gynecol 2007;197:447–56
Systematic review/
meta-analysis
Murphy HR, Kumareswaran K, Elleri D, Allen JM, Caldwell K, Biagioni M, et al. Safety and
efficacy of 24-h closed-loop insulin delivery in well-controlled pregnant women with type 1
diabetes: a randomized crossover case series. Diabetes Care 2011;34:2527–9. [Erratum appears
in Diabetes Care 2012;35:191]
Study design
Myers SJ, Uhrinak AN, Kaufman FR, Lee SW, Yusi J, Huang S, et al. Retrospective analysis of
events preceding low glucose suspend activation in pediatric subjects on the Paradigm Veo
system. J Diabetes Sci Technol 2012;6:A125. Conference: 11th Annual Diabetes Technology
Meeting. San Francisco, CA, USA, 27–29 October 2011
Study design
Nabhan ZM, Kreher NC, Greene DM, Eugster EA, Kronenberger W, DiMeglio LA. A randomized
prospective study of insulin pump vs. insulin injection therapy in very young children with type 1
diabetes: 12-month glycemic, BMI, and neurocognitive outcomes. Pediatr Diabetes
2009;10:202–8
Intervention
Nahata L. Insulin therapy in pediatric patients with type I diabetes: continuous subcutaneous
insulin infusion versus multiple daily injections. Clin Pediatr (Phila) 2006;45:503–8
Study design
Nathan DM, Lou P, Avruch J. Intensive conventional and insulin pump therapies in adult type I
diabetes. A crossover study. Ann Intern Med 1982;97:31–6
Study design
Nemours Children’s Clinic. Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1
Diabetes (T1D). NCT00357890; 2006. URL: https://clinicaltrials.gov/ct2/show/NCT00357890
(accessed 12 November 2015)
Population
JRDF Artificial Pancreas Project. Randomized Study of Real-Time Continuous Glucose Monitors
(RT-CGM) in the Management of Type 1 Diabetes. NCT00406133; 2006. URL: https://clinicaltrials.
gov/ct2/show/NCT00406133 (accessed 12 November 2015)
Outcomes
Erasmus Medical Center. Comparison Between Insulin Pump Treatment and Multiple Daily Insulin
Injections in Diabetic Type 1 Children. NCT00462371; 2007. URL: https://clinicaltrials.gov/ct2/
show/NCT00462371 (accessed 12 November 2015)
Outcomes
Hoffman-La Roche. A Study Comparing Continuous Subcutaneous Insulin Infusion With Multiple
Daily Injections With Insulin Lispro and Glargine. NCT00468754; 2007. URL: https://clinicaltrials.
gov/ct2/show/NCT00468754 (accessed 12 November 2015)
Outcomes
Medtronic Diabetes. Feasibility Study for Training Pump Naive Subjects To Use The Paradigm®
System And Evaluate Effectiveness. NCT00530023; 2007. URL: https://clinicaltrials.gov/ct2/show/
NCT00530023 (accessed 12 November 2015)
Duplicate
Novo Nordisk A/S. Efficacy and Safety of Insulin Aspart in MDI or CSII in Children Below 7 Years
of Age With Type 1 Diabetes. NCT00571935; 2007. URL: https://clinicaltrials.gov/ct2/show/
NCT00571935 (accessed 12 November 2015)
Outcomes
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Arkansas Children’s Hospital Research Institute. Preservation of Pancreatic Beta Cell Function
Through Insulin Pump Therapy. NCT00574405; 2007. URL: https://clinicaltrials.gov/ct2/show/
NCT00574405 (accessed 12 November 2015)
Outcomes
Medtronic. SWITCH – Sensing With Insulin Pump Therapy to Control HbA1c. NCT00598663;
2007. URL: https://clinicaltrials.gov/ct2/show/NCT00598663 (accessed 12 November 2015)
Study design
Boston University. Closed-loop Glucose Control for Automated Management of Type 1 Diabetes.
NCT00811317; 2008. URL: https://clinicaltrials.gov/ct2/show/NCT00811317 (accessed
12 November 2015)
Intervention
Seattle Children’s Hospital. The Effectiveness of Continuous Glucose Monitoring in Diabetes
Treatment for Infants and Young Children. NCT00875290; 2009. URL: https://clinicaltrials.gov/
ct2/show/NCT00875290 (accessed 12 November 2015)
Duplicate
DexCom Inc. Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose
Monitoring System in Children and Adolescents With Type 1 Diabetes Mellitus. NCT01185496;
2010. URL: https://clinicaltrials.gov/ct2/show/NCT01185496 (accessed 12 November 2015)
Study design
Steen Andersen. Effect of CSII and CGM on Progression of Late Diabetic Complications.
NCT01454700; 2011. URL: https://clinicaltrials.gov/ct2/show/NCT01454700 (accessed
12 November 2015)
Duplicate
In Home Closed Loop Study Group. Outpatient Pump Shutoff Pilot Feasibility and Efficacy Study.
NCT01591681; 2012. URL: https://clinicaltrials.gov/ct2/show/NCT01591681 (accessed
12 November 2015)
Study design
DexCom Inc. Effectiveness and Safety of the Dexcom™ G4 Continuous Glucose Monitoring
System in Pediatric Subjects With Diabetes Mellitus. NCT01667185; 2012.
URL: https://clinicaltrials.gov/ct2/show/NCT01667185 (accessed 12 November 2015)
Study design
In Home Closed Loop Study Group. An Outpatient Pump Shutoff Pilot Feasibility and Safety
Study. NCT01736930; 2012. URL: https://clinicaltrials.gov/ct2/show/NCT01736930
(accessed 12 November 2015)
Study design
In Home Closed Loop Study Group. Outpatient Reduction of Nocturnal Hypoglycemia by Using
Predictive Algorithms and Pump Suspension in Children. NCT01823341; 2013.
URL: https://clinicaltrials.gov/ct2/show/NCT01823341 (accessed 12 November 2015)
Study design
Medtronic Diabetes. Post Approval Study of the Threshold Suspend Feature With the Medtronic
MiniMed® 530G Insulin Pump. NCT02003898; 2013. URL: https://clinicaltrials.gov/ct2/show/
NCT02003898 (accessed 12 November 2015)
Study design
Vastra Gotaland Region. CGM Treatment in Patients With Type 1 Diabetes Treated With Insulin
Injections. NCT02092051; 2014. URL: https://clinicaltrials.gov/ct2/show/NCT02092051 (accessed
12 November 2015)
Duplicate
Medtronic Diabetes. Threshold Suspend in Pediatrics at Home. NCT02120794; 2014.
URL: https://clinicaltrials.gov/ct2/show/NCT02120794 (accessed 12 November 2015)
Duplicate
University Hospital, Montpellier. Hybrid Artificial Pancreas in Home Setting. NCT02153190; 2014.
URL: https://clinicaltrials.gov/ct2/show/NCT02153190 (accessed 12 November 2015)
Intervention
University of Ljubljana, Faculty of Medicine. Prevention of Hypoglycaemia With Predictive
Insulin Suspend Using Sensor Augmented Insulin Pump in Children. NCT02179281; 2014.
URL: https://clinicaltrials.gov/ct2/show/NCT02179281 (accessed 12 November 2015)
Study design
Neeser K, Kocher S, Weber C, Heister F. CSII compared to MDI: a health economic analysis in the
German health care setting. Value Health 2009;12:A407. Conference: ISPOR 12th Annual
European Congress. Paris, France, 24–27 October 2009
Outcomes
Neff K, McCarthy A, Forde R, Foley M, Coulter-Smith S, Daly S, et al. Intensive glycaemic control
in type 1 diabetic pregnancy: a comparison of continuous subcutaneous insulin infusion and
multiple daily injection therapy. Diabetologia 2010;53(Suppl. 1):S433. Paper presented at 46th
Annual Meeting of the European Association for the Study of Diabetes (EASD). Stockholm,
Sweden, 20–24 September 2010
Study design
Nemours Children’s Clinic. Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1
Diabetes (T1D). NCT00357890; 2012. URL: https://clinicaltrials.gov/ct2/show/NCT00357890
(accessed 12 November 2015)
Population
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
New J, Ajjan R, Pfeiffer AFH, Freckmann G. Impact of alarm functions with real time continuous
glucose monitoring (CGM). Diabetes Technol Ther 2013;15:A8–9. Conference: 6th International
Conference on Advanced Technologies and Treatments for Diabetes (ATTD). Paris, France,
27 February–2 March 2013
Outcomes
Newman SP, Cooke D, Casbard A, Walker S, Meredith S, Nunn A, et al. A randomised controlled
trial to compare minimally invasive glucose monitoring devices with conventional monitoring in
the management of insulin-treated diabetes mellitus (MITRE). Health Technol Assess 2009;13(28)
Intervention
Neylon OM, O’Connell MA, Donath S, Cameron FJ. Can integrated technology improve self-care
behavior in youth with type 1 diabetes? A randomized crossover trial of automated pump
function. Pediatr Diabetes 2013;14:46. Conference: 39th Annual Conference of the International
Society for Pediatric and Adolescent Diabetes (ISPAD). Gothenburg, Sweden, 16–19 October 2013
Outcomes
Ng Tang Fui S, Pickup JC, Bending JJ, Collins AC, Keen H, Dalton N. Hypoglycemia and
counterregulation in insulin-dependent diabetic patients: a comparison of continuous
subcutaneous insulin infusion and conventional insulin injection therapy. Diabetes Care
1986;9:221–7
Study design
Nimri R, Miller S, Muller I, Atlas E, Fogel A, Bratina N, et al. The home use of MD-logic
closed-loop system during the nights significantly improves daytime glycemic control in subjects
with type 1 diabetes. Diabetes 2014;63:A243. Conference: 74th Scientific Sessions of the
American Diabetes Association. San Francisco, CA, USA, 13–17 June 2014
Intervention
Nimri R, Muller I, Atlas E, Miller S, Fogel A, Bratina N, et al. MD-Logic overnight control for
6 weeks of home use in patients with type 1 diabetes: randomized crossover trial. Diabetes Care
2014;37:3025–32
Intervention
Nixon R, Pickup JC. Fear of hypoglycemia in type 1 diabetes managed by continuous
subcutaneous insulin infusion: is it associated with poor glycemic control? Diabetes Technol Ther
2011;13:93–8
Study design
Norgaard K, Sohlberg A, Goodall G. [Cost-effectiveness of continuous subcutaneous insulin
infusion therapy for type 1 diabetes.] Ugeskr Laeger 2010;172:2020–5
Not found
Hermanides J. Randomized, Controlled, Multinational, Multi-center, Clinical Trial to Examine
Whether HbA1c Can Improve in Type 1 Diabetes Patients who Continuously Use the Paradigm®
REAL-Time System with Alarm Function as Compared to Patients on Multiple Injection Therapy
Receiving One Six-Day Period of Continuous Glucose Monitoring – Without Alarm Function
(Guardian® REAL-Time Clinical). NTR863; 2007. URL: www.trialregister.nl/trialreg/admin/
rctview.asp?TC=863 (accessed 11 January 2016)
Intervention
Nuboer R, Borsboom GJJM, Zoethout JA, Koot HM, Bruining J. Effects of insulin pump vs.
injection treatment on quality of life and impact of disease in children with type 1 diabetes
mellitus in a randomized, prospective comparison. Pediatr Diabetes 2008;9:291–6
Intervention
O’Connell R, Oroszlan G, Hamer G, Yusi J, Kaufman F, Welsh J, et al. Efficacy of low glucose
suspend and low predictive alert: data analysis using the Medtronic carelink therapy
management software database. Diabetes Technol Ther 2011;13:244. Conference: 4th
International Conference on Advanced Technologies and Treatments for Diabetes (ATTD).
London, UK, 16–19 February 2011
Study design
O’Grady MJ, Retterath AJ, Keenan DB, Kurtz N, Cantwell M, Spital G, et al. The use of an
automated, portable glucose control system for overnight glucose control in adolescents and
young adults with type 1 diabetes. Diabetes Care 2012;35:2182–7
Study design
Olivier P, Lawson ML, Huot C, Richardson C, Nakhla M, Romain J. Lessons learned from a pilot
RCT of simultaneous versus delayed initiation of continuous glucose monitoring in children and
adolescents with type 1 diabetes starting insulin pump therapy. J Diabetes Sci Technol
2014;8:523–8
Outcomes
Opipari-Arrigan L, Fredericks EM, Burkhart N, Dale L, Hodge M, Foster C. Continuous
subcutaneous insulin infusion benefits quality of life in preschool-age children with type 1
diabetes mellitus. Pediatr Diabetes 2007;8:377–83
Intervention
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Pankowska E, Blazik M, Dziechciarz P, Szypowska A, Szajewska H. Continuous subcutaneous
insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review
and meta-analysis of randomized control trials. Pediatr Diabetes 2009;10:52–8
Systematic review/
meta-analysis
Patrakeeva EM, Zalevskaya AG, Shlyakhto EV. Fear of hypoglycemia in relatives of young type 1
diabetes mellitus (T1DM) patients on MDI and CSII therapy. Paper presented at 74th Scientific
Sessions of the American Diabetes Association. San Francisco, CA, USA, 13–17 June 2014
Study design
Perkins BA, Halpern EM, Orszag A, Weisman A, Houlden RL, Bergenstal RM, et al.
Sensor-augmented pump and multiple daily injection therapy in the USA and Canada: post-hoc
analysis of a randomized controlled trial. Can J Diabetes 2015;39:50–4
Outcomes
Petkova E, Petkova V, Konstantinova M, Petrova G. Economic evaluation of continuous
subcutaneous insulin infusion for children with diabetes – a pilot study: CSII application for
children – economic evaluation. BMC Pediatr 2013;13:155
Outcomes
Petkova E, Petkova V, Konstantinova M, Petrova G. Economic evaluation of continuous
subcutaneous insulin infusion for children with diabetes – part II. Modern Economy 2013;4:9–13
Outcomes
Petkova V, Petrova G, Petkova E. Comparative analysis of the cost and metabolic control in
diabetic children using insulin pumps. Value Health 2013;16:A437. Conference: ISPOR
16th Annual European Congress. Dublin, Ireland, 2–6 November 2013
Outcomes
Petrovski G, Jovanovska B, Bitovska I, Ahmeti I. Constant or intermittent glucose monitoring:
evaluation on pregnancy and glycemic outcome in type 1 diabetics on insulin pump. Diabetes
2013;62:A684. Conference: 73rd Scientific Sessions of the American Diabetes Association.
Chicago, IL, USA, 21–25 June 2013
Intervention
Phillip M, Battelino T, Atlas E, Kordonouri O, Bratina N, Miller S, et al. Nocturnal glucose control
with an artificial pancreas at a diabetes camp. N Engl J Med 2013;368:824–33
Study design
Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time
continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis
of randomised controlled trials using individual patient data. BMJ 2011;343:d3805
Systematic review/
meta-analysis
Pickup JC. The evidence base for diabetes technology: appropriate and inappropriate
meta-analysis. J Diabetes Sci Technol 2013;7:1567–74
Background
Poolsup N, Suksomboon N, Kyaw AM. Systematic review and meta-analysis of the effectiveness
of continuous glucose monitoring (CGM) on glucose control in diabetes. Diabetol Metab Syndr
2013;5:39
Systematic review/
meta-analysis
Pozzilli P, Crino A, Schiaffini R, Manfrini S, Fioriti E, Coppolino G, et al. A 2-year pilot trial of
continuous subcutaneous insulin infusion versus intensive insulin therapy in patients with newly
diagnosed type 1 diabetes (IMDIAB 8). Diabetes Technol Ther 2003;5:965–74
Intervention
Price D, Nakamura K, Christiansen M, Bailey T, Watkins E, Liljenquist D, et al. Accuracy and
reliability of a next generation continuous glucose monitoring system: the Dexcom G4 platinum
pivotal trial results. Diabetes Technol Ther 2013;15:A70–1. Conference: 6th International
Conference on Advanced Technologies and Treatments for Diabetes (ATTD). Paris, France,
27 February–2 March 2013
Study design
Price DA, Peyser T, Simpson P, Nakamura K, Mahalingam A. Impact of study design and analytic
techniques on the reported accuracy of Continuous Glucose Monitoring (CGM) systems. Diabetes
2012;61:A1. Conference: 72nd Scientific Sessions of the American Diabetes Association.
Philadelphia, PA, USA, 8–12 June 2012
Background
Price DA, Peyser TA, Graham C. Challenges with systematic reviews and meta-analyses of
real-time continuous glucose monitoring (CGM). Diabetes 2013;62:A644. Conference:
73rd Scientific Sessions of the American Diabetes Association. Chicago, IL, USA, 21–25 June 2013
Background
Quiroz M, Machado F, Shafiroff J, Gill M, Molina M, Gonzalez P. Insulin pump cost–utility analysis
compared to multiple daily injection in type 1 diabetic patients in the Mexican social security
institute, 21st century hospital. Value Health 2012;15:A69. Conference: 17th Annual
International Meeting of the International Society for Pharmacoeconomics and Outcomes
Research (ISPOR). Washington, DC, USA, 2–6 June 2012
Outcomes
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
188
TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Rabin Medical Center. Treatment Satisfaction of Using OmniPod System Compared With
Conventional Insulin Pump in Adults With Type 1 Diabetes. 2012. URL: http://ClinicalTrials.gov/
show/NCT00935129 (accessed 12 November 2015)
Intervention
Radermecker RP, Saint Remy A, Scheen AJ, Bringer J, Renard E. Continuous glucose monitoring
reduces both hypoglycaemia and HbA1c in hypoglycaemia-prone type 1 diabetic patients treated
with a portable pump. Diabetes Metab 2010;36:409–13
Outcomes
Ranasinghe P, Maruthur N, Yeh HC, Brown T, Suh Y, Wilson L, et al. Comparative effectiveness
of continuous subcutaneous insulin infusion with multiple daily injections among pregnant
women with diabetes mellitus: a systematic review. J Hos Med 2012;7:S52. Conference: 2012
Annual Meeting of the Society of Hospital Medicine (SHM). San Diego, CA, USA, 1–4 April 2012
Systematic review/
meta-analysis
Reid SM, Lawson ML. Comparison of continuous subcutaneous insulin infusion versus
conventional treatment of type 1 diabetes with respect to metabolic control, quality of life and
treatment satisfaction. Pediatr Res 2002;51(Suppl. 4):122A–3A. Paper presented at Pediatric
Academic Societies’ annual meeting. Baltimore, MD, USA, 4–7 May 2002
Intervention
Riveline J-P, Schaepelynck P, Chaillous L, Renard E, Sola-Gazagnes A, Penfornis A, et al.
Assessment of patient-led or physician-driven continuous glucose monitoring in patients with
poorly controlled type 1 diabetes using basal-bolus insulin regimens: a 1-year multicenter study.
Diabetes Care 2012;35:965–71
Intervention
Robinson-Vincent KA. Systematic review of the effects of continuous glucose monitoring on
metabolic control in children and adolescents with type 1 diabetes. Can J Diabetes 2013;37:S21.
Conference: 16th Annual Canadian Diabetes Association/Canadian Society of Endocrinology
and Metabolism Professional Conference and Annual Meetings. Montreal, QC, Canada,
17–19 October 2013
Systematic review/
meta-analysis
Roy A, Kaufman FR, Spital G, Clark B, Grosman B, Parikh N, et al. An in-silico study of predictive
low glucose management algorithm for minimizing hypoglycemia. Diabetes Technol Ther
2013;15:A81–2. Conference: 6th International Conference on Advanced Technologies and
Treatments for Diabetes (ATTD). Paris, France, 27 February–2 March 2013
Study design
Roze S, Demessinov A, Zeityn M, Toktarova N, Abduakhassova G, Sissemaliev R, et al. Health-
economic comparison of continuous subcutaneous insulin infusion versus multiple daily injections
for the treatment of type 1 diabetes in Kazakhstan children. Value Health 2013;16:A439–40.
Conference: ISPOR 16th Annual European Congress. Dublin, Ireland, 2–6 November 2013
Outcomes
Roze S, Lynch P, Cook M. Projection of long term health-economic benefits of Continuous
Glucose Monitoring (CGM) versus self monitoring of blood glucose in type 1 diabetes, a UK
perspective. Diabetologia 2012;55:S427. Conference: 48th Annual Meeting of the European
Association for the Study of Diabetes (EASD). Berlin, Germany, 1–5 October 2012
Outcomes
Roze S, Valentine WJ, Zakrzewska KE, Palmer AJ. Health-economic comparison of continuous
subcutaneous insulin infusion with multiple daily injection for the treatment of type 1 diabetes in
the UK. Diabet Med 2005;22:1239–45
Outcomes
Rubin RR, Peyrot M. Patient-reported outcomes in the sensor-augmented pump therapy (SAPT)
for A1c reduction (STAR) 3 trial. Diabetes 2011;60:A82. Conference: 71st Scientific Sessions of
the American Diabetes Association. San Diego, CA, USA, 24–28 June 2011
Outcomes
Rys PM, Mucha A, Koprowski M, Nowicki M, Malecki MT. Efficacy and safety of continuous
glucose monitoring systems vs. self-monitoring blood glucose in patients with type 1 diabetes
mellitus: a systematic review and meta-analysis. Diabetes 2011;60:A244. Conference: 71st
Scientific Sessions of the American Diabetes Association. San Diego, CA, USA, 24–28 June 2011
Not found
Sadri H, Bereza BG, Longo CJ. Cost-consequence analysis of CSII vs. MDI: a Canadian
perspective. Value Health 2010;13:A290. Conference: ISPOR 13th Annual European Congress.
Prague, Czech Republic, 6–9 November 2011
Outcomes
Sahin SB, Cetinkalp S, Ozgen AG, Saygili F, Yilmaz C. The importance of anti-insulin antibody in
patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion or
multiple daily insulin injections therapy. Acta Diabetol 2010;47:325–30
Study design
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Saigí I, Chico A, Santos L, Aulinas A, Adelantado J, Ginovart G, et al. Glycaemic control and
perinatal outcomes of pregnancies complicated by type 1 diabetes: multiple daily injections vs.
continuous subcutaneous insulin infusion. Paper presented at 45th EASD Annual Meeting of the
European Association for the Study of Diabetes. Vienna, Austria, 30 September–2 October 2009
Outcomes
Saigi I, Chico A, Santos L, Aulinas A, Adelantado J, Ginovart G, et al. Glycaemic control and
perinatal outcomes of pregnancies complicated by type 1 diabetes: multiple daily injections vs.
continuous subcutaneous insulin infusion. Diabetologia 2009;52(Suppl. 1):S46. Paper presented
at 45th Annual Meeting of the European Association for the Study of Diabetes (EASD). Vienna,
Austria, 29 September–2 October 2009
Study design
Saraiva J, Paiva S, Ruas L, Barros L, Baptista C, Melo M, et al. Type 1 diabetes and pregnancy:
continuous subcutaneous insulin infusion systems versus multiple daily injection therapy. Paper
presented at 49th Annual Meeting of the European Association for the Study of Diabetes (EASD).
Barcelona, Spain, 23–27 September 2013
Study design
Saurbrey N, Arnold-Larsen S, Moller-Jensen B, Kuhl C. Comparison of continuous subcutaneous
insulin infusion with multiple insulin injections using the NovoPen. Diabet Med 1988;5:150–3
Not found
Scaramuzza A, De Angelis L, Bosetti A, Gazzarri A, Platerote F, Redaelli F, et al. Evaluation of
three bolus calculators in children with type 1 diabetes using insulin pump therapy. Pediatr
Diabetes 2011;12:128. Conference: 37th Annual Meeting of the International Society for
Pediatric and Adolescent Diabetes (ISPAD). Miami Beach, FL, USA, 19–22 October 2011
Study design
Scaramuzza AE, De Angelis L, Gazzarri A, Bosetti A, Platerote F, Redaelli F, et al. Evaluation of
3 bolus calculators in children and adolescents with type 1 diabetes using insulin pump therapy.
Diabetologia 2011;54:S352. Conference: 47th Annual Meeting of the European Association for
the Study of Diabetes (EASD). Lisbon, Portugal, 12–16 September 2011
Study design
Schaepelynck P, Rocher L, Hanaire H, Chaillous L, Renard E, Sola A, et al. Patient- or
physician-driven continuous glucose monitoring (CGM) improves control and quality of life (QoL)
in poorly-controlled type 1 diabetic patients on intensified insulin therapy: a one-year multicenter
study. Diabetes 2011;60:A65. Conference: 71st Scientific Sessions of the American Diabetes
Association San Diego, CA, USA, 24–28 June 2011
Outcomes
Schaepelynck-Belicar P, Vague P, Simonin G, Lassmann-Vague V. Improved metabolic control in
diabetic adolescents using the continuous glucose monitoring system (CGMS). Diabetes Metab
2003;29:608–12
Study design
Schiaffini R, Patera PI, Bizzarri C, Ciampalini P, Cappa M. Basal insulin supplementation in
type 1 diabetic children: a long-term comparative observational study between continuous
subcutaneous insulin infusion and glargine insulin. J Endocrinol Invest 2007;30:572–7
Intervention
Schiel R, Burgard D, Bambauer R, Perenthaler T, Kramer G. [Differences between intensified
insulin therapy using multiple insulin injections (ICT) or continuous subcutaneous insulin infusion
using pumps (CSII) in children and adolescents with type 1 diabetes mellitus.] Diabetol
Stoffwechs 2013;8:380–6
Not found
Schiffrin A, Belmonte MM. Comparison between continuous subcutaneous insulin infusion and
multiple injections of insulin. A one-year prospective study. Diabetes 1982;31:255–64
Study design
Schiffrin A, Desrosiers M, Moffatt M, Belmonte MM. Feasibility of strict diabetes control in
insulin-dependent diabetic adolescents. J Pediatr 1983;103:522–7
Outcomes
Schiffrin AD, Desrosiers M, Aleyassine H, Belmonte MM. Intensified insulin therapy in the type 1
diabetic adolescent: a controlled trial. Diabetes Care 1984;7:107–13
Outcomes
Schmidt S, Norgaard K. Long-term effects of sensor-augmented pump therapy in type 1 diabetes:
a 3-year follow-up study. Diabetes 2012;61:A3. Conference: 72nd Scientific Sessions of the
American Diabetes Association. Philadelphia, PA, USA, 8–12 June 2012
Study design
Schmidt S, Norgaard K. Sensor-augmented pump therapy at 36 months. Diabetes Technol Ther
2012;14:1174–7
Study design
Schmitz A, Christiansen JS, Christensen CK, Hermansen K, Mogensen CE. Effect of pump
versus pen treatment on glycaemic control and kidney function in long-term uncomplicated
insulin-dependent diabetes mellitus (IDDM). Dan Med Bull 1989;36:176–8
Outcomes
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Schottenfeld-Naor Y, Galatzer A, Karp M. Comparison of metabolic and psychological
parameters during continuous subcutaneous insulin infusion and intensified conventional insulin
treatment in type I diabetic patients. Isr J Med Sci 1985;21:822–8
Not found
Secher AL, Ringholm L, Andersen HU, Damm P, Mathiesen ER. The effect of real-time continuous
glucose monitoring in pregnant women with diabetes: a randomized controlled trial. Diabetes
Care 2013;36:1877–83
Intervention
Selam JL, Haardt MJ, Slama G, Bethoux JP. A randomized cross-over cost–benefits comparison
of intensive insulin therapy with intraperitoneal infusion via implantable pumps vs multiple
subcutaneous injections in patients with type-I diabetes. Diabetes 1994;43(Suppl. 1):A167. Paper
presented at 54th Annual Meeting of the American Diabetes Association. New Orleans, LA, USA,
11–14 June 1994
Outcomes
Selam JL, Raccah D, Jean-Didier N, Lozano JL, Waxman K, Charles MA. Randomized comparison
of metabolic control achieved by intraperitoneal insulin infusion with implantable pumps versus
intensive subcutaneous insulin therapy in type I diabetic patients. Diabetes Care 1992;15:53–8
Intervention
Self-monitoring of blood glucose. Int J Clin Pract 2012;66(Suppl. 175):2–93 Study design
Sequeira PA, Montoya L, Ruelas V, Xing D, Chen V, Beck R, et al. Continuous glucose monitoring
pilot in low-income type 1 diabetes patients. Diabetes Technol Ther 2013;15:855–8
Outcomes
Shehadeh N, Battelino T, Galatzer A, Naveh T, Hadash A, de Vries L, et al. Insulin pump therapy
for 1–6 year old children with type 1 diabetes. Isr Med Assoc J 2004;6:284–6
Study design
Sherr J, Carria LR, Weyman K, Zgorski M, Steffen AT, Tichy EM, et al. Effect of 2-hr suspensions
of basal insulin on elevating nighttime sensor glucose concentrations. Diabetes 2013;62:A249.
Conference: 73rd Scientific Sessions of the American Diabetes Association. Chicago, IL, USA,
21–25 June 2013
Study design
Sherr J, Collazo PM, Caria L, Steffen A, Weyman K, Zgorski M, et al. Safety of nighttime 2-hour
suspension of basal insulin in pump-treated type 1 diabetes (T1D) even in absence of low
glucose. Diabetes Technol Ther 2013;15:A22. Conference: 6th International Conference on
Advanced Technologies and Treatments for Diabetes. Paris, France, 27 February–2 March 2013.
Study design
Sherr JL, Collazo MMP, Carria LR, Steffen AT, Zgorski M, Weyman K, et al. Safety of nighttime
2-hour suspensions of basal insulin in pump-treated type 1 diabetes (T1D) even in absence of low
glucose. Diabetes 2012;61:A226–7. Conference: 72nd Scientific Sessions of the American
Diabetes Association. Philadelphia, PA, USA, 8–12 June 2012
Study design
Sherr JL, Collazo PM, Cengiz E, Michaud C, Carria L, Steffen AT, et al. Safety of nighttime 2-hour
suspension of basal insulin in pump-treated type 1 diabetes even in the absence of low glucose.
Diabetes Care 2014;37:773–9
Study design
Skogsberg L, Fors H, Hanas R, Chaplin JE, Lindman E, Skogsberg J. Improved treatment
satisfaction but no difference in metabolic control when using continuous subcutaneous insulin
infusion vs. multiple daily injections in children at onset of type 1 diabetes mellitus. Pediatr
Diabetes 2008;9:472–9
Intervention
Skogsberg L, Skogsberg J, Fors H. Improved treatment satisfaction using continuous
subcutaneous insulin infusion compared to multiple daily injections in children at onset of type 1
diabetes mellitus – a five-year follow-up study. Pediatr Diabetes 2010;11:S14. Conference: 36th
Annual Meeting of the International Society for Pediatric and Adolescent Diabetes. Buenos Aires,
Argentina, 27–30 October 2010
Outcomes
Slover R, Daniels MW, Foster CM, Wood MA, Kaufman FR, Welsh JB, et al. Insulin pump
adjustments and glycemic outcomes in the pediatric cohort of the STAR 3 study. Diabetes
2011;60:A254. Conference: 71st Scientific Sessions of the American Diabetes Association.
San Diego, CA, USA, 24–28 June 2011
Outcomes
Slover RH, Buckingham BA, Garg S, Brazg RL, Bailey TS, Klonoff DC, et al. Efficacy of automatic
insulin pump suspension in youth with type 1 diabetes. Pediatr Diabetes 2012;13:40–1.
Conference: 38th Annual Meeting of the International Society for Pediatric and Adolescent
Diabetes. Istanbul, Turkey, 10–13 October 2012
Study design
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Slover RH, Tamborlane WV, Battelino T, Criego A, Daniels M, Foster C, et al. Glucose excursions
in children and adolescents in the STAR 3 study: a 1-year randomized controlled trial
comparing sensor-augmented pump therapy to multiple daily injections. Pediatr Diabetes
2010;11(Suppl.14):33. Conference: 36th Annual Meeting of the International Society for
Pediatric and Adolescent Diabetes. Buenos Aires, Argentina, 27–30 October 2010
Outcomes
St Charles M, Lynch P, Graham C, Minshall ME. A cost-effectiveness analysis of continuous
subcutaneous insulin injection versus multiple daily injections in type 1 diabetes patients:
a third-party US payer perspective. Value Health 2009;12:674–86
Outcomes
St Charles ME, Sadri H, Minshall ME, Tunis SL. Health economic comparison between continuous
subcutaneous insulin infusion and multiple daily injections of insulin for the treatment of adult
type 1 diabetes in Canada. Clin Ther 2009;31:657–67
Outcomes
Szypowska A, Dz˙ygało K, Ramotowska A, Lipka M, Procner-Czaplin´ska M, Trippenbach-Dulska H.
The benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes mellitus
started at diabetes recognition. A 7 year follow-up. Paper presented at 46th Annual Meeting of
the European Association for the Study of Diabetes, 20–24 September 2010, Stockholm, Sweden
Study design
Szypowska A, Ramotowska A, Dzygalo K, Golicki D. Beneficial effect of real-time continuous
glucose monitoring system on glycemic control in type 1 diabetic patients: systematic review and
meta-analysis of randomized trials. Eur J Endocrinol 2012;166:567–74
Systematic review/
meta-analysis
Tamborlane W, Buse J, Slover R, Green J, Kaufman F, Shin J. Comparison of insulin pump
settings and insulin usage patterns in adult and pediatric subjects in the star 3 study. Diabetes
Technol Ther 2011;13:173–293. Conference: 4th International Conference on Advanced
Technologies and Treatments for Diabetes. London, UK, 16–19 February 2011
Outcomes
Tamborlane WV, Batas SE, Rudolf MC. Comparison of continuous subcutaneous insulin infusion
versus multiple daily injections in adolescents with insulin-dependent diabetes. Adv Diabetol
1989;2(Suppl. 1):24–7
Not found
Tamborlane WV, Ruedy KJ, Wysocki T, O’Grady M, Kollman C, Block J, et al. JDRF randomized
clinical trial to assess the efficacy of real-time continuous glucose monitoring in the management
of type 1 diabetes: research design and methods. Diabetes Technol Ther 2008;10:310–21
Intervention
Tanenberg R, Bode B, Lane W, Levetan C, Mestman J, Harmel AP, et al. Use of the continuous
glucose monitoring system to guide therapy in patients with insulin-treated diabetes: a
randomized controlled trial. Mayo Clin Proc 2004;79:1521–6
Intervention
Tanenberg RJ, Houlden RL, Tildesley HD, Kaufman FR, Welsh JB, Shin J. Insulin pump adjustments
and glycemic outcomes in the adult cohort of the STAR 3 study. Diabetes 2011;60:A253–4.
Conference: 71st Scientific Sessions of the American Diabetes Association. San Diego, CA, USA,
24–28 June 2011
Outcomes
Tanenberg RJ, Welsh JB. Patient behaviors associated with optimum glycemic outcomes with
sensor-augmented pump therapy: insights from the STAR 3 study. Endocr Pract 2015;21:41–5
Outcomes
Thabit H, Lubina-Solomon A, Stadler M, Leelarathna L, Walkinshaw E, Pernet A, et al. Home use
of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a
4-week, multicentre, randomised crossover study. Lancet Diabetes Endocrinol 2014;2:701–9
Study design
Thabit H, Lubina-Solomon A, Stadler M, Leelarathna LT, Walkinshaw E, Pernet A, et al. Four
weeks’ home use of overnight closed-loop insulin delivery in adults with type 1 diabetes: a
multicentre, randomised, crossover study. Diabetes 2014;63:A61. Conference: 74th Scientific
Sessions of the American Diabetes Association. San Francisco, CA, USA, 13–17 June 2014
Intervention
Thomas LE, Kane MP, Bakst G, Busch RS, Hamilton RA, Abelseth JM. A glucose meter accuracy
and precision comparison: the freestyle flash versus the Accu-Chek Advantage, Accu-Chek
Compact Plus, Ascensia Contour, and the BD Logic. Diabetes Technol Ther 2008;10:102–10
Intervention
Trossarelli GF, Cavallo-Perin P, Meriggi E, Menato G, Dolfin G, Carta Q, et al. Metabolic and
obstetrical results in type 1 (insulin-dependent) diabetic pregnancy: pump versus optimized
conventional insulin therapy. Diabetologia 1984;27:340A
Not found
Tsioli C, Remus K, Blaesig S, Datz N, Schnell K, Marquardt E, et al. The predictive low glucose
management system in youth with type 1 diabetes during exercise-data from the Pilgrim study.
Pediatr Diabetes 2013;14:48. Conference: 39th Annual Conference of the International Society
for Pediatric and Adolescent Diabetes. Gothenburg, Sweden, 16–19 October 2013
Study design
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Tumminia A, Crimi S, Sciacca L, Buscema M, Frittitta L, Squatrito S, et al. Efficacy of REAL-Time
continuous glucose monitoring on glycaemic control and glucose variability in type 1 diabetic
patients treated with either insulin pumps or multiple insulin injection therapy: a randomised
controlled cross-over trial. Diabetes Metab Res Rev 2015;31:61–8
Outcomes
Uhrinak AN, Myers SJ, Kaufman FR, Lee SW, Yusi J, Huang S, et al. Retrospective analysis of
events preceding low glucose suspend activation in adult subjects on the paradigm veo system.
J Diabetes Sci Technol 2012;6;A182. Conference: 11th Annual Diabetes Technology Meeting.
San Francisco, CA, USA 27–29 October 2011
Study design
Ulf S, Ragnar H, Arne WP, Johnny L. Do high blood glucose peaks contribute to higher HbA1c?
Results from repeated continuous glucose measurements in children. World J Pediatr
2008;4:215–21
Intervention
University of Ljubljana, Faculty of Medicine. Prevention of Hypoglycaemia With Predictive
Insulin Suspend Using Sensor Augmented Insulin Pump in Children. NCT02179281; 2014.
URL: https://clinicaltrials.gov/ct2/show/NCT02179281 (accessed 12 November 2015)
Study design
US Food and Drug Administration. Dexcom G4 PLATINUM (Pediatric) Continuous Glucose
Monitoring System – P120005/S002. US Food and Drug Administration; 2014. URL: www.fda.
gov/medicaldevices/productsandmedicalprocedures/deviceapprovalsandclearances/
recently-approveddevices/ucm386985.htm (accessed 5 September 2014)
Study design
US Food and Drug Administration. Dexcom G4 PLATINUM (Pediatric) Continuous Glucose
Monitoring System. FDA Summary of Safety and Effectiveness Data. US Food and Drug
Administration; 2014. URL: www.accessdata.fda.gov/cdrh_docs/pdf12/P120005S002b.pdf
(accessed 5 September 2014)
Study design
US Food and Drug Administration. MiniMed 530G System – P120010. US Food and Drug
Administration; 2014. URL: www.fda.gov/medicaldevices/productsandmedicalprocedures/
deviceapprovalsandclearances/recently-approveddevices/ucm372176.htm (accessed
5 September 2014)
Study design
Volpe L, Pancani F, Aragona M, Lencioni C, Battini L, Ghio A, et al. Continuous subcutaneous
insulin infusion and multiple dose insulin injections in type 1 diabetic pregnant women:
a case–control study. Gynecol Endocrinol 2010;26:193–6
Study design
von Hagen C, Bechtold S, Temme K, Tremml S, Wex S, Schwarz HP. [Metabolic control and
quality of life in adolescents with type 1 diabetes: insulin pump therapy versus multiple daily
injections.] Diabetol Stoffwechs 2007;2:238–47
Not found
Voormolen DN, DeVries JH, Evers IM, Mol BWJ, Franx A. The efficacy and effectiveness of
continuous glucose monitoring during pregnancy: a systematic review. Obstet Gynecol Surv
2013;68:753–63
Systematic review/
meta-analysis
Weinstock RS, Bergenstal RM, Garg S, Bailey TS, Thrasher J, Mao M, et al. Reduction
in hypoglycemia across a range of definitions in the aspire in-home study. Diabetes
2014;51(Suppl. 2):A240. Conference: 74th Scientific Sessions of the American Diabetes
Association. San Francisco, CA, USA, 13–17 June 2014
Outcomes
Weintrob N, Benzaquen H, Galatzer A, Shalitin S, Lazar L, Fayman G, et al. Comparison of
continuous subcutaneous insulin infusion and multiple daily injection regimens in children with
type 1 diabetes: a randomized open crossover trial. Paper presented at 62nd Annual Meeting
of the American Diabetes Association, 14–18 June 2002, San Francisco, USA. Diabetes
2002;51(Suppl. 2):A479
Outcomes
Weintrob N, Schechter A, Benzaquen H, Shalitin S, Lilos P, Galatzer A, et al. Glycemic patterns
detected by continuous subcutaneous glucose sensing in children and adolescents with type 1
diabetes mellitus treated by multiple daily injections vs continuous subcutaneous insulin infusion.
Arch Pediatr Adolesc Med 2004;158:677–84
Study design
Weintrob N, Schechter A, Bezaquen H, Shalitin S, Lilos P, Galatzer A, et al. Glycemic patterns
detected by continuous subcutaneous glucose sensing in children with type 1 diabetes treated by
MDI or CSII. Diabetes 2003;52(Suppl. 1):A100
Outcomes
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TABLE 63 Studies excluded studies at full-paper screening stage with reason for exclusion (continued )
Excluded study Reason for exclusion
Weinzimer SA, Ahern JH, Doyle EA, Vincent MR, Dziura J, Steffen AT, et al. Persistence of
benefits of continuous subcutaneous insulin infusion in very young children with Type 1 diabetes:
a follow-up report. Pediatrics 2004;114:1601–5
Study design
Weiss R, Bailey TS, Schwartz FL, Garg S, Ahmann AJ, Thrasher J, et al. Time spent (%) in
hypoglycemia following automatic threshold suspend activation in the aspire in-home study.
Diabetes 2014;63:A241. Conference: 74th Scientific Sessions of the American Diabetes
Association. San Francisco, CA, USA, 13–17 June 2014
Outcomes
Weiss R, Schwartz FL, Weinstock RS, Bode BW, Bailey TS, Ahmann AJ, et al. Bolus insulin dosing
and nocturnal hypoglycemia in the aspire in-home study. Diabetes 2014;63:A601. Conference:
74th Scientific Sessions of the American Diabetes Association. San Francisco, CA, USA, 13–17
June 2014
Outcomes
Wender-Ozegowska E, Zawiejska A, Ozegowska K, Wroblewska-Seniuk K, Iciek R, Mantaj U,
et al. Multiple daily injections of insulin versus continuous subcutaneous insulin infusion for
pregnant women with type 1 diabetes. Aust N Z J Obstet Gynaecol 2013;53:130–5
Study design
Wilson DC, Halliday HL, Reid M, McClure G, Dodge JA. Continuous insulin infusion in
hyperglycaemic extremely low birthweight infants? A randomized trial. Proceedings of
14th European Congress of Perinatal Medicine, 14th European Congress. Helsinki, Finland,
5–8 June 1994
Not found
Wilson DM, Buckingham BA, Kunselman EL, Sullivan MM, Paguntalan HU, Gitelman SE.
A two-center randomized controlled feasibility trial of insulin pump therapy in young children
with diabetes. Diabetes Care 2005;28:15–19
Intervention
Wiseman MJ, Saunders AJ, Keen H, Viberti G. Effect of blood glucose control on increased
glomerular filtration rate and kidney size in insulin-dependent diabetes. N Engl J Med
1985;312:617–21
Intervention
Wojciechowski P, Rys P, Lipowska A, Gaweska M, Malecki MT. Efficacy and safety comparison
of continuous glucose monitoring and self-monitoring of blood glucose in type 1 diabetes:
systematic review and meta-analysis. Pol Arch Med Wewn 2011;121:333–43
Systematic review/
meta-analysis
Yates K, Hasnat Milton A, Dear K, Ambler G. Continuous glucose monitoring-guided insulin
adjustment in children and adolescents on near-physiological insulin regimens: a randomized
controlled trial. Diabetes Care 2006;29:1512–17
Outcomes
Yeh HC, Brown TT, Maruthur N, Ranasinghe P, Berger Z, Suh YD, et al. Comparative
effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes
mellitus: a systematic review and meta-analysis. Ann Intern Med 2012;157:336–47
Systematic review/
meta-analysis
Yogev Y, Chen R, Ben-Haroush A, Phillip M, Jovanovic L, Hod M. Continuous glucose monitoring
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Appendix 3 Data extraction tables
TABLE 64 Study characteristics for included studies in adults
Follow-up,
months Study Countries Inclusion Intervention
Number
analysed
for efficacy
per arm
3 Bergenstal
et al., 201332
USA Age: 16–70 years; HbA1c:
5.8–10%; CSII experience:
6 months prior CSII
treatment; number of
hypoglycaemic events:
> 1; episode of severe
hypoglycaemia in the
previous 6 months:
excluded; and ≥ 2
nocturnal hypoglycaemic
events in the run-in period
required
CSII+CGM+ suspend:
Paradigm Veo pump+ Enlite
sensor (Medtronic)
121
CSII+CGM integrated:
Paradigm Revel 2.0
pump+ Enlite sensor
126
3.45 Lee et al.,
200738
USA Age: adults; HbA1c:
≥ 7.5%; CSII experience:
CSII naive; number of
hypoglycaemic events: NR
Integrated CSII+CGM:
MiniMed Paradigm REAL-
Time 722 system as adjunct
to SMBG (Paradigm Link™
glucose meter)a
8
MDI+ SMBG: SMBG
(Paradigm Link glucose
meter)
8
3.69 Peyrot and
Rubin, 200939
USA Age: adults; HbA1c: NR;
CSII experience: CSII naive;
number of hypoglycaemic
events: NR
Integrated CSII+CGM:
Paradigm 722 System (smart
CSII pump with real-time
CGM and CareLink™ data
management software) as
adjunct to SMBG [Becton
Dickinson (Franklin Lakes, NJ)
meters and strips]
14
MDI+ SMBG: SMBG (Becton
Dickinson meters and strips)
with CareLink™ data
management software
13
3.69 DeVries et al.,
200242
The Netherlands Age: 18–70 years; HbA1c:
≥ 8.5%; CSII experience:
NR; number of
hypoglycaemic events: NR
CSII+ SMBG: Disetronic
H-TRONplus insulin pump;
Glucotouch or One Touch
Profile memory glucose
meter (LifeScan, Inc.,
Milpitas, CA)
32
MDI+ SMBG: Glucotouch or
One Touch Profile memory
glucose meter (LifeScan)
40
6 Bolli et al.,
200941
Europe Age: 18–70 years; HbA1c:
6.5–9%; CSII experience:
CSII naive; number of
hypoglycaemic events: ≥ 2;
episodes of severe
hypoglycaemia in the
previous 6 months:
excluded
CSII+ SMBG: MiniMed 508
with SMBG
24
MDI+ SMBG: NR 26
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TABLE 64 Study characteristics for included studies in adults (continued )
Follow-up,
months Study Countries Inclusion Intervention
Number
analysed
for efficacy
per arm
6 Hermanides
et al., 201137
Denmark;
Switzerland;
Sweden;
the Netherlands;
France; UK;
Belgium; Italy
Age: 18–65 years; HbA1c:
≥ 8.2%; CSII experience:
CSII in the previous
6 months excluded;
number of hypoglycaemic
events: NR
Integrated CSII+CGM:
Paradigm REAL-Time system
with SMBG (meter not
described)
41
MDI+ SMBG: SMBG meter
not described
36
6 Hirsch et al.,
200834
USA Age: 18–80 years; HbA1c:
≥ 7.5%; CSII experience:
≥ 6 months prior CSII
treatment; number of
hypoglycaemic events: NR
Integrated CSII+CGM:
Paradigm 722 System
17
CSII+ SMBG: SMBG and a
Paradigm 715 Insulin Pump
(Medtronic)
23
6 Thomas et al.,
200745
UK Age: adults; HbA1c: NR;
CSII experience: NR;
number of hypoglycaemic
events: ≥ 1 episode of
severe hypoglyaemia in
the previous 6 months
CSII+ SMBG: Medtronic 508
with SMBG
7
MDI+ SMBG: NR 7
9 Tsui et al.,
200146
Canada Age: 18–60 years; HbA1c:
NR; CSII experience: CSII
naive; number of
hypoglycaemic events:
≥ 2; episodes of severe
hypoglycaemia in the
previous year excluded
CSII+ SMBG: MiniMed 507
insulin infusion pump;
Advantage meter (Roche
Diagnostics, Bale,
Switzerland)
12
MDI+ SMBG: Advantage
meter (Roche Diagnostics)
14
12 Nosadini et al.,
198843
Italy Age: NR; HbA1c: NR; CSII
experience: NR; number of
hypoglycaemic events: NR
CSII+ SMBG: Betatron II
(Firenze, Italy)+ SMBG
(CSII-HOR)
10
CSII+ SMBG: Microjet Mc 20
(Miles-Ames, Cavenago,
Italy)+ SMBG (CSII-FBR)
19
MDI+ SMBG: NR (ICIT) 15
12 Bergenstal
et al., 201040
USA; Canada Age: 7–70 years; HbA1c:
7.4–9.5%; CSII experience:
CSII naive or no CSII in the
last 3 years; number of
hypoglycaemic events:
≥ 2 episodes of severe
hypoglycaemia in the
previous year excluded
Integrated CSII+CGM:
MiniMed Paradigm
REAL-Time system
166
MDI+ SMBG: Guardian
REAL-Time Clinical
163
84 Brinchmann-
Hansen et al.,
198544
Norway Age: 18–45 years; HbA1c:
NR; CSII experience: NR;
number of hypoglycaemic
events: NR
CSII+ SMBG: Nordisk Infuser
(n= 3) or AutoSyringe AS6C
(n= 12)
15
MDI+ SMBG: NR 15
FBR, fixed basal overnight insulin infusion rate; HOR, higher programmable overnight insulin infusion rate; ICIT, intensified
conventional insulin therapy; NR, not reported.
a Paradigm Link™ glucose meter (Medtronic Inc., Northridge, CA, USA).
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TABLE 65 Study characteristics for included studies in children
Follow-up,
months Study Countries Inclusion Intervention
Number
analysed
for efficacy
per arm
3.5 Weintrob et al.,
200347
Israel Age: 8–14 years; HbA1c:
NR; CSII experience: NR;
number of hypoglycaemic
events: NR
CSII+ SMBG:
programmable external
pump (MiniMed 508) using
insulin lispro
11
MDI+ SMBG: NR 12
3.69 Doyle et al.,
200449
USA Age: 8–21 years; HbA1c:
6.5–11%; CSII experience:
CSII naive; number of
hypoglycaemic events: NR
CSII+ SMBG: Medtronic
MiniMed 508 or Paradigm
511; LifeScan InDuo™
glucose meter
16
MDI+ SMBG: MDI;
LifeScan InDuo glucose
meter
16
6 Hirsch et al.,
200834
USA Age: 12 to < 18 years;
HbA1c: ≥ 7.5%; CSII
experience: ≥ 6 months
prior CSII treatment;
number of hypoglycaemic
events: NR
Integrated CSII+CGM:
Paradigm 722 System
(Medtronic)
49
CSII+ SMBG: SMBG and a
Paradigm 715 Insulin Pump
(Medtronic)
49
12 Bergenstal
et al., 201040
USA;
Canada
Age: 7–70 years; HbA1c:
7.4–9.5%; CSII experience:
CSII naive or no CSII in the
last 3 years; number of
hypoglycaemic events:
≥ 2 episodes of severe
hypoglycaemia in the
previous year excluded
Integrated CSII+CGM:
MiniMed Paradigm
REAL-Time System
(Medtronic)
78
MDI+ SMBG: Medtronic
Guardian REAL-Time
Clinical
78
12 Thrailkill et al.,
201148
USA Age: 8–18 years; HbA1c:
NR; CSII experience: NR;
number of hypoglycaemic
events: NR
CSII+ SMBG: Animas
pump model IR 1250;
OneTouch Ultra blood
glucose meter (LifeScan)
NR
MDI+ SMBG: MDI;
OneTouch Ultra blood
glucose meter (LifeScan)
NR
NR, not reported.
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TABLE 66 Study characteristics for included studies in mixed populations
Follow-up,
months Study Countries Inclusion Intervention
Number
analysed
for efficacy
per arm
3 O’Connell
et al., 200935
Australia Age: 13–40 years; HbA1c:
≤ 8.5%; CSII experience:
> 3 months experience with
CSII; number of
hypoglycaemic events:
history of severe
hypoglycaemia while using
CSII excluded
Integrated CSII+CGM:
MiniMed Paradigm
REAL-Time system
26
CSII+ SMBG: NR; continue
their usual insulin pump
therapy and SMBG regimen
29
6 Hirsch et al.,
200834
USA Age: 12–72 years; HbA1c:
≥ 7.5%; CSII experience:
≥ 6 months prior CSII
treatment; number of
hypoglycaemic events: NR
Integrated CSII+CGM:
Paradigm 722 System
66
CSII+ SMBG: SMBG and a
Paradigm 715 insulin pump
72
6 Ly et al.,
201333
Australia Age: 4–50 years; HbA1c:
≤ 8.5%; CSII experience:
≥ 6 months prior CSII
treatment; number of
hypoglycaemic events: NR
CSII+CGM+ Suspend:
sensor-augmented pump
(Medtronic Paradigm Veo
System, Medtronic MiniMed)
with automated insulin
suspension
46
CSII+ SMBG: continue using
their insulin pump
49
6 Raccah et al.,
200936
France Age: 2–65 years; HbA1c:
> 8%; CSII experience: NR;
number of hypoglycaemic
events: NR
Non-integrated CSII+CGM:
insulin pump with Holter-
type CGM device
55
CSII+ SMBG: Paradigm
512/712 with SMBG
60
12 Bergenstal
et al., 201040
USA;
Canada
Age: 7–70 years; HbA1c:
7.4–9.5%; CSII experience:
CSII naive or no CSII in the
last 3 years; number of
hypoglycaemic events:
≥ 2 episodes of severe
hypoglycaemia in the
previous year excluded
Integrated CSII+CGM:
MiniMed Paradigm
REAL-Time System
244
MDI+ SMBG: Guardian
REAL-Time Clinical
241
NR, not reported.
TABLE 67 Study characteristics for included studies in pregnant women
Follow-up,
months Study Country Inclusion Intervention
Number
analysed
for efficacy
per arm
NR
(9 months)
Nosari et al.,
199350
Italy Age: adults; HbA1c: NR; CSII
experience: NR; number of
hypoglycaemic events: NR
CSII+ SMBG: Microjet MC
20 and Dahedi B.V. portable
battery-powered syringe
infusion pumps (Disetronic
Medical Systems, Inc., FL,
USA)
16
MDI+ SMBG: NR 16
NR, not reported.
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TABLE 71 Baseline characteristics for included studies in pregnant women
Study Intervention
Total
(N)
Age, years
(SD)
Gender,
n (%)
Duration of
diabetes,
years (SD)
BMI,
kg/m2
(SD)
Weight,
kg (SD)
HbA1c
% (SD)
Nosari et al.,
199350
CSII+ SMBG: Microjet MC
20 and Dahedi B.V.
portable battery-powered
syringe infusion pumps
16 25.5 (1.8) Male: 0 (0)
Female: 16
(100.0)
NR (NR) 21.8
(0.4)
NR (NR) NR (NR)
MDI+ SMBG: NR 16 27 (3.0) Male: 0 (0)
Female: 16
(100.0)
NR (NR) 21.6
(0.6)
NR (NR) NR (NR)
NR, not reported.
TABLE 72 Results for change in HbA1c levels from baseline in adults
Follow-up,
months Study Intervention
Number
analysed
Change in HbA1c levels from
baseline, % (SD)
2 Thomas et al.,
200745
CSII+ SMBG: Medtronic 508
with SMBG
7 Baseline: 8.5 (1.9); follow-up:
7.3 (0.67); change from
baseline: NR (NR)
MDI+ SMBG: NR 7 Baseline: 8.6 (1.1); follow-up:
8.3 (1); change from baseline:
NR (NR)
3 Bergenstal et al.,
201332
CSII+CGM+ suspend:
Paradigm Veo pump with
Enlite sensor
121 Baseline: 7.26 (0.71); follow-up:
7.24 (0.67); change from
baseline: 0 (0.44)
Integrated CSII+CGM:
Paradigm Revel 2.0 pump
with Enlite sensor
126 Baseline: 7.21 (0.77); follow-up:
7.14 (0.77); change from
baseline: –0.04 (0.42)
3 Brinchmann-Hansen
et al., 198544
CSII+ SMBG: NR 15 Baseline: 10.1 (NR); follow-up:
8.9 (NR); change from baseline:
NR (NR)
MDI+ SMBG: NR 15 Baseline: 9.4 (NR); follow-up:
8.7 (NR); change from baseline:
NR (NR)
3.45 Lee et al., 200738 Integrated CSII+CGM:
MiniMed Paradigm REAL-Time
722 system as adjunct to
SMBG (Paradigm Link glucose
meter)
8 Baseline: 9.45 (0.55); follow-up:
7.4 (0.66); change from
baseline: –2.05 (NR)
MDI+ SMBG: SMBG
(Paradigm Link glucose meter)
8 Baseline: 8.58 (1.3); follow-up:
7.5 (1.01); change from
baseline: –1.08 (NR)
3.68 Peyrot and Rubin,
200939
Integrated CSII+CGM:
Paradigm 722 system (smart
CSII pump with real-time
CGM and CareLink data
management software) as
adjunct to SMBG (Becton
Dickinson meters and strips)
14 Baseline: 8.87 (0.89); follow-up:
7.16 (0.75); change from
baseline: –1.71 (NR)
MDI+ SMBG: SMBG (Becton
Dickinson meters and strips)
with CareLink™ data
management software
13 Baseline: 8.32 (1.05); follow-up:
7.3 (0.92); change from
baseline: –1.02 (NR)
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TABLE 72 Results for change in HbA1c levels from baseline in adults (continued )
Follow-up,
months Study Intervention
Number
analysed
Change in HbA1c levels from
baseline, % (SD)
3.69 DeVries et al.,
200242
CSII+ SMBG: Disetronic
H-TRONplus insulin pump;
Glucotouch or One Touch
Profile memory glucose meter
(LifeScan)
32 Baseline: 9.27 (1.4); follow-up:
NR (NR); change from baseline:
–0.91 (1.28)
MDI+ SMBG: Glucotouch or
One Touch Profile memory
glucose meter (LifeScan)
40 Baseline: 9.25 (1.4); follow-up:
NR (NR); change from baseline:
–0.07 (0.7)
4 Thomas et al.,
200745
CSII+ SMBG: Medtronic 508
with SMBG
7 Baseline: 8.5 (1.9); follow-up:
7.4 (1.16); change from
baseline: NR (NR)
MDI+ SMBG: NR 7 Baseline: 8.6 (1.1); follow-up:
8 (0.9); change from baseline:
NR (NR)
6 Bolli et al., 200941 CSII+ SMBG: MiniMed
508+ glucose monitor.
Glucose monitor: NR
24 Baseline: 7.7 (0.7); follow-up:
7 (0.8); change from baseline:
–0.7 (0.7)
MDI+ SMBG: insulin glargine
(Lantus®, Sanofi-Aventis) plus
mealtime insulin lispro.
Glucose monitor: NR
26 Baseline: 7.8 (0.6); follow-up:
7.2 (0.7); change from baseline:
–0.6 (0.8)
6 Hermanides et al.,
201137
Integrated CSII+CGM:
Paradigm REAL-Time System
(Medtronic MiniMed Inc.)
with SMBG (meter not
described)
41 Baseline: 8.46 (0.95); follow-up:
7.23 (0.65); change from
baseline: –1.23 (1.01)
MDI+ SMBG: SMBG (meter
not described)
36 Baseline: 8.59 (0.82); follow-up:
8.46 (1.04); change from
baseline: –0.13 (0.56)
6 Hirsch et al., 200834 Integrated CSII+CGM:
Paradigm 722 System
49 Baseline: 8.37 (0.6); follow-up:
7.68 (0.84); change from
baseline: –0.69 (0.73)
CSII+ SMBG: SMBG and a
Paradigm 715 insulin pump
49 Baseline: 8.3 (0.54); follow-up:
7.66 (0.67); change from
baseline: –0.64 (0.57)
6 Brinchmann-Hansen
et al., 198544
CSII+ SMBG: NR 15 Baseline: 10.1 (NR); follow-up:
9.1 (NR); change from baseline:
NR (NR)
MDI+ SMBG: NR 15 Baseline: 9.4 (NR); follow-up:
8.8 (NR); change from baseline:
NR (NR)
6 Thomas et al.,
200745
CSII+ SMBG: Medtronic
508+ SMBG
7 Baseline: 8.5 (1.9); follow-up:
7.4 (1); change from baseline:
NR (NR)
MDI+ SMBG: NR 7 Baseline: 8.6 (1.1); follow-up:
7.6 (0.7); change from baseline:
NR (NR)
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TABLE 72 Results for change in HbA1c levels from baseline in adults (continued )
Follow-up,
months Study Intervention
Number
analysed
Change in HbA1c levels from
baseline, % (SD)
9 Tsui et al., 200146 CSII+ SMBG: MiniMed 507
insulin infusion pump;
Advantage meter (Roche
Diagnostics)
12 Baseline: 7.73 (0.6); follow-up:
7.38 (NR); change from
baseline: NR (NR)
MDI+ SMBG: Advantage
meter (Roche Diagnostics)
14 Baseline: 8.16 (0.7); follow-up:
7.56 (NR); change from
baseline: NR (NR)
12 Nosadini et al.,
198843
CSII+ SMBG: Betatron
II+ SMBG (CSII-HOR)
10 Baseline: NR (NR); follow-up:
6.1 (0.9); change from baseline:
NR (NR)
CSII+ SMBG: Microjet Mc
20+ SMBG (CSII-FBR)
19 Baseline: NR (NR); follow-up:
6.3 (0.7); change from baseline:
NR (NR)
MDI+ SMBG: NR (ICIT) 15 Baseline: NR (NR); follow-up:
7.1 (0.9); change from baseline:
NR (NR)
12 Brinchmann-Hansen
et al., 198544
CSII+ SMBG: NR 15 Baseline: 10.1 (NR); follow-up:
8.5 (NR); change from baseline:
NR (NR)
MDI+ SMBG: NR 15 Baseline: 9.4 (NR); follow-up:
8.5 (NR); change from baseline:
NR (NR)
12 Bergenstal et al.,
201040
Integrated CSII+CGM:
MiniMed Paradigm REAL-Time
System
166 Baseline: 8.3 (0.5); follow-up:
NR (NR); change from baseline:
–1 (0.7)
MDI+ SMBG: Guardian
REAL-Time Clinical
163 Baseline: 8.3 (0.5); follow-up:
NR (NR); change from baseline:
–0.4 (0.8)
24 Brinchmann-Hansen
et al., 198544
CSII+ SMBG: NR 15 Baseline: 10.1 (NR); follow-up:
8.7 (NR); change from baseline:
NR (NR)
MDI+ SMBG: NR 15 Baseline: 9.4 (NR); follow-up:
9.1 (NR); change from baseline:
NR (NR)
FBR, fixed basal overnight insulin infusion rate; HOR, higher programmable overnight insulin infusion rate; ICIT, intensified
conventional insulin therapy; NR, not reported.
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TABLE 73 Results for change in HbA1c levels from baseline in children
Follow-up,
months Study Intervention
Number
analysed
Change in HbA1c levels from
baseline, % (SD)
3.5 Weintrob et al.,
200347
CSII+ SMBG: programmable
external pump (MiniMed 508)
using insulin lispro
11 Baseline: 7.9 (1.3); follow-up:
7.9 (0.7); change from baseline:
NR (NR)
MDI+ SMBG: NR 12 Baseline: 8.6 (0.8); follow-up:
8.2 (0.8); change from baseline:
NR (NR)
3.69 Doyle et al.,
200449
CSII+ SMBG: Medtronic
MiniMed 508 or Paradigm
511; LifeScan InDuo glucose
meter
16 Baseline: 8.1 (1.2); follow-up:
7.2 (1); change from baseline:
NR (NR)
MDI+ SMBG: MDIs and
LifeScan InDuo glucose meter
16 Baseline: 8.2 (1.1); follow-up:
8.1 (1.2); change from baseline:
NR (NR)
6 Hirsch et al.,
200834
Integrated CSII+CGM:
Paradigm 722 System
(Medtronic)
17 Baseline: 8.82 (1.05); follow-up:
8.02 (1.11); change from
baseline: –0.79 (0.65)
CSII+ SMBG: SMBG and a
Paradigm 715 insulin pump
(Medtronic)
23 Baseline: 8.59 (0.8); follow-up:
8.21 (0.97); change from
baseline: –0.37 (0.95)
6 Thrailkill et al.,
201148
CSII+ SMBG: Animas pump
model IR 1250; OneTouch
Ultra blood glucose meter
(LifeScan)
NR Baseline: 11.2 (2.1); follow-up:
6.34 (0.7); change from
baseline: NR (NR)
MDI+ SMBG: MDIs and
OneTouch Ultra blood glucose
meter (LifeScan)
NR Baseline: 11.7 (2.6); follow-up:
7 (1.1); change from baseline:
NR (NR)
12 Bergenstal et al.,
201040
Integrated CSII+CGM:
MiniMed Paradigm REAL-Time
System (Medtronic)
78 Baseline: 8.3 (0.6); follow-up:
NR (NR); change from baseline:
–0.4 (0.9)
MDI+ SMBG: Guardian
REAL-Time Clinical
(Medtronic)
78 Baseline: 8.3 (0.5); follow-up:
NR (NR); change from baseline:
0.2 (1)
12 Thrailkill et al.,
201148
CSII+ SMBG: Animas pump
model IR 1250; OneTouch
Ultra blood glucose meter
(LifeScan)
NR Baseline: 11.2 (2.1); follow-up:
6.9 (0.7); change from baseline:
NR (NR)
MDI+ SMBG: MDIs and
OneTouch Ultra blood glucose
meter (LifeScan)
NR Baseline: 11.7 (2.6); follow-up:
6.9 (0.9); change from baseline:
NR (NR)
NR, not reported.
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TABLE 74 Results for change in HbA1c levels from baseline in mixed populations
Follow-up,
months Study Intervention
Number
analysed
Change from baseline in
HbA1c (%)
3 O’Connell et al.,
200935
CSII+CGM Integrated:
MiniMed Paradigm REAL-Time
system (Medtronic)
26 Baseline: 7.3 (0.6); follow-up:
7.1 (0.8); change from baseline:
NR (NR)
CSII+ SMBG: continue their
usual insulin pump therapy and
SMBG regimen
29 Baseline: 7.5 (0.7); follow-up:
7.8 (0.9); change from baseline:
NR (NR)
6 Hirsch et al.,
200834
Integrated CSII+CGM:
Paradigm 722 system
(Medtronic)
66 Baseline: 8.39 (0.64); follow-up:
7.77 (0.92); change from
baseline: –0.71 (0.71)
CSII+ SMBG: SMBG and a
Paradigm 715 insulin pump
(Medtronic)
72 Baseline: 8.49 (0.76); follow-up:
7.84 (0.81); change from
baseline: –0.56 (0.72)
6 Ly et al., 201333 CSII+CGM+ Suspend:
sensor-augmented pump
(Medtronic Paradigm Veo
System, Medtronic MiniMed)
with automated insulin
suspension
46 Baseline: 7.6 (NR); follow-up:
7.5 (NR); change from baseline:
−0.1 (NR)
CSII+ SMBG: continue using
their insulin pump
49 Baseline: 7.4 (NR); follow-up:
7.4 (NR); change from baseline:
−0.06 (NR)
6 Raccah et al.,
200936
Non-integrated CSII+CGM:
insulin pump with Holter-type
CGM device
55 Baseline: 9.11 (1.28); follow-up:
NR (NR); change from baseline:
–0.81 (1.09)
CSII+ SMBG: Paradigm
512/712+ SMBG
60 Baseline: 9.28 (1.19); follow-up:
NR (NR); change from baseline:
–0.57 (0.94)
12 Bergenstal et al.,
201040
Integrated CSII+CGM:
MiniMed Paradigm REAL-Time
System (Medtronic)
244 Baseline: 8.3 (0.5); follow-up:
7.5 (NR); change from baseline:
–0.8 (0.84)
MDI+ SMBG: Guardian
REAL-Time Clinical (Medtronic)
241 Baseline: 8.3 (0.5); follow-up:
8.1 (NR); change from baseline:
–0.2 (0.89)
NR, not reported.
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TABLE 75 Results for change in HbA1c levels from baseline in pregnant women
Study
Follow-up,
pregnancy
trimester Intervention
Number
analysed
Change in HbA1c levels
from baseline, % (SD)
Nosari et al., 199350 First CSII+ SMBG: Microjet MC 20
and Dahedi B.V. portable battery-
powered syringe infusion pumps
16 Baseline: NR (NR); follow-up:
6 (NR); change from baseline:
NR (NR)
MDI+ SMBG: NR 16 Baseline: NR (NR); follow-up:
6.2 (NR); change from
baseline: NR (NR)
Second CSII+ SMBG: Microjet MC 20 and
Dahedi B.V. portable battery-
powered syringe infusion pumps
16 Baseline: NR (NR); follow-up:
6.8 (NR); change from
baseline: NR (NR)
MDI+ SMBG: NR 16 Baseline: NR (NR); follow-up:
6.1 (NR); change from
baseline: NR (NR)
Third CSII+ SMBG: Microjet MC 20 and
Dahedi B.V. portable battery-
powered syringe infusion pumps
16 Baseline: NR (NR); follow-up:
6.3 (NR); change from
baseline: NR (NR)
MDI+ SMBG: NR 16 Baseline: NR (NR); follow-up:
6.2 (NR); change from
baseline: NR (NR)
NR, not reported.
TABLE 76 Results for proportion achieving HbA1c levels of ≤ 7% in adult populations
Follow-up,
months Study Intervention
Proportion achieving
HbA1c levels of ≤ 7%,
n (%)
Total
number
analysed
6 Hermanides et al.,
201137
Integrated CSII+CGM: Paradigm
REAL-Time System (Medtronic) with
SMBG (meter not described)
14 (34) 41
MDI+ SMBG: SMBG (meter not
described)
0 (0) 36
12 Bergenstal et al.,
201040
Integrated CSII+CGM: MiniMed
Paradigm REAL-Time System (Medtronic)
57 (34) 166
MDI+ SMBG: Guardian REAL-Time
Clinical (Medtronic)
19 (12) 163
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TABLE 77 Results for proportion achieving HbA1c levels of ≤ 7% in child populations
Follow-up,
months Study Intervention
Proportion achieving
HbA1c levels of ≤ 7%,
n (%)
Total
number
analysed
3.69 Doyle et al., 200449 CSII+ SMBG: Medtronic MiniMed 508 or
Paradigm 511; LifeScan InDuo glucose
meter
8 (50) 16
MDI+ SMBG: MDIs and LifeScan InDuo
glucose meter
2 (12.5) 16
12 Bergenstal et al.,
201040
Integrated CSII+CGM: MiniMed
Paradigm REAL-Time system (Medtronic)
10 (13) 78
MDI+ SMBG: Guardian REAL-Time
Clinical (Medtronic)
4 (5) 78
TABLE 78 Results for proportion achieving HbA1c levels of ≤ 7% in mixed populations
Follow-up,
months Study Intervention
Proportion achieving
HbA1c levels of ≤ 7%,
n (%)
Total
number
analysed
3 O’Connell et al.,
200935
Integrated CSII+CGM: MiniMed
Paradigm REAL-Time system (Medtronic)
14 (56) 26
CSII+ SMBG: continue their usual insulin
pump therapy and SMBG regimen
5 (17) 29
6 Hirsch et al.,
200834
Integrated CSII+CGM: Paradigm 722
System (Medtronic)
16 (24.2) 66
CSII+ SMBG: SMBG and a Paradigm 715
insulin pump (Medtronic)
12 (19.4) 72
12 Bergenstal et al.,
201040
Integrated CSII+CGM: MiniMed
Paradigm REAL-Time system (Medtronic)
67 (27) 244
MDI+ SMBG: Guardian REAL-Time
Clinical (Medtronic)
23 (10) 241
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TABLE 81 Results for HRQoL in adults (no data for children, mixed populations or pregnant women)
HRQoL
scale
Follow-up,
months Study Intervention
Number
analysed HRQoL score (SD)
Diabetes
QOL
6 Thomas
et al., 200745
CSII+ SMBG: Medtronic 508
with SMBG
7 Baseline: 69 (19); follow-up:
74 (20); change from
baseline: NR (NR)
MDI+ SMBG: NR 7 Baseline: 47 (20); follow-up:
70 (11); change from
baseline: NR (NR)
Diabetes
QOL;
diabetic
worry
9 Tsui et al.,
200146
CSII+ SMBG: MiniMed 507
insulin infusion pump;
Advantage meter (Roche
Diagnostics)
12 Baseline: NR (NR); follow-up:
85.2 (NR); change from
baseline: NR (NR)
MDI+ SMBG: Advantage
meter (Roche Diagnostics)
14 Baseline: NR (NR); follow-up:
79.8 (NR); change from
baseline: NR (NR)
Diabetes
QOL; global
health
9 Tsui et al.,
200146
CSII+ SMBG: MiniMed 507
insulin infusion pump;
Advantage meter (Roche
Diagnostics)
12 Baseline: NR (NR); follow-up:
68.2 (NR); change from
baseline: NR (NR)
MDI+ SMBG: Advantage
meter (Roche Diagnostics)
14 Baseline: NR (NR); follow-up:
67.3 (NR); change from
baseline: NR (NR)
Diabetes
QOL;
impact
9 Tsui et al.,
200146
CSII+ SMBG: MiniMed 507
insulin infusion pump;
Advantage meter (Roche
Diagnostics)
12 Baseline: NR (NR); follow-up:
69.9 (NR); change from
baseline: NR (NR)
MDI+ SMBG: Advantage
meter (Roche Diagnostics)
14 Baseline: NR (NR); follow-up:
68.4 (NR); change from
baseline: NR (NR)
Diabetes
QOL;
satisfaction
9 Tsui et al.,
200146
CSII+ SMBG: MiniMed 507
insulin infusion pump;
Advantage meter (Roche
Diagnostics)
12 Baseline: NR (NR); follow-up:
75.6 (NR); change from
baseline: NR (NR)
MDI+ SMBG: Advantage
meter (Roche Diagnostics)
14 Baseline: NR (NR); follow-up:
68.3 (NR); change from
baseline: NR (NR)
Diabetes
QOL; social
worry
9 Tsui et al.,
200146
CSII+ SMBG: MiniMed 507
insulin infusion pump;
Advantage meter (Roche
Diagnostics)
12 Baseline: NR (NR); follow-up:
89.6 (NR); change from
baseline: NR (NR)
MDI+ SMBG: Advantage
meter (Roche Diagnostics)
14 Baseline: NR (NR); follow-up:
94 (NR); change from
baseline: NR (NR)
SF-36;
bodily pain
6 Hermanides
et al.,37
Integrated CSII+CGM:
Paradigm REAL-Time System
(Medtronic) with SMBG
(meter not described)
42 Baseline: 78.9 (25.4); follow-
up: 79.9 (24.4); change from
baseline: 1 (NR)
MDI+ SMBG: SMBG (meter
not described)
33 Baseline: 78.7 (23); follow-up:
78.7 (22.6); change from
baseline: 0 (NR)
continued
DOI: 10.3310/hta20170 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 17
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Riemsma et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
217
TABLE 81 Results for HRQoL in adults (no data for children, mixed populations or pregnant women) (continued )
HRQoL
scale
Follow-up,
months Study Intervention
Number
analysed HRQoL score (SD)
SF-36;
general
health
6 Hermanides
et al., 201137
Integrated CSII+CGM:
Paradigm REAL-Time System
(Medtronic) with SMBG
(meter not described)
42 Baseline: 55.5 (20.3);
follow-up: 67.7 (21.6); change
from baseline: 12.2 (NR)
MDI+ SMBG: SMBG (meter
not described)
33 Baseline: 59.8 (22.3);
follow-up: 63.1 (19.1); change
from baseline: 3.3 (NR)
12 Bergenstal
et al., 201040
Integrated CSII+CGM:
MiniMed Paradigm REAL-Time
system (Medtronic)
153 Baseline: NR (NR); follow-up:
NR (NR); change from
baseline: 2.7 (8.07)
MDI+ SMBG: Guardian
REAL-Time Clinical
(Medtronic)
151 Baseline: NR (NR); follow-up:
NR (NR); change from
baseline: –0.3 (7.13)
SF-36;
general
health
3.68 DeVries et al.,
200242
CSII+ SMBG: Disetronic
H-TRONplus insulin pump;
Glucotouch or One Touch
Profile memory glucose meter
(LifeScan)
NR Baseline: 59.8 (37); follow-up:
NR (NR); change from
baseline: –1.2 (NR)
MDI+ SMBG: G Rucotouch or
One Touch Profile memory
glucose meter (Lifescan)
Baseline: 61.4 (20.5);
follow-up: NR (NR); change
from baseline: 5.9 (NR)
SF-36;
mental
composite
score
12 Bergenstal
et al., 201040
Integrated CSII+CGM:
MiniMed Paradigm REAL-Time
System (Medtronic)
166 Baseline: 49.86 (9.64);
follow-up: NR (NR); change
from baseline: 0.05 (NR)
MDI+ SMBG: Guardian
REAL-Time Clinical
(Medtronic)
168 Baseline: 49.5 (9.09);
follow-up: NR (NR); change
from baseline: –1.26 (NR)
SF-36;
mental
health
6 Hermanides
et al., 201137
Integrated CSII+CGM:
Paradigm REAL-Time System
(Medtronic) with SMBG
(meter not described)
42 Baseline: 72.6 (14.8);
follow-up: 79.2 (12.5); change
from baseline: 6.6 (NR)
MDI+ SMBG: SMBG (meter
not described)
33 Baseline: 77.9 (20.2);
follow-up: 76.8 (16.5); change
from baseline: –1.1 (NR)
SF-36;
mental
health
3.68 DeVries et al.,
200242
CSII+ SMBG: Disetronic
H-TRONplus insulin pump;
Glucotouch or One Touch
Profile memory glucose meter
(LifeScan)
NR Baseline: 78 (NR); follow-up:
NR (NR); change from
baseline: –0.6 (NR)
Baseline: 80 (NR); follow-up:
NR (NR); change from
baseline: 5.2 (NR)
SF-36;
physical
composite
score
12 Bergenstal
et al., 201040
Integrated CSII+CGM:
MiniMed Paradigm REAL-Time
System (Medtronic)
166 Baseline: 50.61 (7.12);
follow-up: NR (NR); change
from baseline: 1.22 (NR)
MDI+ SMBG: Guardian
REAL-Time Clinical
(Medtronic)
168 Baseline: 50.97 (7.86);
follow-up: NR (NR); change
from baseline: 0.26 (NR)
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TABLE 81 Results for HRQoL in adults (no data for children, mixed populations or pregnant women) (continued )
HRQoL
scale
Follow-up,
months Study Intervention
Number
analysed HRQoL score (SD)
SF-36;
physical
functioning
6 Hermanides
et al., 201137
Integrated CSII+CGM:
Paradigm REAL-Time System
(Medtronic) with SMBG
(meter not described)
42 Baseline: 89.4 (14.5);
follow-up: 92.7 (11.2);
change from baseline: 3.3 (NR)
MDI+ SMBG: SMBG (meter
not described)
33 Baseline: 90.5 (14.3);
follow-up: 91.4 (12.7);
change from baseline: 0.9 (NR)
SF-36; role –
emotional
6 Hermanides
et al., 201137
Integrated CSII+CGM:
Paradigm REAL-Time System
(Medtronic) with SMBG
(meter not described)
42 Baseline: 84.9 (20.4);
follow-up: 87.1 (19.6);
change from baseline: 2.2 (NR)
MDI+ SMBG: SMBG (meter
not described)
33 Baseline: 89.6 (16.7);
follow-up: 88 (16); change
from baseline: –1.6 (NR)
SF-36; role –
physical
6 Hermanides
et al., 201137
Integrated CSII+CGM:
Paradigm REAL-Time System
(Medtronic with SMBG (meter
not described)
42 Baseline: 76.8 (23.8);
follow-up: 85.7 (20.7);
change from baseline: 8.9 (NR)
MDI+ SMBG: SMBG (meter
not described)
33 Baseline: 84.4 (19.3);
follow-up: 87.3 (20.4);
change from baseline: 2.9 (NR)
SF-36;
social
functioning
6 Hermanides
et al., 201137
Integrated CSII+CGM:
Paradigm REAL-Time System
(Medtronic) with SMBG
(meter not described)
42 Baseline: 81.5 (20.3);
follow-up: 89.3 (16); change
from baseline: 7.8 (NR)
MDI+ SMBG: SMBG (meter
not described)
33 Baseline: 86.4 (21); follow-up:
82.2 (25.2); change from
baseline: –4.2 (NR)
SF-36;
vitality
6 Hermanides
et al., 201137
Integrated CSII+CGM:
Paradigm REAL-Time System
(Medtronic) with SMBG
(meter not described)
42 Baseline: 53.9 (20); follow-up:
66.7 (20.2); change from
baseline: 12.8 (NR)
MDI+ SMBG: SMBG (meter
not described)
33 Baseline: 61 (23.7); follow-up:
65.2 (19.3); change from
baseline: 4.2 (NR)
NR, not reported; QOL, quality of life; SF-36, Short Form questionnaire-36 items.
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TABLE 82 Results for adverse events
Outcome
definition Population
Follow-up,
months Study Intervention
Number
with AE
(%)
Total
number
analysed
All serious AEs Adults 3.45 Lee et al.,
200738
Integrated CSII+CGM:
MiniMed Paradigm REAL-Time
722 System as adjunct to
SMBG (Paradigm Link glucose
meter)
0 (0.0) 8
MDI+ SMBG: SMBG
(Paradigm Link glucose meter)
1 (12.5) 8
Mixed 6 Raccah et al.,
200936
Non-integrated CSII+CGM:
insulin pump+Holter-type
CGM device
3 (NR) NR
CSII+ SMBG: Paradigm
512/712+ SMBG
7 (NR) NR
12 Bergenstal
et al., 201040
Integrated CSII+CGM:
MiniMed Paradigm REAL-Time
system (Medtronic)
32 (13.0) 247
MDI+ SMBG: Guardian
REAL-Time Clinical
(Medtronic)
30 (12.1) 248
Death Adults 3 Bergenstal
et al., 201332
Integrated CSII+CGM:
Paradigm Revel 2.0 pump
with Enlite sensor
0 (0.0) 126
CSII+CGM+ suspend:
Paradigm Veo pump with
Enlite sensor
0 (0.0) 121
Device-related
serious AEs
Adults 3 Bergenstal
et al., 201332
Integrated CSII+CGM:
Paradigm Revel 2.0 pump
with Enlite sensor
0 (0.0) 126
CSII+CGM+ suspend:
Paradigm Veo pump with
Enlite sensor
0 (0.0) 121
Hypoglycaemic
coma
Adults 24 Brinchmann-
Hansen et al.,
198544
MDI+ SMBG: NR 6 (40.0) 15
CSII+ SMBG: NR 2 (13.3) 15
Subcutaneous
abscess
Adults 24 Brinchmann-
Hansen et al.,
198544
MDI+ SMBG: NR 0 (0.0) 15
CSII+ SMBG: NR 6 (40.0) 15
Total AEs, not
including
serious AEs
Mixed 12 Bergenstal
et al., 201040
Integrated CSII+CGM:
MiniMed Paradigm REAL-Time
system (Medtronic)
96 (38.9) 247
MDI+ SMBG: Guardian
REAL-Time Clinical
(Medtronic)
49 (19.8) 248
Treatment
emergent AE
Adults 6 Bolli et al.,
200941
CSII+ SMBG: MiniMed 508
with glucose monitor (NR)
18 (64.3) 28
MDI+ SMBG: insulin glargine
plus mealtime insulin lispro
glucose monitor (NR)
22 (75.9) 29
AE, adverse event; NR, not reported.
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TABLE 83 Results for adverse events in pregnant women
Outcome definition
Follow-up,
months Study ID Intervention
Number
with AE
(%)
Total
number
analysed
Fetal respiratory distress
syndrome
NR Nosari et al.,
199350
CSII+ SMBG: Microjet MC 20 and
Dahedi B.V. portable battery-
powered syringe infusion pumps
1 (6.3) 16
MDI+ SMBG: NR 0 (0.0) 16
Intrauterine death NR Nosari et al.,
199350
CSII+ SMBG: Microjet MC 20 and
Dahedi B.V. portable battery-
powered syringe infusion pumps
2 (12.5) 16
MDI+ SMBG: NR 1 (6.3) 16
Large for gestational age NR Nosari et al.,
199350
CSII+ SMBG: Microjet MC 20 and
Dahedi B.V. portable battery-
powered syringe infusion pumps
1 (6.3) 16
MDI+ SMBG: NR 0 (0.0) 16
Neonatal hypoglycaemia
(plasma glucose of
< 30mg/dl)
NR Nosari et al.,
199350
CSII+ SMBG: Microjet MC 20 and
Dahedi B.V. portable battery-
powered syringe infusion pumps
1 (6.3) 16
MDI+ SMBG: NR 1 (6.3) 16
Premature birth of a
viable fetus
NR Nosari et al.,
199350
CSII+ SMBG: Microjet MC 20 and
Dahedi B.V. portable battery-
powered syringe infusion pumps
0 (0.0) 16
MDI+ SMBG: NR 1 (6.3) 16
Small for gestational age NR Nosari et al.,
199350
CSII+ SMBG: Microjet MC 20 and
Dahedi B.V. portable battery-
powered syringe infusion pumps
0 (0.0) 16
MDI+ SMBG: NR 2 (12.5) 16
AE, adverse event; NR, not reported.
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Appendix 4 Risk-of-bias assessment results
TABLE 84 Risk-of-bias assessment for all included studies
Study ID
Random
sequence
generation
Allocation
concealment
Participant
blinding
Care staff
blinding
Outcome
assessor
blinding
Selective
outcome
reporting
Incomplete
data Overall
Bergenstal
et al., 201332
Unclear Unclear High High High Low High High
Bolli et al.,
200941
Low Low High High High Low High High
DeVries et al.,
200242
Low Low High High High Low High High
Doyle et al.,
200449
Low Low High High High High Low Low
Hermanides
et al., 201137
Low Low High High High Low Unclear Low
Hirsch et al.,
200834
Unclear Unclear High High High Low High High
Lee et al.,
200738
Unclear Unclear Unclear Unclear Unclear Low Unclear Unclear
Ly et al.,
201333
Low Unclear High High High Low High High
Nosadini et al.,
198843
Unclear Low High High High High High High
Nosari et al.,
199350
Unclear Unclear High High High Low High High
O’Connell
et al., 200935
Low Unclear High High High Low High High
Brinchmann-
Hansen et al.,
198544
Low Unclear High High High Low Low Low
Peyrot and
Rubin, 200939
Unclear Unclear Unclear Unclear Unclear Low Unclear Unclear
Raccah et al.,
200936
Unclear Unclear High High High High High High
Bergenstal
et al., 201040
Unclear Low High High High Low High High
Thomas et al.,
200745
Unclear Unclear High High High Low Unclear Unclear
Thrailkill et al.,
201148
Low Unclear High High High Low High High
Tsui et al.,
200146
Low Low Unclear Unclear Unclear Low High Unclear
Weintrob
et al., 200347
Unclear Unclear Unclear Unclear Unclear Low Low Low
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Appendix 5 Conversion tables for glycated
haemoglobin and glucose values
TABLE 85 Glycated haemoglobin conversion table: older DCCT-aligned (%) and newer IFCC-standardised
(mmol/mol) concentrations (IFCC-standardised values are rounded to the nearest whole number)
HbA1c ‘old’ HbA1c ‘new’ HbA1c ‘old’ HbA1c ‘new’
4.0 20 9.1 76
4.1 21 9.2 77
4.2 22 9.3 78
4.3 23 9.4 79
4.4 25 9.5 80
4.5 26 9.6 81
4.6 27 9.7 83
4.7 28 9.8 84
4.8 29 9.9 85
4.9 30 10.0 86
5.0 31 10.1 87
5.1 32 10.2 88
5.2 33 10.3 89
5.3 34 10.4 90
5.4 36 10.5 91
5.5 37 10.6 92
5.6 38 10.7 93
5.7 39 10.8 95
5.8 40 10.9 96
5.9 41 11.0 97
6.0 42 11.1 98
6.1 43 11.2 99
6.2 44 11.3 100
6.3 45 11.4 101
6.4 46 11.5 102
6.5 48 11.6 103
6.6 49 11.7 104
6.7 50 11.8 105
6.8 51 11.9 107
continued
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TABLE 85 Glycated haemoglobin conversion table: older DCCT-aligned (%) and newer IFCC-standardised
(mmol/mol) concentrations (IFCC-standardised values are rounded to the nearest whole number) (continued )
HbA1c ‘old’ HbA1c ‘new’ HbA1c ‘old’ HbA1c ‘new’
6.9 52 12.0 108
7.0 53 13.0 119
7.1 54 13.1 120
7.2 55 13.2 121
7.3 56 13.3 122
7.4 57 13.4 123
7.5 58 13.5 124
7.6 60 13.6 125
7.7 61 13.7 126
7.8 62 13.8 127
7.9 63 13.9 128
8.0 64 14.0 130
8.1 65 14.1 131
8.2 66 14.2 132
8.3 67 14.3 133
8.4 68 14.4 134
8.5 69 14.5 135
8.6 70 14.6 136
8.7 72 14.7 137
8.8 73 14.8 138
8.9 74 14.9 139
9.0 75
IFCC, International Federation of Clinical Chemistry.
Definitions: ‘old’ unit=DCCT unit (%); ‘new’ unit= IFCC unit (mmol/mol).
Conversion formulas: ‘old’= (0.0915 × ‘new’)+ 2.15%; ‘new’= (10.93 × ‘old’) – 23.5mmol/mol.
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TABLE 86 Glucose values conversion table (mg/dl to mmol/l)
mg/dl to mmol/l mmol/l to mg/dl
mg/dl mmol/l mmol/l mg/dl
40 2.2 2.0 36
45 2.5 2.5 45
50 2.8 3.0 54
55 3.1 3.5 63
60 3.3 4.0 72
65 3.6 4.5 81
70 3.9 5.0 90
75 4.2 5.5 99
80 4.4 6.0 108
85 4.7 6.5 117
90 5.0 7.0 126
95 5.3 7.5 135
100 5.6 8.0 144
110 6.2 8.5 153
120 6.7 9.0 162
130 7.2 9.5 171
140 7.8 10.0 180
150 8.3 10.5 189
160 8.9 11.0 198
170 9.4 11.5 207
180 10.0 12.0 216
190 10.6 12.5 225
200 11.1 13.0 234
220 12.2 13.5 243
240 13.3 14.0 252
260 14.4 14.5 261
280 15.5 15.0 270
300 16.7 16.0 288
320 17.8 17.0 306
340 18.9 18.0 324
360 20.0 19.0 342
380 21.1 20.0 360
400 22.2 21.0 378
420 23.3 22.0 396
440 24.4 23.0 414
460 25.5 24.0 432
Conversion formulas: mg/dl × 0.0555=mmol/l; mmol/l × 18.018=mg/dl.
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Appendix 6 Detailed description of the IMS core
diabetes model
The IMS CDM is a multilayer internet application linked to a mathematical calculation model andstructured query language (SQL) database sited on a central server. Online access to the IMS CDM
software is available under license from IMS, the developers of the model. The structure is based on four
separate elements: the user interface, the input databases, the data processor and the output databases.
Figure 24 outlines the overview of the IMS CDM software structure.
User interface
• Access input databases
• Define scenarios to be 
   compared
• Define time horizon
• Define number of patients
• Define type of analysis – 
   closed/open cohort, 
   sensitivity analysis, budget 
   impact analysis
Clinical database
• Define/select transition
   probabilities
• Define/select 
   progression of risk 
   factors
Cohort database
Define:
• Age
• Gender
• Duration of diabetes
• Racial characteristics
• Baseline HbA1c
• Blood pressure
• BMI
• Lipid levels
• Smoking
• Baseline complications
Treatment database
Define effects of 
treatments on:
• Screening rates
• Progression of risk
   factors
Economic database
• Define/select 
   country-specific 
   economic parameters
Data processor
• Update risk profile and complication history at each cycle
• Calculate changes in treatment, progression of 
   complications, mortality and total costs
Output database
• Cumulative event rates/incidences
• Annual costs per patient
• Cumulative costs per patient
• Breakdown of costs per complications/treatment
• Life expectancy
• Quality-adjusted life expectancy
• Incremental cost-effectiveness ratios
• Sensitivity analysis
• Budget impact analysis
User interface
• Present results in graphical and tabular format
In
p
u
t 
d
at
ab
as
es
FIGURE 24 IMS CDM software model structure.
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Complication submodels
The myocardial infarction submodel
The MI submodel is made up of three states: no history of MI, history of MI and death following MI.
Transition probabilities between the states can be taken from the UK Prospective Diabetes Study (UKPDS)
risk engine,98 Framingham93 or the UKPDS outcomes model.91 In our calculations, Framingham92 was
chosen as it is the only one that is based on T1DM only.
Unstable angina submodel
The unstable angina submodel is made up of two states: no history of angina and history of angina.
Transition probabilities between the states are derived from Framingham.93 They are adjusted according to
HbA1c levels and renal function.
Congestive heart failure submodel
The CHF submodel is composed of three states: no CHF, history of CHF and death following CHF. A
logistic regression based on Framingham95 generates the risk profile and includes the following risk factors:
age, sex, left ventricular hypertrophy, heart rate, SBP, congenital heart disease, valve disease, presence of
diabetes, BMI, presence of diabetes and valve disease jointly.
Stroke submodel
The stroke submodel is composed of three states: no stroke, history of stroke and death following stroke.
Transition probabilities between the states can be taken from the UKPDS risk engine,96 Framingham153 or
the UKPDS outcomes model.91 In our calculations, Framingham was chosen as it is the only one that is
based on T1DM only.
Peripheral vascular disease submodel
The PVD submodel is made up of two states: no PVD and PVD. Transition probabilities are the same as
T1DM and T2DM. A logistic regression based on Framingham97 is used to generate the risk for PVD,
including the following risk factors: age, sex, blood pressure (normal–high), stage 1 hypertension (yes/no),
stage 2 hypertension (yes/no), presence of diabetes, number of cigarettes per day, cholesterol level and
heart failure history.
Neuropathy submodel
The neuropathy submodel is made up of two states: no neuropathy and neuropathy. Transition
probabilities for T1DM are derived from DCCT.92 Transition probabilities are indexed by diabetes duration
and are adjusted for HbA1c levels, SBP and angiotensin-converting enzyme inhibitor (ACEI) use.
Foot ulcer/amputation submodel
This submodel consists of nine states: (1) no foot ulcer; (2) uninfected ulcer; (3) infected ulcer; (4) healed
ulcer; (5) uninfected recurrent ulcer; (6) infected recurrent ulcer; (7) gangrene; (8) history of amputation;
and (9) death resulting from foot ulcer. Transition probabilities are the same for T1DM and T2DM. Unlike
other submodels, this submodel runs in monthly cycles. Therefore, patients may have multiple foot ulcers
in a single year.
Diabetic retinopathy submodel
This submodel is composed of 10 states: (1) no retinopathy and not screened; (2) no retinopathy and
screened; (3) background diabetic retinopathy (BDR) and not screened; (4) BDR and screened; (5) BDR and
wrongly diagnosed as proliferative; (6) diabetic retinopathy and laser (retinal photocoagulation) treated;
(7) proliferative diabetic retinopathy (PDR), not screened and no laser treatment; (8) PDR, screened,
detected and laser treated; (9) PDR, screened and not detected; and (10) severe vision loss.
Severe vision loss is a terminal state. Transition probabilities for T1DM are derived from DCCT,92 and are
adjusted for HbA1c levels, SBP and ACEI use.
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Macular oedema submodel
The macular oedema submodel consists of six states: (1) no macular oedema and not screened; (2) no
macular oedema and screened; (3) macular oedema, not screened and no laser treatment; (4) macular
oedema, screened and not detected; (5) macular oedema, screened, detected and laser treated; and
(6) severe vision loss.
Severe vision loss is a terminal state. Transition probabilities for T1DM are derived from DCCT,92 and are
adjusted for HbA1c levels, SBP and ACEI use.
Cataract submodel
The cataract submodel is composed of three states: no cataract, first cataract with operation and second
cataract with operation. Transition probabilities are the same for T1DM and T2DM and are taken from a
study in diabetes outpatients in the UK published by Janghorbani et al.154
Nephropathy submodel
This submodel is composed of 13 states: (1) no renal complications and no treatment with ACEI;
(2) no renal complications and treated with ACEI; (3) no renal complications after ACEI side effects;
(4) microalbuminuira and no treatment with ACEI; (5) microalbuminuira, screened, detected and treated
with ACEI; (6) microalbuminuira after ACEI side effects; (7) gross proteinuria and no treatment with ACEI;
(8) gross proteinuria, screened, detected and treated with ACEI; (9) gross proteinuria after ACEI side
effects; (10) end-stage renal disease, treated with haemodialysis; (11) end-stage renal disease, treated with
peritoneal dialysis; (12) end-stage renal disease, treated with renal transplant; and (13) end-stage renal
disease death.
Data on the cumulative incidence of progression of microalbuminuria and gross proteinuria were taken
from the DCCT,92 probabilities for the progression from gross proteinuria to end-stage renal disease are
based on cumulative incidence data for T2DM patients in the Rochester population.155 It is assumed that
the probability of progression from gross proteinuria to end-stage renal disease is the same for T1DM and
T2DM. The probability of progression from end-stage renal disease states to death is dependent on
treatment and ethnic group (Wolfe et al.156). Transition probabilities are adjusted according to patient
HbA1c levels, SBP and concomitant ACEI treatment
Hypoglycaemia submodel
The hypoglycaemia submodel is a state in which the minor and severe hypoglycaemic episodes are
counted. Minor hypoglycaemic events are calculated on a daily basis (cycle length= 1 day). For the
simulation of severe hypoglycaemic events, the submodel runs four times for each year of simulation. All
rates (defined as number of events per 100 patient-years) are adjusted to the 1-day or 3-month cycle
length. Therefore, patients can have multiple hypoglycaemic episodes in a single year. The patients may die
after a severe hypoglycaemic episode. The definition of severe and minor hypoglycaemia can be refined by
the user according to the available data. In our analysis, hypoglycaemic episode rates are treatment specific
and any hypoglycaemic episode that required assistance from a third party is considered as severe. It
should be noted that in our base-case analysis the probability of death as a result of a severe
hypoglycaemic episode was assumed to be zero.
Ketoacidosis submodel
The ketoacidosis submodel has two states: alive and dead (as a result of ketoacidosis). There are no
probability adjustments in the ketoacidosis submodel.
Depression submodel
The depression submodel has three states: no depression, depression receiving antidepression programme
and depression not receiving antidepression programme. The onset probability of depression is the same
for T1DM and T2DM, and is dependent on gender.
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Lactic acidosis submodel
This submodel is relevant for T2DM only.
Peripheral oedema submodel
This submodel is relevant for T2DM only.
Non-specific mortality submodel
This submodel consists of two states: alive or dead. The transition probabilities are indexed by age, sex and
ethnicity, and reflect the UK life tables.94
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Appendix 7 Results (full incremental and
intervention vs. comparator) of base-case and
scenario analyses
TABLE 87 Base-case model results (all technologies) for probabilistic simulation
Intervention QALYs Cost (£) Incremental QALY Incremental cost (£) ICER (£)
MDI+ SMBG 11.4146 61,050 – – –
CSII+ SMBG 11.9756 90,436 0.561 29,386 52,381
MiniMed Veo system 12.0412 138,357 Extendedly dominateda by stand-alone CSII+CGM
Stand-alone CSII+CGM 12.0604 146,476 0.0849 56,039 660,376
Integrated CSII+CGM (Vibe) 12.0604 147,150 Dominated by stand-alone CSII+CGM
a An extendedly dominated strategy has an ICER higher than that of the next most effective strategy.
TABLE 88 Base-case model results (intervention vs. comparator only) for probabilistic simulation
Intervention Comparator Incremental QALY Incremental cost (£) ICER (£)
MiniMed Veo system MDI+ SMBG 0.6266 77,307 123,375
MiniMed Veo system CSII+ SMBG 0.0656 47,921 730,501
MiniMed Veo system Stand-alone CSII+CGM –0.0192 –8119 422,849
Integrated CSII+CGM (Vibe) MDI+ SMBG 0.6458 86,100 133,323
Integrated CSII+CGM (Vibe) CSII+ SMBG 0.0849 56,713 668,789
Integrated CSII+CGM (Vibe) Stand-alone CSII+CGM 0 674 Undefined
TABLE 89 Base-case model results (all technologies) for deterministic simulation
Intervention QALYs Cost (£) Incremental QALY Incremental cost (£) ICER (£)
MDI+ SMBG 12.1450 62,927 – – –
CSII+ SMBG 12.7258 93,433 0.5808 30,506 52,524
MiniMed Veo system 12.8087 143,309 0.0829 49,876 601,641
Stand-alone CSII+CGM 12.8223 151,671 0.0136 8363 614,910
Integrated CSII+CGM
(Vibe)
12.8223 152,372 Dominated by stand-alone CSII+ CGM
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TABLE 90 Base-case model results (intervention vs. comparator only) for deterministic simulation
Intervention Comparator Incremental QALY Incremental cost (£) ICER (£)
MiniMed Veo system MDI+ SMBG 0.6637 80,382 121,112
MiniMed Veo system CSII+ SMBG 0.0829 49,876 601,639
MiniMed Veo system Stand-alone CSII+CGM –0.0136 –8363 614,910
Integrated CSII+CGM (Vibe) MDI+ SMBG 0.6773 89,445 132,061
Integrated CSII+CGM (Vibe) CSII+ SMBG 0.0965 58,939 610,772
Integrated CSII+CGM (Vibe) Stand-alone CSII+CGM 0 701 Undefined
TABLE 91 Model results (all technologies) for scenario with different baseline population characteristics
Intervention QALYs Cost (£) Incremental QALY Incremental cost (£) ICER (£)
MDI+ SMBG 9.6117 65,070 – – –
CSII+ SMBG 10.0991 91,189 0.4874 26,119 53,588
MiniMed Veo system 10.1474 132,149 Extendedly dominated by stand-alone CSII+CGM
Stand-alone CSII+CGM 10.164 139,157 0.0649 47,967 738,593
Integrated CSII+CGM (Vibe) 10.164 139,733 Dominated by stand-alone CSII+CGM
TABLE 92 Model results (intervention vs. comparator only) for scenario with different baseline
population characteristics
Intervention Comparator Incremental QALY Incremental cost (£) ICER (£)
MiniMed Veo system MDI+ SMBG 0.5357 67,079 125,217
MiniMed Veo system CSII+ SMBG 0.0483 40,960 848,028
MiniMed Veo system Stand-alone CSII+CGM –0.0166 –7008 422,148
Integrated CSII+CGM (Vibe) MDI+ SMBG 0.5523 74,663 135,186
Integrated CSII+CGM (Vibe) CSII+ SMBG 0.0649 48,543 747,971
Integrated CSII+CGM (Vibe) Stand-alone CSII+CGM 0 576 Undefined
TABLE 93 Model results (all technologies) for scenario with two (CGM) vs. eight (SMBG) BG tests per day
Intervention QALYs Cost (£) Incremental QALY Incremental cost (£) ICER (£)
MDI+ SMBG 11.4146 68,460 – – –
CSII+ SMBG 11.9756 98,034 0.561 29,574 52,717
MiniMed Veo system 12.0412 138,357 Extendedly dominated by stand-alone CSII+CGM
Stand-alone CSII+CGM 12.0604 146,476 0.0849 48,441 570,844
Integrated CSII+CGM (Vibe) 12.0604 147,150 Dominated by stand-alone CSII+CGM
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TABLE 94 Model results (intervention vs. comparator only) for scenario with two (CGM) vs. eight (SMBG) BG tests
per day
Intervention Comparator Incremental QALY Incremental cost (£) ICER (£)
MiniMed Veo system MDI+ SMBG 0.6266 69,897 111,550
MiniMed Veo system CSII+ SMBG 0.0656 40,323 614,683
MiniMed Veo system Stand-alone CSII+CGM –0.0192 –8119 422,849
Integrated CSII+CGM (Vibe) MDI+ SMBG 0.6458 78,690 121,849
Integrated CSII+CGM (Vibe) CSII+ SMBG 0.0849 49,116 579,194
Integrated CSII+CGM (Vibe) Stand-alone CSII+CGM 0 674 Undefined
TABLE 95 Model results (all technologies) for scenario with increased amount of daily insulin for MDIs
Intervention QALYs Cost (£) Incremental QALY Incremental cost (£) ICER (£)
MDI+ SMBG 11.4146 62,114 – – –
CSII+ SMBG 11.9756 90,437 0.5610 28,323 50,487
MiniMed Veo system 12.0412 138,358 Extendedly dominated by stand-alone CSII+CGM
Stand-alone CSII+CGM 12.0604 146,476 0.0849 56,040 660,376
Integrated CSII+CGM (Vibe) 12.0604 147,150 Dominated by stand-alone CSII+CGM
TABLE 96 Model results (intervention vs. comparator only) for scenario with increased amount of daily insulin
for MDIs
Intervention Comparator Incremental QALY Incremental cost (£) ICER (£)
MiniMed Veo system MDI+ SMBG 0.6266 76,244 121,679
MiniMed Veo system CSII+ SMBG 0.0656 47,921 730,501
MiniMed Veo system Stand-alone CSII+CGM –0.0192 –8119 422,849
Integrated CSII+CGM (Vibe) MDI+ SMBG 0.6458 85,036 131,675
Integrated CSII+CGM (Vibe) CSII+ SMBG 0.0848 56,713 668,789
Integrated CSII+CGM (Vibe) Stand-alone CSII+CGM 0 674 Undefined
TABLE 97 Model results (all technologies) for scenario with no HbA1c progression
Intervention QALYs Cost (£) Incremental QALY Incremental cost (£) ICER (£)
MDI+ SMBG 11.8715 58,520 – – –
CSII+ SMBG 12.4558 88,663 0.5843 30,143 51,615
MiniMed Veo system 12.5228 137,739 Extendedly dominated by stand-alone CSII+CGM
Stand-alone CSII+CGM 12.5398 146,076 0.0840 57,414 683,889
Integrated CSII+CGM (Vibe) 12.5398 146,767 Dominated by stand-alone CSII+CGM
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TABLE 98 Model results (intervention vs. comparator only) for scenario with no HbA1c progression
Intervention Comparator Incremental QALY Incremental cost (£) ICER (£)
MiniMed Veo system MDI+ SMBG 0.6513 79,219 121,632
MiniMed Veo system CSII+ SMBG 0.067 49,076 732,483
MiniMed Veo system Stand-alone CSII+CGM –0.017 –8337 490,424
Integrated CSII+CGM (Vibe) MDI+ SMBG 0.6683 88,247 132,047
Integrated CSII+CGM (Vibe) CSII+ SMBG 0.084 58,104 691,715
Integrated CSII+CGM (Vibe) Stand-alone CSII+CGM 0 690 Undefined
TABLE 99 Cost-effectiveness results when no treatment effect (in terms of change in HbA1c levels) is assumed in the
first year (all technologies)
Intervention QALYs Cost (£) Incremental QALY Incremental cost (£) ICER (£)
Stand-alone CSII+CGM 12.0006 146,632 Dominated by MDI+ SMBG
Integrated CSII+CGM (Vibe) 12.0006 147,304 Dominated by MDI+ SMBG
MDI+ SMBG 12.0016 56,928 – – –
CSII+ SMBG 12.016 90,178 0.0144 33,250 2,309,028
MiniMed Veo system 12.026 138,538 0.0099 48,360 4,871,356
TABLE 100 Cost-effectiveness results when no treatment effect (in terms of change in HbA1c levels) is assumed in
the first year (intervention vs. comparator only)
Intervention Comparator Incremental QALY Incremental cost (£) ICER (£)
MiniMed Veo system MDI+ SMBG 0.0244 81,610 3,344,672
MiniMed Veo system CSII+ SMBG 0.0099 48,360 4,871,356
MiniMed Veo system Stand-alone CSII+CGM 0.0254 –8093 –318,634
Integrated CSII+CGM (Vibe) MDI+ SMBG –0.0009 90,376 –100,417,778
Integrated CSII+CGM (Vibe) CSII+ SMBG –0.0154 57,126 –3,709,460
Integrated CSII+CGM (Vibe) Stand-alone CSII+CGM 0 672 Undefined
TABLE 101 Cost-effectiveness results if a RR of 0.125 is used for the MiniMed Veo system severe hypoglycaemic
rate (all technologies)
Hypo MiniMed Veo
system RR QALYs Cost (£) Incremental QALY Incremental cost (£) ICER (£)
MDI+ SMBG 11.412 60,812 – – –
CSII+ SMBG 11.9597 91,195 0.5477 30,383 55,474
MiniMed Veo system 12.0453 138,333 Extendedly dominated by stand-alone CSII+CGM
Stand-alone CSII+CGM 12.0604 146,476 0.1007 55,281 549,080
Integrated CSII+CGM (Vibe) 12.0604 147,150 Dominated by stand-alone CSII+CGM
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TABLE 102 Cost-effectiveness results if a RR of 0.125 is used for the MiniMed Veo system severe hypoglycaemic
rate (intervention vs. comparator only)
Intervention Comparator Incremental QALY Incremental cost (£) ICER (£)
MiniMed Veo system MDI+ SMBG 0.6333 77,521 122,408
MiniMed Veo system CSII+ SMBG 0.0856 47,138 550,675
MiniMed Veo system Stand-alone CSII+CGM –0.0151 –8143 539,295
Integrated CSII+CGM (Vibe) MDI+ SMBG 0.6484 86,338 133,155
Integrated CSII+CGM (Vibe) CSII+ SMBG 0.1007 55,955 555,659
Integrated CSII+CGM (Vibe) Stand-alone CSII+CGM 0 674 Undefined
TABLE 103 Cost-effectiveness results for mortality due to severe hypoglycaemia scenario (all technologies)
Intervention QALYs Cost (£) Incremental QALY Incremental cost (£) ICER (£)
MDI+ SMBG 11.1041 58,510 – – –
Stand-alone CSII+CGM 11.7701 142,215 Dominated by CSII+ SMBG
Integrated CSII+CGM (Vibe) 11.7701 142,872 Dominated by CSII+ SMBG
CSII+ SMBG 11.8781 89,475 0.774 30,965 40,006
MiniMed Veo system 12.0071 137,801 0.129 8326 374,531
TABLE 104 Cost-effectiveness results for mortality due to severe hypoglycaemia scenario (intervention vs.
comparator only)
Intervention Comparator Incremental QALY Incremental cost (£) ICER (£)
MiniMed Veo system MDI+ SMBG 0.9029 79,291 87,818
MiniMed Veo system CSII+ SMBG 0.1290 48,327 374,626
MiniMed Veo system Stand-alone CSII+CGM 0.2369 –4413 –18,622
Integrated CSII+CGM (Vibe) MDI+ SMBG 0.6659 84,362 126,689
Integrated CSII+CGM (Vibe) CSII+ SMBG –0.1079 53,397 –494,418
Integrated CSII+CGM (Vibe) Stand-alone CSII+CGM 0 657 Undefined
TABLE 105 Cost-effectiveness results for minimum QALY estimation method scenario (all technologies)
Intervention QALYs Cost (£) Incremental QALY Incremental cost (£) ICER (£)
MDI+ SMBG 12.1327 61,050
CSII+ SMBG 12.5861 90,436 0.4534 29,386 64,813
MiniMed Veo system 12.6408 138,357 0.0546 47,920 876,987
Stand-alone CSII+CGM 12.6462 146,476 0.0601 56,039 932,305
Integrated CSII+CGM (Vibe) 12.6462 147,150 Dominated by stand-alone CSII+CGM
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TABLE 106 Cost-effectiveness results for minimum QALY estimation method scenario (intervention vs.
comparator only)
Intervention Comparator Incremental QALY Incremental cost (£) ICER (£)
MiniMed Veo system MDI+ SMBG 0.5081 77,307 152,149
MiniMed Veo system CSII+ SMBG 0.0547 47,921 876,067
MiniMed Veo system Stand-alone CSII+CGM –0.0054 –8119 1,503,465
Integrated CSII+CGM (Vibe) MDI+ SMBG 0.5135 86,100 167,673
Integrated CSII+CGM (Vibe) CSII+ SMBG 0.0601 56,713 943,649
Integrated CSII+CGM (Vibe) Stand-alone CSII+CGM 0 674 Undefined
TABLE 107 Four-year time horizon scenario (all technologies)
Intervention QALYs Cost (£) Incremental QALY Incremental cost (£) ICER (£)
MDI+ SMBG 2.7718 6706 – – –
Stand-alone CSII+CGM 2.7882 24,803 Dominated by CSII+ SMBG
Integrated CSII+CGM (Vibe) 2.7886 24,939 Dominated by CSII+ SMBG
CSII+ SMBG 2.7906 13,365 0.0188 6659 354,202
MiniMed Veo system 2.7928 23,144 0.0022 9778 4,461,063
TABLE 108 Four-year time horizon scenario (intervention vs. comparator only)
Intervention Comparator Incremental QALY Incremental cost (£) ICER (£)
MiniMed Veo system MDI+ SMBG 0.0210 16,438 782,762
MiniMed Veo system CSII+ SMBG 0.0022 9779 4,445,000
MiniMed Veo system Stand-alone CSII+CGM 0.0046 –1659 –360,652
Integrated CSII+CGM (Vibe) MDI+ SMBG 0.0168 18,233 1,085,298
Integrated CSII+CGM (Vibe) CSII+ SMBG –0.0020 11,574 –5,787,000
Integrated CSII+CGM (Vibe) Stand-alone CSII+CGM 0.0004 136 340,000
TABLE 109 Cost-effectiveness results for fear of hypoglycaemia scenario (all technologies)
Intervention QALYs Cost (£) Incremental QALY Incremental cost (£) ICER (£)
MDI+ SMBG 11.4146 61,050 – – –
CSII+ SMBG 11.9756 90,436 0.5610 29,386 52,381
Stand-alone CSII+CGM 12.0604 146,476 Extendedly dominated by MiniMed Veo system
MiniMed Veo system 12.6224 138,357 0.6468 47,920 74,088
Integrated CSII+CGM (Vibe) 12.6429 147,150 0.0205 8792 428,595
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TABLE 110 Cost-effectiveness results for fear of hypoglycaemia scenario (intervention vs. comparator only)
Intervention Comparator Incremental QALY Incremental cost (£) ICER (£)
MiniMed Veo system MDI+ SMBG 1.2077 77,307 64,012
MiniMed Veo system CSII+ SMBG 0.6468 47,921 74,088
MiniMed Veo system Stand-alone CSII+CGM 0.5619 –8119 –14,448
Integrated CSII+CGM (Vibe) MDI+ SMBG 1.2282 86,100 70,103
Integrated CSII+CGM (Vibe) CSII+ SMBG 0.6468 47,921 74,089
Integrated CSII+CGM (Vibe) Stand-alone CSII+CGM 0.5824 674 1157
TABLE 111 Cost-effectiveness results for cost of stand-alone CSII+CGM without market share scenario
(all technologies)
Intervention QALYs Cost (£) Incremental QALY Incremental cost (£) ICER (£)
MDI+ SMBG 11.4146 61,050 – – –
CSII+ SMBG 11.9756 92,272 0.561 31,222 55,654
MiniMed Veo system 12.0412 138,357 Extendedly dominated by Integrated CSII+CGM
Integrated CSII+CGM (Vibe) 12.0604 147,150 0.0849 54,878 646,692
Stand-alone CSII+CGM 12.0604 150,063 Dominated by integrated CSII+CGM
TABLE 112 Cost-effectiveness results for cost of stand-alone CSII+CGM without market share scenario
(intervention vs. comparator only)
Intervention Comparator Incremental QALY Incremental cost (£) ICER (£)
MiniMed Veo system MDI+ SMBG 0.6266 77,307 123,375
MiniMed Veo system CSII+ SMBG 0.0656 46,086 702,530
MiniMed Veo system Stand-alone CSII+CGM –0.0192 –11,705 609,635
Integrated CSII+CGM (Vibe) MDI+ SMBG 0.6458 86,100 133,323
Integrated CSII+CGM (Vibe) CSII+ SMBG 0.0848 54,878 647,146
Integrated CSII+CGM (Vibe) Stand-alone CSII+CGM 0 –2913 Undefined
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Appendix 8 Disease natural history parameters
and transition probabilities
The parameters that will determine the natural course of the disease and their corresponding sourcescan be seen in Table 113. We considered the same values as in NICE Guideline NG17.81
Transition probabilities values were provided by the IMS CDM developers and were not changed in our
analyses given the high degree of validation of the model. These were UK specific if possible and based on
relevant sources (e.g. DCCT trial).92 In Table 114 we report these sources. We do not report the complete
set of probabilities as we believe this would be too extensive and not very informative because of the
complexity of the model.
TABLE 113 Disease natural history parameters
Parameter
Mean
value Source
HbA1c adjustments
Risk reduction of BDR with 10% lower HbA1c 39% DCCT
92
Risk reduction of proliferative diabetic retinopathy with 10%
lower HbA1c
43% DCCT92
Risk reduction of sever vision loss with 10% lower HbA1c 0% No data
Risk reduction of macular oedema with 10% lower HbA1c 13% Klein et al., 2009
157
Risk reduction of microalbuminuria with 10% lower HbA1c 28% DCCT
92
Risk reduction of gross proteinuria with 10% lower HbA1c 37% DCCT
92
Risk reduction of end-stage renal disease with 10% lower HbA1c 21% Rosolowsky et al., 2011
158
Risk reduction of neuropathy with 10% lower HbA1c 32% DCCT
92
Risk reduction of MI with 1% lower HbA1c 20% DCCT
92
Risk reduction of cataract with 1% lower HbA1c 0% Grauslund et al., 2011
159
Risk reduction of heart failure with 1% lower HbA1c 23% Lind et al., 2011
160
Risk reduction of stroke with 1% lower HbA1c 20% DCCT
92
Risk reduction of angina with 1% lower HbA1c 20% DCCT
92
Risk reduction of haemodialysis mortality with 1% lower HbA1c 12% Morioka et al., 2001
161
Risk reduction of peritoneal dialysis mortality with 1% lower
HbA1c
12% Morioka et al., 2001161
Risk reduction of renal transplant mortality with 1% lower HbA1c 0% Wiesbauer et al., 2010
162
Risk reduction of first ulcer with 1% lower HbA1c 17% Monami et al., 2009
163
SBP adjustments
Risk reduction of microalbuminuria with 10mmHg lower SBP 13% Adler et al., 2000164
Risk reduction of severe vision loss with 10mmHg lower SBP 0% No data
continued
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TABLE 113 Disease natural history parameters (continued )
Parameter
Mean
value Source
MI adjustments
Proportion with MI having an initial CHD event, female 0.361 D’Agostino et al., 200093
Proportion with MI having an initial CHD event, male 0.522 D’Agostino et al., 200093
Proportion with MI having a subsequent CHD event MI, female 0.474 D’Agostino et al., 200093
Proportion with MI having a subsequent CHD event MI, male 0.451 D’Agostino et al., 200093
RR of MI if microalbuminuria is present 1 No data
RR of MI if gross proteinuria is present 1 No data
RR of MI if end-stage renal disease is present 1 No data
RR of recurrent MI if DIGAMI165 intensive control is used 1 No data
RR of MI mortality if DIGAMI165 intensive control is used 1 No data
RR of MI if aspirin used for primary prevention 0.82 Baigent et al., 2009166
RR of MI if aspirin used for secondary prevention 0.80 Baigent et al., 2009166
RR of MI if statins used for primary prevention 0.70 Brugts et al., 2009167
RR of MI if statins used for secondary prevention 0.81 Shepherd et al., 2002168
RR of MI if ACEIs used for primary prevention 0.78 HOPE Study Investigators, 2000169
RR of MI if ACEIs used for secondary prevention 0.78 D’Agostino et al., 200093
MI mortality
Probability of sudden death after first MI, male 0.393 Sonke et al., 1996170
Probability of sudden death after first MI, female 0.364 Sonke et al., 1996170
Probability of sudden death after recurrent MI, male 0.393 Sonke et al., 1996170
Probability of sudden death after recurrent MI, female 0.364 Sonke et al., 1996170
RR of 12-month mortality after MI conventional treatment 1.45 Malmberg et al., 1995165
RR of mortality first year after MI aspirin treatment 0.88 Antiplatelet Triallists’ Collaboration,
1994171
RR of mortality each subsequent year after MI aspirin treatment 0.88
RR of mortality first year after MI statin treatment 0.75 Stenestrand et al., 2001172
RR of mortality each subsequent year after MI statin treatment 1.00 No data
RR of sudden death after MI aspirin treatment 1.00 No data
RR of sudden death after MI statin treatment 1.00 Briel et al., 2006173
RR of sudden death after MI ACEI treatment 1.00 No data
RR of long-term mortality after MI using ACEIs 0.64 Gustafsson et al., 1999174
RR 12-month mortality after MI using ACEIs 0.64 Sonke et al., 1996170
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TABLE 113 Disease natural history parameters (continued )
Parameter
Mean
value Source
Stroke
RR of stroke with microalbuminuria 1.00 No data
RR of stroke with gross proteinuria 1.00 No data
RR of stroke with end-stage renal disease 1.00 No data
RR of first stroke if aspirin used 0.86 Baigent et al., 2009166
RR of second stroke if aspirin used 0.78 Baigent et al., 2009166
RR of first stroke if statins used 0.81 Brugts et al., 2009167
RR of second stroke if statins used 0.84 Stroke Prevention by Aggressive
Reduction in Cholesterol Levels (SPARCL)
investigators, 2006175
RR of first stroke if ACEIs used 0.67 HOPE Study investigators, 2000169
RR of recurrent stroke if ACEIs used 0.72 PROGRESS Collaborative Group, 2001176
Stroke mortality
Probability of 30-day death after first stroke 0.124 Eriksson and Olsson, 2001177
Probability of 30-day death after recurrent stroke 0.422
RR of mortality after stroke if aspirin used 0.84 Antiplatelet Triallists’ Collaboration,
1994171
RR of mortality if statins used 1.00 Manktelow and Potter, 2009178
RR of sudden death after stroke if aspirin used 0.95 Sandercock et al., 2008179
RR of sudden death after stroke if statins used 1.00 Briel et al., 2006173
RR of sudden death after stroke if ACEIs used 0.49 Chitravas et al., 2007180
RR of long-term mortality after stroke using ACEIs 1.000 Asberg et al., 2010181
RR of 12-month mortality after stroke using ACEIs 1.000 Eriksson and Olsson, 2001177
Angina adjustments
Proportion with angina having first CHD event, female 0.621 D’Agostino et al., 200093
Proportion with angina having first CHD event, male 0.420 D’Agostino et al., 200093
Proportion with angina having subsequent CHD event, female 0.359 D’Agostino et al., 200093
Proportion with angina having subsequent CHD event, male 0.301 D’Agostino et al., 200093
RR of angina with microalbuminuria 1.00 No data
RR of angina with gross proteinuria 1.00 No data
RR of angina with end-stage renal disease 1.00 No data
continued
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TABLE 113 Disease natural history parameters (continued )
Parameter
Mean
value Source
CHF adjustments
RR of heart failure with microalbuminuria 1.00 No data
RR of heart failure with gross proteinuria 1.00 No data
RR of heart failure with end-stage renal disease 1.00 No data
RR of heart failure if aspirin used 1.00 No data
RR of heart failure if statins used 1.00 No data
RR of heart failure if ACEIs used 0.80 HOPE Study Investigators, 2000169
RR of heart failure death if ACEIs used 0.80 Ascenção et al., 2008182
RR of heart failure death diabetic, male 1.00 Ho et al., 1993183
RR of heart failure death diabetic, female 1.70 Ho et al., 1993183
ACEI adjustments for micro-vascular complications
RR of BDR if ACEIs used 0.75 Chaturvedi et al., 1998184
RR of proliferative diabetic retinopathy if ACEIs used 0.19 Chaturvedi et al., 1998184
RR of macular oedema if ACEIs used 1.00 No data
RR of severe vision loss if ACEIs used 1.00 No data
RR of worsening microalbuminuria if ACEIs used,
no complications
0.79 Penno et al., 1998185
RR of worsening gross proteinuria if ACEIs used,
with microalbuminuria
0.41 Penno et al., 1998185
RR of worsening end stage renal disease if ACEIs used,
with gross proteinuria
0.63 Lewis et al., 1993186
RR of neuropathy if ACEIs used 1.00 No data
Side effects of ACEIs
Probability stopping ACEIs because of side effects first year 0 Assumption
Probability stopping ACEIs because of side effects each
subsequent year
0 Assumption
Adverse events
Probability death from severe hypoglycaemic event 0 Assumption
Probability death from severe ketoacidosis event 0.027 MacIsaac et al., 2002187
RR of hypoglycaemic events with ACEIs 1.00 No data
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TABLE 113 Disease natural history parameters (continued )
Parameter
Mean
value Source
Foot ulcer and amputation
Probability gangrene to amputation 0.181800 Persson et al., 2000188
Probability gangrene to healed amputation 0.308200 Persson et al., 2000188
Probability death following onset gangrene 0.009800 Persson et al., 2000188
Probability death with history amputation 0.004000 Persson et al., 2000188
Probability death following healed ulcer 0.004000 Persson et al., 2000188
Probability developing recurrent uninfected ulcer 0.039300 Persson et al., 2000188
Probability amputation following infected ulcer 0.003700 Persson et al., 2000188
Probability infected ulcer after amputation healed 0.044500 Persson et al., 2000188
Probability of death from infected ulcer 0.009800 Persson et al., 2000188
Probability of gangrene from infected ulcer 0.007500 Persson et al., 2000188
Probability of infected ulcer from uninfected ulcer 0.139700 Persson et al., 2000188
Probability of recurrent amputation 0.008451 Borkosky et al., 2012189
Probability of death from uninfected ulcer 0.004000 Persson et al., 2000188
Probability of uninfected ulcer from infected ulcer 0.047300 Persson et al., 2000188
Probability of healed ulcer from uninfected ulcer 0.078700 Persson et al., 2000188
Probability developing ulcer with neither neuropathy or PVD 0.000250 Ragnarson et al., 2001190
Probability developing ulcer with either neuropathy or PVD 0.006092 Ragnarson et al., 2001190
Probability developing ulcer with both neuropathy or PVD 0.006092 Persson et al., 2000188
Depression
RR for all-cause death if depression 1.33 Egede et al., 2005191
RR for CHF if depression 1.00 No data
RR for MI if depression 1.00 No data
RR for depression if neuropathy 3.10 Yoshida et al., 2009192
RR for depression if stroke 6.30 Whyte et al., 2004193
RR for depression if amputation 1.00 No data
Other
Probability of severe vision loss from BDR 0.015 CORE default, 200481
Probability of reversal of neuropathy 0.000 No data
CHD, coronary heart disease; CORE, Centre for Outcomes Research and Effectiveness; DIGAMI, Diabetes Mellitus Insulin
Glucose Infusion in Acute Myocardial Infarction.
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TABLE 114 Transition probabilities dependencies and sources
Parameter Dependent on Source
Renal disease
Probability of onset of microalbuminuria Duration of diabetes DCCT92
Probability of worsening from microalbuminuria to gross
proteinuria
Duration of diabetes DCCT92
Probability of worsening from gross proteinuria to end-stage renal
disease
Duration of gross
proteinuria
Rosolowsky et al., 2011158
Proportion of end-stage renal disease with haemodialysis,
peritoneal dialysis or renal transplant
Current age US Renal Data System
(USRDS), 2010194
Probability of death end-stage renal disease under haemodialysis,
peritoneal dialysis or renal transplant
Current age US Renal Data System
(USRDS), 2010194
Eye disease
Probability of onset BDR, proliferative diabetic retinopathy,
macular oedema or severe vision loss
Duration of diabetes DCCT92
Probability of onset of cataract extraction; male, female Current age Janghorbani et al., 2000154
Probability of recurrent cataract extraction; male, female Current age Janghorbani et al., 2000154
Neuropathy
Probability of onset of neuropathy Duration of diabetes DCCT92
Heart failure
Probability of heart failure long-term mortality, per gender and
age range
Time since onset of
heart failure
Ho et al., 1993183
MI
Probability of death within 12 months of first/recurrent MI;
male, female
Current age Malmberg et al., 1995165
Probability of post-MI long-term mortality; male, female Time since first MI Malmberg et al., 1995165
Stroke
Probability of death within 12 months of first/recurrent stroke;
male, female
Current age Eriksson and Olsson, 2001177
Probability of post-stroke long-term mortality; male, female Time since first stroke Eriksson and Olsson, 2001177
Probability of recurrent stroke; male, female Time since first stroke Eriksson and Olsson, 2001177
Depression
Probability of onset of depression; male, female Time of simulation Golden et al., 2008195
Probability of depression reversal for patients receiving/not
receiving anti-depression programme
Time of simulation Valenstein et al., 2001196
Non-specific mortality
Probability of non-specific mortality per ethnicity and gender Current age UK life tables94
Physiological parameter progression tables
HbA1c progression Time of simulation DCCT
92
BMI, haemodialysis, LDL, SBP, T-CHOL, triglyceride progression Time of simulation CORE default, 200481
Other adjustment factors
Quality of life adjustment based on current BMI BMI Bagust and Beale, 2005197
Age adjustment for MI mortality Current age Herlitz et al., 1996198
CORE, Centre for Outcomes Research and Effectiveness; LOL, low-density lipoprotein; T-CHOL, total cholesterol.
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Appendix 9 Guidance relevant to the treatment
of type 1 diabetes
Published National Institute for Health and Care Excellence
guidance
NICE Pathway. Diabetes Overview. 2013. URL: http://pathways.nice.org.uk/pathways/diabetes (accessed
15 February 2016).
NICE Pathway. Preventing Type 2 Diabetes. June 2013. URL: http://pathways.nice.org.uk/pathways/
preventing-type-2-diabetes (accessed 15 February 2016).
NICE Clinical Guideline CG15. Diagnosis and Management of Type 1 Diabetes in Children, Young People
and Adults. 2004. URL: www.nice.org.uk/CG15 (accessed 15 February 2016). Date for review: reviewed in
August 2011 and decision was made to update the guideline. Update scheduled to be published in 2015.
NICE Clinical Guideline CG119. Diabetic Foot: Inpatient Management of People with Diabetic Foot Ulcers
and Infection. 2011. URL: http://guidance.nice.org.uk/CG119 (accessed 15 February 2016). Date for
review: to be confirmed.
NICE Clinical Guideline CG66. Type 2 Diabetes: The Management of Type 2 Diabetes (update). 2008.
URL: http://guidance.nice.org.uk/CG66 (accessed 15 February 2016). Date for review: following a review in
2011 an update of this guideline is currently in the process of being scheduled into the work programme.
NICE Clinical Guideline CG10. Type 2 Diabetes: Prevention and Management of Foot Problems. 2004.
URL: http://guidance.nice.org.uk/CG10 (accessed 15 February 2016). Date for review: an update of this
guideline is under way to coincide with publication of the four diabetes guidelines currently being updated.
NICE Clinical Guideline CG87. Type 2 Diabetes: Newer Agents (Partial Update of CG66) (CG87). 2009.
URL: http://guidance.nice.org.uk/CG87 (accessed 15 February 2016). Date for review: following the recent
review recommendation, an update of this guideline is in progress.
NICE Clinical Guideline. Diabetes in Pregnancy: Management of Diabetes and its Complications from
Pre-conception to the Postnatal Period. 2008. URL: http://guidance.nice.org.uk/CG63 (accessed
15 February 2016). Date for review: this guideline is currently being updated. Further information can be
found on the Diabetes in Pregnancy guideline in development page.
NICE Clinical Guideline CG173. Neuropathic Pain – Pharmacological Management: the Pharmacological
Management of Neuropathic Pain in Adults in Non-specialist Settings. 2013. URL: http://guidance.nice.org.
uk/CG173 (accessed 15 February 2016). Date for review: to be confirmed.
NICE Clinical Guideline CG130. Hyperglycaemia in Acute Coronary Syndrome. 2011.
URL: www.nice.org.uk/guidance/CG130 (accessed 15 February 2016). Date for review: to be confirmed.
NICE Technology Appraisal Guidance TA53. The Clinical Effectiveness and Cost-effectiveness of Long
Acting Insulin Analogues for Diabetes. 2002. URL: www.nice.org.uk/guidance/TA53 (accessed 15 February
2016). Date for review: the recommendations in this technology appraisal relating to type 2 diabetes
have been replaced by recommendations in the Diabetes: Type 2 (update) clinical guideline published in
May 2008. Please note that the recommendations in this technology appraisal relating to type 1 diabetes
have not changed.
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NICE Technology Appraisal Guidance TA151. Continuous Subcutaneous Insulin Infusion for the Treatment
of Diabetes Mellitus (Review). 2008. URL: http://guidance.nice.org.uk/TA151 (accessed 15 February 2016).
Date for review: to be confirmed.
NICE Technology Appraisal Guidance TA301. Fluocinolone Acetonide Intravitreal Implant for Treating
Chronic Diabetic Macular Oedema After an Inadequate Response to Prior Therapy (Rapid Review of
Technology Appraisal Guidance 271). 2013. URL: http://guidance.nice.org.uk/TA301 (accessed
15 February 2016). Date for review: to be confirmed.
NICE Technology Appraisal Guidance TA288. Dapagliflozin in Combination Therapy for Treating Type 2
Diabetes. 2013. URL: http://guidance.nice.org.uk/TA288 (accessed 15 February 2016). Date for review:
to be confirmed.
NICE Technology Appraisal Guidance TA274. Ranibizumab for the Treatment of Diabetic Macular Oedema
(Rapid Review of TA237). 2013. URL: http://guidance.nice.org.uk/TA274 (accessed 15 February 2016).
Date for review: to be confirmed.
NICE Technology Appraisal Guidance TA248. Exenatide Prolonged-release Suspension for Injection
in Combination with Oral Antidiabetic Therapy for the Treatment of Type 2 Diabetes: 2012.
URL: http://guidance.nice.org.uk/TA248 (accessed 15 February 2016). Date for review: to be confirmed.
NICE Technology Appraisal Guidance TA203. Liraglutide for the Treatment of Type 2 Diabetes Mellitus. 2010.
URL: http://guidance.nice.org.uk/TA203 (accessed 15 February 2016). Date for review: to be confirmed.
NICE Technology Appraisal Guidance TA60. The Clinical Effectiveness and Cost-effectiveness of Patient
Education Models for Diabetes. 2003. URL: http://guidance.nice.org.uk/TA60 (accessed 15 February 2016).
Date for review: in December 2005, following consultation, the Institute proposed that the guidance be
updated as part of the reviews of the guidelines on type 1 and type 2 diabetes. The recommendations in
this technology appraisal relating to type 2 diabetes have been replaced by recommendations in the
Diabetes: Type 2 (update) clinical guideline published in May 2008. Please note that the recommendations
in this technology appraisal relating to type 1diabetes have not changed.
NICE Technology Appraisal TA288. Dapagliflozin in Combination Therapy for Treating Type 2 Diabetes.
2013. URL: http://guidance.nice.org.uk/TA288 (accessed 15 February 2016). Date for review: to
be confirmed.
NICE Technology Appraisal TA271. Fluocinolone Acetonide Intravitreal Implant for the Treatment
of Chronic Diabetic Macular Oedema After an Inadequate Response to Prior Therapy. 2013.
URL: http://guidance.nice.org.uk/TA271 (accessed 15 February 2016). Date for review: to be confirmed.
NICE Interventional Procedure IPG257. Allogenic Pancreatic Islet Cell Transplantation for Type 1 Diabetes
Mellitus. 2008. URL: http://guidance.nice.org.uk/IPG257 (accessed 15 February 2016). Date for review:
to be confirmed.
NICE Interventional Procedure IPG274. Autologous Pancreatic Islet Cell Transplantation for Improved
Glycaemic Control After Pancreatectomy. 2008. URL: http://guidance.nice.org.uk/IPG274 (accessed
15 February 2016). Date for review: to be confirmed.
NICE Interventional Procedure IPG316. Extracorporeal Albumin Dialysis for Acute Liver Failure. 2009.
URL: http://guidance.nice.org.uk/IPG316 (accessed 15 February 2016). Date for review: to be confirmed.
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NICE Public Health Guidance PH38. Preventing Type 2 Diabetes: Risk Identification and Interventions for
Individuals at High Risk. 2012. URL: http://guidance.nice.org.uk/PH38 (accessed 15 February 2016).
Date for review: to be confirmed.
NICE Public Health Guidance PH35. Preventing Type 2 Diabetes: Population and Community-level
Interventions in High-risk Groups and the General Population. 2011. URL: www.nice.org.uk/guidance/PH35
(accessed 15 February 2016). Date for review: May 2014.
NICE Evidence Summaries: New Medicines ESNM20. Type 2 Diabetes: Alogliptin. 2013.
URL: http://publications.nice.org.uk/esnm20-type-2-diabetes-alogliptin-esnm20 (accessed 15 February 2016).
Date for review: to be confirmed.
NICE Evidence Summaries: New Medicines ESNM26. Type 2 Diabetes: Lixisenatide. 2013
URL: http://publications.nice.org.uk/esnm26type-2-diabetes-lixisenatide-esnm26 (accessed 15 February
2016). Date for review: to be confirmed.
NICE Evidence Summaries: New Medicines ESNM5. Type 1 Diabetes: Insulin Degludec. 2012.
URL: www.nice.org.uk/mpc/evidencesummariesnewmedicines/ESNM5.jsp (accessed 15 February 2016).
Date for review: to be confirmed.
NICE Evidence Summaries: New Medicines ESNM4. Type 2 Diabetes: Insulin Degludec. 2012.
URL: www.nice.org.uk/mpc/evidencesummariesnewmedicines/ESNM4.jsp (accessed 15 February 2016).
Date for review: to be confirmed.
NICE Quality Standard QS6. Diabetes in Adults. 2011. URL: http://guidance.nice.org.uk/QS6. In a statement
dated August 2015, NICE explains that this quality standard was updated to make sure it was aligned with
new NICE guidance (NG17 and NG19) for diabetes and diabetic foot problems, which superseded some
previous development sources for the quality standard.
National Institute for Health and Care Excellence guidance
under development
Diabetes in children and young people (update); NICE clinical guideline (publication expected August 2015).
Type 1 Diabetes (update); NICE clinical guideline (publication expected August 2015).
Type 2 Diabetes (update); NICE clinical guideline (publication expected August 2015).
Diabetes in Pregnancy (update); NICE clinical guideline (publication expected February 2015).
Diabetic Foot Problems (update); NICE clinical guideline (publication expected June 2015).
National Institute for Health and Care Excellence pathways
The guidance Type 1 Diabetes: Integrated Sensor-augmented Pump Therapy Systems for Managing Blood
Glucose Levels (the MiniMed Paradigm Veo System and the Vibe and G4 PLATINUM CGM system) will be
included in the NICE diabetes pathway.
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Relevant guidance from other organisations
Scottish Intercollegiate Guidelines Network guideline 116. Management of Diabetes. 2010.
URL: www.sign.ac.uk/guidelines/fulltext/116/ (accessed 15 February 2016).
Diabetes UK. The Hospital Management of Hypoglycaemia in Adults with Diabetes Mellitus. 2010.
URL: www.diabetologists-abcd.org.uk/JBDS/JBDS_IP_Hypo_Adults.pdf (accessed 15 February 2016).
Diabetes UK. State of the Nation: England 2013. 2013. URL: www.diabetes.org.uk/Documents/
About%20Us/What%20we%20say/0160b-state-nation-2013-england-1213.pdf (accessed
15 February 2016).
Diabetes UK. Use of Analogue Insulins. 2012. URL: www.diabetes.org.uk/Documents/
Position%20statements/Analogue-insulin-pos-statement.2012.pdf (accessed 15 February 2016).
Diabetes UK. End of Life Diabetes Care. 2013. URL: www.diabetes.org.uk/upload/Position%20statements/
End-of-life-care-Clinical-recs111113.pdf (accessed 15 February 2016).
Diabetes UK. Recommendations for the Provision of Services in Primary Care for People with Diabetes.
2005. URL: www.diabetes.org.uk/documents/professionals/primary_recs.pdf (accessed 15 February 2016).
Joint Royal Colleges Ambulance Liaison Committee. Glycaemic Emergencies in Children. 2006. URL: www.
swast.nhs.uk/Downloads/SWASFT%20campaigns/clinical_guidelines_2006.pdf (accessed 15 February
2016). (See Part 3 – Paediatric Guidelines; Section 1: Emergencies in Children – Glycaemic emergencies
in children.)
National Metabolic Biochemistry Network. Guidelines for the Investigation of Hypoglycaemia in Infants and
Children. 2012. URL: www.metbio.net/docs/MetBio-Guideline-GARU968012-23-01-2012.pdf (accessed
15 February 2016).
British Inherited Metabolic Diseases Group. Recurrent Hypoglycaemia. 2013. URL: www.bimdg.org.uk/
store/guidelines/Hypoglycaemiav1-2-461185-22-05-2013.pdf (accessed 15 February 2016).
British Inherited Metabolic Diseases Group. Ketotic Hypoglycaemia. 2008. URL: www.bimdg.org.uk/store/
guidelines/ER-KH-v3_616477_18032015.pdf (accessed 15 February 2016).
British Inherited Metabolic Diseases Group. Management of Surgery in Children at Risk of Hypoglycaemia.
2013. URL: www.bimdg.org.uk/store/guidelines/Management-of-surgery-in-those-at-risk-of-
hypoglycaemiav4-755756-22-05-2013.pdf (accessed 15 February 2016).
Joint Royal Colleges Ambulance Liaison Committee. Glycaemic Emergencies in Adults. 2006.
URL: www.swast.nhs.uk/Downloads/SWASFT%20campaigns/clinical_guidelines_2006.pdf (accessed
15 February 2016). (See Part 2 – Adult Guidelines, Section 3: Specific Treatment Options, Glycaemic emergencies
in adults.)
Driver and Vehicle Licensing Agency. DVLA’s Current Medical Guidelines for Professionals –
Conditions D to F. 2013. URL: www.gov.uk/guidance/current-medical-guidelines-dvla-guidance-for-
professionals-conditions-d-to-f (accessed 15 February 2016).
Driver and Vehicle Licensing Agency. DVLA’s Current Medical Guidelines for Professionals –
Conditions G to I. 2013. URL: www.gov.uk/guidance/current-medical-guidelines-dvla-guidance-for-
professionals-conditions-g-to-i (accessed 15 February 2016).
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Royal College of Nursing. Children and Young People with Diabetes: RCN Guidance for Newly-appointed
Nurse Specialists. 2013. URL: www2.rcn.org.uk/__data/assets/pdf_file/0009/78633/002474.pdf
(accessed 15 February 2016).
Royal College of Nursing. Supporting Children and Young People with Diabetes. 2013. URL: www2.rcn.
org.uk/__data/assets/pdf_file/0008/267389/003_318.pdf (accessed 15 February 2016).
Royal College of Nursing. Specialist Nursing Services for Children and Young People with Diabetes. 2006.
URL: www2.rcn.org.uk/__data/assets/pdf_file/0009/78687/003015.pdf (accessed 15 February 2016).
Royal College of Nursing. Starting Injectable Treatment in Adults with Type 2 Diabetes. 2012. URL: www2.
rcn.org.uk/__data/assets/pdf_file/0009/78606/002254.pdf (accessed 15 February 2016).
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